

A Trial of Lopinavir–Ritonavir in Adults Hospitalized

New England Journal of Medicine

382, 1787-1799

DOI: [10.1056/nejmoa2001282](https://doi.org/10.1056/nejmoa2001282)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Novel 2019-Coronavirus on New Year's Eve. Indian Journal of Medical Microbiology, 2019, 37, 459-477.	0.3	22
2	Development of a Standardized Data Collection Tool for Evaluation and Management of Coronavirus Disease 2019. Open Forum Infectious Diseases, 2020, 7, ofaa320.	0.4	0
3	Treatment of coronavirus disease 2019. Current Opinion in HIV and AIDS, 2020, 15, 336-340.	1.5	8
4	Antiretrovirals and Risk of COVID-19 Diagnosis and Hospitalization in HIV-Positive Persons. Epidemiology, 2020, 31, e49-e51.	1.2	24
5	Overview of coronavirus disease 2019: Treatment updates and advances. Journal of the Chinese Medical Association, 2020, 83, 805-808.	0.6	10
6	Inferred duration of infectious period of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases. BMJ Open, 2020, 10, e039856.	0.8	299
7	Computational Evaluation of the Inhibition Efficacies of HIV Antivirals on SARS-CoV-2 (COVID-19) Protease and Identification of 3D Pharmacophore and Hit Compounds. Advances in Pharmacological and Pharmaceutical Sciences, 2020, 2020, 1-10.	0.7	9
8	Consequences of the COVID-19 pandemic on the continuum of care in a cohort of people living with HIV followed in a single center of Northern Italy. AIDS Research and Therapy, 2020, 17, 59.	0.7	49
9	COVID-19 and HIV. Colombia Medica, 2020, 51, 1-10.	0.7	3
10	COVID-19: Current Developments and Further Opportunities in Drug Delivery and Therapeutics. Pharmaceutics, 2020, 12, 945.	2.0	14
11	Drug Weaponry to Fight Against SARS-CoV-2. Frontiers in Molecular Biosciences, 2020, 7, 204.	1.6	2
13	Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review. Drugs, 2020, 80, 1929-1946.	4.9	74
15	COVID-19 outbreak: Challenges in pharmacotherapy based on pharmacokinetic and pharmacodynamic aspects of drug therapy in patients with moderate to severe infection. Heart and Lung: Journal of Acute and Critical Care, 2020, 49, 763-773.	0.8	19
16	COVID-19 therapies and their impact on QT interval prolongation: A multicentre retrospective study on 196 patients. IJC Heart and Vasculature, 2020, 30, 100637.	0.6	6
17	Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness. International Journal of Infectious Diseases, 2020, 101, 290-297.	1.5	33
18	Factors associated with clinical outcomes in patients with Coronavirus Disease 2019 in Guangzhou, China. Journal of Clinical Virology, 2020, 133, 104661.	1.6	9
19	Comparative epidemiology between the 2009 H1N1 influenza and COVID-19 pandemics. Journal of Infection and Public Health, 2020, 13, 1797-1804.	1.9	45
20	Time to Treat: Applying Lessons Learned from Other Viral Syndromes to SARS-CoV-2. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2020, 4, 759-763.	1.2	8

#	ARTICLE	IF	CITATIONS
21	Novel cyclohexanone compound as a potential ligand against SARS-CoV-2 main-protease. <i>Microbial Pathogenesis</i> , 2020, 149, 104546.	1.3	30
22	SARS-CoV-2 virus infection: Targets and antiviral pharmacological strategies. <i>Journal of Evidence-Based Medicine</i> , 2020, 13, 255-260.	0.7	30
23	Immunopathogenesis of Coronavirus-Induced Acute Respiratory Distress Syndrome (ARDS): Potential Infection-Associated Hemophagocytic Lymphohistiocytosis. <i>Clinical Microbiology Reviews</i> , 2020, 34, .	5.7	28
24	<i>In Silico</i> De Novo Curcuminoid Derivatives From the Compound Library of Natural Products Research Laboratories Inhibit COVID-19 3CL ^{pro} Activity. <i>Natural Product Communications</i> , 2020, 15, 1934578X2095326.	0.2	4
25	Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients. <i>Stem Cell Research and Therapy</i> , 2020, 11, 437.	2.4	54
26	Strategies for Targeting SARS CoV-2: Small Molecule Inhibitors—The Current Status. <i>Frontiers in Immunology</i> , 2020, 11, 552925.	2.2	38
27	Mild SARS-CoV-2 Infection After Gene Therapy in a Child With Wiskott-Aldrich Syndrome: A Case Report. <i>Frontiers in Immunology</i> , 2020, 11, 603428.	2.2	8
28	Efficacy of Early Combination Therapy With Lianhuaqingwen and Arbidol in Moderate and Severe COVID-19 Patients: A Retrospective Cohort Study. <i>Frontiers in Pharmacology</i> , 2020, 11, 560209.	1.6	20
29	A Narrative Literature Review of Global Pandemic Novel Coronavirus Disease 2019 (COVID-19): Epidemiology, Virology, Potential Drug Treatments Available. , 2020, 12, .		3
30	Chest CT Features of 182 Patients with Mild Coronavirus Disease 2019 (COVID-19) Pneumonia: A Longitudinal, Retrospective and Descriptive Study. <i>Infectious Diseases and Therapy</i> , 2020, 9, 1029-1041.	1.8	7
31	Treatment for COVID-19: An overview. <i>European Journal of Pharmacology</i> , 2020, 889, 173644.	1.7	226
32	Coronavirus Historical Perspective, Disease Mechanisms, and Clinical Outcomes. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1999-2010.	1.2	23
33	Clinical Challenges in an Outbreak of COVID-19 in Wuhan, China: Concerns from Frontiers. <i>Current Infectious Disease Reports</i> , 2020, 22, 30.	1.3	2
34	Role of proteolytic enzymes in the COVID-19 infection and promising therapeutic approaches. <i>Biochemical Pharmacology</i> , 2020, 182, 114225.	2.0	83
35	Azithromycin: The First Broad-spectrum Therapeutic. <i>European Journal of Medicinal Chemistry</i> , 2020, 207, 112739.	2.6	64
36	COVID-19 associated complications and potential therapeutic targets. <i>European Journal of Pharmacology</i> , 2020, 886, 173548.	1.7	23
37	Can pentoxifylline and similar xanthine derivatives find a niche in COVID-19 therapeutic strategies? A ray of hope in the midst of the pandemic. <i>European Journal of Pharmacology</i> , 2020, 887, 173561.	1.7	14
38	Interferon β -1b in treatment of severe COVID-19: A randomized clinical trial. <i>International Immunopharmacology</i> , 2020, 88, 106903.	1.7	150

#	ARTICLE	IF	CITATIONS
39	Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 281-287.	0.1	8
40	Baseline electrolyte abnormalities would be related to poor prognosis in hospitalized coronavirus disease 2019 patients. <i>New Microbes and New Infections</i> , 2020, 37, 100753.	0.8	61
41	Immunosuppression in a lung transplant recipient with COVID-19? Lessons from an early case. <i>Respiratory Medicine and Research</i> , 2020, 78, 100782.	0.4	3
42	COVID-19 infection and cardiac arrhythmias. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 451-460.	2.3	90
43	COVID-19 Infection: Concise Review Based on the Immunological Perspective. <i>Immunological Investigations</i> , 2020, , 1-20.	1.0	11
44	Expression of ACE2 in airways: Implication for COVID-19 risk and disease management in patients with chronic inflammatory respiratory diseases. <i>Clinical and Experimental Allergy</i> , 2020, 50, 1313-1324.	1.4	69
45	Different clinical presentations of two renal transplant recipients with coronavirus disease 2019: a case report. <i>BMC Infectious Diseases</i> , 2020, 20, 707.	1.3	5
46	ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19. <i>Biomedicine and Pharmacotherapy</i> , 2020, 131, 110678.	2.5	184
47	Efficacy and Safety of Triazavirin Therapy for Coronavirus Disease 2019: A Pilot Randomized Controlled Trial. <i>Engineering</i> , 2020, 6, 1185-1191.	3.2	47
48	Screening and evaluation of approved drugs as inhibitors of main protease of SARS-CoV-2. <i>International Journal of Biological Macromolecules</i> , 2020, 164, 2622-2631.	3.6	46
49	Síndrome DRESS en paciente con enfermedad por SARS-CoV-2. <i>Open Respiratory Archives</i> , 2020, 2, 205-206.	0.0	0
50	An open-label, randomized trial of the combination of IFN- β plus TFF2 with standard care in the treatment of patients with moderate COVID-19. <i>EclinicalMedicine</i> , 2020, 27, 100547.	3.2	29
51	SARS-CoV-2 Treatment Approaches: Numerous Options, No Certainty for a Versatile Virus. <i>Frontiers in Pharmacology</i> , 2020, 11, 1224.	1.6	30
52	Remdesivir and COVID-19. <i>Lancet, The</i> , 2020, 396, 953.	6.3	9
53	Gastrointestinal symptoms, pathophysiology, and treatment in COVID-19. <i>Genes and Diseases</i> , 2021, 8, 385-400.	1.5	60
54	Mechanisms and treatments of myocardial injury in patients with corona virus disease 2019. <i>Life Sciences</i> , 2020, 262, 118496.	2.0	8
55	Multivalent nanomedicines to treat COVID-19: A slow train coming. <i>Nano Today</i> , 2020, 35, 100962.	6.2	34
56	Leukotrienes, a potential target for Covid-19. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2020, 161, 102174.	1.0	12

#	ARTICLE	IF	CITATIONS
57	Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach. <i>Toxicology and Applied Pharmacology</i> , 2020, 406, 115237.	1.3	15
58	Plant-Derived Secondary Metabolites as Potential Mediators against COVID-19: A Review. <i>Prithvi Academic Journal</i> , 2020, , 1-18.	0.1	0
60	A review of medications used to control and improve the signs and symptoms of COVID-19 patients. <i>European Journal of Pharmacology</i> , 2020, 887, 173568.	1.7	3
61	Quality of early evidence on the pathogenesis, diagnosis, prognosis and treatment of COVID-19. <i>BMJ Evidence-Based Medicine</i> , 2021, 26, 302-306.	1.7	11
62	Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study. <i>Diabetes Care</i> , 2020, 43, 2999-3006.	4.3	201
63	A review on coronavirus survivability on materialâ€™s surfaces: present research scenarios, technologies and future directions. <i>Surface Engineering</i> , 2020, 36, 1226-1239.	1.1	14
64	Potential Therapeutic Options for COVID-19. <i>Infectious Microbes & Diseases</i> , 2020, 2, 89-95.	0.5	0
65	Pandemic treatments on trial: the bigger picture. N of many thinking in an N of one scenario. <i>European Respiratory Journal</i> , 2020, 56, 2002281.	3.1	2
66	The Important Role of Volatile Components From a Traditional Chinese Medicine Dayuan-Yin Against the COVID-19 Pandemic. <i>Frontiers in Pharmacology</i> , 2020, 11, 583651.	1.6	15
67	Early management of critically ill patients with COVID-19. <i>Journal of the American College of Emergency Physicians Open</i> , 2020, 1, 1418-1426.	0.4	2
68	Critically Ill Patients with COVID-19: A Narrative Review on Prone Position. <i>Pulmonary Therapy</i> , 2020, 6, 233-246.	1.1	30
69	Clinical spectrum and risk factors for complicated disease course in children admitted with SARS-CoV-2 infection. <i>Anales De PediatrÃa (English Edition)</i> , 2020, 93, 323-333.	0.1	7
70	Impact of COVID-19 on people living with HIV: A review. <i>Journal of Virus Eradication</i> , 2020, 6, 100019.	0.3	63
71	The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells. <i>Journal of Virology</i> , 2020, 95, .	1.5	178
72	The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis. <i>Canadian Respiratory Journal</i> , 2020, 2020, 1-16.	0.8	20
73	Convalescent Plasma: The Relay Baton in the Race for Coronavirus Disease 2019 Treatment. <i>Frontiers in Immunology</i> , 2020, 11, 570063.	2.2	13
74	Buying Time for an Effective Epidemic Response: The Impact of a Public Holiday for Outbreak Control on COVID-19 Epidemic Spread. <i>Engineering</i> , 2020, 6, 1108-1114.	3.2	28
75	Strategies and Advances in Combating COVID-19 in China. <i>Engineering</i> , 2020, 6, 1076-1084.	3.2	16

#	ARTICLE	IF	CITATIONS
76	2020 update on human coronaviruses: One health, one world. <i>Medicine in Novel Technology and Devices</i> , 2020, 8, 100043.	0.9	21
77	A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics. <i>Nature Communications</i> , 2020, 11, 5284.	5.8	66
78	Targeting the 3CLpro and RdRp of SARS-CoV-2 with phytochemicals from medicinal plants of the Andean Region: molecular docking and molecular dynamics simulations. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 2010-2023.	2.0	48
79	Bibliometric Analysis of Early COVID-19 Research: The Top 50 Cited Papers. <i>Infectious Diseases: Research and Treatment</i> , 2020, 13, 117863372096293.	0.7	36
80	The first consecutive 5000 patients with Coronavirus Disease 2019 from Qatar; a nation-wide cohort study. <i>BMC Infectious Diseases</i> , 2020, 20, 777.	1.3	41
81	The Pipeline of Therapeutics Testing During the Emergency Phase of the COVID-19 Outbreak. <i>Frontiers in Medicine</i> , 2020, 7, 552991.	1.2	2
82	Targeting Proteases for Treating COVID-19. <i>Journal of Proteome Research</i> , 2020, 19, 4316-4326.	1.8	68
83	Cytokine Storm in COVID-19 Patients, Its Impact on Organs and Potential Treatment by QTY Code-Designed Detergent-Free Chemokine Receptors. <i>Mediators of Inflammation</i> , 2020, 2020, 1-7.	1.4	49
84	Immunomodulation Through Low-Dose Radiation for Severe COVID-19: Lessons From the Past and New Developments. <i>Dose-Response</i> , 2020, 18, 155932582095680.	0.7	8
85	Current treatment of COVID-19 in renal patients: hope or hype?. <i>Internal and Emergency Medicine</i> , 2020, 15, 1389-1398.	1.0	9
86	Clinical characteristics and risk factors of liver injury in COVID-19: a retrospective cohort study from Wuhan, China. <i>Hepatology International</i> , 2020, 14, 723-732.	1.9	35
87	Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses. <i>Antiviral Research</i> , 2020, 182, 104927.	1.9	9
88	COVID-19 pneumonia in an HIV-positive woman on antiretroviral therapy and undetectable viral load in Porto Alegre, Brazil. <i>Brazilian Journal of Infectious Diseases</i> , 2020, 24, 455-457.	0.3	9
89	CURRENT THERAPEUTIC OPTIONS FOR CORONAVIRUS DISEASE-2019 " A PHARMACOLOGICAL REVIEW. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 2020, , 42-50.	0.3	2
90	Potential Inhibitors for SARS-CoV-2 and Functional Food Components as Nutritional Supplement for COVID-19: A Review. <i>Plant Foods for Human Nutrition</i> , 2020, 75, 458-466.	1.4	34
91	A perspective on potential target proteins of COVID-19: Comparison with SARS-CoV for designing new small molecules. <i>Bioorganic Chemistry</i> , 2020, 104, 104326.	2.0	18
92	Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment. <i>European Journal of Pharmacology</i> , 2020, 889, 173634.	1.7	35
93	Novel hybrid antiviral VTRRT-13V2.1 against SARS-CoV2 main protease: retro-combinatorial synthesis and molecular dynamics analysis. <i>Heliyon</i> , 2020, 6, e05122.	1.4	7

#	ARTICLE	IF	CITATIONS
94	Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial. <i>International Immunopharmacology</i> , 2020, 88, 106869.	1.7	40
95	Molecular dynamics analysis predicts ritonavir and nalmefegol strongly block the SARS-CoV-2 spike protein-hACE2 binding. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 1597-1606.	2.0	9
96	Antiviral monotherapy for hospitalised patients with COVID-19 is not enough. <i>Lancet, The</i> , 2020, 396, 1310-1311.	6.3	16
98	The care of kidney transplant recipients during a global pandemic: Challenges and strategies for success. <i>Transplantation Reviews</i> , 2020, 34, 100567.	1.2	9
99	Clinical characteristics of imported and second-generation coronavirus disease 2019 (COVID-19) cases in Shaanxi outside Wuhan, China: a multicentre retrospective study. <i>Epidemiology and Infection</i> , 2020, 148, e238.	1.0	30
100	Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial. <i>Clinical Infectious Diseases</i> , 2021, 73, e4073-e4081.	2.9	219
101	Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2021, 73, e3996-e4004.	2.9	90
102	A quantitative framework for exploring exit strategies from the COVID-19 lockdown. <i>Chaos, Solitons and Fractals</i> , 2020, 140, 110244.	2.5	21
103	A systematic review of SARS-CoV-2 vaccine candidates. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 237.	7.1	427
104	Novel corona virus (COVID-19) pandemic: current status and possible strategies for detection and treatment of the disease. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 1275-1298.	2.0	21
105	Novel coronavirus disease in patients with end-stage kidney disease. <i>Therapeutic Apheresis and Dialysis</i> , 2020, 25, 544-550.	0.4	9
106	Pathophysiology and Potential Therapeutic Candidates for COVID-19: A Poorly Understood Arena. <i>Frontiers in Pharmacology</i> , 2020, 11, 585888.	1.6	11
107	Severe coronavirus disease 2019 (COVID-19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 3142-3147.	0.2	3
108	Remdesivir against COVID-19 and Other Viral Diseases. <i>Clinical Microbiology Reviews</i> , 2020, 34, .	5.7	181
109	SARS-CoV2 and Co-Infections: A Review of Two Cases. <i>Case Reports in Infectious Diseases</i> , 2020, 2020, 1-4.	0.2	7
110	A case report of toxic epidermal necrolysis (TEN) in a patient with COVID-19 treated with hydroxychloroquine: are these two partners in crime?. <i>Clinical and Molecular Allergy</i> , 2020, 18, 19.	0.8	23
111	<p>Pharmacogenomics and Pharmacogenetics: In Silico Prediction of Drug Effects in Treatments for Novel Coronavirus SARS-CoV2 Disease</p>. <i>Pharmacogenomics and Personalized Medicine</i> , 2020, Volume 13, 463-484.	0.4	8
112	Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies. <i>Immunobiology</i> , 2020, 225, 152008.	0.8	65

#	ARTICLE	IF	CITATIONS
113	Coronaviruses: Innate Immunity, Inflammasome Activation, Inflammatory Cell Death, and Cytokines. Trends in Immunology, 2020, 41, 1083-1099.	2.9	154
114	Treatment estimands in clinical trials of patients hospitalised for COVID-19: ensuring trials ask the right questions. BMC Medicine, 2020, 18, 286.	2.3	17
115	In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors. Computers in Biology and Medicine, 2020, 126, 104046.	3.9	98
116	Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort). EClinicalMedicine, 2020, 28, 100591.	3.2	74
117	Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). European Journal of Cancer, 2020, 140, 86-104.	1.3	33
118	Pandemic and promise: progress towards finding an effective treatment for Novel Coronavirus 19. Australian and New Zealand Journal of Public Health, 2020, 44, 437-439.	0.8	1
119	Therapeutic strategy for severe COVID-19 pneumonia from clinical experience. European Journal of Inflammation, 2020, 18, 205873922096159.	0.2	2
120	SARS-CoV-2: From Structure to Pathology, Host Immune Response and Therapeutic Management. Microorganisms, 2020, 8, 1468.	1.6	9
121	Peptides: Prospects for Use in the Treatment of COVID-19. Molecules, 2020, 25, 4389.	1.7	29
122	Covid-19 in patients with hematological and solid cancers at a Comprehensive Cancer Center in Germany. Cancer Medicine, 2020, 9, 8412-8422.	1.3	29
123	Management Considerations for the COVID-19 Patient with Severe Disease: a Case Scenario and Literature Review. HSS Journal, 2020, 16, 153-159.	0.7	2
124	Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet, The, 2020, 396, 1345-1352.	6.3	569
125	Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2. Biomedicine and Pharmacotherapy, 2020, 131, 110668.	2.5	98
126	Site mapping and small molecule blind docking reveal a possible target site on the SARS-CoV-2 main protease dimer interface. Computational Biology and Chemistry, 2020, 89, 107372.	1.1	30
127	Cardiac arrest and drug-related cardiac toxicity in the Covid-19 era. Epidemiology, pathophysiology and management. Food and Chemical Toxicology, 2020, 145, 111742.	1.8	5
128	Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19. International Journal of Antimicrobial Agents, 2020, 56, 106142.	1.1	6
129	Novel insights into the treatment of SARS-CoV-2 infection: An overview of current clinical trials. International Journal of Biological Macromolecules, 2020, 165, 18-43.	3.6	35
130	Molecular modelling investigation for drugs and nutraceuticals against protease of SARS-CoV-2. Journal of Molecular Graphics and Modelling, 2020, 101, 107717.	1.3	26

#	ARTICLE	IF	CITATIONS
132	Ensemble forecast modeling for the design of COVID-19 vaccine efficacy trials. <i>Vaccine</i> , 2020, 38, 7213-7216.	1.7	32
133	Pre-exposure prophylaxis during the SARS-CoV-2 pandemic: can PrEP prevent COVID-19-related symptoms?. <i>Epidemiology and Infection</i> , 2020, 148, e231.	1.0	9
134	Analysis of the clinical characteristics of 77 COVID-19 deaths. <i>Scientific Reports</i> , 2020, 10, 16384.	1.6	37
135	Interferon Beta-1b and Lopinavir/Ritonavir for Middle East Respiratory Syndrome. <i>New England Journal of Medicine</i> , 2020, 383, 1645-1656.	13.9	61
136	In silico exploration of small-molecule β -helix mimetics as inhibitors of SARS-COV-2 attachment to ACE2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 1546-1557.	2.0	7
137	Insult to Injury-Potential Contribution of Coronavirus Disease-19 to Neuroinflammation and the Development of HIV-Associated Neurocognitive Disorders. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 601-609.	0.5	2
138	In the Fog of Coronavirus Disease (COVID). <i>Clinical Infectious Diseases</i> , 2020, , .	2.9	1
139	An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics. <i>Journal of Infection and Public Health</i> , 2020, 13, 1405-1414.	1.9	38
140	Reacciones adversas a fármacos utilizados en el tratamiento específico de la infección por SARS-CoV-2. <i>Medicina Clínica</i> , 2020, 155, 448-453.	0.3	10
141	Agentes terapéuticos utilizados en 238 pacientes hospitalizados por COVID-19 y su relación con la mortalidad. <i>Medicina Clínica</i> , 2020, 155, 375-381.	0.3	5
142	COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. <i>Nature Reviews Cardiology</i> , 2020, 17, 543-558.	6.1	999
143	Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies. <i>Cytotherapy</i> , 2020, 22, 474-481.	0.3	29
144	Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19. <i>ACS Infectious Diseases</i> , 2020, 6, 2304-2318.	1.8	42
145	In-silico drug repurposing and molecular dynamics puzzled out potential SARS-CoV-2 main protease inhibitors. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 5756-5767.	2.0	48
146	Pharmacokinetics of lopinavir/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2657-2660.	1.3	13
147	Model-informed drug repurposing: Viral kinetic modelling to prioritize rational drug combinations for COVID-19. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3439-3450.	1.1	24
148	The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: The Padua province experience. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2629-2635.	1.9	71
149	Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1143-1151.	0.5	187

#	ARTICLE	IF	CITATIONS
150	Extracorporeal Membrane Oxygenation for COVID-19. <i>Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery</i> , 2020, 15, 306-313.	0.4	5
151	Potential Repurposed Therapeutics and New Vaccines against COVID-19 and Their Clinical Status. <i>SLAS Discovery</i> , 2020, 25, 1097-1107.	1.4	5
152	Repurposing Existing Drugs for the Treatment of COVID-19. <i>Annals of the American Thoracic Society</i> , 2020, 17, 1186-1194.	1.5	19
153	A bibliometric analysis using VOSviewer of publications on COVID-19. <i>Annals of Translational Medicine</i> , 2020, 8, 816-816.	0.7	247
154	Interferon beta in COVID-19: a landmark looming in the uncharted sea of COVID-19?. <i>Journal of Public Health and Emergency</i> , 0, 4, 8-8.	4.4	1
155	Potential Fast COVID-19 Containment With Trehalose. <i>Frontiers in Immunology</i> , 2020, 11, 1623.	2.2	18
156	Recent Advancements in the Diagnosis, Prevention, and Prospective Drug Therapy of COVID-19. <i>Frontiers in Public Health</i> , 2020, 8, 384.	1.3	13
157	The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections. <i>Journal of NeuroImmune Pharmacology</i> , 2020, 15, 359-386.	2.1	391
158	Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19. <i>Cellular Signalling</i> , 2020, 74, 109721.	1.7	105
159	Severe acute respiratory SARS-CoV-2 infection in dialysis patients in northern Italy: a single-centre experience. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 334-339.	1.4	19
160	Consensus virtual screening of dark chemical matter and food chemicals uncover potential inhibitors of SARS-CoV-2 main protease. <i>RSC Advances</i> , 2020, 10, 25089-25099.	1.7	23
161	A Randomized Clinical Trial of the Efficacy and Safety of Interferon β -1a in Treatment of Severe COVID-19. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	255
162	Lopinavir-Ritonavir Treatment for COVID-19 Infection in Intensive Care Unit. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008798.	2.1	26
163	Clinical trials in the time of a pandemic. <i>Clinical Trials</i> , 2020, 17, 467-471.	0.7	5
164	Evolving geographic diversity in SARS-CoV2 and in silico analysis of replicating enzyme 3CLpro targeting repurposed drug candidates. <i>Journal of Translational Medicine</i> , 2020, 18, 278.	1.8	29
165	A Hypothesis for the Possible Role of Zinc in the Immunological Pathways Related to COVID-19 Infection. <i>Frontiers in Immunology</i> , 2020, 11, 1736.	2.2	56
166	No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labelled Prospective Study. <i>Frontiers in Pharmacology</i> , 2020, 11, 1071.	1.6	46
167	Acceptance of a COVID-19 Vaccine in Southeast Asia: A Cross-Sectional Study in Indonesia. <i>Frontiers in Public Health</i> , 2020, 8, 381.	1.3	440

#	ARTICLE	IF	CITATIONS
168	A Randomized, Open-Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID-19, a Pilot Study. <i>Advanced Science</i> , 2020, 7, 2001435.	5.6	89
169	Characteristics of the Coronavirus Disease 2019 and related Therapeutic Options. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 18, 367-375.	1.8	24
170	Identification of therapeutic target in S2 domain of SARS nCov-2 Spike glycoprotein: Key to design and discover drug candidates for inhibition of viral entry into host cell. <i>Journal of Theoretical and Computational Chemistry</i> , 2020, 19, 2050028.	1.8	3
171	Turning the Tide: Natural Products and Natural-Product-Inspired Chemicals as Potential Counters to SARS-CoV-2 Infection. <i>Frontiers in Pharmacology</i> , 2020, 11, 1013.	1.6	59
172	Immune response in COVID-19: A review. <i>Journal of Infection and Public Health</i> , 2020, 13, 1619-1629.	1.9	281
173	Five variables that rule your life – Home mortgage and biostatistical power. <i>Ocular Surface</i> , 2020, 18, 533-536.	2.2	5
174	The Economic and Public Health Imperatives Around Making Potential Coronavirus Disease-2019 Treatments Available and Affordable. <i>Value in Health</i> , 2020, 23, 1427-1431.	0.1	8
175	Gaining insights on immune responses to the novel coronavirus, COVID-19 and therapeutic challenges. <i>Life Sciences</i> , 2020, 257, 118058.	2.0	11
176	Testing COVID-19 therapies to prevent progression of mild disease. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1367.	4.6	12
177	Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning. <i>Journal of Proteome Research</i> , 2020, 19, 4624-4636.	1.8	183
178	Current Status of Multiple Drug Molecules, and Vaccines: An Update in SARS-CoV-2 Therapeutics. <i>Molecular Neurobiology</i> , 2020, 57, 4106-4116.	1.9	38
179	FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. <i>Drug Resistance Updates</i> , 2020, 53, 100719.	6.5	110
180	Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort. <i>EClinicalMedicine</i> , 2020, 25, 100449.	3.2	155
181	COVID-19 treatment: Much research and testing, but far, few magic bullets against SARS-CoV-2 coronavirus. <i>European Journal of Medicinal Chemistry</i> , 2020, 203, 112647.	2.6	26
182	Bioactivity Profile Similarities to Expand the Repertoire of COVID-19 Drugs. <i>Journal of Chemical Information and Modeling</i> , 2020, 60, 5730-5734.	2.5	3
183	Pharmacotherapeutic considerations in solid organ transplant patients with COVID-19. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1813-1819.	0.9	6
184	Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa241.	0.4	97
185	Guidance for the management of adult patients with coronavirus disease 2019. <i>Chinese Medical Journal</i> , 2020, 133, 1575-1594.	0.9	20

#	ARTICLE	IF	CITATIONS
186	Discovery of M Protease Inhibitors Encoded by SARS-CoV-2. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	73
187	Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations. BMC Medicine, 2020, 18, 215.	2.3	52
188	<p>Major Neurologic Adverse Drug Reactions, Potential DrugâDrug Interactions and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review</p>. Therapeutics and Clinical Risk Management, 2020, Volume 16, 595-605.	0.9	47
189	Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials. SN Comprehensive Clinical Medicine, 2020, 2, 1120-1131.	0.3	19
190	Advances in the possible treatment of COVID-19: A review.. European Journal of Pharmacology, 2020, 883, 173372.	1.7	50
191	The epidemiology and therapeutic options for the COVID-19. Precision Clinical Medicine, 2020, 3, 71-84.	1.3	17
192	Hyperglycemia, Hypertriglyceridemia, and Acute Pancreatitis in COVID-19 Infection. Pancreas, 2020, 49, e62-e63.	0.5	24
193	Endpoints for randomized controlled clinical trials for COVID-19 treatments. Clinical Trials, 2020, 17, 472-482.	0.7	55
194	<p>Coronavirus Disease 2019 (COVID-19) and Transplantation: Pharmacotherapeutic Management of Immunosuppression Regimen</p>. Therapeutics and Clinical Risk Management, 2020, Volume 16, 617-629.	0.9	29
195	High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects. Frontiers in Immunology, 2020, 11, 1660.	2.2	48
196	Convalescent Plasma Coupled With Medications for the Treatment of a Severe COVID-19 Patient: Drugs Analysis and Pharmaceutical Care Based on the Newly Established Guidelines for COVID-19 Remedy. Frontiers in Pharmacology, 2020, 11, 966.	1.6	7
197	COVID-19/SARS-CoV-2 Infection: Lysosomes and Lysosomotropism Implicate New Treatment Strategies and Personal Risks. International Journal of Molecular Sciences, 2020, 21, 4953.	1.8	41
198	Clinical presentation and management of COVID-19. Medical Journal of Australia, 2020, 213, 134-139.	0.8	52
199	In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2. Antiviral Research, 2020, 181, 104878.	1.9	114
200	COVID-19 and the Heart. Colombia Medica, 2020, 51, 1-5.	0.7	10
201	Emergency Nursing Care of Patients With Novel Coronavirus Disease 2019. Journal of Emergency Nursing, 2020, 46, 748-759.	0.5	18
202	Interacciones medicamentosas potenciales en pacientes COVID 19 en tratamiento con lopinavir/ritonavir. Medicina Cl�nica, 2020, 155, 281-287.	0.3	7
203	Convalescent plasma transfusion a promising therapy for coronavirus diseases 2019 (COVID-19): current updates. Antibody Therapeutics, 2020, 3, 115-125.	1.2	12

#	ARTICLE	IF	CITATIONS
204	Pruritic papular eruption in HIV-positive patients in Brazil. <i>Aids</i> , 2020, 34, 1576-1578.	1.0	1
205	Safety perspectives on presently considered drugs for the treatment of COVID-19. <i>British Journal of Pharmacology</i> , 2020, 177, 4353-4374.	2.7	17
206	Exploring an Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial. <i>Chinese Journal of Integrative Medicine</i> , 2020, 26, 648-655.	0.7	46
207	The dynamic treatment of SARS-CoV-2 disease. <i>Baylor University Medical Center Proceedings</i> , 2020, 33, 572-579.	0.2	2
208	Imatinib a Tyrosine Kinase Inhibitor: a potential treatment for SARS- COV-2 induced pneumonia. <i>Alexandria Journal of Medicine</i> , 2020, 56, 68-72.	0.4	8
209	Low rate of COVID-19 pneumonia in kidney transplant recipientsâ€”A battle between infection and immune response?. <i>Transplant Infectious Disease</i> , 2020, 22, e13406.	0.7	13
210	Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis. <i>Critical Care</i> , 2020, 24, 418.	2.5	41
211	SARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, Therapeutics, and Clinical Readouts in the Current Settings. <i>Pathogens</i> , 2020, 9, 546.	1.2	31
212	SARS-CoV-2 and HIV coinfection: clinical experience from Rhode Island, United States. <i>Journal of the International AIDS Society</i> , 2020, 23, e25573.	1.2	57
213	Emerging pharmacological therapies for ARDS: COVID-19 and beyond. <i>Intensive Care Medicine</i> , 2020, 46, 2265-2283.	3.9	52
214	Coronavirus Disease-19: An Interim Evidence Synthesis of the World Association for Infectious Diseases and Immunological Disorders (Waidid). <i>Frontiers in Medicine</i> , 2020, 7, 572485.	1.2	15
215	Prevalence, Mechanisms, and Implications of Gastrointestinal Symptoms in COVID-19. <i>Frontiers in Medicine</i> , 2020, 7, 588711.	1.2	37
216	Current and Future Direct-Acting Antivirals Against COVID-19. <i>Frontiers in Microbiology</i> , 2020, 11, 587944.	1.5	16
217	Pharmacogenomics of genetic polymorphism within the genes responsible for SARS-CoV-2 susceptibility and the drug-metabolising genes used in treatment. <i>Reviews in Medical Virology</i> , 2021, 31, e2194.	3.9	20
218	Bioengineered <i>in Vitro</i> Tissue Models to Study SARS-CoV-2 Pathogenesis and Therapeutic Validation. <i>ACS Biomaterials Science and Engineering</i> , 2020, 6, 6540-6555.	2.6	20
219	Cardiovascular Disease and SARS-CoV-2: the Role of Host Immune Response Versus Direct Viral Injury. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8141.	1.8	4
220	The effect of tocilizumab on cytokine release syndrome in COVID-19 patients. <i>Pharmacological Reports</i> , 2020, 72, 1529-1537.	1.5	8
221	Convalescent Plasma Therapy: An Effective Therapeutic Option to Treat COVID-19? A Narrative Review. <i>International Journal of Clinical Transfusion Medicine</i> , 2020, Volume 8, 7-21.	0.8	4

#	ARTICLE	IF	CITATIONS
222	Overcoming nonstructural protein 15-nidoviral uridylylate-specific endoribonuclease (nsp15/NendoU) activity of SARS-CoV-2. <i>Future Drug Discovery</i> , 2020, 2, .	0.8	9
223	Structure-guided discovery approach identifies potential lead compounds targeting Mpro of SARS-CoV-2. <i>VirusDisease</i> , 2020, 31, 549-553.	1.0	2
224	High-content screening of Thai medicinal plants reveals <i>Boesenbergia rotunda</i> extract and its component Panduratin A as anti-SARS-CoV-2 agents. <i>Scientific Reports</i> , 2020, 10, 19963.	1.6	97
225	Efficacy and safety of transfusing plasma from COVID-19 survivors to COVID-19 victims with severe illness. A double-blinded controlled preliminary study. <i>Egyptian Journal of Anaesthesia</i> , 2020, 36, 264-272.	0.2	19
226	Advances in the treatment of novel coronavirus disease (COVID-19) with Western medicine and traditional Chinese medicine: a narrative review. <i>Journal of Thoracic Disease</i> , 2020, 12, 6054-6069.	0.6	14
227	Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function. <i>Advances in Chronic Kidney Disease</i> , 2020, 27, 434-441.	0.6	5
228	Vaccines to prevent COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING VACCINE Project). <i>Systematic Reviews</i> , 2020, 9, 262.	2.5	23
229	Increasing Age, the Existence of Comorbidities, and Corticosteroid Treatment in Combination With Antiviral Therapy Prolongs the Recovery of SARS-COV-2-Infected Patients, Measured as the Conversion From Positive to Negative rtPCR: A 239 Patients' Retrospective Study. <i>Frontiers in Medicine</i> , 2020, 7, 575439.	1.2	2
231	Drugâ€“Drug, Drugâ€“Disease and Diseaseâ€“Disease Interactions in COVID-19 with Cardiovascular Diseases (CVDs). <i>Indian Journal of Cardiovascular Disease in Women WINCARS</i> , 2020, 5, 216-222.	0.1	0
232	An asthmatic pregnant woman with COVID-19: A case report study. <i>Respiratory Medicine Case Reports</i> , 2020, 31, 101296.	0.2	1
233	Drug Repurposing Approaches to Combating Viral Infections. <i>Journal of Clinical Medicine</i> , 2020, 9, 3777.	1.0	23
234	Recommendations for treatment of critically ill patients with COVID-19. <i>Der Anaesthetist</i> , 2020, , 1.	0.5	22
235	Targeted intracellular degradation of SARS-CoV-2 via computationally optimized peptide fusions. <i>Communications Biology</i> , 2020, 3, 715.	2.0	37
236	Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2â€™s main protease. <i>Virology Journal</i> , 2020, 17, 190.	1.4	73
237	<p>Repurposing Anti-Cancer Drugs for COVID-19 Treatment</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 5045-5058.	2.0	28
238	COVID-19: Advances in diagnostic tools, treatment strategies, and vaccine development. <i>Journal of Biosciences</i> , 2020, 45, 1.	0.5	79
239	First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients. <i>Medicine (United States)</i> , 2020, 99, e23357.	0.4	49
240	Prescribing practices of lopinavir/ritonavir, hydroxychloroquine and azithromycin during the COVID-19 epidemic crisis and pharmaceutical interventions in a French teaching hospital. <i>European Journal of Hospital Pharmacy</i> , 2021, 28, 242-247.	0.5	3

#	ARTICLE	IF	CITATIONS
241	Management of Pediatric Kidney Transplant Patients During the COVID-19 Pandemic: Guidance From the Canadian Society of Transplantation Pediatric Group. Canadian Journal of Kidney Health and Disease, 2020, 7, 205435812096784.	0.6	17
242	High anal swab viral load predisposes adverse clinical outcomes in severe COVID-19 patients. Emerging Microbes and Infections, 2020, 9, 2706-2713.	3.0	11
243	Perinatal Maternal-Fetal/Neonatal Transmission of COVID-19: A Guide to Safe Maternal and Neonatal Care in the Era of COVID-19 and Physical Distancing. NeoReviews, 2020, 21, e783-e794.	0.4	9
244	Docking Characterization and in vitro Inhibitory Activity of Flavan-3-ols and Dimeric Proanthocyanidins Against the Main Protease Activity of SARS-Cov-2. Frontiers in Plant Science, 2020, 11, 601316.	1.7	74
245	Status of Novel Coronavirus Disease 2019 (COVID-19) and Animal Production. Frontiers in Veterinary Science, 2020, 7, 586919.	0.9	12
246	COVID-19 Clinical Trials: A Teachable Moment for Improving Our Research Infrastructure and Relevance. Annals of Internal Medicine, 2020, 173, 652-653.	2.0	20
247	How to Quantify and Interpret Treatment Effects in Comparative Clinical Studies of COVID-19. Annals of Internal Medicine, 2020, 173, 632-637.	2.0	37
248	Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy. Drugs and Aging, 2020, 37, 925-933.	1.3	23
249	Association between early treatment with Qingfei Paidu decoction and favorable clinical outcomes in patients with COVID-19: A retrospective multicenter cohort study. Pharmacological Research, 2020, 161, 105290.	3.1	67
250	Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities. Journal of Medicinal Chemistry, 2022, 65, 2716-2746.	2.9	149
251	Reprofiling of approved drugs against SARS-CoV-2 main protease: an in-silico study. Journal of Biomolecular Structure and Dynamics, 2022, 40, 3170-3184.	2.0	20
252	Comprehensive Literature Review and Evidence evaluation of Experimental Treatment in COVID 19 Contagion. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2020, 14, 117954842096414.	0.5	4
253	COVID-19 in Elderly Adults: Clinical Features, Molecular Mechanisms, and Proposed Strategies. , 2020, 11, 1481.		12
254	Is Machine Learning a Better Way to Identify COVID-19 Patients Who Might Benefit from Hydroxychloroquine Treatment? The IDENTIFY Trial. Journal of Clinical Medicine, 2020, 9, 3834.	1.0	8
255	Convalescent Plasma – Is it Useful for Treating SARS Co-V2 infection?. Indian Journal of Medical Microbiology, 2020, 38, 252-260.	0.3	7
256	Efficacy and Safety of Lopinavir/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis. Tropical Medicine and Infectious Disease, 2020, 5, 180.	0.9	34
257	Therapeutic agents tested in 238 COVID-19 hospitalized patients and their relationship with mortality. Medicina Clínica (English Edition), 2020, 155, 375-381.	0.1	1
258	FDA efficiency for approval process of COVID-19 therapeutics. Infectious Agents and Cancer, 2020, 15, 73.	1.2	8

#	ARTICLE	IF	CITATIONS
259	In Silico Discovery of Antimicrobial Peptides as an Alternative to Control SARS-CoV-2. <i>Molecules</i> , 2020, 25, 5535.	1.7	21
260	From empiricism to scientific evidence in antiviral treatment in severe cases of coronavirus infection in times of epidemic. <i>Medicina Intensiva (English Edition)</i> , 2020, 44, 509-512.	0.1	0
261	Remdesivir Use in Patients Requiring Mechanical Ventilation due to COVID-19. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa481.	0.4	22
262	Combating the Pandemic COVID-19: Clinical Trials, Therapies and Perspectives. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 606393.	1.6	21
263	The "sex gap" in COVID-19 trials: a scoping review. <i>EClinicalMedicine</i> , 2020, 29-30, 100652.	3.2	30
264	Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 2083-2095.	0.4	145
265	Clinical Characteristics, Diagnosis, and Treatment of Major Coronavirus Outbreaks. <i>Frontiers in Medicine</i> , 2020, 7, 581521.	1.2	42
266	Biology of COVID-19 and related viruses: Epidemiology, signs, symptoms, diagnosis, and treatment. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2021, 35, 269-292.	1.7	12
267	Coronavirus and Homo Sapiens in Coronavirus Disease 2019 (COVID-19). <i>Journal of Cardiac Critical Care TSS</i> , 2020, 4, 121-131.	0.0	0
268	Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study. <i>EClinicalMedicine</i> , 2020, 28, 100590.	3.2	129
269	Corticosteroid therapy for coronavirus disease 2019-related acute respiratory distress syndrome: a cohort study with propensity score analysis. <i>Critical Care</i> , 2020, 24, 643.	2.5	42
271	Epitope-Based Immunoinformatics Approach on Nucleocapsid Protein of Severe Acute Respiratory Syndrome-Coronavirus-2. <i>Molecules</i> , 2020, 25, 5088.	1.7	33
272	Herbal plants coordinate COVID-19 in multiple dimensions - An insight analysis for clinically applied remedies. <i>International Journal of Medical Sciences</i> , 2020, 17, 3125-3145.	1.1	12
273	Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19). <i>Annals of Internal Medicine</i> , 2020, 173, 670-672.	2.0	64
274	Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 448-453.	0.1	4
275	Clinical presentations, laboratory and radiological findings, and treatments for 11,028 COVID-19 patients: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2020, 10, 19765.	1.6	56
276	Potential use of RNA-dependent RNA polymerase (RdRp) inhibitors against SARS-CoV2 infection. <i>International Journal of Transgender Health</i> , 2020, 13, 608-614.	1.1	11
277	Efficacy of early prone or lateral positioning in patients with severe COVID-19: a single-center prospective cohort. <i>Precision Clinical Medicine</i> , 2020, 3, 260-271.	1.3	10

#	ARTICLE	IF	CITATIONS
278	Antiviral Dosing Modification for Coronavirus Disease 2019â€“Infected Patients Receiving Extracorporeal Therapy. , 2020, 2, e0242.		8
279	Dissecting the Drug Development Strategies Against SARS-CoV-2 Through Diverse Computational Modeling Techniques. Methods in Pharmacology and Toxicology, 2020, , 329-431.	0.1	4
280	COVID-19: a review. IJS Short Reports, 2020, 5, e07-e07.	0.1	23
281	Daily Viral Kinetics and Innate and Adaptive Immune Response Assessment in COVID-19: a Case Series. MSphere, 2020, 5, .	1.3	52
282	Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements. Frontiers in Pharmacology, 2020, 11, 559996.	1.6	4
284	The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research, 2020, 182, 104902.	1.9	25
285	COVID-19: Therapeutics and interventions currently under consideration. Disease-a-Month, 2020, 66, 101058.	0.4	21
286	The development of Coronavirus 3C-Like protease (3CLpro) inhibitors from 2010 to 2020. European Journal of Medicinal Chemistry, 2020, 206, 112711.	2.6	119
287	Computational identification of disulfiram and neratinib as putative SARS-CoV-2 main protease inhibitors. Mendeleev Communications, 2020, 30, 419-420.	0.6	11
288	Early Report on Published Outcomes in Kidney Transplant Recipients Compared to Nontransplant Patients Infected With Coronavirus Disease 2019. Transplantation Proceedings, 2020, 52, 2659-2662.	0.3	21
289	The COVIDâ€“19 pandemic: A community approach. Clinical Transplantation, 2020, 34, e14059.	0.8	10
290	COVID-19: The Immune Responses and Clinical Therapy Candidates. International Journal of Molecular Sciences, 2020, 21, 5559.	1.8	25
291	SARS-CoV-2 infection in Chinaâ€“Before the pandemic. PLoS Neglected Tropical Diseases, 2020, 14, e0008472.	1.3	6
292	Multi-organ Dysfunction in Patients with COVID-19: A Systematic Review and Meta-analysis. , 2020, 11, 874.		97
293	Physiologicallyâ€“Based Pharmacokinetic Modeling to Predict the Clinical Efficacy of the Coadministration of Lopinavir and Ritonavir against SARSâ€“CoVâ€“2. Clinical Pharmacology and Therapeutics, 2020, 108, 1176-1184.	2.3	6
294	Remdesivir: A beacon of hope from Ebola virus disease to <sc>COVID</sc>â€“19. Reviews in Medical Virology, 2020, 30, 1-13.	3.9	25
295	Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients. Neurological Sciences, 2020, 41, 2353-2366.	0.9	60
296	COVID-19: A review of the proposed pharmacological treatments. European Journal of Pharmacology, 2020, 886, 173451.	1.7	88

#	ARTICLE	IF	CITATIONS
297	What to expect from different drugs used in the treatment of COVID-19: A study on applications and in vivo and in vitro results. <i>European Journal of Pharmacology</i> , 2020, 887, 173467.	1.7	16
298	Coronavirus disease 2019 (COVID-19): Immunological approaches and emerging pharmacologic treatments. <i>International Immunopharmacology</i> , 2020, 88, 106885.	1.7	30
299	Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: A guide for the dermatologist. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1738-1748.	0.6	36
300	COVID-19: Pharmacology and kinetics of viral clearance. <i>Pharmacological Research</i> , 2020, 161, 105114.	3.1	17
301	A severe COVID-19 despite ongoing treatment with Lopinavir-Ritonavir. <i>Respiratory Medicine and Research</i> , 2020, 78, 100780.	0.4	3
302	The trade-off dilemma in pharmacotherapy of COVID-19: systematic review, meta-analysis, and implications. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1821-1849.	0.9	6
303	Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 957-975.	1.3	6
304	The hidden role of NLRP3 inflammasome in obesity-related COVID-19 exacerbations: Lessons for drug repurposing. <i>British Journal of Pharmacology</i> , 2020, 177, 4921-4930.	2.7	30
305	Covid-19 pandemic and pregnancy. <i>Journal of Obstetrics and Gynaecology Research</i> , 2020, 46, 1958-1966.	0.6	20
306	Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	109
307	COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers. <i>Blood Cancer Discovery</i> , 2020, 1, 234-243.	2.6	46
308	Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past. <i>Frontiers in Immunology</i> , 2020, 11, 1949.	2.2	345
309	Emerging Therapeutic Modalities against COVID-19. <i>Pharmaceuticals</i> , 2020, 13, 188.	1.7	24
310	Drugs against SARS-CoV-2: What do we know about their mode of action?. <i>Reviews in Medical Virology</i> , 2020, 30, 1-10.	3.9	30
311	Genomics insights of SARS-CoV-2 (COVID-19) into target-based drug discovery. <i>Medicinal Chemistry Research</i> , 2020, 29, 1777-1791.	1.1	34
312	Potential strategies for combating COVID-19. <i>Archives of Virology</i> , 2020, 165, 2419-2438.	0.9	12
313	Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2689-2700.	2.4	50
314	Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review. <i>Journal of Infection and Public Health</i> , 2020, 13, 1187-1195.	1.9	67

#	ARTICLE	IF	CITATIONS
315	COVID-19: pathophysiology, diagnosis, complications and investigational therapeutics. <i>New Microbes and New Infections</i> , 2020, 37, 100738.	0.8	88
316	Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia. <i>Cell Reports Medicine</i> , 2020, 1, 100059.	3.3	188
317	Genetic Polymorphisms Complicate COVID-19 Therapy: Pivotal Role of HO-1 in Cytokine Storm. <i>Antioxidants</i> , 2020, 9, 636.	2.2	39
318	A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial. <i>Virologica Sinica</i> , 2020, 35, 725-733.	1.2	40
319	Care for Patients with Stroke During the COVID-19 Pandemic: Physical Therapy and Rehabilitation Suggestions for Preventing Secondary Stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 105182.	0.7	24
320	Computational drug repurposing for the identification of SARS-CoV-2 main protease inhibitors. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 6242-6248.	2.0	11
321	Covering coronavirus“emerging tools for the fight against the common enemy. <i>Oxford Medical Case Reports</i> , 2020, 2020, omaa035.	0.2	0
322	Potential Drugs and Remedies for the Treatment of COVID-19: a Critical Review. <i>Biological Procedures Online</i> , 2020, 22, 15.	1.4	22
323	<p>A Review on Currently Available Potential Therapeutic Options for COVID-19</p>. <i>International Journal of General Medicine</i> , 2020, Volume 13, 443-467.	0.8	15
324	An overview of the safety assessment of medicines currently used in the COVID-19 disease treatment. <i>Food and Chemical Toxicology</i> , 2020, 144, 111639.	1.8	42
325	Virtual screening, ADMET prediction and dynamics simulation of potential compounds targeting the main protease of SARS-CoV-2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 6617-6632.	2.0	34
326	Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care. <i>Clinical Infectious Diseases</i> , 2021, 73, e4166-e4174.	2.9	135
327	The Course of Mild and Moderate COVID-19 Infections“The Unexpected Long-Lasting Challenge. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa286.	0.4	19
328	The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2315.	1.0	33
329	Evaluation of Current Therapies for COVID-19 Treatment. <i>Microorganisms</i> , 2020, 8, 1097.	1.6	11
330	Substance Use Disorder in the COVID-19 Pandemic: A Systematic Review of Vulnerabilities and Complications. <i>Pharmaceuticals</i> , 2020, 13, 155.	1.7	88
331	Global Efforts towards Potential Therapeutic Options for COVID-19. , 2020, 12, .		0
332	COVID-19: A Review on Diagnosis, Treatment, and Prophylaxis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5145.	1.8	18

#	ARTICLE	IF	CITATIONS
333	COVID-19 outbreak in Jordan: Epidemiological features, clinical characteristics, and laboratory findings. <i>Annals of Medicine and Surgery</i> , 2020, 57, 103-108.	0.5	44
334	Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2. <i>Biochemical Pharmacology</i> , 2020, 180, 114169.	2.0	26
335	The therapeutic potential of colchicine in the complications of COVID19. Could the immunometabolic properties of an old and cheap drug help?. <i>Metabolism Open</i> , 2020, 7, 100045.	1.4	8
336	Potential repurposed SARS-CoV-2 (COVID-19) infection drugs. <i>RSC Advances</i> , 2020, 10, 26895-26916.	1.7	40
337	Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 2041-2052.	13.9	903
338	Dual inhibitors of SARS-CoV-2 proteases: pharmacophore and molecular dynamics based drug repositioning and phytochemical leads. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 6324-6337.	2.0	21
339	Important Interactions of Immunosuppressants With Experimental Therapies for Novel Coronavirus Disease (COVID-19): How to Act. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 652-653.	1.0	8
340	Kidney transplant recipients infected by COVID-19: Review of the initial published experience. <i>Transplant Infectious Disease</i> , 2020, 22, e13426.	0.7	12
341	Treating COVID-19: Review of Drug Hypersensitivity Reactions. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2020, 30, 385-399.	0.6	7
342	COVID-19, State of the Adult and Pediatric Heart: From Myocardial Injury to Cardiac Effect of Potential Therapeutic Intervention. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 140.	1.1	9
343	While We Wait for a Vaccine Against SARS-CoV-2, Why Not Think About Available Drugs?. <i>Frontiers in Physiology</i> , 2020, 11, 820.	1.3	13
344	Pipeline Pharmacological Therapies in Clinical Trial for COVID-19 Pandemic: a Recent Update. <i>Current Pharmacology Reports</i> , 2020, 6, 228-240.	1.5	17
345	Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. <i>Lancet Respiratory Medicine</i> , 2020, 8, 853-862.	5.2	628
346	Placental transfer and safety in pregnancy of medications under investigation to treat coronavirus disease 2019. <i>American Journal of Obstetrics & Gynecology MFM</i> , 2020, 2, 100159.	1.3	34
347	Subcutaneous tocilizumab treatment in patients with severe COVID-19-related cytokine release syndrome: An observational cohort study. <i>EClinicalMedicine</i> , 2020, 24, 100410.	3.2	25
348	Identification of some novel oxazine substituted 9-anilinoacridines as SARS-CoV-2 inhibitors for COVID-19 by molecular docking, free energy calculation and molecular dynamics studies. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 5551-5562.	2.0	21
349	Immunothrombotic Dysregulation in COVID-19 Pneumonia Is Associated With Respiratory Failure and Coagulopathy. <i>Circulation</i> , 2020, 142, 1176-1189.	1.6	429
350	COVID-19: A Multidisciplinary Review. <i>Frontiers in Public Health</i> , 2020, 8, 383.	1.3	208

#	ARTICLE	IF	CITATIONS
351	Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 776-787.	3.7	82
352	A clinical pilot study on the safety and efficacy of aerosol inhalation treatment of IFN- γ plus TFF2 in patients with moderate COVID-19. <i>EClinicalMedicine</i> , 2020, 25, 100478.	3.2	20
353	Potential treatment methods targeting 2019-nCoV infection. <i>European Journal of Medicinal Chemistry</i> , 2020, 205, 112687.	2.6	32
354	A comparative overview of COVID-19, MERS and SARS: Review article. <i>International Journal of Surgery</i> , 2020, 81, 1-8.	1.1	81
355	An overview of key potential therapeutic strategies for combat in the COVID-19 battle. <i>RSC Advances</i> , 2020, 10, 28243-28266.	1.7	34
356	Multiorgan Involvement in COVID-19 and Possible Therapies. <i>Journal of Cardiac Critical Care TSS</i> , 2020, 04, 20-24.	0.0	0
357	Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial Protocol and statistical analysis plan. <i>Acta Anaesthesiologica Scandinavica</i> , 2020, 64, 1365-1375.	0.7	26
358	Nanomedicine as a promising approach for diagnosis, treatment and prophylaxis against COVID-19. <i>Nanomedicine</i> , 2020, 15, 2085-2102.	1.7	60
359	COVID-19 and the Kidneys: An Update. <i>Frontiers in Medicine</i> , 2020, 7, 423.	1.2	79
360	The Role of Health Preconditions on COVID-19 Deaths in Portugal: Evidence from Surveillance Data of the First 20293 Infection Cases. <i>Journal of Clinical Medicine</i> , 2020, 9, 2368.	1.0	33
361	Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1195-1216.	1.6	28
362	A minimal common outcome measure set for COVID-19 clinical research. <i>Lancet Infectious Diseases</i> , The, 2020, 20, e192-e197.	4.6	1,165
363	The four horsemen of a viral Apocalypse: The pathogenesis of SARS-CoV-2 infection (COVID-19). <i>EBioMedicine</i> , 2020, 58, 102887.	2.7	114
364	Severe Acute Respiratory Syndrome Coronavirus 2 and Coronavirus Disease 2019: A Clinical Overview and Primer. <i>Biopreservation and Biobanking</i> , 2020, 18, 492-502.	0.5	9
365	Infection of severe acute respiratory syndrome coronavirus 2 in a patient with AIDS. <i>Aids</i> , 2020, 34, 1575-1576.	1.0	15
366	Predictors of adverse prognosis in COVID-19: A systematic review and meta-analysis. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13362.	1.7	275
367	Drug treatments for covid-19: living systematic review and network meta-analysis. <i>BMJ</i> , The, 2020, 370, m2980.	3.0	592
368	SARS-CoV-2: characteristics and current advances in research. <i>Virology Journal</i> , 2020, 17, 117.	1.4	84

#	ARTICLE	IF	CITATIONS
369	Clinical Factors Associated with Progression and Prolonged Viral Shedding in COVID-19 Patients: A Multicenter Study. , 2020, 11, 1069.		28
370	<p>Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients</p>. Drug Design, Development and Therapy, 2020, Volume 14, 3001-3013.	2.0	21
371	Flavonoids Activation of the Transcription Factor Nrf2 as a Hypothesis Approach for the Prevention and Modulation of SARS-CoV-2 Infection Severity. Antioxidants, 2020, 9, 659.	2.2	76
372	Classification of the present pharmaceutical agents based on the possible effective mechanism on the COVID-19 infection. DARU, Journal of Pharmaceutical Sciences, 2020, 28, 745-764.	0.9	14
373	Improved prediction model for flood-season rainfall based on a nonlinear dynamics-statistic combined method. Chaos, Solitons and Fractals, 2020, 140, 110160.	2.5	17
374	Chinese herbal medicine for COVID-19: Current evidence with systematic review and meta-analysis. Journal of Integrative Medicine, 2020, 18, 385-394.	1.4	73
375	Treatment of the COVID-19 pandemic: Preventing a missed opportunity. Revista Cl&#amp;#x00ed;nica Espanõla, 2020, 220, 386-387.	0.3	1
376	Pharmacotherapeutic considerations for the management of cardiovascular diseases among hospitalized COVID-19 patients. Expert Review of Cardiovascular Therapy, 2020, 18, 475-485.	0.6	4
377	Development and progress of clinical trials of Coronavirus Disease 2019 antiviral drugs. Expert Review of Clinical Pharmacology, 2020, 13, 945-956.	1.3	3
378	Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer. Cancer Discovery, 2020, 10, 1465-1474.	7.7	151
379	Desperate times call for evidence-based measures: Prioritizing science during the COVID-19 pandemic. Jammi, 2020, 5, 127-129.	0.3	0
381	Review: An insight into coronaviruses: Challenges, security and scope. Reviews in Medical Virology, 2020, 30, 1-8.	3.9	6
382	Impact of medical care, including use of anti-infective agents, on prognosis of COVID-19 hospitalized patients over time. International Journal of Antimicrobial Agents, 2020, 56, 106129.	1.1	13
383	SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial. International Journal of Infectious Diseases, 2020, 99, 84-91.	1.5	50
384	Could herbal medicine (Soshihotang) be a new treatment option for COVID-19?: a narrative review. Integrative Medicine Research, 2020, 9, 100480.	0.7	15
385	Therapeutic plasma exchange in adult critically ill patients with life-threatening SARS-CoV-2 disease: A pilot study. Journal of Critical Care, 2020, 60, 328-333.	1.0	37
386	The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status. Journal of Infection and Public Health, 2020, 13, 1601-1610.	1.9	127
387	COVID-19 Pandemic: Time to Revive the Cyclophilin Inhibitor Alisporivir. Clinical Infectious Diseases, 2020, 71, 2191-2194.	2.9	20

#	ARTICLE	IF	CITATIONS
388	Efficacy and safety of Lianhua Qingwen combined with conventional antiviral Western Medicine in the treatment of coronavirus disease (covid-19) in 2019. <i>Medicine (United States)</i> , 2020, 99, e21404.	0.4	8
389	Diagnostic and Treatment Strategies for COVID-19. <i>AAPS PharmSciTech</i> , 2020, 21, 222.	1.5	31
390	The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 1991.	2.2	124
391	Physicians's Perspectives on COVID-19: An International Survey. <i>Healthcare (Switzerland)</i> , 2020, 8, 250.	1.0	9
392	Is Antioxidant Therapy a Useful Complementary Measure for Covid-19 Treatment? An Algorithm for Its Application. <i>Medicina (Lithuania)</i> , 2020, 56, 386.	0.8	56
393	Tocilizumab in severe COVID-19. <i>Archives of Medical Science</i> , 2020, 16, 1457-1458.	0.4	4
394	COVID-19: Rational discovery of the therapeutic potential of Melatonin as a SARS-CoV-2 main Protease Inhibitor. <i>International Journal of Medical Sciences</i> , 2020, 17, 2133-2146.	1.1	46
395	Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection. <i>European Journal of Pharmacology</i> , 2020, 885, 173450.	1.7	15
396	The COVID-19 Pandemic and Planetary Health. A Critical Review of Epidemiology, Prevention, Clinical Characteristics and Treatments for Oral, Head and Neck Health Professionals. Do We Have a Roadmap?. <i>International Archives of Otorhinolaryngology</i> , 2020, 24, e351-e358.	0.3	4
397	COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials. <i>Biochemical Pharmacology</i> , 2020, 180, 114184.	2.0	50
398	In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2. <i>European Journal of Pharmacology</i> , 2020, 886, 173430.	1.7	70
399	Role of comorbidities like diabetes on severe acute respiratory syndrome coronavirus-2: A review. <i>Life Sciences</i> , 2020, 258, 118202.	2.0	43
400	Identification of promising drug candidates against NSP16 of SARS-CoV-2 through computational drug repurposing study. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 6713-6727.	2.0	20
401	A case series of novel coronavirus infection in heart transplantation from 2 centers in the pandemic area in the North of Italy. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 1081-1088.	0.3	28
402	Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2181-2189.	2.0	51
403	Coronaviruses disease 2019 (COVID-19): Causative agent, mental health concerns, and potential management options. <i>Journal of Infection and Public Health</i> , 2020, 13, 1840-1844.	1.9	34
404	ADRS due to COVID-19 in midterm pregnancy: successful management with plasma transfusion and corticosteroids. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2022, 35, 3040-3043.	0.7	18
405	The Combined Use of Tocilizumab and Hemoadsorption in a Patient with SARS-COV-2-19-Associated Pneumonia: A Case Report. <i>Nephron</i> , 2020, 144, 459-462.	0.9	16

#	ARTICLE	IF	CITATIONS
406	COVID-19 Outbreak in a Hemodialysis Center: A Retrospective Monocentric Case Series. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812094429.	0.6	17
407	Plants Metabolites: Possibility of Natural Therapeutics Against the COVID-19 Pandemic. <i>Frontiers in Medicine</i> , 2020, 7, 444.	1.2	119
408	â€œTomorrow Never Diesâ€: Recent Advances in Diagnosis, Treatment, and Prevention Modalities against Coronavirus (COVID-19) amid Controversies. <i>Diseases (Basel, Switzerland)</i> , 2020, 8, 30.	1.0	19
409	Investigating Virological, Immunological, and Pathological Avenues to Identify Potential Targets for Developing COVID-19 Treatment and Prevention Strategies. <i>Vaccines</i> , 2020, 8, 443.	2.1	16
410	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. <i>Lancet Haematology</i> , 2020, 7, e737-e745.	2.2	430
411	Immunoinformatics-guided design of an epitope-based vaccine against severe acute respiratory syndrome coronavirus 2 spike glycoprotein. <i>Computers in Biology and Medicine</i> , 2020, 124, 103967.	3.9	62
412	Derivatization and combination therapy of current COVID-19 therapeutic agents: a review of mechanistic pathways, adverse effects, and binding sites. <i>Drug Discovery Today</i> , 2020, 25, 1822-1838.	3.2	13
413	Potential mechanisms of Chinese Herbal Medicine that implicated in the treatment of COVID-19 related renal injury. <i>Saudi Pharmaceutical Journal</i> , 2020, 28, 1138-1148.	1.2	16
414	COVID-19 treatment with lopinavirâ€ritonavir resulting in sick sinus syndrome: a case report. <i>European Heart Journal - Case Reports</i> , 2020, 4, 1-6.	0.3	7
415	The pharmacological development of direct acting agents for emerging needed therapy against severe acute respiratory syndrome coronavirus-2. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 712-718.	0.6	1
416	Evidence of potent humoral immune activity in COVID-19-infected kidney transplant recipients. <i>American Journal of Transplantation</i> , 2020, 20, 3149-3161.	2.6	54
417	A scientificity and feasibility evaluation of COVID-19 clinical studies registered in China. <i>Annals of Translational Medicine</i> , 2020, 8, 817-817.	0.7	4
418	Serum Activity of Liver Enzymes Is Associated With Higher Mortality in COVID-19: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 2020, 7, 431.	1.2	28
419	Relationship Between COVID-19 Infection and Liver Injury: A Review of Recent Data. <i>Frontiers in Medicine</i> , 2020, 7, 458.	1.2	57
420	Second Update for Anaesthetists on Clinical Features of COVID-19 Patients and Relevant Management. <i>Journal of Clinical Medicine</i> , 2020, 9, 2542.	1.0	2
421	A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review. <i>Life</i> , 2020, 10, 146.	1.1	6
422	Immune Response and COVID-19: A mirror image of Sepsis. <i>International Journal of Biological Sciences</i> , 2020, 16, 2479-2489.	2.6	60
423	Cardiovascular manifestation and treatment in COVID-19. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 704-709.	0.6	29

#	ARTICLE	IF	CITATIONS
424	Cardiovascular involvement during COVID-19 and clinical implications in elderly patients. A review. <i>Annals of Medicine and Surgery</i> , 2020, 57, 236-243.	0.5	36
425	Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1537-1544.	2.8	84
426	Microwave-assisted extraction, characterization and immunomodulatory activity on RAW264.7 cells of polysaccharides from <i>Trichosanthes kirilowii</i> Maxim seeds. <i>International Journal of Biological Macromolecules</i> , 2020, 164, 2861-2872.	3.6	34
427	Hanshiyi Formula, a medicine for Sars-CoV2 infection in China, reduced the proportion of mild and moderate COVID-19 patients turning to severe status: A cohort study. <i>Pharmacological Research</i> , 2020, 161, 105127.	3.1	37
428	Emerging therapeutics for the management of COVID 19. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 337-351.	1.0	6
429	Ongoing non-industry-sponsored COVID-19 clinical trials in the first trimester of the pandemic: significant differences between the European and the USA approaches. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1067-1072.	1.3	1
430	A Systematic Review of Treatment and Outcomes of Pregnant Women With COVID-19—A Call for Clinical Trials. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa350.	0.4	25
431	Outcomes Among HIV-Positive Patients Hospitalized With COVID-19. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 6-10.	0.9	149
432	The 11th Trial of a Cardiovascular Clinical Trialist. <i>Cardiology in Review</i> , 2020, 28, 217-218.	0.6	1
433	Understanding COVID-19: From Origin to Potential Therapeutics. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 5904.	1.2	13
434	COVID-19 and financial toxicity in patients with renal cell carcinoma. <i>World Journal of Urology</i> , 2021, 39, 2559-2565.	1.2	11
435	The Extent of Commitment of Saudis During Holy Ramadan to Social Distancing Measures Required for the Prevention of Transmission of COVID-19. <i>Journal of Community Health</i> , 2020, 46, 693-702.	1.9	3
436	Early Treatment of COVID-19 Disease: A Missed Opportunity. <i>Infectious Diseases and Therapy</i> , 2020, 9, 715-720.	1.8	18
437	Antivirals for COVID-19 in Solid Organ Transplant Recipients. <i>Current Transplantation Reports</i> , 2020, 7, 355-365.	0.9	12
438	Evaluation of mechanisms of action of re-purposed drugs for treatment of COVID-19. <i>Cellular Immunology</i> , 2020, 358, 104240.	1.4	6
439	Anti-COVID-19 drug screening: Frontier concepts and core technologies. <i>Chinese Medicine</i> , 2020, 15, 115.	1.6	8
440	Potential therapeutic target identification in the novel 2019 coronavirus: insight from homology modeling and blind docking study. <i>Egyptian Journal of Medical Human Genetics</i> , 2020, 21, .	0.5	4
441	Tocilizumab for treating severe COVID-19 pneumonia refractory to combined hydroxychloroquine, lopinavir plus ritonavir, and favipiravir: A case series. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 3264-3277.	0.2	2

#	ARTICLE	IF	CITATIONS
442	<p>Current Options in the Treatment of COVID-19: A Review</p>. Risk Management and Healthcare Policy, 2020, Volume 13, 1999-2010.	1.2	8
443	SARS-CoV-2: Pathogenesis, and Advancements in Diagnostics and Treatment. Frontiers in Immunology, 2020, 11, 570927.	2.2	28
444	COVID-19 disease: novel clinical manifestations and therapeutic exploration. Archives of Medical Science, 2020, , .	0.4	2
445	Coronary Artery Calcification and Complications in Patients With COVID-19. JACC: Cardiovascular Imaging, 2020, 13, 2468-2470.	2.3	56
446	Chinese guidelines related to novel coronavirus pneumonia. Journal of Market Access & Health Policy, 2020, 8, 1818446.	0.8	31
447	The impact of the COVID-19 pandemic on antimicrobial resistance: a debate. JAC-Antimicrobial Resistance, 2020, 2, dlaa053.	0.9	28
448	PHARMACOLOGICAL TREATMENTS OF COVID-19 â€“ A REVIEW. Asian Journal of Pharmaceutical and Clinical Research, 0, , 16-22.	0.3	4
449	COVID-19 update: The race to therapeutic development. Drug Resistance Updates, 2020, 53, 100733.	6.5	49
450	Stabilizing Cellular Barriers: Raising the Shields Against COVID-19. Frontiers in Endocrinology, 2020, 11, 583006.	1.5	8
451	Citation Network Analysis of the Novel Coronavirus Disease 2019 (COVID-19). International Journal of Environmental Research and Public Health, 2020, 17, 7690.	1.2	22
452	Assessing via Simulation the Operating Characteristics of the WHO Scale for COVID-19 Endpoints. Statistics in Biopharmaceutical Research, 2020, 12, 451-460.	0.6	3
453	Current Understanding of COVID-19 Clinical Course and Investigational Treatments. Frontiers in Medicine, 2020, 7, 555301.	1.2	23
455	Counterbalancing COVID-19 with Cancer Surveillance and Therapy: A Survey of Patients with Renal Cell Carcinoma. European Urology Focus, 2021, 7, 1355-1362.	1.6	9
456	Coronavirus disease 2019: scientific overview of the global pandemic. New Microbes and New Infections, 2020, 38, 100800.	0.8	3
457	COVID-19â€™ Lessons Learned and Questions Remaining. Clinical Infectious Diseases, 2021, 72, 2225-2240.	2.9	54
458	Impact of the COVID-19 Pandemic on the Medical Follow-up and Psychosocial Well-Being of People Living With HIV: A Cross-Sectional Survey. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 257-262.	0.9	35
459	Traditional Herbal Medicine Candidates as Complementary Treatments for COVID-19: A Review of Their Mechanisms, Pros and Cons. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-12.	0.5	128
460	Understanding Severe Acute Respiratory Syndrome Coronavirus 2 Replication to Design Efficient Drug Combination Therapies. Intervirology, 2020, 63, 2-9.	1.2	15

#	ARTICLE	IF	CITATIONS
461	Recent Advances in Pathophysiology, Drug Development and Future Perspectives of SARS-CoV-2. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 580202.	1.8	20
462	A 21st Century Evil: Immunopathology and New Therapies of COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 562264.	2.2	8
463	Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response. <i>Science Advances</i> , 2020, 6, .	4.7	128
464	The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial. <i>BMC Infectious Diseases</i> , 2020, 20, 786.	1.3	106
465	COVID-19 multidisciplinary high dependency unit: the Milan model. <i>Respiratory Research</i> , 2020, 21, 260.	1.4	22
466	Immunomodulatory Therapies for COVID-19 in Solid Organ Transplant Recipients. <i>Current Transplantation Reports</i> , 2020, 7, 379-389.	0.9	12
467	Pro resolving inflammatory effects of the lipid mediators of omega 3 fatty acids and its implication in SARS COVID-19. <i>Medical Hypotheses</i> , 2020, 145, 110340.	0.8	31
469	The Regulatory Challenges for Drug Repurposing During the Covid-19 Pandemic: The Italian Experience. <i>Frontiers in Pharmacology</i> , 2020, 11, 588132.	1.6	15
470	Efficacy and safety of remdesivir in hospitalized Covid-19 patients: Systematic review and meta-analysis including network meta-analysis. <i>Reviews in Medical Virology</i> , 2021, 31, e2187.	3.9	76
471	Kakkonto, shosaikoto, Platycodon grandiflorum root, and gypsum (a Japanese) Tj ETQq1 1 0.784314 rgBT /Overlook viral infections and respiratory inflammatory conditions and a discussion of its applications to COVID-19. <i>Traditional & Kampo Medicine</i> , 2020, 7, 115-127.	0.2	18
472	Answering 20 more questions on COVID-19 (March-April 2020). <i>Journal of Global Health</i> , 2020, 10, 020102.	1.2	9
473	In silico identification of drug candidates against COVID-19. <i>Informatics in Medicine Unlocked</i> , 2020, 21, 100461.	1.9	17
475	Drug binding dynamics of the dimeric SARS-CoV-2 main protease, determined by molecular dynamics simulation. <i>Scientific Reports</i> , 2020, 10, 16986.	1.6	54
476	Finding disease modules for cancer and COVID-19 in gene co-expression networks with the Core&Peel method. <i>Scientific Reports</i> , 2020, 10, 17628.	1.6	6
477	Giant Cell Arteritis and COVID-19: Similarities and Discriminators. A Systematic Literature Review. <i>Journal of Rheumatology</i> , 2021, 48, 1053-1059.	1.0	22
478	Transmission risk of infectious droplets in physical spreading process at different times: A review. <i>Building and Environment</i> , 2020, 185, 107307.	3.0	48
479	Novel Î ² -Coronavirus (SARS-CoV-2): Current and future aspects of pharmacological treatments. <i>Saudi Pharmaceutical Journal</i> , 2020, 28, 1243-1252.	1.2	6
480	Coronavirus Disease 2019 Pandemic. <i>Pancreas</i> , 2020, 49, e61-e62.	0.5	3

#	ARTICLE	IF	CITATIONS
481	How achievable are COVID-19 clinical trial recruitment targets? A UK observational cohort study and trials registry analysis. <i>BMJ Open</i> , 2020, 10, e044566.	0.8	11
482	Tocilizumab use in Kidney Transplant Patients with COVID-19. <i>Clinical Transplantation</i> , 2020, 34, e14072.	0.8	19
483	Statistical design of Phase II/III clinical trials for testing therapeutic interventions in COVID-19 patients. <i>BMC Medical Research Methodology</i> , 2020, 20, 220.	1.4	6
484	Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2020, 28, 625-634.	0.9	21
485	Comorbidity indices in people with HIV and considerations for coronavirus disease 2019 outcomes. <i>Aids</i> , 2020, 34, 1795-1800.	1.0	7
486	Persistent SARS-CoV-2 RNA positivity in a patient for 92 days after disease onset. <i>Medicine (United States)</i> 100(14):e20004. doi:10.1093/med/100.14/e20004	0.4	20
487	COVID-19 length of hospital stay: a systematic review and data synthesis. <i>BMC Medicine</i> , 2020, 18, 270.	2.3	430
488	A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 1777-1789.	0.3	51
489	Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3373-3378.	1.3	78
490	Removal of Remdesivir's Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	21
491	SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2020, 19, 40.	1.7	93
492	Potential use of noncoding RNAs and innovative therapeutic strategies to target the 5'UTR of SARS-CoV-2. <i>Epigenomics</i> , 2020, 12, 1349-1361.	1.0	34
493	Recommendations for prenatal, intrapartum, and postpartum care during COVID-19 pandemic in India. <i>American Journal of Reproductive Immunology</i> , 2020, 84, e13336.	1.2	7
494	Interferon-β spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients: a preliminary matched case-control study. <i>Journal of Zhejiang University: Science B</i> , 2020, 21, 628-636.	1.3	23
495	Drug repurposing approach to fight COVID-19. <i>Pharmacological Reports</i> , 2020, 72, 1479-1508.	1.5	323
496	Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. <i>Lancet, The</i> , 2020, 396, 959-967.	6.3	278
497	Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 1008-1016.	2.5	162
498	Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. <i>Nature Communications</i> , 2020, 11, 4417.	5.8	394

#	ARTICLE	IF	CITATIONS
499	Coronavirus disease 2019 attack rate in HIV-infected patients and in preexposure prophylaxis users. <i>Aids</i> , 2020, 34, 1765-1770.	1.0	29
500	Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline (updated version). <i>Military Medical Research</i> , 2020, 7, 41.	1.9	56
501	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2851-2852.	2.4	0
502	Can elevated concentrations of ALT and AST predict the risk of "recurrence"™ of COVID-19?. <i>Epidemiology and Infection</i> , 2020, 148, e218.	1.0	15
503	Case of "relapsing" COVID 19 in a kidney transplant recipient. <i>Nephrology</i> , 2020, 25, 933-936.	0.7	8
504	Characteristics of COVID-19 clinical trials registered with ClinicalTrials.gov: cross-sectional analysis. <i>BMJ Open</i> , 2020, 10, e041276.	0.8	29
505	Intensive care for seriously ill patients affected by novel coronavirus sars - CoV " 2: Experience of the Crema Hospital, Italy. <i>American Journal of Emergency Medicine</i> , 2021, 45, 156-161.	0.7	14
506	Derivation and Validation of a Predictive Score for Disease Worsening in Patients with COVID-19. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1680-1690.	1.8	38
507	Xuebijing injection in the treatment of COVID-19: a retrospective case-control study. <i>Annals of Palliative Medicine</i> , 2020, 9, 3235-3248.	0.5	36
508	Coronavirus global pandemic: An overview of current findings among pediatric patients. <i>Pediatric Pulmonology</i> , 2020, 55, 3252-3267.	1.0	20
509	Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort. <i>Nature Cancer</i> , 2020, 1, 965-975.	5.7	98
511	Therapeutic Effectiveness of Interferon-β Against COVID-19: The Cuban Experience. <i>Journal of Interferon and Cytokine Research</i> , 2020, 40, 438-442.	0.5	36
512	Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults. <i>BMJ Open</i> , 2020, 10, e041437.	0.8	46
513	Treatment of children with COVID-19: position paper of the Italian Society of Pediatric Infectious Disease. <i>Italian Journal of Pediatrics</i> , 2020, 46, 139.	1.0	47
514	Denovo designing, retrosynthetic analysis, and combinatorial synthesis of a hybrid antiviral (VTAR-01) to inhibit the interaction of SARS-CoV2 spike glycoprotein with human angiotensin-converting enzyme 2. <i>Biology Open</i> , 2020, 9, .	0.6	9
515	<p>Study Design Characteristics and Pharmacological Mechanisms in International Clinical Trials Registry Platform: Registered Clinical Trials on Antiviral Drugs for COVID-19</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 3803-3813.	2.0	6
516	Can Adenosine Fight COVID-19 Acute Respiratory Distress Syndrome?. <i>Journal of Clinical Medicine</i> , 2020, 9, 3045.	1.0	19
518	Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings. <i>Europace</i> , 2020, 22, 1855-1863.	0.7	28

#	ARTICLE	IF	CITATIONS
519	Review of Clinical Trials in COVID-19: Trying to Solve the Clinicians's™ Conundrum. <i>Annals of the National Academy of Medical Sciences (India)</i> , 2020, 56, 119-125.	0.2	0
520	Descriptive Analysis of Patients Living With HIV Affected by COVID-19. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 123-126.	0.9	28
521	Brief Report: Retrospective Evaluation on the Efficacy of Lopinavir/Ritonavir and Chloroquine to Treat Nonsevere COVID-19 Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 239-243.	0.9	16
522	A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19. <i>SLAS Discovery</i> , 2020, 25, 1108-1122.	1.4	25
523	Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). <i>PLoS Medicine</i> , 2020, 17, e1003293.	3.9	73
524	Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?. <i>Cells</i> , 2020, 9, 2100.	1.8	60
525	Treatment Options Available for COVID-19 and an Analysis on Possible Role of Combination of rhACE2, Angiotensin (1-7) and Angiotensin (1-9) as Effective Therapeutic Measure. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 1761-1766.	0.3	21
526	SARS-CoV-2 pharmacologic therapies and their safety/effectiveness according to level of evidence. <i>American Journal of Emergency Medicine</i> , 2020, 38, 2405-2415.	0.7	12
527	Supportive treatment of COVID 19 patients with mild respiratory failure in a primary hospital. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 222-223.	0.1	0
528	Signal amplification by reversible exchange for COVID-19 antiviral drug candidates. <i>Scientific Reports</i> , 2020, 10, 14290.	1.6	10
529	COVID-19 in Children: Present and Future Perspective, An Interim Review. <i>Journal of Child Science</i> , 2020, 10, e53-e62.	0.1	4
530	Treatment Modalities in the Intensive Care Unit for Coronavirus Disease 2019. <i>Annals of the National Academy of Medical Sciences (India)</i> , 2020, 56, 154-160.	0.2	0
531	Study of the Mechanism of the Reyaning Mixture Involved in Treating Novel Coronavirus Pneumonia Based on Network Pharmacology. <i>Natural Product Communications</i> , 2020, 15, 1934578X2095459.	0.2	0
532	Cardiovascular Complications Associated with COVID-19 and Potential Therapeutic Strategies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6790.	1.8	52
533	Selecting appropriate endpoints for assessing treatment effects in comparative clinical studies for COVID-19. <i>Contemporary Clinical Trials</i> , 2020, 97, 106145.	0.8	10
534	Treatment of Coronavirus Disease 2019 Patients With Prolonged Postsymptomatic Viral Shedding With Leflunomide: A Single-center Randomized Controlled Clinical Trial. <i>Clinical Infectious Diseases</i> , 2021, 73, e4012-e4019.	2.9	25
535	Hospital-acquired SARS-CoV-2 pneumonia in a person living with HIV. <i>International Journal of STD and AIDS</i> , 2020, 31, 1320-1322.	0.5	11
536	Overview of the First 6 Months of Clinical Trials for COVID-19 Pharmacotherapy: The Most Studied Drugs. <i>Frontiers in Public Health</i> , 2020, 8, 497.	1.3	14

#	ARTICLE	IF	CITATIONS
537	Treatment Armamentarium of COVID-19: Evolving Strategies and Evidence So Far. <i>Journal of Clinical and Experimental Hepatology</i> , 2020, 10, 599-609.	0.4	5
538	A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. <i>Trials</i> , 2020, 21, 718.	0.7	25
539	The Significance of Natural Product Derivatives and Traditional Medicine for COVID-19. <i>Processes</i> , 2020, 8, 937.	1.3	23
540	Coinfección por SARS-CoV-2 y rinovirus-enterovirus en una paciente adulta joven cr�ticamente enferma en Colombia. <i>Biomedica</i> , 2020, 40, 34-43.	0.3	9
541	Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). <i>Journal of Medicinal Chemistry</i> , 2020, 63, 13205-13227.	2.9	40
542	The role of the urologist, BCG vaccine administration, and SARS-CoV-2: An overview. <i>BJUI Compass</i> , 2020, 1, 87-92.	0.7	6
543	Canakinumab to reduce deterioration of cardiac and respiratory function in SARS-CoV-2 associated myocardial injury with heightened inflammation (canakinumab in Covid-19 cardiac injury: The three C) <i>Tj ETQq0 00rgBT /Overlock 10</i>		
544	Therapeutic Options for the Treatment of Coronavirus Disease (COVID-19). <i>Critical Care Nursing Quarterly</i> , 2020, 43, 349-368.	0.4	3
545	Coronavirus Disease of 2019 in Patients With Well-Controlled Human Immunodeficiency Virus on Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, e1-e4.	0.9	6
546	Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL^{pro} Reporter Assay. <i>Journal of Virology</i> , 2020, 94, .	1.5	85
547	Covid-19: Should doctors recommend treatments and vaccines when full data are not publicly available?. <i>BMJ, The</i> , 2020, 370, m3260.	3.0	11
548	Reverse takotsubo cardiomyopathy in fulminant COVID-19 associated with cytokine release syndrome and resolution following therapeutic plasma exchange: a case-report. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 389.	0.7	28
549	Quality Assessment of the Chinese Clinical Trial Protocols Regarding Treatments for Coronavirus Disease 2019. <i>Frontiers in Pharmacology</i> , 2020, 11, 1330.	1.6	1
550	Thrombosis in COVID-19. <i>American Journal of Hematology</i> , 2020, 95, 1578-1589.	2.0	235
552	Acute Kidney Injury Associated With Lopinavir/Ritonavir Combined Therapy in Patients With COVID-19. <i>Kidney International Reports</i> , 2020, 5, 1787-1790.	0.4	26
553	An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants. <i>Kidney International</i> , 2020, 98, 1549-1558.	2.6	213
554	COVID-19 in the pre-pandemic period: a survey of the time commitment and perceptions of infectious diseases physicians in Australia and New Zealand. <i>Internal Medicine Journal</i> , 2020, 50, 924-930.	0.5	7
555	Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?. <i>Frontiers in Microbiology</i> , 2020, 11, 1818.	1.5	81

#	ARTICLE	IF	CITATIONS
556	Finding the Best Antiviral Regimen for COVID-19: A Double-Center Retrospective Cohort Study of 207 Cases in Hunan, China. <i>Dose-Response</i> , 2020, 18, 155932582094974.	0.7	0
557	Is Nanotechnology Helping in the Fight Against COVID-19?. <i>Frontiers in Nanotechnology</i> , 2020, 2, .	2.4	27
558	Reply to: "Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19". <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa321.	0.4	5
559	Chinese herbal medicine reduces mortality in patients with severe and critical Coronavirus disease 2019: a retrospective cohort study. <i>Frontiers of Medicine</i> , 2020, 14, 752-759.	1.5	27
560	Probiotics and Coronavirus disease 2019: think about the link. <i>British Journal of Nutrition</i> , 2021, 126, 1564-1570.	1.2	19
561	Hydroxychloroquine and dexamethasone in COVID-19: who won and who lost?. <i>Clinical and Molecular Allergy</i> , 2020, 18, 17.	0.8	27
562	Coronavirus disease 2019 infection in patients with recent cardiac surgery: does chronic anticoagulant therapy have a protective effect?. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 765-771.	0.6	11
563	COVID-19 Outbreak: Pathogenesis, Current Therapies, and Potentials for Future Management. <i>Frontiers in Pharmacology</i> , 2020, 11, 563478.	1.6	45
564	Potential protease inhibitors and their combinations to block SARS-CoV-2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 903-917.	2.0	15
565	Analysis of type I IFN response and T cell activation in severe COVID-19/HIV-1 coinfection. <i>Medicine (United States)</i> , 2020, 99, e21803.	0.4	18
566	Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID-19. <i>Clinical and Translational Science</i> , 2020, 13, 1071-1076.	1.5	36
567	COVID-19: Review of a 21st Century Pandemic from Etiology to Neuro-psychiatric Implications. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 459-504.	1.2	63
568	COVID-19: in the uncertainty, do not try this at home. <i>Internal and Emergency Medicine</i> , 2020, 15, 1599-1600.	1.0	2
569	What Should Be Known by a Urologist About the Medical Management of COVID-19's Patients?. <i>Current Urology Reports</i> , 2020, 21, 44.	1.0	0
570	Steroids and COVID-19: We Need a Precision Approach, Not One Size Fits All. <i>Infectious Diseases and Therapy</i> , 2020, 9, 701-705.	1.8	23
571	Sequence Characterization and Molecular Modeling of Clinically Relevant Variants of the SARS-CoV-2 Main Protease. <i>Biochemistry</i> , 2020, 59, 3741-3756.	1.2	30
572	Targeted, Site-Specific, Delivery Vehicles of Therapeutics for COVID-19 Patients. Brief Review. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962095491.	0.7	9
573	Available Compounds With Therapeutic Potential Against COVID-19: Antimicrobial Therapies, Supportive Care, and Probable Vaccines. <i>Frontiers in Pharmacology</i> , 2020, 11, 582025.	1.6	14

#	ARTICLE	IF	CITATIONS
574	What are the drugs having potential against COVID-19?. Medicinal Chemistry Research, 2020, 29, 1935-1955.	1.1	8
575	COVID-19-related organ dysfunction and management strategies on the intensive care unit: a narrative review. British Journal of Anaesthesia, 2020, 125, 912-925.	1.5	36
576	Management of pregnancy-related hypertensive disorders in patients infected with SARS CoV-2: pharmacological and clinical issues. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 346-351.	1.4	3
577	SARS-CoV-2/COVID-19: Evolving Reality, Global Response, Knowledge Gaps, and Opportunities. Shock, 2020, 54, 416-437.	1.0	41
578	Pathophysiology and treatment strategies for COVID-19. Journal of Translational Medicine, 2020, 18, 353.	1.8	71
579	The New Coronavirus COVID-19 Infection. Molecular Genetics, Microbiology and Virology, 2020, 35, 53-60.	0.0	6
580	Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives. Frontiers in Pharmacology, 2020, 11, 572870.	1.6	72
581	Crosstalk between coronavirus disease 2019 and cardiovascular disease and its treatment. ESC Heart Failure, 2020, 7, 3464-3472.	1.4	19
582	Feasibility and Efficacy of Cardiopulmonary Rehabilitation After COVID-19. American Journal of Physical Medicine and Rehabilitation, 2020, 99, 865-869.	0.7	88
583	Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE) Tj ETQq1 1 0.784314 rgBT /Over	1.0	15
584	Clinical, laboratory and radiological characteristics and outcomes of novel coronavirus (SARS-CoV-2) infection in humans: A systematic review and series of meta-analyses. PLoS ONE, 2020, 15, e0239235.	1.1	61
585	Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients. Cancer Medicine, 2020, 9, 8571-8578.	1.3	43
586	In Silico Drug Repurposing for SARS-CoV-2 Main Proteinase and Spike Proteins. Journal of Proteome Research, 2020, 19, 4637-4648.	1.8	50
587	Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltration with nafamostat mesylate. Journal of Infection and Chemotherapy, 2020, 26, 1319-1323.	0.8	10
588	Remdesivir, a remedy or a ripple in severe COVID-19?. Expert Opinion on Investigational Drugs, 2020, 29, 1195-1198.	1.9	9
589	Acute kidney injury and kidney replacement therapy in COVID-19: a systematic review and meta-analysis. CKJ: Clinical Kidney Journal, 2020, 13, 550-563.	1.4	75
590	The Dual Role of Echocardiography in the Diagnosis of Acute Cardiac Complications and Treatment Monitoring for Coronavirus Disease 2019 (COVID-19). Frontiers in Cardiovascular Medicine, 2020, 7, 129.	1.1	14
591	Does Lithium Deserve a Place in the Treatment Against COVID-19? A Preliminary Observational Study in Six Patients, Case Report. Frontiers in Pharmacology, 2020, 11, 557629.	1.6	23

#	ARTICLE	IF	CITATIONS
592	Compassionate use of convalescent plasma for treatment of moderate and severe pneumonia in COVID-19 patients and association with IgG antibody levels in donated plasma. <i>EClinicalMedicine</i> , 2020, 26, 100525.	3.2	64
593	Challenges in the Management of Sickle Cell Disease During SARS-CoV-2 Pandemic. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962095524.	0.7	11
595	Possible Retinal Impairment Secondary to Ritonavir Use in SARS-CoV-2 Patients: A Narrative Systematic Review. <i>Journal of Ophthalmology</i> , 2020, 2020, 1-7.	0.6	5
596	Methodological Issues and Controversies in COVID-19 Coagulopathy: A Tale of Two Storms. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962094539.	0.7	5
597	Genetic and pathogenic characterization of SARS-CoV-2: a review. <i>Future Virology</i> , 2020, 15, 533-549.	0.9	13
598	The New Coronavirus (SARS-CoV-2): A Comprehensive Review on Immunity and the Application of Bioinformatics and Molecular Modeling to the Discovery of Potential Anti-SARS-CoV-2 Agents. <i>Molecules</i> , 2020, 25, 4086.	1.7	9
599	It Takes a Village. <i>Chest</i> , 2020, 158, 2414-2424.	0.4	33
600	COVID-19: an update and cardiac involvement. <i>Journal of Cardiothoracic Surgery</i> , 2020, 15, 239.	0.4	10
601	Response to the Novel Corona Virus (COVID-19) Pandemic Across Africa: Successes, Challenges, and Implications for the Future. <i>Frontiers in Pharmacology</i> , 2020, 11, 1205.	1.6	143
602	Comparative Antiviral Efficacy of Viral Protease Inhibitors against the Novel SARS-CoV-2 In Vitro. <i>Virologica Sinica</i> , 2020, 35, 776-784.	1.2	24
603	Is a step-down antiretroviral therapy necessary to fight severe acute respiratory syndrome coronavirus 2 in HIV-infected patients?. <i>Aids</i> , 2020, 34, 1865-1867.	1.0	3
604	The HMOX1 Pathway as a Promising Target for the Treatment and Prevention of SARS-CoV-2 of 2019 (COVID-19). <i>International Journal of Molecular Sciences</i> , 2020, 21, 6412.	1.8	28
605	Predictive Value of 5 Early Warning Scores for Critical COVID-19 Patients. <i>Disaster Medicine and Public Health Preparedness</i> , 2020, , 1-8.	0.7	38
606	Improvement of Severe COVID-19 in an Elderly Man by Sequential Use of Antiviral Drugs. <i>Case Reports in Infectious Diseases</i> , 2020, 2020, 1-4.	0.2	1
607	Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy. , 2020, 8, e001089.		72
608	Directly Acting Antivirals for COVID-19: Where Do We Stand?. <i>Frontiers in Microbiology</i> , 2020, 11, 1857.	1.5	18
609	Therapeutic Strategies in the Development of Anti-viral Drugs and Vaccines Against SARS-CoV-2 Infection. <i>Molecular Neurobiology</i> , 2020, 57, 4856-4877.	1.9	26
610	COVID-19 Pandemic: from Molecular Biology, Pathogenesis, Detection, and Treatment to Global Societal Impact. <i>Current Pharmacology Reports</i> , 2020, 6, 212-227.	1.5	31

#	ARTICLE	IF	CITATIONS
611	Expert Consensus for Treating Cancer Patients During the Pandemic of SARS-CoV-2. <i>Frontiers in Oncology</i> , 2020, 10, 1555.	1.3	5
612	COVID-19 Therapeutic Options Under Investigation. <i>Frontiers in Pharmacology</i> , 2020, 11, 1196.	1.6	65
613	Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19. <i>Frontiers in Pharmacology</i> , 2020, 11, 1258.	1.6	91
614	Natural products as home-based prophylactic and symptom management agents in the setting of COVID-19. <i>Phytotherapy Research</i> , 2020, 34, 3148-3167.	2.8	60
615	Accumulated Clinical Experiences from Successful Treatment of 1377 Severe and Critically Ill COVID-19 Cases. <i>Current Medical Science</i> , 2020, 40, 597-601.	0.7	6
616	Is there any potential management against COVID-19? A systematic review and meta-analysis. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2020, 28, 765-777.	0.9	13
617	Gastrointestinal and liver involvement in patients with COVID-19. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 798-799.	3.7	6
618	An <i>in silico</i> perception for newly isolated flavonoids from peach fruit as privileged avenue for a countermeasure outbreak of COVID-19. <i>RSC Advances</i> , 2020, 10, 29983-29998.	1.7	22
619	The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3366-3372.	1.3	81
620	Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3379-3385.	1.3	95
621	Evaluation of Coronavirus Disease 2019 Severity Using Urine Biomarkers. , 2020, 2, e0170.		20
622	Efficacy of various treatment modalities for nCoV-2019: A systematic review and meta-analysis. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13383.	1.7	18
623	Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1544-1549.	0.5	173
624	Hydroxychloroquine use in COVID-19: is the risk of cardiovascular toxicity justified?. <i>Open Heart</i> , 2020, 7, e001362.	0.9	21
625	Oxytocin's anti-inflammatory and proimmune functions in COVID-19: a transcriptomic signature-based approach. <i>Physiological Genomics</i> , 2020, 52, 401-407.	1.0	31
626	Tocilizumab and steroid treatment in patients with COVID-19 pneumonia. <i>PLoS ONE</i> , 2020, 15, e0237831.	1.1	85
627	Analysis of Risk Factors on Readmission Cases of COVID-19 in the Republic of Korea: Using Nationwide Health Claims Data. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 5844.	1.2	42
628	Pharmacological treatments of COVID-19. <i>Pharmacological Reports</i> , 2020, 72, 1446-1478.	1.5	35

#	ARTICLE	IF	CITATIONS
629	Coinfection With HIV and SARS-CoV-2 in Wuhan, China: A 12-Person Case Series. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 85, 1-5.	0.9	15
630	Macrophage activation syndrome and COVID-19. <i>Inflammation and Regeneration</i> , 2020, 40, 19.	1.5	94
631	Progress in Developing Inhibitors of SARS-CoV-2 3C-Like Protease. <i>Microorganisms</i> , 2020, 8, 1250.	1.6	90
632	Novel Antiviral Strategies in the Treatment of COVID-19: A Review. <i>Microorganisms</i> , 2020, 8, 1259.	1.6	14
633	SARS-CoV-2 ORF8 and SARS-CoV ORF8ab: Genomic Divergence and Functional Convergence. <i>Pathogens</i> , 2020, 9, 677.	1.2	44
634	A Narrative Review of Emerging Therapeutics for COVID-19. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2020, 4, 745-758.	1.2	7
635	COVID-19 pandemic: How close are we for an effective therapy?. <i>Journal of Biomedical Sciences</i> , 2020, 7, 1-3.	0.5	5
636	Repositioning of Ligands That Target the Spike Glycoprotein as Potential Drugs for SARS-CoV-2 in an In Silico Study. <i>Molecules</i> , 2020, 25, 5615.	1.7	15
637	Nano-Biomimetic Drug Delivery Vehicles: Potential Approaches for COVID-19 Treatment. <i>Molecules</i> , 2020, 25, 5952.	1.7	29
638	Taming the Autophagy as a Strategy for Treating COVID-19. <i>Cells</i> , 2020, 9, 2679.	1.8	52
639	Development of vaccines and antivirals for combating viral pandemics. <i>Nature Biomedical Engineering</i> , 2020, 4, 1128-1133.	11.6	66
640	High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment. <i>Scientific Reports</i> , 2020, 10, 20958.	1.6	15
641	Blockage of interleukin-1 β with canakinumab in patients with Covid-19. <i>Scientific Reports</i> , 2020, 10, 21775.	1.6	58
642	Ten Epidemiological Parameters of COVID-19: Use of Rapid Literature Review to Inform Predictive Models During the Pandemic. <i>Frontiers in Public Health</i> , 2020, 8, 598547.	1.3	16
643	Structure-Based Virtual Screening and Biochemical Validation to Discover a Potential Inhibitor of the SARS-CoV-2 Main Protease. <i>ACS Omega</i> , 2020, 5, 33151-33161.	1.6	27
644	A systematic review assessing the under-representation of elderly adults in COVID-19 trials. <i>BMC Geriatrics</i> , 2020, 20, 538.	1.1	38
645	A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs. <i>Frontiers in Pharmacology</i> , 2020, 11, 584956.	1.6	51
646	Rationale for COVID-19 Treatment by Nebulized Interferon- β : Literature Review and Personal Preliminary Experience. <i>Frontiers in Pharmacology</i> , 2020, 11, 592543.	1.6	11

#	ARTICLE	IF	CITATIONS
647	1-Phenyl-N-(benzothiazol-2-yl)methanimine derivatives as Middle East respiratory syndrome coronavirus inhibitors. <i>RSC Advances</i> , 2020, 10, 43299-43311.	1.7	0
648	Pharmacotherapy of Acute COVID-19 Infection and Multisystem Inflammatory Syndrome in Children: Current State of Knowledge. <i>Pediatric, Allergy, Immunology, and Pulmonology</i> , 2020, 33, 177-189.	0.3	2
649	SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments. <i>Frontiers in Immunology</i> , 2020, 11, 569760.	2.2	30
650	The Need for Antiviral Drugs for Pandemic Coronaviruses From a Global Health Perspective. <i>Frontiers in Medicine</i> , 2020, 7, 596587.	1.2	12
651	Recent Progress in the Drug Development Targeting SARS-CoV-2 Main Protease as Treatment for COVID-19. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 616341.	1.6	83
652	Ethical Challenges in Health Care Policy during COVID-19 Pandemic in Italy. <i>Medicina (Lithuania)</i> , 2020, 56, 691.	0.8	17
653	Investigating the interaction between nifedipine and ritonavir containing antiviral regimens: A physiologically based pharmacokinetic/pharmacodynamic analysis. <i>British Journal of Clinical Pharmacology</i> , 2020, 87, 2790-2806.	1.1	10
654	Trials of treatments for COVID-19: Review of drugs are tested. <i>Journal of Physics: Conference Series</i> , 2020, 1664, 012086.	0.3	1
655	Incidence of Suspected Serious Adverse Drug Reactions in Corona Virus Disease-19 Patients Detected by a Pharmacovigilance Program by Laboratory Signals in a Tertiary Hospital in Spain: Cautionary Data. <i>Frontiers in Pharmacology</i> , 2020, 11, 602841.	1.6	18
656	Computational Prediction of Potential Inhibitors of the Main Protease of SARS-CoV-2. <i>Frontiers in Chemistry</i> , 2020, 8, 590263.	1.8	24
657	Sharing CD4+ T Cell Loss: When COVID-19 and HIV Collide on Immune System. <i>Frontiers in Immunology</i> , 2020, 11, 596631.	2.2	79
658	Case Report: Famotidine for Neuropsychiatric Symptoms in COVID-19. <i>Frontiers in Medicine</i> , 2020, 7, 614393.	1.2	3
659	Molecular Docking Studies on the Anti-viral Effects of Compounds From Kabasura Kudineer on SARS-CoV-2 3CLpro. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 613401.	1.6	42
660	COVID-19 and dermatology. <i>Turkish Journal of Medical Sciences</i> , 2020, 50, 1751-1759.	0.4	26
661	Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2021, 73, e3572-e3605.	2.9	123
662	Clinical Profile, Treatment and Predictors during the First COVID-19 Wave: A Population-Based Registry Analysis from Castile and Leon Hospitals. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 9360.	1.2	11
663	Understanding clinical decision-making during the COVID-19 pandemic: A cross-sectional worldwide survey. <i>EClinicalMedicine</i> , 2020, 27, 100539.	3.2	15
664	Liver transplant immunosuppression during the COVID-19 pandemic. <i>GastroenterologÅa Y HepatologÅa (English Edition)</i> , 2020, 43, 457-463.	0.0	3

#	ARTICLE	IF	CITATIONS
665	Reply. Journal of Allergy and Clinical Immunology, 2020, 146, 1453-1454.	1.5	1
666	Chasing COVID-19 chemotherapeutics without putting the cart before the horse. British Journal of Clinical Pharmacology, 2023, 89, 421-423.	1.1	5
667	Emerging role of artificial intelligence in therapeutics for COVID-19: a systematic review. Journal of Biomolecular Structure and Dynamics, 2022, 40, 4750-4765.	2.0	17
668	An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies. Expert Review of Anti-Infective Therapy, 2021, 19, 877-888.	2.0	184
669	COVID-19 Investigational Treatments in Use Among Hospitalized Patients Identified Through the US Coronavirus Disease 2019-Associated Hospitalization Surveillance Network, March 1- June 30, 2020. Open Forum Infectious Diseases, 2020, 7, ofaa528.	0.4	8
670	Tocilizumab Use in a Chronic Hemodialysis Patient for the Management of COVID-19-Associated Pneumonia and Acute Respiratory Distress Syndrome. Case Reports in Nephrology, 2020, 2020, 1-5.	0.2	4
671	A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study. Trials, 2020, 21, 1005.	0.7	16
672	Global strategies and effectiveness for COVID-19 prevention through contact tracing, screening, quarantine, and isolation: a systematic review. Tropical Medicine and Health, 2020, 48, 91.	1.0	113
673	Pathophysiology of SARS-CoV-2 in Lung of Diabetic Patients. Frontiers in Physiology, 2020, 11, 587013.	1.3	12
674	Diagnosis and Management of Acute Respiratory Distress Syndrome in a Time of COVID-19. Diagnostics, 2020, 10, 1053.	1.3	13
675	Clinical and epidemiological profile of patients infected by COVID-19 at a tertiary care centre in North India. Monaldi Archives for Chest Disease, 2020, 90, .	0.3	2
676	Gender differences in treatment of Coronavirus Disease-2019. Monaldi Archives for Chest Disease, 2020, 90, .	0.3	10
677	A High-Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury. Cell Reports Medicine, 2020, 1, 100137.	3.3	56
678	First hospitalized case of laboratory-confirmed coronavirus disease 2019 (COVID-19) in Alberta, Canada. Jammi, 2020, 5, 98-103.	0.3	1
679	Potential clinically significant life-threatening drug-drug interactions of lopinavir and ritonavir used in the treatment of COVID-19. Experimental Results, 2020, 1, .	0.2	1
682	Virological and Serological Discordant Profiles in COVID-19 Pneumonia: Two Atypical Clinical Cases. Frontiers in Immunology, 2020, 11, 580867.	2.2	3
683	Coronavirus pandemic: treatment and future prevention. Future Microbiology, 2020, 15, 1507-1521.	1.0	2
684	COVID-19 Pandemic: Epidemiology, Etiology, Conventional and Non-Conventional Therapies. International Journal of Environmental Research and Public Health, 2020, 17, 8155.	1.2	63

#	ARTICLE	IF	CITATIONS
685	Current Prevention of COVID-19: Natural Products and Herbal Medicine. <i>Frontiers in Pharmacology</i> , 2020, 11, 588508.	1.6	99
686	Whether the timing of patient randomization interferes with the assessment of the efficacy of ruxolitinib for severe COVID-19. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 1453.	1.5	5
687	Accelerated Preclinical Paths to Support Rapid Development of COVID-19 Therapeutics. <i>Cell Host and Microbe</i> , 2020, 28, 638-645.	5.1	30
688	Searching for target-specific and multi-targeting organics for Covid-19 in the Drugbank database with a double scoring approach. <i>Scientific Reports</i> , 2020, 10, 19125.	1.6	47
690	The Origin, Transmission, and Clinical Therapies in the Management of Coronavirus Diseases. <i>Methods in Pharmacology and Toxicology</i> , 2020, , 25-44.	0.1	1
691	Quantum mechanical, spectroscopic and docking studies of (2E)-1-(4-aminophenyl)-3-(4-benzyloxyphenyl)-prop-2-en-1-one Chalcone derivative by density functional theory " A prospective respiratory drug. <i>Materials Today: Proceedings</i> , 2020, 50, 2816-2816.	0.9	1
692	A connectivity map-based drug repurposing study and integrative analysis of transcriptomic profiling of SARS-CoV-2 infection. <i>Infection, Genetics and Evolution</i> , 2020, 86, 104610.	1.0	25
693	Risk factors associated with disease aggravation among 126 hospitalized patients with COVID-19 in different places in China. <i>Medicine (United States)</i> , 2020, 99, e22971.	0.4	3
694	Coronavirus in human diseases: Mechanisms and advances in clinical treatment. <i>MedComm</i> , 2020, 1, 270-301.	3.1	22
695	SARS-CoV-2: A critical review of its history, pathogenesis, transmission, diagnosis and treatment. <i>Biosafety and Health</i> , 2020, 2, 217-225.	1.2	35
696	Early triple antiviral therapy for COVID-19 " Authors' reply. <i>Lancet, The</i> , 2020, 396, 1488.	6.3	5
697	Early triple antiviral therapy for COVID-19. <i>Lancet, The</i> , 2020, 396, 1487-1488.	6.3	3
698	Effect of statin therapy on SARS-CoV-2 infection-related mortality in hospitalized patients. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 157-164.	1.4	64
699	COVID-19: the epidemiology and treatment. <i>British Journal of Hospital Medicine (London, England:)</i> Tj ETQq1 1 0.784314 rgBT /Overlo	0.2	9
700	Predicting Clinical Outcome with Phenotypic Clusters in COVID-19 Pneumonia: An Analysis of 12,066 Hospitalized Patients from the Spanish Registry SEMI-COVID-19. <i>Journal of Clinical Medicine</i> , 2020, 9, 3488.	1.0	59
701	Questions and Answers on Practical Thrombotic Issues in SARS-CoV-2 Infection: A Guidance Document from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 559-570.	1.0	7
702	Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity. <i>Drugs</i> , 2020, 80, 1961-1972.	4.9	24
703	Advanced Pulmonary and Cardiac Support of COVID-19 Patients. <i>Circulation: Heart Failure</i> , 2020, 13, e007175.	1.6	39

#	ARTICLE	IF	CITATIONS
704	A current review of COVID-19 for the cardiovascular specialist. American Heart Journal, 2020, 226, 29-44.	1.2	97
705	Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2. Microbial Pathogenesis, 2020, 145, 104236.	1.3	154
706	Current targeted therapeutics against COVID-19: Based on first-line experience in China. Pharmacological Research, 2020, 157, 104854.	3.1	30
707	Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis. Pharmacological Research, 2020, 157, 104872.	3.1	81
708	Risk Factors Associated With Clinical Outcomes in 323 Coronavirus Disease 2019 (COVID-19) Hospitalized Patients in Wuhan, China. Clinical Infectious Diseases, 2020, 71, 2089-2098.	2.9	309
709	The Novel Coronavirus " Latest Findings. Microbial Biotechnology, 2020, 13, 819-828.	2.0	5
710	Medical treatment options for COVID-19. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 209-214.	0.4	39
711	The Covid-19, Epidemiology, Clinic and Prevention. Current Genomics, 2020, 21, 157-160.	0.7	7
712	New Insights of Emerging SARS-CoV-2: Epidemiology, Etiology, Clinical Features, Clinical Treatment, and Prevention. Frontiers in Cell and Developmental Biology, 2020, 8, 410.	1.8	96
713	Interdisciplinary Perspectives on Health Literacy Research Around the World: More Important Than Ever in a Time of COVID-19. International Journal of Environmental Research and Public Health, 2020, 17, 3010.	1.2	166
714	Epidemiological features after emergency declaration in Hokkaido and report of 15 cases of COVID-19 including 3 cases requiring mechanical ventilation. Global Health & Medicine, 2020, 2, 112-117.	0.6	6
715	The management of coronavirus disease 2019 (COVID-19). Journal of Medical Virology, 2020, 92, 1484-1490.	2.5	75
716	Clinical features of patients with coronavirus disease 2019 from a designated hospital in Beijing, China. Journal of Medical Virology, 2020, 92, 2055-2066.	2.5	68
717	Acute hemolysis by hydroxychloroquine was observed in G6PD-deficient patient with severe COVID-19 related lung injury. European Journal of Internal Medicine, 2020, 77, 136-137.	1.0	19
718	A Trial of Lopinavir"Ritonavir in Covid-19. New England Journal of Medicine, 2020, 382, e68.	13.9	224
719	Potential therapeutic targets and promising drugs for combating <scp>SARS-CoV-2</scp>. British Journal of Pharmacology, 2020, 177, 3147-3161.	2.7	70
720	Early experience with remdesivir in SARS-CoV-2 pneumonia. Infection, 2020, 48, 779-782.	2.3	23
721	COVID-19 " What does a paediatrician need to know?. Paediatric Respiratory Reviews, 2020, 35, 3-8.	1.2	5

#	ARTICLE	IF	CITATIONS
722	Obstetrics risk Assessment: Evaluation of selection criteria for vaccine research studies in pregnant women. <i>Vaccine</i> , 2020, 38, 4542-4547.	1.7	0
723	The Rationale for Potential Pharmacotherapy of COVID-19. <i>Pharmaceuticals</i> , 2020, 13, 96.	1.7	40
724	COVID-19. A review. <i>Monaldi Archives for Chest Disease</i> , 2020, 90, .	0.3	101
725	Emerging therapies for COVID-19 pneumonia. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 633-637.	1.9	13
726	The changing landscape of SARS-CoV-2: Implications for the maternal-infant dyad. <i>Journal of Neonatal-Perinatal Medicine</i> , 2020, 13, 293-305.	0.4	4
727	Protracted course of coronavirus disease with severe acute respiratory distress syndrome: a case report. <i>Acute Medicine & Surgery</i> , 2020, 7, e521.	0.5	6
728	COVID-19 in patients with HIV. <i>Lancet HIV</i> , 2020, 7, e383.	2.1	19
729	Old and re-purposed drugs for the treatment of COVID-19. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 843-847.	2.0	49
730	<i>Artemisia annua</i> : Trials are needed for COVID-19. <i>Phytotherapy Research</i> , 2020, 34, 2423-2424.	2.8	42
731	The liver in times of COVID-19: What hepatologists should know. <i>Annals of Hepatology</i> , 2020, 19, 353-358.	0.6	72
732	Factors associated with the duration of viral shedding in adults with COVID-19 outside of Wuhan, China: a retrospective cohort study. <i>International Journal of Infectious Diseases</i> , 2020, 96, 531-537.	1.5	106
733	Psychopharmacology of COVID-19. <i>Psychosomatics</i> , 2020, 61, 411-427.	2.5	62
734	Current scenario of COVID-19 in pediatric age group and physiology of immune and thymus response. <i>Saudi Journal of Biological Sciences</i> , 2020, 27, 2567-2573.	1.8	43
735	Early Short-Course Corticosteroids in Hospitalized Patients With COVID-19. <i>Clinical Infectious Diseases</i> , 2020, 71, 2114-2120.	2.9	322
736	Lung tissue distribution of drugs as a key factor for COVID-19 treatment. <i>British Journal of Pharmacology</i> , 2020, 177, 4995-4996.	2.7	16
737	COVID-19: An Update about the Discovery Clinical Trial. <i>Pharmaceuticals</i> , 2020, 13, 98.	1.7	10
738	Recent Insight into SARS-CoV2 Immunopathology and Rationale for Potential Treatment and Preventive Strategies in COVID-19. <i>Vaccines</i> , 2020, 8, 224.	2.1	47
739	A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19). <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2020, 393, 1137-1152.	1.4	37

#	ARTICLE	IF	CITATIONS
740	COVID-19-associated cardiovascular morbidity in older adults: a position paper from the Italian Society of Cardiovascular Researches. <i>GeroScience</i> , 2020, 42, 1021-1049.	2.1	115
741	Covid-19 Pandemic and Current Medical Interventions. <i>Archives of Medical Research</i> , 2020, 51, 473-481.	1.5	11
742	Improvisation in times of pandemic, a reason for reflection. <i>International Journal of Infectious Diseases</i> , 2020, 96, 361-362.	1.5	4
743	The effect of potential therapeutic agents on QT interval in patients with COVID-19 Infection: The importance of close monitoring and correction of electrolytes. <i>Medical Hypotheses</i> , 2020, 143, 109847.	0.8	4
744	Anti-coagulant and anti-platelet therapy in the COVID-19 patient: a best practices quality initiative across a large health system. <i>Hospital Practice (1995)</i> , 2020, 48, 169-179.	0.5	42
745	COVID-19 Clinical trials: Quality matters more than quantity. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2542-2547.	2.7	20
746	HIV and SARS-CoV-2 coinfection: A case report from Uganda. <i>Journal of Medical Virology</i> , 2020, 92, 2351-2353.	2.5	22
747	Major ongoing clinical trials for COVID-19 treatment and studies currently being conducted or scheduled in Japan. <i>Global Health & Medicine</i> , 2020, 2, 96-101.	0.6	20
748	Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines. <i>Thrombosis and Haemostasis</i> , 2020, 120, 937-948.	1.8	294
749	Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. <i>Cell Discovery</i> , 2020, 6, 31.	3.1	644
750	Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 215-221.	0.4	105
751	Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines. <i>Military Medical Research</i> , 2020, 7, 22.	1.9	57
752	Clinical trials on drug repositioning for COVID-19 treatment. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2020, 44, 1.	0.6	296
753	Potential Cytoprotective Activity of Ozone Therapy in SARS-CoV-2/COVID-19. <i>Antioxidants</i> , 2020, 9, 389.	2.2	77
754	COVID-19 and Cancer: a Comprehensive Review. <i>Current Oncology Reports</i> , 2020, 22, 53.	1.8	220
755	Novel Coronavirus COVID-19. <i>Journal of Bone and Joint Surgery - Series A</i> , 2020, 102, 734-744.	1.4	106
756	A global treatments for coronaviruses including COVID-19. <i>Journal of Cellular Physiology</i> , 2020, 235, 9133-9142.	2.0	91
757	Patient follow-up after discharge after COVID-19 pneumonia: Considerations for infectious control. <i>Journal of Medical Virology</i> , 2020, 92, 2412-2419.	2.5	32

#	ARTICLE	IF	CITATIONS
758	Triple combination of interferon beta-1b, lopinavirâ€“ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. <i>Lancet</i> , The, 2020, 395, 1695-1704.	6.3	1,244
759	Convalescent plasma in Covid-19: Possible mechanisms of action. <i>Autoimmunity Reviews</i> , 2020, 19, 102554.	2.5	401
760	La pandemia COVID-19 y el cirujano cardiovascular en EspaÃ±a: lecciones aprendidas. <i>Cirugia Cardiovascular</i> , 2020, 27, 37-38.	0.1	0
761	Urgent need for evaluating agonists of angiotensin-(1-7)/Mas receptor axis for treating patients with COVID-19. <i>International Journal of Infectious Diseases</i> , 2020, 96, 348-351.	1.5	33
762	Current development of COVID-19 diagnostics, vaccines and therapeutics. <i>Microbes and Infection</i> , 2020, 22, 231-235.	1.0	44
763	COVID-19: Living through Another Pandemic. <i>ACS Infectious Diseases</i> , 2020, 6, 1548-1552.	1.8	38
764	Severe Acute Respiratory Syndrome Coronavirus 2: Genomic Observations and Emerging Therapies. <i>Pediatric, Allergy, Immunology, and Pulmonology</i> , 2020, 33, 49-52.	0.3	1
765	Early experience of COVID-19 in 2 heart transplant recipients: Case reports and review of treatment options. <i>American Journal of Transplantation</i> , 2020, 20, 2916-2922.	2.6	41
766	Atrial Arrhythmias in a Patient Presenting With Coronavirus Disease-2019 (COVID-19) Infection. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2020, 8, 232470962092557.	0.3	45
767	Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project). <i>Systematic Reviews</i> , 2020, 9, 108.	2.5	40
768	Coronavirus Pandemicâ€“Therapy and Vaccines. <i>Biomedicines</i> , 2020, 8, 109.	1.4	42
769	Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill COVID-19 patients: compassionate-use case series. <i>Basic Research in Cardiology</i> , 2020, 115, 36.	2.5	44
770	Covid-19 and drug therapy, what we learned. <i>International Journal of Clinical Pharmacy</i> , 2020, 42, 833-836.	1.0	11
771	COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients. <i>Infection</i> , 2020, 48, 681-686.	2.3	191
772	Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e325-e331.	2.2	808
773	Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids. <i>International Immunopharmacology</i> , 2020, 84, 106560.	1.7	143
774	Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 89-100.	1.5	269
775	Sample sizes in COVID-19â€“related research. <i>Cmaj</i> , 2020, 192, E461-E461.	0.9	3

#	ARTICLE	IF	CITATIONS
776	An Update on Current Therapeutic Drugs Treating COVID-19. <i>Current Pharmacology Reports</i> , 2020, 6, 56-70.	1.5	438
777	Novel coronavirus (COVID-19) infection: What a doctor on the frontline needs to know. <i>Annals of Medicine and Surgery</i> , 2020, 55, 24-29.	0.5	15
778	The Topic of COVID-19-Related Liver Injury Needs More Rigorous Research. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2848.	2.4	3
779	Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection. <i>Medical Hypotheses</i> , 2020, 142, 109783.	0.8	41
780	Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?. <i>Medical Hypotheses</i> , 2020, 142, 109815.	0.8	131
781	Does lopinavir really inhibit SARS-CoV-2?. <i>Pharmacological Research</i> , 2020, 158, 104898.	3.1	29
782	Tomar o no tomar "decisiones en caliente" respecto al tratamiento de la infección por SARS-CoV-2. <i>Revista Clinica Espanola</i> , 2020, 220, 461-462.	0.2	2
784	"Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. <i>Therapie</i> , 2020, 75, 371-379.	0.6	97
785	AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19. <i>Gastroenterology</i> , 2020, 159, 320-334.e27.	0.6	330
786	Drug repurposing against COVID-19: focus on anticancer agents. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 86.	3.5	57
787	A Collaborative Multidisciplinary Approach to the Management of Coronavirus Disease 2019 in the Hospital Setting. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1467-1481.	1.4	21
788	SARS-CoV-2 Infection and COVID-19 During Pregnancy: A Multidisciplinary Review. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1750-1765.	1.4	175
789	Clinical Characteristics and Outcomes in People Living With Human Immunodeficiency Virus Hospitalized for Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2020, 71, 2294-2297.	2.9	111
790	Why not to use colchicine in COVID-19? An old anti-inflammatory drug for a novel auto-inflammatory disease. <i>Rheumatology</i> , 2020, 59, 1769-1770.	0.9	18
791	Advanced Pulmonary and Cardiac Support of COVID-19 Patients: Emerging Recommendations From ASAIO "A Living Working Document". <i>ASAIO Journal</i> , 2020, 66, 588-598.	0.9	46
792	Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines. <i>Biomedical Journal</i> , 2020, 43, 341-354.	1.4	81
793	Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?. <i>Journal of Microbiology, Immunology and Infection</i> , 2020, 53, 674-675.	1.5	30
794	Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a Promising Therapeutic Option for COVID-19?. <i>Frontiers in Pharmacology</i> , 2020, 11, 791.	1.6	16

#	ARTICLE	IF	CITATIONS
795	Tocilizumab challenge: A series of cytokine storm therapy experiences in hospitalized COVID-19 pneumonia patients. <i>Journal of Medical Virology</i> , 2020, 92, 2648-2656.	2.5	34
796	Overview: The history and pediatric perspectives of severe acute respiratory syndromes: Novel or just like SARS. <i>Pediatric Pulmonology</i> , 2020, 55, 1584-1591.	1.0	25
797	Data Monitoring for the Chinese Clinical Trials of Remdesivir in Treating Patients with COVID-19 During the Pandemic Crisis. <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 1236-1255.	0.8	9
798	Lack of antiviral activity of darunavir against SARS-CoV-2. <i>International Journal of Infectious Diseases</i> , 2020, 97, 7-10.	1.5	108
800	Discovery of New Hydroxyethylamine Analogs against 3CL ^{pro} Protein Target of SARS-CoV-2: Molecular Docking, Molecular Dynamics Simulation, and Structure-Activity Relationship Studies. <i>Journal of Chemical Information and Modeling</i> , 2020, 60, 5754-5770.	2.5	92
801	Quest for a COVID-19 Cure by Repurposing Small-Molecule Drugs: Mechanism of Action, Clinical Development, Synthesis at Scale, and Outlook for Supply. <i>Organic Process Research and Development</i> , 2020, 24, 940-976.	1.3	77
802	Antimicrobial use, drug-resistant infections and COVID-19. <i>Nature Reviews Microbiology</i> , 2020, 18, 409-410.	13.6	177
803	Efficacy and safety of Chinese herbal medicine for Coronavirus disease 2019. <i>Medicine (United States)</i> , 2020, 99, e20157.	0.4	4
804	May Polyphenols Have a Role Against Coronavirus Infection? An Overview of in vitro Evidence. <i>Frontiers in Medicine</i> , 2020, 7, 240.	1.2	69
805	SARS-CoV-2: A comprehensive review from pathogenicity of the virus to clinical consequences. <i>Journal of Medical Virology</i> , 2020, 92, 1864-1874.	2.5	93
806	Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: A retrospective study in two designated hospitals in Anhui, China. <i>Journal of Medical Virology</i> , 2020, 92, 2666-2674.	2.5	44
807	COVID-19 patients benefit from early antiviral treatment: A comparative, retrospective study. <i>Journal of Medical Virology</i> , 2020, 92, 2675-2683.	2.5	7
809	Cancer and COVID-19: Unmasking their ties. <i>Cancer Treatment Reviews</i> , 2020, 88, 102041.	3.4	82
810	Pulmonary delivery of nanostructured lipid carriers for effective repurposing of salinomycin as an antiviral agent. <i>Medical Hypotheses</i> , 2020, 143, 109858.	0.8	33
811	Does lopinavir measure up in the treatment of COVID-19?. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 793-796.	1.9	6
812	Development and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic Context. <i>Frontiers in Medicine</i> , 2020, 7, 225.	1.2	171
813	Impact of COVID-19 on the Cardiovascular System: A Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 1407.	1.0	42
814	Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COVID19 REgistry (SMACORE). <i>Microorganisms</i> , 2020, 8, 695.	1.6	186

#	ARTICLE	IF	CITATIONS
815	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions. <i>Viruses</i> , 2020, 12, 526.	1.5	197
816	COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics. <i>Therapeutic Delivery</i> , 2020, 11, 245-268.	1.2	113
817	Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2. <i>Archives of Medical Science</i> , 2020, 16, 519-521.	0.4	14
818	Clinical Trials for COVID-19: Can we Better Use the Short Window of Opportunity?. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 730-733.	2.3	22
819	The quality of the reported sample size calculation in clinical trials on COVID-19 patients indexed in PubMed. <i>European Journal of Internal Medicine</i> , 2020, 77, 139-140.	1.0	5
820	Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status. <i>Pharmacological Research</i> , 2020, 158, 104899.	3.1	175
821	<i>In Silico</i> Exploration of the Molecular Mechanism of Clinically Oriented Drugs for Possibly Inhibiting SARS-CoV-2's Main Protease. <i>Journal of Physical Chemistry Letters</i> , 2020, 11, 4413-4420.	2.1	118
822	Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 717-723.	1.4	20
823	Positive detection of SARS-CoV-2 combined HSV1 and HHV6B virus nucleic acid in tear and conjunctival secretions of a non-conjunctivitis COVID-19 patient with obstruction of common lacrimal duct. <i>Acta Ophthalmologica</i> , 2020, 98, 859-863.	0.6	34
824	Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. <i>BMJ, The</i> , 2020, 369, m1844.	3.0	355
825	Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. <i>BMJ, The</i> , 2020, 369, m1849.	3.0	811
826	What every orthopaedic surgeon should know about COVID-19: A review of the current literature. <i>Journal of Orthopaedic Surgery</i> , 2020, 28, 230949902092349.	0.4	7
827	Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy). <i>Future Oncology</i> , 2020, 16, 1425-1432.	1.1	75
828	Interferon- β Treatment for COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 1061.	2.2	314
829	Clinical characteristics and drug therapies in patients with the common-type coronavirus disease 2019 in Hunan, China. <i>International Journal of Clinical Pharmacy</i> , 2020, 42, 837-845.	1.0	31
830	Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019. <i>American Journal of Cardiology</i> , 2020, 128, 147-150.	0.7	33
831	Prescribing COVID-19 treatments: what we should never forget. <i>Journal of Infection</i> , 2020, 81, e85.	1.7	2
832	The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. <i>Bone Marrow Transplantation</i> , 2020, 55, 2071-2076.	1.3	163

#	ARTICLE	IF	CITATIONS
833	COVID-19: implications for immunosuppression in kidney disease and transplantation. <i>Nature Reviews Nephrology</i> , 2020, 16, 365-367.	4.1	87
834	Compassionate Use of Remdesivir in Covid-19. <i>New England Journal of Medicine</i> , 2020, 382, e101.	13.9	126
835	Severe Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 2451-2460.	13.9	1,147
836	iBioProVis: interactive visualization and analysis of compound bioactivity space. <i>Bioinformatics</i> , 2020, 36, 4227-4230.	1.8	7
837	Risk Factors for Severe Disease and Efficacy of Treatment in Patients Infected With COVID-19: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis. <i>Clinical Infectious Diseases</i> , 2020, 71, 2199-2206.	2.9	227
838	Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2704-2706.	1.3	30
839	COVID-19: Learning from Lessons To Guide Treatment and Prevention Interventions. <i>MSphere</i> , 2020, 5, .	1.3	66
840	Coronavirus Disease 2019 (COVID-19) in Neonates and Children From China: A Review. <i>Frontiers in Pediatrics</i> , 2020, 8, 287.	0.9	37
841	Drug repurposing in the era of COVID-19: a call for leadership and government investment. <i>Medical Journal of Australia</i> , 2020, 212, 450.	0.8	14
842	Current evidence for directed and supportive investigational therapies against COVID-19. <i>African Journal of Thoracic and Critical Care Medicine</i> , 2020, 26, 45.	0.3	1
843	Interferon beta-1b for COVID-19. <i>Lancet, The</i> , 2020, 395, 1670-1671.	6.3	56
844	Use of herbal drugs to treat COVID-19 should be with caution. <i>Lancet, The</i> , 2020, 395, 1689-1690.	6.3	81
845	Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 667-678.	3.7	804
846	Immunology of COVID-19: Current State of the Science. <i>Immunity</i> , 2020, 52, 910-941.	6.6	1,387
847	Development of passive immunity against SARS-CoV-2 for management of immunodeficient patients—a perspective. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 58-60.	1.5	24
848	First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study. <i>American Journal of Transplantation</i> , 2020, 20, 2876-2882.	2.6	102
849	COVID-19, chronic inflammatory rheumatic disease and anti-rheumatic treatments. <i>Clinical Rheumatology</i> , 2020, 39, 2069-2075.	1.0	29
850	Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy?. <i>Internal and Emergency Medicine</i> , 2020, 15, 801-812.	1.0	57

#	ARTICLE	IF	CITATIONS
851	COVID-19: Transmission, prevention, and potential therapeutic opportunities. Clinica Chimica Acta, 2020, 508, 254-266.	0.5	629
852	Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review. Diagnostic Microbiology and Infectious Disease, 2020, 98, 115094.	0.8	293
853	Systematic analysis of acute liver injury during SARS-CoV-2 infection. Digestive and Liver Disease, 2020, 52, 953-955.	0.4	4
854	COVID-19 treatments, QT interval, and arrhythmic risk: The need for an international registry on arrhythmias. Heart Rhythm, 2020, 17, 1423-1424.	0.3	12
855	Difficulty of downscaling the precautions for coronavirus disease-19 based on negative throat polymerase chain results in the early phase of infection. Journal of Infection and Chemotherapy, 2020, 26, 851-853.	0.8	1
856	Considerations for the outpatient practice in pediatric surgery during the novel SARS-CoV-2 pandemic. Journal of Pediatric Surgery, 2020, 55, 1169-1170.	0.8	2
857	Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients. , 2020, 213, 107587.		216
858	A review of potential treatments to date in COVID-19 patients according to the stage of the disease. Current Research in Translational Medicine, 2020, 68, 93-104.	1.2	18
860	Nature as a treasure trove of potential anti-SARS-CoV drug leads: a structural/mechanistic rationale. RSC Advances, 2020, 10, 19790-19802.	1.7	71
861	A Case Series of Five People Living with HIV Hospitalized with COVID-19 in Chicago, Illinois. AIDS Patient Care and STDs, 2020, 34, 331-335.	1.1	52
862	Liver injury in COVID-19: The current evidence. United European Gastroenterology Journal, 2020, 8, 509-519.	1.6	182
863	Awake prone positioning for non-intubated oxygen dependent COVID-19 pneumonia patients. European Respiratory Journal, 2020, 56, 2001198.	3.1	79
864	Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Additional Benefit. AAPS Journal, 2020, 22, 77.	2.2	98
865	HIV and SARS-Coronavirus-2 Epidemics: Possible Interactions and Need for Studies, Especially in Africa. Frontiers in Medicine, 2020, 7, 216.	1.2	6
866	The Exponential Phase of the Covid-19 Pandemic in Central Italy: An Integrated Care Pathway. International Journal of Environmental Research and Public Health, 2020, 17, 3792.	1.2	46
867	Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment in COVID-19. International Journal of Molecular Sciences, 2020, 21, 3812.	1.8	23
868	A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19). Pharmacological Research, 2020, 158, 104929.	3.1	95
869	Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008688.	2.1	17

#	ARTICLE	IF	CITATIONS
870	Potential specific therapies in COVID-19. <i>Therapeutic Advances in Respiratory Disease</i> , 2020, 14, 175346662092685.	1.0	18
871	The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19â€“infected patients. <i>Blood</i> , 2020, 135, 1912-1915.	0.6	253
872	Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection. <i>European Respiratory Journal</i> , 2020, 56, 2000799.	3.1	140
873	Use of anakinra in severe COVID-19: A case report. <i>International Journal of Infectious Diseases</i> , 2020, 96, 607-609.	1.5	58
874	Management of heart failure patients with <scp>COVID</scp>â€“19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 941-956.	2.9	95
875	A Comprehensive Updated Review on SARSâ€“CoVâ€“2 and COVIDâ€“19. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 954-975.	1.0	14
876	<scp>COVID</scp>â€“19: a brief history and treatments in development. <i>The Prescriber</i> , 2020, 31, 23-28.	0.1	35
877	Navigating COVID-19 in the developing world. <i>Clinical Rheumatology</i> , 2020, 39, 2039-2042.	1.0	10
878	Treatment algorithm for COVID-19: a multidisciplinary point of view. <i>Clinical Rheumatology</i> , 2020, 39, 2077-2084.	1.0	38
879	Genetic susceptibility for COVID-19â€“associated sudden cardiac death in African Americans. <i>Heart Rhythm</i> , 2020, 17, 1487-1492.	0.3	71
880	Predisposition or Protection?. <i>JACC: Case Reports</i> , 2020, 2, 1337-1341.	0.3	16
881	Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 137-146.e3.	1.5	374
882	Co-infections in people with COVID-19: a systematic review and meta-analysis. <i>Journal of Infection</i> , 2020, 81, 266-275.	1.7	1,114
883	Crushing lopinavir-ritonavir tablets may decrease the efficacy of therapy in COVID-19 patients. <i>Travel Medicine and Infectious Disease</i> , 2020, 38, 101749.	1.5	4
884	Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 1827-1837.	13.9	1,152
885	Hospitalized Patients With COVID-19 and Human Immunodeficiency Virus: A Case Series. <i>Clinical Infectious Diseases</i> , 2020, 71, 2021-2022.	2.9	69
886	Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19. <i>National Science Review</i> , 2020, 7, 1428-1436.	4.6	73
887	Nonâ€“steroidal antiâ€“inflammatory drugs in management of COVIDâ€“19; A systematic review on current evidence. <i>International Journal of Clinical Practice</i> , 2020, 74, e13557.	0.8	51

#	ARTICLE	IF	CITATIONS
888	COVID-19 in an HIV-positive kidney transplant recipient. <i>Transplant Infectious Disease</i> , 2020, 22, e13338.	0.7	31
889	COVID-19 in solid organ transplant recipients: a single-center experience. <i>Transplant International</i> , 2020, 33, 1099-1105.	0.8	71
890	COVID-19 and Spine Surgery: A Review and Evolving Recommendations. <i>Global Spine Journal</i> , 2020, 10, 528-533.	1.2	21
891	Fighting the Host Reaction to SARS-CoV-2 in Critically Ill Patients: The Possible Contribution of Off-Label Drugs. <i>Frontiers in Immunology</i> , 2020, 11, 1201.	2.2	15
892	Lung Surfactant for Pulmonary Barrier Restoration in Patients With COVID-19 Pneumonia. <i>Frontiers in Medicine</i> , 2020, 7, 254.	1.2	70
893	COVID-19: Emergence, Spread, Possible Treatments, and Global Burden. <i>Frontiers in Public Health</i> , 2020, 8, 216.	1.3	168
894	Research Progress of Coronavirus Based on Bibliometric Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 3766.	1.2	53
895	Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3793.	1.8	123
896	Computational Determination of Potential Inhibitors of SARS-CoV-2 Main Protease. <i>Journal of Chemical Information and Modeling</i> , 2020, 60, 5771-5780.	2.5	118
897	Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype?. <i>Autophagy</i> , 2020, 16, 2267-2270.	4.3	18
898	Should cyclosporine be useful in renal transplant recipients affected by SARS-CoV-2?. <i>American Journal of Transplantation</i> , 2020, 20, 3173-3181.	2.6	50
899	Practice considerations on the use of investigational anti-COVID-19 medications: Dosage, administration and monitoring. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 1199-1205.	0.7	10
900	Abnormal liver function tests predict transfer to intensive care unit and death in COVID-19. <i>Liver International</i> , 2020, 40, 2394-2406.	1.9	103
901	Clinical course and treatment efficacy of COVID-19 near Hubei Province, China: A multicentre, retrospective study. <i>Transboundary and Emerging Diseases</i> , 2020, 67, 2971-2982.	1.3	26
902	SARS-CoV-2 COVID-19 susceptibility and lung inflammatory storm by smoking and vaping. <i>Journal of Inflammation</i> , 2020, 17, 21.	1.5	73
903	Novel Coronavirus (COVID-19) Outbreak: Hope and Search for Effective Therapeutic Agent. <i>Letters in Drug Design and Discovery</i> , 2020, 17, 940-942.	0.4	6
904	Covid-19: a comprehensive review of a formidable foe and the road ahead. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 869-879.	1.0	15
905	Eyes on New Product Development. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2020, 36, 267-268.	0.6	0

#	ARTICLE	IF	CITATIONS
906	When cancer encounters COVID-19 in China: what have we suffered, experienced and learned. Japanese Journal of Clinical Oncology, 2020, 50, 712-717.	0.6	8
907	Ethical rationale for better coordination of clinical research on COVID-19. Research Ethics, 2020, 16, 1-10.	0.8	6
908	Cardiovascular Implications and Therapeutic Considerations in COVID-19 Infection. Cardiology and Therapy, 2020, 9, 293-305.	1.1	11
910	COVID-19 and Myocarditis: What Do We Know So Far?. CJC Open, 2020, 2, 278-285.	0.7	96
911	COVID-19 and the liver. Journal of Hepatology, 2020, 73, 1231-1240.	1.8	379
912	Repurposing cefuroxime for treatment of COVID-19: a scoping review of <i>in silico</i> studies. Journal of Biomolecular Structure and Dynamics, 2021, 39, 4547-4554.	2.0	35
913	Possible therapeutic agents for COVID-19: a comprehensive review. Expert Review of Anti-Infective Therapy, 2020, 18, 1005-1020.	2.0	24
914	A compendium answering 150 questions on COVID-19 and SARS-CoV-2. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2503-2541.	2.7	95
915	COVID19 inhibitors: A prospective therapeutics. Bioorganic Chemistry, 2020, 101, 104027.	2.0	22
916	COVID-19: What you need to know. Gene Reports, 2020, 20, 100756.	0.4	13
917	The Effects of ARBs, ACEIs, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents. Journal of the American Medical Directors Association, 2020, 21, 909-914.e2.	1.2	145
918	Are black and Hispanic persons disproportionately affected by COVID-19 because of higher obesity rates?. Surgery for Obesity and Related Diseases, 2020, 16, 1096-1099.	1.0	47
919	Innovative highlights of clinical drug trial design. Translational Research, 2020, 224, 71-77.	2.2	11
920	Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Research, 2020, 30, 678-692.	5.7	662
921	COVID-19 Drug Treatment in China. Current Pharmacology Reports, 2020, 6, 146-154.	1.5	14
922	The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19. Cytokine and Growth Factor Reviews, 2020, 54, 51-61.	3.2	84
923	Current Status of COVID-19 Therapies and Drug Repositioning Applications. IScience, 2020, 23, 101303.	1.9	77
924	Clinical characteristics of the coronavirus disease 2019 (COVID-19) outbreak on a cruise ship. Journal of Infection and Chemotherapy, 2020, 26, 1177-1180.	0.8	16

#	ARTICLE	IF	CITATIONS
925	Nanotechnology for COVID-19: Therapeutics and Vaccine Research. ACS Nano, 2020, 14, 7760-7782.	7.3	289
926	Clinical Management of Critical COVID-19 Patients: Insights from the Literature and "On the Field" Experience. Journal of Neuroanaesthesiology and Critical Care, 2020, 07, 054-061.	0.1	2
927	Drug repurposing against SARS-CoV-2 using E-pharmacophore based virtual screening, molecular docking and molecular dynamics with main protease as the target. Journal of Biomolecular Structure and Dynamics, 2021, 39, 4647-4658.	2.0	62
928	Involvement of digestive system in COVID-19: manifestations, pathology, management and challenges. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482093462.	1.4	48
929	Coronaviruses and SARS-CoV-2: A Brief Overview. Anesthesia and Analgesia, 2020, 131, 93-96.	1.1	238
930	nCOVID-19 Pandemic: From Molecular Pathogenesis to Potential Investigational Therapeutics. Frontiers in Cell and Developmental Biology, 2020, 8, 616.	1.8	56
931	Tackling SARS-CoV-2: proposed targets and repurposed drugs. Future Medicinal Chemistry, 2020, 12, 1579-1601.	1.1	46
932	The Impact of the COVID-19 "Infodemic" on Drug-Utilization Behaviors: Implications for Pharmacovigilance. Drug Safety, 2020, 43, 699-709.	1.4	56
933	SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management. Biochemical Pharmacology, 2020, 178, 114114.	2.0	89
934	Clinical characteristics and management of a liver transplanted patient admitted with SARS-CoV-2 infection. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, e141-e144.	0.7	4
935	A narrative literature review on traditional medicine options for treatment of corona virus disease 2019 (COVID-19). Complementary Therapies in Clinical Practice, 2020, 40, 101214.	0.7	107
936	Current and future therapeutical approaches for COVID-19. Drug Discovery Today, 2020, 25, 1545-1552.	3.2	15
937	Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort study. EClinicalMedicine, 2020, 24, 100418.	3.2	148
938	The pivotal role of pharmacists during the 2019 coronavirus pandemic. Journal of the American Pharmacists Association: JAPhA, 2020, 60, e73-e75.	0.7	14
939	Mitochondria and microbiota dysfunction in COVID-19 pathogenesis. Mitochondrion, 2020, 54, 1-7.	1.6	245
940	COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking. Virus Research, 2020, 286, 198070.	1.1	107
941	Targeting SARS-COV-2 non-structural protein 16: a virtual drug repurposing study. Journal of Biomolecular Structure and Dynamics, 2021, 39, 4633-4646.	2.0	53
942	SARS-CoV-2 infection in kidney transplant recipients: Experience of the italian marche region. Transplant Infectious Disease, 2020, 22, e13377.	0.7	22

#	ARTICLE	IF	CITATIONS
943	Structure-based drug designing and immunoinformatics approach for SARS-CoV-2. <i>Science Advances</i> , 2020, 6, eabb8097.	4.7	138
944	Clinical characteristics of acute respiratory syndrome with SARS-CoV-2 infection in children in South China. <i>Pediatric Pulmonology</i> , 2020, 55, 2419-2426.	1.0	22
945	Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment. <i>Drug Safety</i> , 2020, 43, 809-821.	1.4	49
946	Tocilizumab in patients with severe COVID-19: a retrospective cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e474-e484.	2.2	772
947	Persistent Viral Presence Determines the Clinical Course of the Disease in COVID-19. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2585-2591.e1.	2.0	34
948	Is there any supportive evidence for low dose radiotherapy for COVID-19 pneumonia?. <i>International Journal of Radiation Biology</i> , 2020, 96, 1228-1235.	1.0	21
949	Guideline for the management of COVID-19 patients during hospital admission in a non-intensive care setting. <i>European Clinical Respiratory Journal</i> , 2020, 7, 1761677.	0.7	26
950	Rationale and Design of ORCHID: A Randomized Placebo-controlled Clinical Trial of Hydroxychloroquine for Adults Hospitalized with COVID-19. <i>Annals of the American Thoracic Society</i> , 2020, 17, 1144-1153.	1.5	24
951	A Review on SARS-CoV-2 Virology, Pathophysiology, Animal Models, and Anti-Viral Interventions. <i>Pathogens</i> , 2020, 9, 426.	1.2	47
952	COVID-19 in teriflunomide-treated patients with multiple sclerosis. <i>Journal of Neurology</i> , 2020, 267, 2790-2796.	1.8	56
953	Fragment tailoring strategy to design novel chemical entities as potential binders of novel corona virus main protease. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 3733-3746.	2.0	39
954	Virus, veritas, vita. <i>Postgraduate Medical Journal</i> , 2020, 96, 371-372.	0.9	1
955	SARS-CoV-2 and COVID-19: From the Bench to the Bedside. <i>Physiological Reviews</i> , 2020, 100, 1455-1466.	13.1	116
956	Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis. <i>Cmaj</i> , 2020, 192, E734-E744.	0.9	60
957	Implications of COVID-19 in pediatric rheumatology. <i>Rheumatology International</i> , 2020, 40, 1193-1213.	1.5	35
958	Anakinra for severe forms of COVID-19: a cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e393-e400.	2.2	526
959	SARS-CoV-2 Infection and Cardiovascular Disease: COVID-19 Heart. <i>Heart Lung and Circulation</i> , 2020, 29, 973-987.	0.2	136
960	Aberrant hyperactivation of cytotoxic T-cell as a potential determinant of COVID-19 severity. <i>International Journal of Infectious Diseases</i> , 2020, 97, 313-321.	1.5	77

#	ARTICLE	IF	CITATIONS
961	Clinical update on COVID-19 in pregnancy: A review article. Journal of Obstetrics and Gynaecology Research, 2020, 46, 1235-1245.	0.6	92
962	Acute Coronary Syndromes and Covid-19: Exploring the Uncertainties. Journal of Clinical Medicine, 2020, 9, 1683.	1.0	82
963	COVID-19: Current Knowledge and Best Practices for Orthopaedic Surgeons. Indian Journal of Orthopaedics, 2020, 54, 411-425.	0.5	36
964	A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir. European Journal of Medicinal Chemistry, 2020, 201, 112527.	2.6	85
965	Potential therapeutic agents against COVID-19: What we know so far. Journal of the Chinese Medical Association, 2020, 83, 534-536.	0.6	153
966	Efficacy and safety of Lian-Hua Qing-Wen granule for COVID-2019. Medicine (United States), 2020, 99, e20203.	0.4	7
967	SARS-CoV-2 infection in a highly experienced person living with HIV. Aids, 2020, 34, 1257-1258.	1.0	9
968	An Early Test-and-Treat Strategy for Severe Acute Respiratory Syndrome Coronavirus 2. Open Forum Infectious Diseases, 2020, 7, ofaa232.	0.4	16
969	COVID-19 research: an opinion piece. HIV Medicine, 2020, 21, 536-540.	1.0	6
970	Deciphering the Role of Host Genetics in Susceptibility to Severe COVID-19. Frontiers in Immunology, 2020, 11, 1606.	2.2	43
971	Inmunosupresión en el trasplante hepático en la era covid-19. Gastroenterología Y Hepatología, 2020, 43, 457-463.	0.2	17
972	In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. Journal of Infection and Public Health, 2020, 13, 1210-1223.	1.9	203
973	Dermatological therapies with relevance to COVID-19. Dermatologic Therapy, 2020, 33, e13813.	0.8	2
975	Literature-based review of the drugs used for the treatment of COVID-19. Current Medicine Research and Practice, 2020, 10, 100-109.	0.1	32
976	Clinical characteristics and outcomes of the first 63 adult patients hospitalized with COVID-19: An experience from Oman. Journal of Infection and Public Health, 2020, 13, 906-913.	1.9	81
978	Management of the first severe case of COVID-19 in the small islands of Maldives. Respiratory Medicine Case Reports, 2020, 30, 101118.	0.2	3
979	Identification of bioactive compounds from <i>Glycyrrhiza glabra</i> as possible inhibitor of SARS-CoV-2 spike glycoprotein and non-structural protein-15: a pharmacoinformatics study. Journal of Biomolecular Structure and Dynamics, 2021, 39, 4686-4700.	2.0	98
980	COVID-19 research: pandemic versus paperdemic; integrity, values and risks of the speed science. Forensic Sciences Research, 2020, 5, 174-187.	0.9	84

#	ARTICLE	IF	CITATIONS
981	Potential effectiveness and safety of antiviral agents in children with coronavirus disease 2019: a rapid review and meta-analysis. <i>Annals of Translational Medicine</i> , 2020, 8, 624-624.	0.7	10
982	ACE2, Much More Than Just a Receptor for SARS-COV-2. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 317.	1.8	276
983	Potential Treatments for SARS-CoV-2 Infection. <i>Clinical Liver Disease</i> , 2020, 15, 181-186.	1.0	6
984	Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 509-514.	1.3	170
985	COVID-19 and the elderly: insights into pathogenesis and clinical decision-making. <i>Aging Clinical and Experimental Research</i> , 2020, 32, 1599-1608.	1.4	277
987	Targeting Cytokine Storm to Manage Patients with COVID-19: A Mini-Review. <i>Archives of Medical Research</i> , 2020, 51, 608-612.	1.5	56
988	Overview of therapeutic drug research for COVID-19 in China. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 1133-1140.	2.8	38
991	The laboratory's role in combating COVID-19. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2020, 57, 400-414.	2.7	42
992	Oral Methioninase for Covid-19 Methionine-restriction Therapy. <i>In Vivo</i> , 2020, 34, 1593-1596.	0.6	12
993	Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research. <i>In Vivo</i> , 2020, 34, 1597-1602.	0.6	53
994	Ocular Manifestations of COVID-19 (SARS-CoV-2): A Critical Review of Current Literature. <i>In Vivo</i> , 2020, 34, 1619-1628.	0.6	55
995	SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death. <i>European Journal of Cancer</i> , 2020, 135, 242-250.	1.3	74
996	COVID-19 pneumonia in a dual heart-kidney recipient. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 612-614.	0.3	8
997	COVID-19: Drug Targets and Potential Treatments. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 12359-12386.	2.9	348
998	Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2022, 35, 2174-2187.	0.7	34
999	COVID-19: from epidemiology to treatment. <i>European Heart Journal</i> , 2020, 41, 2092-2112.	1.0	67
1000	Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2775-2793.	2.7	23
1001	Redundancy and methodological issues in articles on COVID-19. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13301.	1.7	3

#	ARTICLE	IF	CITATIONS
1002	COVID-19 in lung transplant recipients: A case series from Milan, Italy. <i>Transplant Infectious Disease</i> , 2020, 22, e13356.	0.7	19
1003	The hopes for a cure for COVID-19. <i>Independent Nurse</i> , 2020, 2020, 6-8.	0.0	1
1004	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review. <i>Archives of Virology</i> , 2020, 165, 1729-1737.	0.9	32
1005	Influence of conflicts of interest on public positions in the COVID-19 era, the case of Gilead Sciences. <i>New Microbes and New Infections</i> , 2020, 38, 100710.	0.8	13
1006	COVID-19 infection: the China and Italy perspectives. <i>Cell Death and Disease</i> , 2020, 11, 438.	2.7	76
1007	Endocrine Conditions and COVID-19. <i>Hormone and Metabolic Research</i> , 2020, 52, 471-484.	0.7	34
1008	Topological analysis of SARS CoV-2 main protease. <i>Chaos</i> , 2020, 30, 061102.	1.0	47
1009	Early experience with convalescent plasma as immunotherapy for COVID-19 in China: Knowns and unknowns. <i>Vox Sanguinis</i> , 2020, 115, 507-514.	0.7	30
1010	Suramin Inhibits SARS-CoV-2 Infection in Cell Culture by Interfering with Early Steps of the Replication Cycle. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	87
1011	The Good, the Bad, and the Hoax: When Publication Instantaneously Impacts Treatment Strategies for COVID-19. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	4
1012	How and When to End the COVID-19 Lockdown: An Optimization Approach. <i>Frontiers in Public Health</i> , 2020, 8, 262.	1.3	57
1013	Diet Supplementation, Probiotics, and Nutraceuticals in SARS-CoV-2 Infection: A Scoping Review. <i>Nutrients</i> , 2020, 12, 1718.	1.7	155
1014	What we know so far about Coronavirus Disease 2019 in children: A meta-analysis of 551 laboratory-confirmed cases. <i>Pediatric Pulmonology</i> , 2020, 55, 2115-2127.	1.0	56
1015	Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics. <i>Protein and Cell</i> , 2020, 11, 707-722.	4.8	97
1016	Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106054.	1.1	410
1017	The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. <i>Leukemia</i> , 2020, 34, 1805-1815.	3.3	188
1018	Case 18-2020: A 73-Year-Old Man with Hypoxemic Respiratory Failure and Cardiac Dysfunction. <i>New England Journal of Medicine</i> , 2020, 382, 2354-2364.	13.9	15
1019	How should I manage immunosuppression in a kidney transplant patient with COVID-19? An ERA-EDTA DESCARTES expert opinion. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 899-904.	0.4	96

#	ARTICLE	IF	CITATIONS
1020	Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir. <i>Frontiers in Medicine</i> , 2020, 7, 241.	1.2	7
1021	Management of patients with SARS-CoV-2 infections and of patients with chronic lung diseases during the COVID-19 pandemic (as of 9 May 2020). <i>Wiener Klinische Wochenschrift</i> , 2020, 132, 365-386.	1.0	17
1022	Cytokine storm induced by SARS-CoV-2. <i>Clinica Chimica Acta</i> , 2020, 509, 280-287.	0.5	405
1023	The eighth alternative to evidence based medicine in the early era of the COVID-19 pandemic: Too much emergency and emotion, too little evidence. <i>European Journal of Internal Medicine</i> , 2020, 77, 163-164.	1.0	2
1024	Need for innovative and timely synthesis of evidence during Covid-19 outbreak. <i>European Journal of Internal Medicine</i> , 2020, 77, 165-166.	1.0	5
1025	Current global vaccine and drug efforts against COVID-19: Pros and cons of bypassing animal trials. <i>Journal of Biosciences</i> , 2020, 45, 1.	0.5	30
1026	The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2020, 28, 507-516.	0.9	12
1027	Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3084-3086.	1.3	43
1028	Varied clinical presentation and outcome of SARS-CoV-2 infection in liver transplant recipients: Initial experience at a single center in Madrid, Spain. <i>Transplant Infectious Disease</i> , 2020, 22, e13372.	0.7	19
1029	Covid-19 – The Search for Effective Therapy. <i>New England Journal of Medicine</i> , 2020, 382, 1851-1852.	13.9	258
1030	COVID-19 illness in native and immunosuppressed states: A clinical therapeutic staging proposal. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 405-407.	0.3	1,349
1031	Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa105.	0.4	255
1032	Rising to the Challenge of COVID-19: Advice for Pulmonary and Critical Care and an Agenda for Research. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 1019-1022.	2.5	32
1033	No Time for Tears. <i>Ophthalmology</i> , 2020, 127, 980-981.	2.5	20
1034	Potential Effects of Coronaviruses on the Cardiovascular System. <i>JAMA Cardiology</i> , 2020, 5, 831.	3.0	1,469
1035	Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). <i>Intensive Care Medicine</i> , 2020, 46, 854-887.	3.9	1,536
1036	Covid-19: what treatments are being investigated?. <i>BMJ, The</i> , 2020, 368, m1252.	3.0	79
1037	Chloroquine in COVID-19: the evidence. <i>Monaldi Archives for Chest Disease</i> , 2020, 90, .	0.3	17

#	ARTICLE	IF	CITATIONS
1038	Nano Research for COVID-19. ACS Nano, 2020, 14, 3719-3720.	7.3	97
1039	Why the immune system fails to mount an adaptive immune response to a COVID-19 infection. Transplant International, 2020, 33, 824-825.	0.8	124
1040	A fatal case of COVID-19 pneumonia occurring in a patient with severe acute ulcerative colitis. Gut, 2020, 69, 1148-1149.	6.1	60
1041	The New Challenge of Geriatrics: Saving Frail Older People from the SARS-COV-2 Pandemic Infection,. Journal of Nutrition, Health and Aging, 2020, 24, 466-470.	1.5	94
1042	The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmunity Reviews, 2020, 19, 102537.	2.5	1,357
1043	Overview: Systemic Inflammatory Response Derived From Lung Injury Caused by SARS-CoV-2 Infection Explains Severe Outcomes in COVID-19. Frontiers in Immunology, 2020, 11, 1626.	2.2	135
1044	COVID-19 in patients with HIV – Authors' reply. Lancet HIV,the, 2020, 7, e383-e384.	2.1	10
1045	COVID-19 in people with HIV. Lancet HIV,the, 2020, 7, e524-e526.	2.1	26
1046	SARS-CoV-2 pandemic expanding in sub-Saharan Africa: Considerations for COVID-19 in people living with HIV. EClinicalMedicine, 2020, 22, 100342.	3.2	39
1047	Current pharmacological treatments for SARS-COV-2: A narrative review. European Journal of Pharmacology, 2020, 882, 173328.	1.7	35
1049	Can early treatment of patients with risk factors contribute to managing the COVID-19 pandemic?. Journal of Global Health, 2020, 10, 010377.	1.2	17
1050	Narrative review of the immune response against coronavirus: An overview, applicability for SARS-COV-2, and therapeutic implications. Anales De Pediatr�a (English Edition), 2020, 93, 60.e1-60.e7.	0.1	3
1051	Drug treatment of coronavirus disease 2019 (COVID-19) in China.. European Journal of Pharmacology, 2020, 883, 173326.	1.7	21
1052	Extracorporeal Life Support Organization Coronavirus Disease 2019 Interim Guidelines: A Consensus Document from an International Group of Interdisciplinary Extracorporeal Membrane Oxygenation Providers. ASAIO Journal, 2020, 66, 707-721.	0.9	296
1053	Semantic and Geographical Analysis of COVID-19 Trials Reveals a Fragmented Clinical Research Landscape Likely to Impair Informativeness. Frontiers in Medicine, 2020, 7, 367.	1.2	8
1054	Coronavirus Disease Pandemic (COVID-19): Challenges and a Global Perspective. Pathogens, 2020, 9, 519.	1.2	102
1055	Emerging Pharmacotherapy for Covid-19. Journal of the Royal College of Physicians of Edinburgh, The, 2020, 50, 133-137.	0.2	3
1056	Comparison of the computed tomography findings in COVID-19 and other viral pneumonia in immunocompetent adults: a systematic review and meta-analysis. European Radiology, 2020, 30, 6485-6496.	2.3	48

#	ARTICLE	IF	CITATIONS
1057	Supportive treatment of COVID 19 patients with mild respiratory failure in a primary hospital. <i>Medicina Clínica</i> , 2020, 155, 222-223.	0.3	4
1058	Class A G Protein-Coupled Receptor Antagonist Famotidine as a Therapeutic Alternative against SARS-CoV2: An In Silico Analysis. <i>Biomolecules</i> , 2020, 10, 954.	1.8	43
1059	Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19. <i>Journal of Clinical Medicine</i> , 2020, 9, 2030.	1.0	28
1060	Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician's perspective. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 971-978.	1.8	167
1061	GS-5734: a potentially approved drug by FDA against SARS-Cov-2. <i>New Journal of Chemistry</i> , 2020, 44, 12417-12429.	1.4	24
1062	In silico analysis and identification of promising hits against 2019 novel coronavirus 3C-like main protease enzyme. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 5290-5303.	2.0	28
1063	COVID-19 and the Drug Repurposing Tsunami. <i>Assay and Drug Development Technologies</i> , 2020, 18, 211-214.	0.6	18
1064	A Comprehensive Analysis of Clinical Trials in the COVID-19 Pandemic Era. <i>Medicina (Lithuania)</i> , 2020, 56, 315.	0.8	4
1065	SARS-CoV-2 and Norovirus Co-Infection after Lung Transplantation. <i>Transplantology</i> , 2020, 1, 16-23.	0.3	3
1066	Novel Coronavirus (nCoV): a Bitter Old Enemy in a New Avatar. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 1083-1088.	0.3	3
1067	The SARS-CoV-2 main protease as drug target. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127377.	1.0	550
1068	Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. <i>International Journal of Infectious Diseases</i> , 2020, 97, 396-403.	1.5	445
1069	Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 285-299.	1.5	46
1070	SARS-CoV-2 detection, viral load and infectivity over the course of an infection. <i>Journal of Infection</i> , 2020, 81, 357-371.	1.7	572
1071	Laboratory findings and a combined multifactorial approach to predict death in critically ill patients with COVID-19: a retrospective study. <i>Epidemiology and Infection</i> , 2020, 148, e129.	1.0	20
1072	Natural history of COVID-19 and current knowledge on treatment therapeutic options. <i>Biomedicine and Pharmacotherapy</i> , 2020, 129, 110493.	2.5	118
1073	CORDITE: The Curated CORona Drug INTERactions Database for SARS-CoV-2. <i>IScience</i> , 2020, 23, 101297.	1.9	30
1074	Emerging Treatment and Prevention Strategies against COVID-19: A Brief Update. <i>Journal of Digestive Endoscopy</i> , 2020, 11, 69-72.	0.1	3

#	ARTICLE	IF	CITATIONS
1075	Interim Management of COVID-19 by Repurposed Homeopathic Medicines. <i>Homeopathy</i> , 2020, 109, 182-183.	0.5	9
1076	Coronavirus 2019 and People Living With Human Immunodeficiency Virus: Outcomes for Hospitalized Patients in New York City. <i>Clinical Infectious Diseases</i> , 2020, 71, 2933-2938.	2.9	189
1077	Development of a Clinical Decision Support System for Severity Risk Prediction and Triage of COVID-19 Patients at Hospital Admission: an International Multicenter Study. <i>European Respiratory Journal</i> , 2020, 56, 2001104.	3.1	172
1078	Coronavirus disease 2019 (COVID-19): an evidence map of medical literature. <i>BMC Medical Research Methodology</i> , 2020, 20, 177.	1.4	68
1079	Acute complications and mortality in hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. <i>Critical Care</i> , 2020, 24, 389.	2.5	158
1080	Trajectory of the COVID-19 pandemic: chasing a moving target. <i>Annals of Translational Medicine</i> , 2020, 8, 694-694.	0.7	30
1081	Endemic and Emerging Coronavirus Pulmonary Infections. <i>American Journal of the Medical Sciences</i> , 2020, 360, 728-732.	0.4	0
1082	COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2). <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106080.	1.1	149
1083	The peripheral lymphocyte count as a predictor of severe COVID-19 and the effect of treatment with ciclesonide. <i>Virus Research</i> , 2020, 290, 198089.	1.1	27
1084	Clinical Trials of Repurposed Antivirals for SARS-CoV-2. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	36
1085	Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives. <i>Journal of Clinical Medicine</i> , 2020, 9, 2050.	1.0	66
1086	Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review. <i>Viruses</i> , 2020, 12, 705.	1.5	43
1087	Update on therapeutic approaches and emerging therapies for SARS-CoV-2 virus. <i>European Journal of Pharmacology</i> , 2020, 883, 173348.	1.7	55
1088	Pandemic COVID-19: Current status and challenges of antiviral therapies. <i>Genes and Diseases</i> , 2020, 7, 502-519.	1.5	11
1089	Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients. <i>Journal of Autoimmunity</i> , 2020, 114, 102511.	3.0	72
1090	The characteristics and outcomes of 681 severe cases with COVID-19 in China. <i>Journal of Critical Care</i> , 2020, 60, 32-37.	1.0	60
1091	Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 584-599.	1.9	194
1092	The mechanism and treatment of gastrointestinal symptoms in patients with COVID-19. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 319, G245-G252.	1.6	120

#	ARTICLE	IF	CITATIONS
1093	Clinical Use of Short-Course and Low-Dose Corticosteroids in Patients With Non-severe COVID-19 During Pneumonia Progression. <i>Frontiers in Public Health</i> , 2020, 8, 355.	1.3	34
1094	Treatment of Severe COVID-19 with Tocilizumab Mitigates Cytokine Storm and Averts Mechanical Ventilation during Acute Respiratory Distress: A Case Report and Literature Review. <i>Tropical Medicine and Infectious Disease</i> , 2020, 5, 112.	0.9	33
1095	Research progress on repositioning drugs and specific therapeutic drugs for SARS-CoV-2. <i>Future Medicinal Chemistry</i> , 2020, 12, 1565-1578.	1.1	22
1096	Consecutive false-negative rRT-PCR test results for SARS-CoV-2 in patients after clinical recovery from COVID-19. <i>Journal of Medical Virology</i> , 2020, 92, 2887-2890.	2.5	11
1097	Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review. <i>Reviews in Medical Virology</i> , 2020, 30, e2136.	3.9	12
1098	Pharmacological and non-pharmacological efforts at prevention, mitigation, and treatment for COVID-19. <i>Journal of Drug Targeting</i> , 2020, 28, 742-754.	2.1	34
1099	COVID-19 fulminant myocarditis: a case report. <i>European Heart Journal - Case Reports</i> , 2020, 4, 1-6.	0.3	31
1100	The impact of type 2 diabetes and its management on the prognosis of patients with severe COVID-19. <i>Journal of Diabetes</i> , 2020, 12, 909-918.	0.8	27
1101	Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	50
1102	Intravenous high-dose vitamin C for the treatment of severe COVID-19: study protocol for a multicentre randomised controlled trial. <i>BMJ Open</i> , 2020, 10, e039519.	0.8	113
1103	Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study. <i>Trials</i> , 2020, 21, 622.	0.7	18
1104	Clinical characteristics of different subtypes and risk factors for the severity of illness in patients with COVID-19 in Zhejiang, China. <i>Infectious Diseases of Poverty</i> , 2020, 9, 85.	1.5	65
1105	Progress in the Research and Development of Anti-COVID-19 Drugs. <i>Frontiers in Public Health</i> , 2020, 8, 365.	1.3	21
1106	Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19). <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 782.	3.8	3,597
1107	COVID-19 and Mesenchymal Stem Cell Treatment; Mystery or Not. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1298, 167-176.	0.8	8
1111	Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab. <i>Journal of Autoimmunity</i> , 2020, 114, 102512.	3.0	59
1112	What Is the Best Drug to Treat COVID-19? The Need for Randomized Controlled Trials. <i>Med</i> , 2020, 1, 9-10.	2.2	5
1113	Cutaneous manifestations in hospitalized patients diagnosed as COVID-19. <i>Dermatologic Therapy</i> , 2020, 33, e13896.	0.8	56

#	ARTICLE	IF	CITATIONS
1114	Coronavirus Disease 2019—COVID-19. <i>Clinical Microbiology Reviews</i> , 2020, 33, .	5.7	767
1115	Pharmacotherapeutics Advice in Guidelines for COVID-19. <i>Frontiers in Pharmacology</i> , 2020, 11, 950.	1.6	6
1116	Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019. <i>JAMA Network Open</i> , 2020, 3, e2013136.	2.8	344
1117	Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. <i>Travel Medicine and Infectious Disease</i> , 2020, 36, 101791.	1.5	209
1118	Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection. <i>Virus Research</i> , 2020, 286, 198073.	1.1	35
1119	In vivo expressed biologics for infectious disease prophylaxis: rapid delivery of DNA-based antiviral antibodies. <i>Emerging Microbes and Infections</i> , 2020, 9, 1523-1533.	3.0	9
1120	Meditation and Yoga Practices as Potential Adjunctive Treatment of SARS-CoV-2 Infection and COVID-19: A Brief Overview of Key Subjects. <i>Journal of Alternative and Complementary Medicine</i> , 2020, 26, 547-556.	2.1	59
1121	Could Coronavirus Disease 2019 (COVID-19) Render Natural Immunity to Re-infections? A Spotlight on the Therapeutic Pipeline. <i>Frontiers in Immunology</i> , 2020, 11, 1294.	2.2	17
1122	A Perspective on Emerging Therapeutic Interventions for COVID-19. <i>Frontiers in Public Health</i> , 2020, 8, 281.	1.3	49
1123	COVID-19 and Heart: From Clinical Features to Pharmacological Implications. <i>Journal of Clinical Medicine</i> , 2020, 9, 1944.	1.0	36
1124	Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. <i>JAMA Neurology</i> , 2020, 77, 1079.	4.5	357
1125	Coronavirus in Continuous Flux: From SARS-CoV to SARS-CoV-2. <i>Advanced Science</i> , 2020, 7, 2001474.	5.6	14
1126	COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. <i>The Lancet Child and Adolescent Health</i> , 2020, 4, 653-661.	2.7	978
1127	Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 749-757.	0.4	38
1128	Clinical Characteristics and Disease Progression in Early-Stage COVID-19 Patients in South Korea. <i>Journal of Clinical Medicine</i> , 2020, 9, 1959.	1.0	41
1129	SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries. <i>Vaccines</i> , 2020, 8, 335.	2.1	43
1130	Epidemic and pandemic viral infections: impact on tuberculosis and the lung. <i>European Respiratory Journal</i> , 2020, 56, 2001727.	3.1	89
1131	Extrapulmonary manifestations of COVID-19. <i>Nature Medicine</i> , 2020, 26, 1017-1032.	15.2	2,300

#	ARTICLE	IF	CITATIONS
1132	Remdesivir for the Treatment of Covid-19 – Preliminary Report. New England Journal of Medicine, 2020, 383, 992-994.	13.9	274
1133	The Emerging Role of Convalescent Plasma in the Treatment of COVID-19. HemaSphere, 2020, 4, e409.	1.2	42
1134	COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium. American Journal of Transplantation, 2020, 20, 3140-3148.	2.6	305
1135	Current therapies under investigation for COVID-19: potential COVID-19 treatments. Canadian Journal of Physiology and Pharmacology, 2020, 98, 483-489.	0.7	6
1136	COVID-19 in Children: Clinical Approach and Management- Correspondence. Indian Journal of Pediatrics, 2020, 87, 970-972.	0.3	3
1137	Minimum costs to manufacture new treatments for COVID-19. Journal of Virus Eradication, 2020, 6, 61-69.	0.3	63
1138	mTORC inhibitor Sirolimus deprograms monocytes in –cytokine storm– in SARS-CoV2 secondary hemophagocytic lymphohistiocytosis- like syndrome. Clinical Immunology, 2020, 218, 108539.	1.4	7
1139	Acute respiratory distress syndrome due to SARS-CoV-2 and Influenza A co-infection in an Italian patient: Mini-review of the literature. International Journal of Infectious Diseases, 2020, 97, 236-239.	1.5	32
1140	Associations of clinical characteristics and treatment regimens with the duration of viral RNA shedding in patients with COVID-19. International Journal of Infectious Diseases, 2020, 98, 252-260.	1.5	71
1141	Profiles of COVID-19 clinical trials in the Chinese Clinical Trial Registry. Emerging Microbes and Infections, 2020, 9, 1695-1701.	3.0	7
1142	Randomization amid a pandemic – a critical appraisal regarding convalescent plasma therapy clinical trials for COVID-19 patients. ISBT Science Series, 2020, 15, 417-418.	1.1	2
1143	Dexamethasone in the management of covid -19. BMJ, The, 2020, 370, m2648.	3.0	158
1144	BET 2: Hydroxychloroquine in the treatment of COVID-19. Emergency Medicine Journal, 2020, 37, 451-453.	0.4	0
1145	Clinical trials for the prevention and treatment of COVID-19: current state of play. Medical Journal of Australia, 2020, 213, 86-93.	0.8	32
1146	Gastrointestinal and Liver Manifestations of COVID-19. Annals of the National Academy of Medical Sciences (India), 2020, 56, 091-098.	0.2	0
1147	Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. Emergency Medicine Journal, 2020, 37, 450.1-450.	0.4	0
1148	BET 1: Lopinavir–ritonavir and COVID-19. Emergency Medicine Journal, 2020, 37, 450.2-451.	0.4	2
1149	Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents. Therapeutic Advances in Psychopharmacology, 2020, 10, 204512532093530.	1.2	39

#	ARTICLE	IF	CITATIONS
1150	Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review. Drug Development Research, 2020, 81, 919-941.	1.4	35
1151	Outbreak of COVID-19: An emerging global pandemic threat. Biomedicine and Pharmacotherapy, 2020, 129, 110499.	2.5	48
1152	Identification of potential inhibitors of SARS-CoV-2 main protease from Aloe vera compounds: A molecular docking study. Chemical Physics Letters, 2020, 754, 137751.	1.2	58
1153	Kidney transplant patients with SARS-CoV-2 infection: The Brescia Renal COVID task force experience. American Journal of Transplantation, 2020, 20, 3019-3029.	2.6	81
1154	Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation. Transfusion, 2020, 60, 1765-1772.	0.8	58
1155	Dual antiplatelet therapy in patients with acute coronary syndrome during the coronavirus disease of 2019 pandemic: the right choice at the right time. Journal of Cardiovascular Medicine, 2020, 21, 535-537.	0.6	8
1157	Scoping review of prevalence of neurologic comorbidities in patients hospitalized for COVID-19. Neurology, 2020, 95, 77-84.	1.5	111
1158	On Facing the SARS-CoV-2 (COVID-19) with Combination of Nanomaterials and Medicine: Possible Strategies and First Challenges. Nanomaterials, 2020, 10, 852.	1.9	102
1159	Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, The, 2020, 395, 1569-1578.	6.3	2,875
1160	Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). Clinical Microbiology and Infection, 2020, 26, 880-894.	2.8	36
1162	Can melatonin reduce the severity of COVID-19 pandemic?. International Reviews of Immunology, 2020, 39, 153-162.	1.5	140
1163	Review article: prevention, diagnosis and management of COVID-19 in the IBD patient. Alimentary Pharmacology and Therapeutics, 2020, 52, 54-72.	1.9	93
1164	COVID-19 diagnosis and management: a comprehensive review. Journal of Internal Medicine, 2020, 288, 192-206.	2.7	924
1165	Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19. Viruses, 2020, 12, 486.	1.5	94
1166	Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action. Advances in Therapy, 2020, 37, 2575-2579.	1.3	36
1167	Remdesivir for COVID-19: challenges of underpowered studies. Lancet, The, 2020, 395, 1525-1527.	6.3	74
1168	Treatment Considerations for COVID-19. Mayo Clinic Proceedings, 2020, 95, 1454-1466.	1.4	79
1169	COVID-19: treating and managing severe cases. Cell Research, 2020, 30, 370-371.	5.7	19

#	ARTICLE	IF	CITATIONS
1170	Current Perspectives on Coronavirus Disease 2019 and Cardiovascular Disease: A White Paper by the <i>JAHA</i> Editors. Journal of the American Heart Association, 2020, 9, e017013.	1.6	52
1171	Increasing the Signal-to-Noise Ratio: COVID-19 Clinical Synopsis for Outpatient Providers. Journal of Primary Care and Community Health, 2020, 11, 215013272092295.	1.0	5
1172	Treatment of patients with nonsevere and severe coronavirus disease 2019: an evidence-based guideline. Cmaj, 2020, 192, E536-E545.	0.9	45
1173	Emergence of Drift Variants That May Affect COVID-19 Vaccine Development and Antibody Treatment. Pathogens, 2020, 9, 324.	1.2	184
1174	Employing drug delivery strategies to create safe and effective pharmaceuticals for ^{sc}COVID</sc>â€19. Bioengineering and Translational Medicine, 2020, 5, e10163.	3.9	7
1175	COVID-19: Therapeutics and Their Toxicities. Journal of Medical Toxicology, 2020, 16, 284-294.	0.8	82
1176	Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacological Research, 2020, 157, 104859.	3.1	426
1177	Nurture to nature via COVID-19, a self-regenerating environmental strategy of environment in global context. Science of the Total Environment, 2020, 729, 139088.	3.9	144
1178	Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients. Cell Reports Medicine, 2020, 1, 100016.	3.3	102
1179	Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China. Critical Care, 2020, 24, 188.	2.5	291
1180	Outpatient Management of the Kidney Transplant Recipient during the SARS-CoV-2 Virus Pandemic. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 892-895.	2.2	23
1181	Twenty-Year Span of Global Coronavirus Research Trends: A Bibliometric Analysis. International Journal of Environmental Research and Public Health, 2020, 17, 3082.	1.2	40
1182	Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why Were We Convinced to Evaluate the Drug in a Registered/Approved Clinical Trial?. Archives of Medical Research, 2020, 51, 577-581.	1.5	59
1183	Master Regulator Analysis of the SARS-CoV-2/Human Interactome. Journal of Clinical Medicine, 2020, 9, 982.	1.0	160
1184	Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management. Clinical Gastroenterology and Hepatology, 2020, 18, 1663-1672.	2.4	437
1185	COVID-19 for the Cardiologist. JACC Basic To Translational Science, 2020, 5, 518-536.	1.9	256
1186	Development of a Novel, Genome Subtraction-Derived, SARS-CoV-2-Specific COVID-19-nsp2 Real-Time RT-PCR Assay and Its Evaluation Using Clinical Specimens. International Journal of Molecular Sciences, 2020, 21, 2574.	1.8	74
1187	Critical Illness in Patients With COVID-19. JAMA - Journal of the American Medical Association, 2020, 323, 1559.	3.8	36

#	ARTICLE	IF	CITATIONS
1188	Addressing COVID-19 Drug Development with Artificial Intelligence. <i>Advanced Intelligent Systems</i> , 2020, 2, 2000070.	3.3	41
1189	COVID-19: A review of therapeutics under investigation. <i>Journal of the American College of Emergency Physicians Open</i> , 2020, 1, 231-237.	0.4	29
1190	Global interim guidance on coronavirus disease 2019 (COVID-19) during pregnancy and puerperium from FIGO and allied partners: Information for healthcare professionals. <i>International Journal of Gynecology and Obstetrics</i> , 2020, 149, 273-286.	1.0	220
1191	Roles of the clinical pharmacist during the COVID-19 pandemic. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2020, 3, 564-566.	0.5	54
1192	Reply to Comments on "Co-infection of SARS-CoV-2 and HIV in a patient in Wuhan city, China". <i>Journal of Medical Virology</i> , 2020, 92, 1417-1418.	2.5	26
1193	COVID-19: The Uninvited Guest in the Intensive Care Unit – Implications for Pharmacotherapy. <i>Pharmacotherapy</i> , 2020, 40, 382-386.	1.2	8
1194	COVID-19: Important Therapy Considerations and Approaches in this Hour of Need. <i>Pharmacotherapy</i> , 2020, 40, 379-381.	1.2	5
1195	Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019. <i>Pharmacotherapy</i> , 2020, 40, 416-437.	1.2	166
1198	Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. <i>Clinical Rheumatology</i> , 2020, 39, 2055-2062.	1.0	215
1199	SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes. <i>GeroScience</i> , 2020, 42, 505-514.	2.1	404
1200	Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation. <i>Hepatology International</i> , 2020, 14, 432-436.	1.9	54
1201	Learnings for Health Economics from the Early Stages of the COVID-19 Pandemic. <i>PharmacoEconomics - Open</i> , 2020, 4, 203-205.	0.9	13
1202	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. <i>Lancet Respiratory Medicine</i> , 2020, 8, 506-517.	5.2	1,177
1203	Care of the pregnant woman with coronavirus disease 2019 in labor and delivery: anesthesia, emergency cesarean delivery, differential diagnosis in the acutely ill parturient, care of the newborn, and protection of the healthcare personnel. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 66-74.e3.	0.7	104
1204	Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. <i>Annals of Oncology</i> , 2020, 31, 961-964.	0.6	280
1205	Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. <i>Antiviral Research</i> , 2020, 178, 104786.	1.9	737
1206	Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Chest</i> , 2020, 158, e9-e13.	0.4	359
1207	Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society. <i>Canadian Journal of Cardiology</i> , 2020, 36, 948-951.	0.8	100

#	ARTICLE	IF	CITATIONS
1208	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic. <i>Clinical Immunology</i> , 2020, 215, 108409.	1.4	217
1209	An overview of coronaviruses including the SARS-2 coronavirus " Molecular biology, epidemiology and clinical implications. <i>Current Medicine Research and Practice</i> , 2020, 10, 54-64.	0.1	74
1210	Management of Patients on Dialysis and With Kidney Transplantation During the SARS-CoV-2 (COVID-19) Pandemic in Brescia, Italy. <i>Kidney International Reports</i> , 2020, 5, 580-585.	0.4	195
1211	The Greek study in the effects of colchicine in COVID-19 complications prevention (GRECCO-19 study): Rationale and study design. <i>Hellenic Journal of Cardiology</i> , 2020, 61, 42-45.	0.4	114
1212	Perspectives: potential therapeutic options for SARS-CoV-2 patients based on feline infectious peritonitis strategies: central nervous system invasion and drug coverage. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105964.	1.1	9
1213	COVID-19 in the Eastern Mediterranean Region and Saudi Arabia: prevention and therapeutic strategies. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105968.	1.1	95
1214	The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease. <i>International Journal of Cardiology</i> , 2020, 309, 70-77.	0.8	217
1215	SARS-CoV-2 inflames the heart. The importance of awareness of myocardial injury in COVID-19 patients. <i>International Journal of Cardiology</i> , 2020, 311, 122-123.	0.8	38
1216	Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. <i>JHEP Reports</i> , 2020, 2, 100113.	2.6	378
1217	Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan. <i>Journal of Microbiology, Immunology and Infection</i> , 2020, 53, 488-492.	1.5	68
1218	Treatment options for COVID-19: The reality and challenges. <i>Journal of Microbiology, Immunology and Infection</i> , 2020, 53, 436-443.	1.5	393
1219	COVID-19 infection in kidney transplant recipients. <i>Kidney International</i> , 2020, 97, 1076-1082.	2.6	296
1220	A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia. <i>Kidney International</i> , 2020, 97, 1083-1088.	2.6	314
1221	In silico studies on therapeutic agents for COVID-19: Drug repurposing approach. <i>Life Sciences</i> , 2020, 252, 117652.	2.0	293
1222	Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19). <i>Mayo Clinic Proceedings</i> , 2020, 95, 1213-1221.	1.4	332
1223	Chloroquine and COVID-19, where do we stand?. <i>Médecine Et Maladies Infectieuses</i> , 2020, 50, 229-230.	5.1	14
1225	Recommendations on management of the SARS-CoV-2 coronavirus pandemic (Covid-19) in kidney transplant patients. <i>Nefrologia</i> , 2020, 40, 265-271.	0.2	39
1226	3CLpro inhibitors as a potential therapeutic option for COVID-19: Available evidence and ongoing clinical trials. <i>Pharmacological Research</i> , 2020, 156, 104779.	3.1	38

#	ARTICLE	IF	CITATIONS
1228	Compassionate Use of Remdesivir for Patients with Severe Covid-19. <i>New England Journal of Medicine</i> , 2020, 382, 2327-2336.	13.9	2,241
1229	Factors Associated With Prolonged Viral RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19). <i>Clinical Infectious Diseases</i> , 2020, 71, 799-806.	2.9	395
1230	The Late Arrival of Coronavirus Disease 2019 (COVID-19) in Africa: Mitigating Pan-continental Spread. <i>Clinical Infectious Diseases</i> , 2020, 71, 875-878.	2.9	64
1231	COVID-19 disease: tackling a pandemic in 21st century. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2020, 113, 519-520.	0.2	7
1232	Response to: COVID-19 disease: tackling a pandemic in 21st century. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2020, 113, 521-522.	0.2	1
1233	A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19). <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 613-619.	0.9	106
1234	Novel Coronavirus-19 (COVID-19) in the immunocompromised transplant recipient: #Flatteningthecurve. <i>American Journal of Transplantation</i> , 2020, 20, 1765-1767.	2.6	98
1235	Letter from China. <i>Respirology</i> , 2020, 25, 657-658.	1.3	4
1236	Threatening drug-drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVID-19). <i>Transplant Infectious Disease</i> , 2020, 22, e13286.	0.7	58
1237	An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	886
1238	Coronavirus Diseases (COVID-19) Current Status and Future Perspectives: A Narrative Review. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 2690.	1.2	439
1239	Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19. <i>Journal of Clinical Medicine</i> , 2020, 9, 1131.	1.0	112
1240	COVID-19: A Brief Overview of the Discovery Clinical Trial. <i>Pharmaceuticals</i> , 2020, 13, 65.	1.7	30
1241	Molecular Investigation of SARS-CoV-2 Proteins and Their Interactions with Antiviral Drugs. <i>Viruses</i> , 2020, 12, 445.	1.5	102
1242	Antiviral treatment of COVID-19. <i>Turkish Journal of Medical Sciences</i> , 2020, 50, 611-619.	0.4	214
1243	Novel coronavirus disease (COVID-19) in children. <i>Turkish Journal of Medical Sciences</i> , 2020, 50, 592-603.	0.4	144
1244	Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. <i>The Cochrane Library</i> , 0, , .	1.5	18
1245	15-day mortality and associated risk factors for hospitalized patients with COVID-19 in Wuhan, China: an ambispective observational cohort study. <i>Intensive Care Medicine</i> , 2020, 46, 1472-1474.	3.9	75

#	ARTICLE	IF	CITATIONS
1246	A real-time dashboard of clinical trials for COVID-19. <i>The Lancet Digital Health</i> , 2020, 2, e286-e287.	5.9	192
1248	Current pharmacological treatments for COVID-19: What's next?. <i>British Journal of Pharmacology</i> , 2020, 177, 4813-4824.	2.7	210
1249	Direct oral anticoagulant plasma levelsâ€™ striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1320-1323.	1.9	139
1250	Severe liver failure during SARS-CoV-2 infection. <i>Gut</i> , 2020, 69, 1365-1367.	6.1	58
1251	COVID-19 Drug Discovery Using Intensive Approaches. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2839.	1.8	55
1252	COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. <i>American Journal of Transplantation</i> , 2020, 20, 1800-1808.	2.6	683
1254	Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. <i>Journal of Infection</i> , 2020, 81, 318-356.	1.7	358
1255	Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2020, 19, 16.	1.7	36
1256	Inpatient Care of Patients with COVID-19: A Guide for Hospitalists. <i>American Journal of Medicine</i> , 2020, 133, 1019-1024.	0.6	16
1257	COVID-19 in Children: Clinical Approach and Management. <i>Indian Journal of Pediatrics</i> , 2020, 87, 433-442.	0.3	87
1258	Novel Coronavirus 2019 (2019-nCoV) Infection: Part I - Preparedness and Management in the Pediatric Intensive Care Unit in Resource-limited Settings. <i>Indian Pediatrics</i> , 2020, 57, 324-334.	0.2	17
1259	Practical recommendations for the management of diabetes in patients with COVID-19. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 546-550.	5.5	680
1260	Addressing the Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hematopoietic Cell Transplantation: Learning Networks as a Means for Sharing Best Practices. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e147-e160.	2.0	37
1261	COVID-19 pathophysiology: A review. <i>Clinical Immunology</i> , 2020, 215, 108427.	1.4	1,414
1262	COVID-19: Immunology and treatment options. <i>Clinical Immunology</i> , 2020, 215, 108448.	1.4	485
1263	COVID-19 pandemicâ€™ a focused review for clinicians. <i>Clinical Microbiology and Infection</i> , 2020, 26, 842-847.	2.8	289
1265	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With Coronavirus Disease 2019 (COVID-19). <i>Clinical Infectious Diseases</i> , 2020, , .	2.9	708
1266	Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics. <i>American Journal of Transplantation</i> , 2020, 20, 1896-1901.	2.6	51

#	ARTICLE	IF	CITATIONS
1268	Implicaciones de la pandemia por COVID-19 para el paciente con insuficiencia cardiaca, trasplante cardiaco y asistencia ventricular. Recomendaciones de la Asociación de Insuficiencia Cardiaca de la Sociedad Española de Cardiología. REC: CardioClinics, 2020, 55, 94-102.	0.1	8
1269	Inter nation social lockdown versus medical care against COVID-19, a mild environmental insight with special reference to India. Science of the Total Environment, 2020, 728, 138914.	3.9	179
1270	The Clinical Presentation and Immunology of Viral Pneumonia and Implications for Management of Coronavirus Disease 2019. , 2020, 2, e0109.		12
1271	A Review of SARS-CoV-2 and the Ongoing Clinical Trials. International Journal of Molecular Sciences, 2020, 21, 2657.	1.8	530
1272	Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department. Western Journal of Emergency Medicine, 2020, 21, 510-513.	0.6	1
1274	COVID-19 and rheumatology: first steps towards a different future?. Annals of the Rheumatic Diseases, 2020, 79, 551-552.	0.5	48
1275	Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis. Journal of Medical Virology, 2020, 92, 776-785.	2.5	178
1276	American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Position Statement on Pharmacy Practice Management and Clinical Management for COVID-19 in Hematopoietic Cell Transplantation and Cellular Therapy Patients in the United States. Biology of Blood and Marrow Transplantation. 2020. 26. 1043-1049.	2.0	30
1277	The important role of polysaccharides from a traditional Chinese medicine-Lung Cleansing and Detoxifying Decoction against the COVID-19 pandemic. Carbohydrate Polymers, 2020, 240, 116346.	5.1	84
1278	Prior and novel coronaviruses, Coronavirus Disease 2019 (COVID-19), and human reproduction: what is known?. Fertility and Sterility, 2020, 113, 1140-1149.	0.5	128
1279	Co-Infection with SARS-COV-2 and Parainfluenza in a young adult patient with pneumonia: Case Report. IDCases, 2020, 20, e00762.	0.4	17
1280	Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies. International Journal of Antimicrobial Agents, 2020, 55, 105982.	1.1	204
1281	Scientific research progress of COVID-19/SARS-CoV-2 in the first five months. Journal of Cellular and Molecular Medicine, 2020, 24, 6558-6570.	1.6	86
1282	Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover. Pediatric Allergy and Immunology, 2020, 31, 565-569.	1.1	298
1283	Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome. Circulation, 2020, 141, 1903-1914.	1.6	448
1284	Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement. Hepatology, 2020, 72, 287-304.	3.6	408
1285	Evaluation of antiviral therapies for coronavirus disease 2019 pneumonia in Shanghai, China. Journal of Medical Virology, 2020, 92, 1922-1931.	2.5	18
1286	Off-label use of tocilizumab in patients with SARS-CoV-2 infection. Journal of Medical Virology, 2020, 92, 1787-1788.	2.5	102

#	ARTICLE	IF	CITATIONS
1287	COVID-19 in otolaryngologist practice: a review of current knowledge. <i>European Archives of Oto-Rhino-Laryngology</i> , 2020, 277, 1885-1897.	0.8	145
1288	Advances in COVID-19: the virus, the pathogenesis, and evidence-based control and therapeutic strategies. <i>Frontiers of Medicine</i> , 2020, 14, 117-125.	1.5	69
1289	Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response. <i>Current Cardiology Reports</i> , 2020, 22, 32.	1.3	146
1290	COVID-19 in patients with HIV: clinical case series. <i>Lancet HIV</i> , 2020, 7, e314-e316.	2.1	350
1291	Pharmacotherapy in COVID-19; A narrative review for emergency providers. <i>American Journal of Emergency Medicine</i> , 2020, 38, 1488-1493.	0.7	79
1292	Current status of potential therapeutic candidates for the COVID-19 crisis. <i>Brain, Behavior, and Immunity</i> , 2020, 87, 59-73.	2.0	239
1293	Elevated Troponin in Patients With Coronavirus Disease 2019: Possible Mechanisms. <i>Journal of Cardiac Failure</i> , 2020, 26, 470-475.	0.7	253
1294	Will the Quality of Research Remain the Same During the COVID-19 Pandemic?. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2142.	2.4	28
1295	Management and Treatment of COVID-19: The Chinese Experience. <i>Canadian Journal of Cardiology</i> , 2020, 36, 915-930.	0.8	147
1296	Echoes of 2009 H1N1 Influenza Pandemic in the COVID Pandemic. <i>Clinical Therapeutics</i> , 2020, 42, 736-740.	1.1	21
1297	Coronavirus disease 2019 and the cardiovascular system: Impacts and implications. <i>Indian Heart Journal</i> , 2020, 72, 1-6.	0.2	14
1298	Therapeutic management of patients with COVID-19: a systematic review. <i>Infection Prevention in Practice</i> , 2020, 2, 100061.	0.6	161
1299	COVID-19 Clinical Trials. <i>JACC Basic To Translational Science</i> , 2020, 5, 501-517.	1.9	16
1300	COVID-19 Clinical Trials. <i>JACC: CardioOncology</i> , 2020, 2, 254-269.	1.7	12
1301	Weathering the Cytokine Storm in Susceptible Patients with Severe SARS-CoV-2 Infection. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 1798-1801.	2.0	40
1302	Implications of COVID-19 for the management of patients with inflammatory rheumatic diseases. <i>Joint Bone Spine</i> , 2020, 87, 187-189.	0.8	29
1303	Current epidemiological and clinical features of COVID-19; a global perspective from China. <i>Journal of Infection</i> , 2020, 81, 1-9.	1.7	285
1304	Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status. <i>Infection, Genetics and Evolution</i> , 2020, 83, 104327.	1.0	248

#	ARTICLE	IF	CITATIONS
1305	All about COVID-19 in brief. <i>New Microbes and New Infections</i> , 2020, 35, 100678.	0.8	56
1306	El tratamiento de la pandemia por COVID 19. Ante la expectativa de evitar una oportunidad perdida. <i>Revista Clinica Espanola</i> , 2020, 220, 386-387.	0.2	0
1307	Desperate Times Call for Temperate Measures: Practicing Infectious Diseases During a Novel Pandemic. <i>Journal of Infectious Diseases</i> , 2020, 222, 1084-1085.	1.9	3
1308	Multicenter Initial Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 701-715.	0.6	130
1309	Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa130.	0.4	160
1310	How should we treat pregnant women infected with SARS-CoV-2?. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2020, 127, 1050-1052.	1.1	8
1311	COVID-19 in solid organ transplant recipients: A single-center case series from Spain. <i>American Journal of Transplantation</i> , 2020, 20, 1849-1858.	2.6	358
1312	A case of SARS-CoV-2 pneumonia with successful antiviral therapy in a 77-year-old man with a heart transplant. <i>American Journal of Transplantation</i> , 2020, 20, 1925-1929.	2.6	30
1313	Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. <i>Science</i> , 2020, 368, 1331-1335.	6.0	1,135
1314	Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. <i>BMJ, The</i> , 2020, 369, m1443.	3.0	1,226
1315	A Call for Rational Intensive Care in the Era of COVID-19. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2020, 63, 132-133.	1.4	20
1316	Pediatric Characteristics of 2019 Novel Coronavirus: Review of Available Published Literature. <i>Clinical Pediatrics</i> , 2020, 59, 849-852.	0.4	14
1317	Methodological challenges of analysing COVID-19 data during the pandemic. <i>BMC Medical Research Methodology</i> , 2020, 20, 81.	1.4	64
1318	COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country. <i>Pediatric Rheumatology</i> , 2020, 18, 35.	0.9	35
1319	Visit to Singapore Medical Journal during COVID-19 outbreak: learning "beyond" the expectation. <i>Medical Journal of Indonesia</i> , 2020, 29, 3-5.	0.2	2
1320	COVID-19 and the Heart. <i>Circulation Research</i> , 2020, 126, 1443-1455.	2.0	574
1321	Coronavirus Disease 2019 (COVID-19): Considerations for the Competitive Athlete. <i>Sports Health</i> , 2020, 12, 221-224.	1.3	155
1322	The daily impact of COVID-19 in gastroenterology. <i>United European Gastroenterology Journal</i> , 2020, 8, 520-527.	1.6	37

#	ARTICLE	IF	CITATIONS
1323	Generating randomized trial evidence to optimize treatment in the COVID-19 pandemic. <i>Cmaj</i> , 2020, 192, E405-E407.	0.9	36
1324	COVID-19 and Lessons to Be Learned from Prior Coronavirus Outbreaks. <i>Annals of the American Thoracic Society</i> , 2020, 17, 790-794.	1.5	10
1325	Clinical and epidemiologic profile of the initial COVID-19 patients at a tertiary care centre in India. <i>Monaldi Archives for Chest Disease</i> , 2020, 90, .	0.3	148
1326	Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 253-263.	2.3	86
1327	Computed tomography imaging of an HIV-1 infected patient with coronavirus disease 2019. <i>Journal of Medical Virology</i> , 2020, 92, 1774-1776.	2.5	41
1328	Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 110-118.	1.5	1,730
1329	Ongoing Clinical Trials for the Management of the COVID-19 Pandemic. <i>Trends in Pharmacological Sciences</i> , 2020, 41, 363-382.	4.0	311
1330	Drug Evaluation during the Covid-19 Pandemic. <i>New England Journal of Medicine</i> , 2020, 382, 2282-2284.	13.9	133
1331	SARS-CoV-2 outbreak: How can pharmacists help?. <i>Research in Social and Administrative Pharmacy</i> , 2021, 17, 480-482.	1.5	73
1332	Hospital pharmacists' pharmaceutical care for hospitalized patients with COVID-19: Recommendations and guidance from clinical experience. <i>Research in Social and Administrative Pharmacy</i> , 2021, 17, 2027-2031.	1.5	75
1333	When fear and misinformation go viral: Pharmacists' role in deterring medication misinformation during the 'infodemic' surrounding COVID-19. <i>Research in Social and Administrative Pharmacy</i> , 2021, 17, 1954-1963.	1.5	148
1334	Chloroquine and hydroxychloroquine to treat COVID-19: between hope and caution. <i>Clinical Toxicology</i> , 2021, 59, 70-71.	0.8	29
1335	Coronavirus Disease (COVID-19): A primer for emergency physicians. <i>American Journal of Emergency Medicine</i> , 2021, 44, 220-229.	0.7	201
1336	Every cloud: how the COVID-19 pandemic may benefit child health. <i>Pediatric Research</i> , 2021, 89, 413-414.	1.1	2
1337	Many brains are better than one: the importance of interdisciplinary studies on COVID-19 in and beyond tourism. <i>Tourism Recreation Research</i> , 2021, 46, 310-313.	3.3	123
1338	Non-evidenced based treatment: An unintended cause of morbidity and mortality related to COVID-19. <i>American Journal of Emergency Medicine</i> , 2021, 39, 221-222.	0.7	21
1339	Never Give Up: Lesson learned from a severe COVID-19 patient. <i>Pulmonology</i> , 2021, 27, 257-260.	1.0	0
1340	Pharmacotherapy for hospitalized patients with COVID-19: Waiting or doing?. <i>Research in Social and Administrative Pharmacy</i> , 2021, 17, 2049.	1.5	1

#	ARTICLE	IF	CITATIONS
1341	Overview of transnational recommendations for COVID-19 transmission control in dental care settings. <i>Oral Diseases</i> , 2021, 27, 655-664.	1.5	96
1342	SARS-CoV-2 infection presenting as ST-elevation myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, E339-E342.	0.7	10
1343	Can Zn Be a Critical Element in COVID-19 Treatment?. <i>Biological Trace Element Research</i> , 2021, 199, 550-558.	1.9	100
1344	Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19. <i>Journal of Infection</i> , 2021, 82, 159-198.	1.7	14
1345	Inmunoglobulinas por vía intravenosa: una alternativa terapéutica a tener en cuenta en el paciente trasplantado renal con COVID-19. <i>Nefrología</i> , 2021, 41, 220-222.	0.2	2
1346	Poor outcome in patients with acute leukemia on intensive chemotherapy and COVID-19. <i>Bone Marrow Transplantation</i> , 2021, 56, 267-269.	1.3	17
1347	Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection. <i>Journal of Chemotherapy</i> , 2021, 33, 193-197.	0.7	13
1348	Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. <i>Journal of Medical Virology</i> , 2021, 93, 481-490.	2.5	83
1349	Lopinavir/ritonavir is associated with pneumonia resolution in COVID-19 patients with influenza coinfection: A retrospective matched-pair cohort study. <i>Journal of Medical Virology</i> , 2021, 93, 472-480.	2.5	20
1350	The future is now: a call for action for cardiac telerehabilitation in the COVID-19 pandemic from the secondary prevention and rehabilitation section of the European Association of Preventive Cardiology. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 524-540.	0.8	146
1351	COVID-19 and therapeutic drugs repurposing in hand: The need for collaborative efforts. <i>Pharmacie Hospitalier Et Clinicien</i> , 2021, 56, 3-11.	0.3	16
1352	Severe COVID-19 in a patient with chronic graft-versus-host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib. <i>Transplant Infectious Disease</i> , 2021, 23, e13401.	0.7	26
1353	COVID-19 in Immunocompromised Hosts: What We Know So Far. <i>Clinical Infectious Diseases</i> , 2021, 72, 340-350.	2.9	389
1354	SARS-CoV-2 infection in kidney transplant recipients: Early report of five cases. <i>Transplant Infectious Disease</i> , 2021, 23, e13394.	0.7	13
1355	Severe Acute Respiratory Syndrome Coronavirus-2 Cardiovascular Complications: Implications for Cardiothoracic Anesthesiology. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2021, 35, 932-943.	0.6	2
1356	Clinical Outcomes and Immunologic Characteristics of Coronavirus Disease 2019 in People With Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2021, 223, 403-408.	1.9	76
1357	A Double-Edged Sword? Cardiovascular Concerns of Potential Anti-COVID-19 Drugs. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 205-214.	1.3	18
1358	Impaired glucose metabolism in patients with diabetes, prediabetes, and obesity is associated with severe COVID-19. <i>Journal of Medical Virology</i> , 2021, 93, 409-415.	2.5	141

#	ARTICLE	IF	CITATIONS
1359	Heparin 2.0: A New Approach to the Infection Crisis. <i>Blood Purification</i> , 2021, 50, 28-34.	0.9	69
1360	Surprise!. <i>American Journal of Epidemiology</i> , 2021, 190, 191-193.	1.6	25
1361	Recent insights for the emerging COVID-19: Drug discovery, therapeutic options and vaccine development. <i>Asian Journal of Pharmaceutical Sciences</i> , 2021, 16, 4-23.	4.3	46
1362	In silico identification of strong binders of the SARS-CoV-2 receptor-binding domain. <i>European Journal of Pharmacology</i> , 2021, 890, 173701.	1.7	17
1363	Role of favipiravir in the treatment of COVID-19. <i>International Journal of Infectious Diseases</i> , 2021, 102, 501-508.	1.5	293
1364	MuLBSTA score is a useful tool for predicting COVID-19 disease behavior. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 284-290.	0.8	11
1365	Immunopathological similarities between COVID-19 and influenza: Investigating the consequences of Co-infection. <i>Microbial Pathogenesis</i> , 2021, 152, 104554.	1.3	88
1366	Adverse events associated with potential drugs for COVID-19: a case study from real-world data. <i>Briefings in Bioinformatics</i> , 2021, 22, 1232-1238.	3.2	10
1367	A review on drug repurposing applicable to COVID-19. <i>Briefings in Bioinformatics</i> , 2021, 22, 726-741.	3.2	117
1368	Detection and quantification of Covid-19 antiviral drugs in biological fluids and tissues. <i>Talanta</i> , 2021, 224, 121862.	2.9	43
1369	An overview on the use of antivirals for the treatment of patients with COVID19 disease. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 45-59.	1.9	4
1370	Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry. <i>Internal and Emergency Medicine</i> , 2021, 16, 957-966.	1.0	22
1371	A computational study to disclose potential drugs and vaccine ensemble for COVID-19 conundrum. <i>Journal of Molecular Liquids</i> , 2021, 324, 114734.	2.3	15
1372	Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment. <i>Biomedical Journal</i> , 2021, 44, 43-53.	1.4	41
1373	Treating COVID-19: are we missing out the window of opportunity?. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 283-285.	1.3	19
1374	Experience of SARS-CoV-2 infection in two kidney transplant recipients living with HIV-1 infection. <i>Transplant Infectious Disease</i> , 2021, 23, e13500.	0.7	3
1375	SARS-CoV-2 and the pandemic of COVID-19. <i>Postgraduate Medical Journal</i> , 2021, 97, 110-116.	0.9	179
1376	Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 284-291.	1.0	24

#	ARTICLE	IF	CITATIONS
1377	Insights on 3D Structures of Potential Drug-Targeting Proteins of SARS-CoV-2: Application of Cavity Search and Molecular Docking. <i>Molecular Informatics</i> , 2021, 40, e2000096.	1.4	13
1378	COVID-19 in patients with HIV-1 infection: a single-centre experience in northern Italy. <i>Infection</i> , 2021, 49, 333-337.	2.3	33
1379	Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. <i>Journal of Hepatology</i> , 2021, 74, 148-155.	1.8	261
1380	Effectiveness of a On-site Medicalization Program for Nursing Homes With COVID-19 Outbreaks. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, e19-e27.	1.7	20
1381	Emerging Human Coronavirus Infections (SARS, MERS, and COVID-19): Where They Are Leading Us. <i>International Reviews of Immunology</i> , 2021, 40, 5-53.	1.5	20
1382	Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells. <i>Journal of Medical Virology</i> , 2021, 93, 1403-1408.	2.5	94
1383	Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort study. <i>Journal of Medical Virology</i> , 2021, 93, 1421-1427.	2.5	24
1384	Lung Ultrasound in COVID-19 A Role Beyond the Acute Phase?. <i>Journal of Ultrasound in Medicine</i> , 2021, 40, 503-511.	0.8	11
1385	Plastic Surgery in the Time of COVID-19. <i>Journal of Reconstructive Microsurgery</i> , 2021, 37, 124-131.	1.0	24
1386	Viral Infections of the Upper Airway in the Setting of COVID-19: A Primer for Rhinologists. <i>American Journal of Rhinology and Allergy</i> , 2021, 35, 122-131.	1.0	5
1387	Response to: Letter to the Editor on "Bonafá M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. <i>Cytokine Growth Factor Reviews</i> by Eugenia Quiros-Roldan, Giorgio Biasiotto and Isabella Zanella. <i>Cytokine and Growth Factor Reviews</i> , 2021, 58, 141-143.	3.2	9
1388	COVID-19 and AIDS: Outcomes from the coexistence of two global pandemics and the importance of chronic antiretroviral therapy. <i>Journal of Medical Virology</i> , 2021, 93, 641-643.	2.5	12
1389	Antivirals for COVID-19: A critical review. <i>Clinical Epidemiology and Global Health</i> , 2021, 9, 90-98.	0.9	127
1390	QSAR Modeling of SARS-CoV-2 Inhibitors Identifies Sufugolix, Cenicriviroc, Proglumetacin, and other Drugs as Candidates for Repurposing against SARS-CoV-2. <i>Molecular Informatics</i> , 2021, 40, e2000113.	1.4	57
1391	Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19. <i>Drug Development Research</i> , 2021, 82, 12-26.	1.4	15
1392	HIV and COVID-19: Intersecting Epidemics With Many Unknowns. <i>American Journal of Epidemiology</i> , 2021, 190, 10-16.	1.6	62
1393	Abnormal laboratory findings and plasma concentration monitoring of lopinavir and ritonavir in COVID-19. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1547-1553.	1.1	9
1394	Covid-19 and the cardiovascular system: a comprehensive review. <i>Journal of Human Hypertension</i> , 2021, 35, 4-11.	1.0	238

#	ARTICLE	IF	CITATIONS
1395	Systematic review and meta-analysis of effectiveness of treatment options against SARS-CoV-2 infection. <i>Journal of Medical Virology</i> , 2021, 93, 775-785.	2.5	19
1396	Clinical outcomes and adverse events in patients hospitalised with COVID-19, treated with off-label hydroxychloroquine and azithromycin. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1150-1154.	1.1	30
1397	Treatment of COVID-19 Pneumonia: the Case for Placenta-derived Cell Therapy. <i>Stem Cell Reviews and Reports</i> , 2021, 17, 63-70.	1.7	5
1398	COVID-19 – Important considerations for developing and using a vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 414-415.	1.4	3
1399	Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection. <i>Heart and Vessels</i> , 2021, 36, 115-120.	0.5	16
1400	Tratamiento farmacológico de la COVID-19: revisión narrativa de los Grupos de Trabajo de Enfermedades Infecciosas y Sepsis (GTEIS) y del Grupo de Trabajo de Transfusiones Hemoderivados (GTTH). <i>Medicina Intensiva</i> , 2021, 45, 104-121.	0.4	18
1401	Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19. <i>Clinical Microbiology and Infection</i> , 2021, 27, 112-117.	2.8	33
1402	Primed for global coronavirus pandemic: Emerging research and clinical outcome. <i>European Journal of Medicinal Chemistry</i> , 2021, 209, 112862.	2.6	24
1403	Characteristics of SARS-CoV-2 and COVID-19. <i>Nature Reviews Microbiology</i> , 2021, 19, 141-154.	13.6	3,334
1404	External validation of a clinical risk score to predict hospital admission and in-hospital mortality in COVID-19 patients. <i>Annals of Medicine</i> , 2021, 53, 78-86.	1.5	30
1406	Early prediction of mortality risk among patients with severe COVID-19, using machine learning. <i>International Journal of Epidemiology</i> , 2021, 49, 1918-1929.	0.9	92
1407	Inflammation Triggered by SARS-CoV-2 and ACE2 Augment Drives Multiple Organ Failure of Severe COVID-19: Molecular Mechanisms and Implications. <i>Inflammation</i> , 2021, 44, 13-34.	1.7	162
1408	An Assessment on Impact of COVID-19 Infection in a Gender Specific Manner. <i>Stem Cell Reviews and Reports</i> , 2021, 17, 94-112.	1.7	37
1409	COVID-19 outbreak in Italy: Clinical-radiological presentation and outcome in three oncologic patients. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 99-102.	0.8	1
1410	Potentially fatal severe brady arrhythmias related to Lopinavir-Ritonavir in a COVID 19 patient. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 133-135.	1.5	2
1411	Can N-3 polyunsaturated fatty acids be considered a potential adjuvant therapy for COVID-19-associated cardiovascular complications?. , 2021, 219, 107703.		50
1412	COVID-19: Discovery, diagnostics and drug development. <i>Journal of Hepatology</i> , 2021, 74, 168-184.	1.8	302
1413	Corticosteroids as adjunctive therapy in the treatment of coronavirus disease 2019: A report of two cases and literature review. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 94-98.	0.8	7

#	ARTICLE	IF	CITATIONS
1414	<scp>SARSâ€COV</scp>â€2 (<scp>COVID</scp>â€19): Cellular and biochemical properties and pharmacological insights into new therapeutic developments. Cell Biochemistry and Function, 2021, 39, 10-28.	1.4	13
1415	Prevention and treatment of COVID-19 using Traditional Chinese Medicine: A review. Phytomedicine, 2021, 85, 153308.	2.3	167
1416	Antiviral therapies: advances and perspectives. Fundamental and Clinical Pharmacology, 2021, 35, 305-320.	1.0	30
1417	Targeting pivotal inflammatory pathways in COVID-19: A mechanistic review. European Journal of Pharmacology, 2021, 890, 173620.	1.7	24
1418	COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. Postgraduate Medical Journal, 2021, 97, 312-320.	0.9	444
1419	Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nature Reviews Nephrology, 2021, 17, 46-64.	4.1	444
1420	The roles of nausea and vomiting in COVID-19: did we miss something?. Journal of Microbiology, Immunology and Infection, 2021, 54, 541-546.	1.5	20
1421	MCCS: a novel recognition pattern-based method for fast track discovery of anti-SARS-CoV-2 drugs. Briefings in Bioinformatics, 2021, 22, 946-962.	3.2	21
1422	Shufeng Jiedu, a promising herbal therapy for moderate COVID-19:Antiviral and anti-inflammatory properties, pathways of bioactive compounds, and a clinical real-world pragmatic study. Phytomedicine, 2021, 85, 153390.	2.3	60
1423	SARS-CoV-2 (COVID-19) in patients with some degree of immunosuppression. ReumatologÃa ClÃnica (English Edition), 2021, 17, 408-419.	0.2	17
1424	Computational Intelligence Methods in COVID-19: Surveillance, Prevention, Prediction and Diagnosis. Studies in Computational Intelligence, 2021, , .	0.7	0
1425	Pharmacological insight into potential therapeutic agents for the deadly Covid-19 pandemic. European Journal of Pharmacology, 2021, 890, 173643.	1.7	14
1426	Evidence and speculations: vaccines and therapeutic options for COVID-19 pandemic. Human Vaccines and Immunotherapeutics, 2021, 17, 1113-1121.	1.4	4
1427	COVID 19 and liver: An Aâ€Z literature review. Digestive and Liver Disease, 2021, 53, 146-152.	0.4	65
1428	Anti-COVID-19 terpenoid from marine sources: A docking, admet and molecular dynamics study. Journal of Molecular Structure, 2021, 1228, 129433.	1.8	44
1429	Characteristics and Management of Children With COVID-19 in a Tertiary Care Hospital in Turkey. Clinical Pediatrics, 2021, 60, 170-177.	0.4	17
1430	Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis. Journal of Antimicrobial Chemotherapy, 2021, 76, 286-291.	1.3	29
1431	Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients. European Journal of Clinical Pharmacology, 2021, 77, 389-397.	0.8	15

#	ARTICLE	IF	CITATIONS
1432	Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus. <i>Journal of Molecular Graphics and Modelling</i> , 2021, 102, 107769.	1.3	18
1433	C4 article: Implications of COVID-19 in transplantation. <i>American Journal of Transplantation</i> , 2021, 21, 1801-1815.	2.6	15
1434	Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis. <i>Journal of Clinical Immunology</i> , 2021, 41, 303-314.	2.0	41
1435	Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 29, 115860.	1.4	126
1436	Risk factors for severe and critically ill COVID-19 patients: A review. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 428-455.	2.7	904
1437	<scp>COVID</scp>â€19 in Australia: our national response to the first cases of <scp>SARSâ€CoV</scp>â€2 infection during the early biocontainment phase. <i>Internal Medicine Journal</i> , 2021, 51, 42-51.	0.5	3
1438	Effect and safety of Chinese herbal medicine granules in patients with severe coronavirus disease 2019 in Wuhan, China: a retrospective, single-center study with propensity score matching. <i>Phytomedicine</i> , 2021, 85, 153404.	2.3	16
1439	Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 679-687.	2.0	13
1440	Continuous renal replacement therapy with the addition of CytoSorb cartridge in critically ill patients with COVID-19 plus acute kidney injury: A caseâ€series. <i>Artificial Organs</i> , 2021, 45, E101-E112.	1.0	54
1441	Novel coronavirus disease (COVID-19) update on epidemiology, pathogenicity, clinical course and treatments. <i>International Journal of Clinical Practice</i> , 2021, 75, e13868.	0.8	54
1442	Novaferon, treatment in COVID-19 patients. <i>International Journal of Infectious Diseases</i> , 2021, 103, 297.	1.5	2
1443	Evaluation of acridinedione analogs as potential SARS-CoV-2 main protease inhibitors and their comparison with repurposed anti-viral drugs. <i>Computers in Biology and Medicine</i> , 2021, 128, 104117.	3.9	90
1444	A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center. <i>Journal of Autoimmunity</i> , 2021, 117, 102580.	3.0	23
1445	Nanotechnology for virus treatment. <i>Nano Today</i> , 2021, 36, 101031.	6.2	58
1446	Key genetic elements, single and in clusters, underlying geographically dependent SARS-CoV-2 genetic adaptation and their impact on binding affinity for drugs and immune control. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 396-412.	1.3	16
1447	Repurposing medications. <i>Ocular Surface</i> , 2021, 19, 336-340.	2.2	18
1448	Impact of SARS-CoV-2 Pandemic on Patients with Primary Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2021, 41, 345-355.	2.0	97
1449	One year update on the COVID-19 pandemic: Where are we now?. <i>Acta Tropica</i> , 2021, 214, 105778.	0.9	142

#	ARTICLE	IF	CITATIONS
1450	Nucleic Acid-Based Technologies Targeting Coronaviruses. Trends in Biochemical Sciences, 2021, 46, 351-365.	3.7	35
1451	Repurposed Antiviral Drugs for Covid-19 " Interim WHO Solidarity Trial Results. New England Journal of Medicine, 2021, 384, 497-511.	13.9	2,014
1452	The role of CT chest in screening for asymptomatic COVID-19 infection in self-isolating patients prior to elective oncological surgery: findings from a UK Cancer Hub. British Journal of Radiology, 2021, 94, 20200994.	1.0	8
1453	Interpretative immune targets and contemporary position for vaccine development against SARS-CoV-2: A systematic review. Journal of Medical Virology, 2021, 93, 1967-1982.	2.5	15
1454	COVID-19 in people living with HIV: A multicenter case-series study. International Journal of Infectious Diseases, 2021, 102, 310-315.	1.5	41
1455	A comparative analysis for anti-viral drugs: Their efficiency against SARS-CoV-2. International Immunopharmacology, 2021, 90, 107232.	1.7	27
1456	SARS-CoV-2: Targeted managements and vaccine development. Cytokine and Growth Factor Reviews, 2021, 58, 16-29.	3.2	44
1457	WGO Guidance for the Care of Patients With COVID-19 and Liver Disease. Journal of Clinical Gastroenterology, 2021, 55, 1-11.	1.1	37
1458	COVID-19; current situation and recommended interventions. International Journal of Clinical Practice, 2021, 75, e13886.	0.8	18
1459	Drug repurposing approach to combating coronavirus: Potential drugs and drug targets. Medicinal Research Reviews, 2021, 41, 1375-1426.	5.0	28
1460	Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies. Archives of Medical Research, 2021, 52, 261-269.	1.5	14
1461	Inclusion complexation of chloroquine with β and γ -cyclodextrin: Theoretical insights from the new B97-3c composite method. Journal of Molecular Structure, 2021, 1227, 129696.	1.8	21
1462	Repurposing potential of FDA-approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm. Chemical Biology and Drug Design, 2021, 97, 836-853.	1.5	36
1463	Risk factors of liver injury in patients with coronavirus disease 2019 in Jiangsu, China: A retrospective, multi-center study. Journal of Medical Virology, 2021, 93, 3305-3311.	2.5	11
1464	Stem cell therapy in coronavirus disease 2019: current evidence and future potential. Cytotherapy, 2021, 23, 471-482.	0.3	11
1465	Effects and safety of herbal medicines among community-dwelling residents during COVID-19 pandemic: A large prospective, randomized controlled trial (RCT). Phytomedicine, 2021, 85, 153403.	2.3	12
1466	Resveratrol inhibits the replication of severe acute respiratory syndrome coronavirus 2 (<sc>SARS-CoV</sc>) in cultured Vero cells. Phytotherapy Research, 2021, 35, 1127-1129.	2.8	76
1467	Combining Antivirals and Immunomodulators to Fight COVID-19. Trends in Immunology, 2021, 42, 31-44.	2.9	46

#	ARTICLE	IF	CITATIONS
1468	An effective drug against COVID-19: reality or dream?. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 505-518.	1.0	11
1469	A comprehensive review on potential therapeutics interventions for COVID-19. <i>European Journal of Pharmacology</i> , 2021, 890, 173741.	1.7	30
1470	Dendritic cells in COVID-19 immunopathogenesis: insights for a possible role in determining disease outcome. <i>International Reviews of Immunology</i> , 2021, 40, 108-125.	1.5	53
1471	Decoding the silent walk of COVID-19: Halting its spread using old bullets. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 110891.	2.5	1
1472	Pharmacokinetics under the COVID-19 storm. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	1.1	12
1473	COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges. <i>Theranostics</i> , 2021, 11, 731-753.	4.6	60
1474	Research response to coronavirus disease 2019 needed better coordination and collaboration: a living mapping of registered trials. <i>Journal of Clinical Epidemiology</i> , 2021, 130, 107-116.	2.4	20
1475	<sc>IDentif</sc>. <sc>AI</sc>: Rapidly optimizing combination therapy design against severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) with digital drug development. <i>Bioengineering and Translational Medicine</i> , 2021, 6, e10196.	3.9	27
1476	COVID-19 in HIV-infected patients: A case series and literature review. <i>Journal of Medical Virology</i> , 2021, 93, 2557-2563.	2.5	12
1477	Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review. <i>Bioorganic Chemistry</i> , 2021, 106, 104490.	2.0	119
1478	Potential inhibitors of SARS-CoV-2: recent advances. <i>Journal of Drug Targeting</i> , 2021, 29, 349-364.	2.1	27
1479	The potential effects of clinical antidiabetic agents on <sc>SARS-CoV</sc>-2. <i>Journal of Diabetes</i> , 2021, 13, 243-252.	0.8	15
1480	Antiretrovirals for Prophylaxis Against COVID-19: A Comprehensive Literature Review. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 581-590.	1.0	19
1481	Investigational Treatments for COVID-19 may Increase Ventricular Arrhythmia Risk Through Drug Interactions. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 100-107.	1.3	22
1482	Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19. <i>Medical Hypotheses</i> , 2021, 146, 110394.	0.8	42
1483	Hydroxychloroquine versus Azithromycin for Hospitalized Patients with COVID-19. Results of a Randomized, Active Comparator Trial. <i>Annals of the American Thoracic Society</i> , 2021, 18, 590-597.	1.5	28
1484	COVID-19 and diabetes mellitus: from pathophysiology to clinical management. <i>Nature Reviews Endocrinology</i> , 2021, 17, 11-30.	4.3	653
1485	A proposal for clinical trials of COVID-19 treatment using homo-harringtonine. <i>National Science Review</i> , 2021, 8, nwaa257.	4.6	9

#	ARTICLE	IF	CITATIONS
1486	Characterising and managing paediatric SARS-CoV-2 infection: Learning about the virus in a global classroom. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2021, 110, 409-422.	0.7	2
1487	Zoonotic coronavirus epidemics. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 321-337.	0.5	8
1488	COVID-19- clinical presentation and therapeutic considerations. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 125-131.	1.0	26
1489	Reporting and design of randomized controlled trials for COVID-19: A systematic review. <i>Contemporary Clinical Trials</i> , 2021, 101, 106239.	0.8	9
1490	Identification of Distinct Immunophenotypes in Critically Ill Coronavirus Disease 2019 Patients. <i>Chest</i> , 2021, 159, 1884-1893.	0.4	20
1491	COVID-19 in hospitalised patients in Spain: a cohort study in Madrid. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106249.	1.1	26
1492	Ritonavir may inhibit exoribonuclease activity of nsp14 from the SARS-CoV-2 virus and potentiate the activity of chain terminating drugs. <i>International Journal of Biological Macromolecules</i> , 2021, 168, 272-278.	3.6	27
1493	Decoding information on COVID-19: Ontological approach towards design possible therapeutics. <i>Informatics in Medicine Unlocked</i> , 2021, 22, 100486.	1.9	4
1494	Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19. <i>Journal of Electrocardiology</i> , 2021, 64, 30-35.	0.4	9
1495	Recent Insights into Emerging Coronavirus: SARS-CoV-2. <i>ACS Infectious Diseases</i> , 2021, 7, 1369-1388.	1.8	27
1496	Repurposing drugs for the management of COVID-19. <i>Expert Opinion on Therapeutic Patents</i> , 2021, 31, 295-307.	2.4	49
1497	A systematic review on treatment-related mucocutaneous reactions in COVID-19 patients. <i>Dermatologic Therapy</i> , 2021, 34, e14662.	0.8	26
1498	Risk and Management of Venous Thromboembolism in Patients with COVID-19. <i>Annals of Vascular Surgery</i> , 2021, 73, 78-85.	0.4	8
1499	A retrospective comparison of drugs against COVID-19. <i>Virus Research</i> , 2021, 294, 198262.	1.1	12
1500	Synergistic and Antagonistic Drug Combinations against SARS-CoV-2. <i>Molecular Therapy</i> , 2021, 29, 873-885.	3.7	78
1501	Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 206-212.	2.5	27
1502	Dynamic anti-spike protein antibody profiles in COVID-19 patients. <i>International Journal of Infectious Diseases</i> , 2021, 103, 540-548.	1.5	25
1503	Convalescent plasma may be a possible treatment for COVID-19: A systematic review. <i>International Immunopharmacology</i> , 2021, 91, 107262.	1.7	37

#	ARTICLE	IF	CITATIONS
1504	Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of <i>in vitro</i>, <i>in vivo</i>, and clinical trials. <i>Theranostics</i> , 2021, 11, 1207-1231.	4.6	24
1505	Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 753-757.	1.3	50
1506	A novel, automated, quantification of abnormal lung parenchyma in patients with COVID-19 infection: Initial description of feasibility and association with clinical outcome. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2021, 40, 100780.	0.6	6
1507	A brief review on potential application of mesenchymal stem cell and secretome in combating mortality and morbidity in COVID-19 patients. <i>Biomedical Journal</i> , 2021, 44, 63-73.	1.4	14
1508	Virological cure, clinical efficacy and safety of Remdesivir supplementation against SARS-CoV 2 infection; evidence from human studies. <i>Pharmacie Hospitalier Et Clinicien</i> , 2021, 56, 90-93.	0.3	0
1509	Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel. <i>European Journal of Pharmacology</i> , 2021, 893, 173813.	1.7	26
1510	COVID-19 and Solid Organ Transplantation: A Review Article. <i>Transplantation</i> , 2021, 105, 37-55.	0.5	241
1511	Direct hemoperfusion using a polymyxin B-immobilized polystyrene column for COVID-19. <i>Journal of Clinical Apheresis</i> , 2021, 36, 313-321.	0.7	29
1513	Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 1-15.	1.9	18
1514	Biocatalytic routes to anti-viral agents and their synthetic intermediates. <i>Chemical Society Reviews</i> , 2021, 50, 1968-2009.	18.7	39
1515	COVID-19. <i>Critical Care Nursing Quarterly</i> , 2021, 44, 128-137.	0.4	17
1516	The Decline of the Experimental Paradigm During the COVID-19 Pandemic: A Template for the Future. <i>American Journal of Medicine</i> , 2021, 134, 166-175.	0.6	11
1517	Clinical predictors of COVID-19 disease progression and death: Analysis of 214 hospitalised patients from Wuhan, China. <i>Clinical Respiratory Journal</i> , 2021, 15, 293-309.	0.6	17
1518	Evidence-Based Management of the Critically Ill Adult With SARS-CoV-2 Infection. <i>Journal of Intensive Care Medicine</i> , 2021, 36, 18-41.	1.3	7
1519	Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 157, 105631.	1.9	141
1520	Challenges of drug development during the COVID-19 pandemic: Key considerations for clinical trial designs. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2170-2185.	1.1	15
1521	Emerging treatment strategies for COVID-19 infection. <i>Clinical and Experimental Medicine</i> , 2021, 21, 167-179.	1.9	232
1522	The comprehensive study on the therapeutic effects of baicalin for the treatment of COVID-19 in vivo and in vitro. <i>Biochemical Pharmacology</i> , 2021, 183, 114302.	2.0	98

#	ARTICLE	IF	CITATIONS
1523	Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically ill patients with COVID-19. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 454-459.	0.7	22
1524	Transfusion reactions associated with COVID-19 convalescent plasma therapy for SARS-CoV-2. <i>Transfusion</i> , 2021, 61, 78-93.	0.8	17
1525	Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 27-36.	1.5	28
1526	COVID-19 in transplant recipients: The Spanish experience. <i>American Journal of Transplantation</i> , 2021, 21, 1825-1837.	2.6	156
1527	Clinical characteristics of COVID-19 patients with HIV coinfection in Wuhan, China. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 403-409.	1.0	15
1528	Repurposed Drugs, Molecular Vaccines, Immune Modulators, and Nanotherapeutics to Treat and Prevent COVID-19 Associated with SARS-CoV-2, a Deadly Nanovector. <i>Advanced Therapeutics</i> , 2021, 4, 2000172.	1.6	24
1529	An enlightening role for cytokine storm in coronavirus infection. <i>Clinical Immunology</i> , 2021, 222, 108615.	1.4	27
1530	Recent progress of antiviral therapy for coronavirus disease 2019. <i>European Journal of Pharmacology</i> , 2021, 890, 173646.	1.7	32
1531	Clinical Characteristics, Treatment, and Outcomes of Critically Ill Patients With COVID-19: A Scoping Review. <i>Mayo Clinic Proceedings</i> , 2021, 96, 183-202.	1.4	62
1532	Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience. <i>Internal and Emergency Medicine</i> , 2021, 16, 669-675.	1.0	19
1533	Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia. <i>International Journal of Infectious Diseases</i> , 2021, 102, 303-309.	1.5	9
1534	Combating COVID-19: The role of drug repurposing and medicinal plants. <i>Journal of Infection and Public Health</i> , 2021, 14, 495-503.	1.9	43
1535	Efficacy and safety of Chinese herbal medicine versus Lopinavir-Ritonavir in adult patients with coronavirus disease 2019: A non-randomized controlled trial. <i>Phytomedicine</i> , 2021, 81, 153367.	2.3	48
1536	Union is strength: antiviral and anti-inflammatory drugs for COVID-19. <i>Drug Discovery Today</i> , 2021, 26, 229-239.	3.2	23
1537	Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study. <i>International Journal of Infectious Diseases</i> , 2021, 102, 275-281.	1.5	8
1538	Prospective Longitudinal Evaluation of Point-of-Care Lung Ultrasound in Critically Ill Patients With Severe COVID-19 Pneumonia. <i>Journal of Ultrasound in Medicine</i> , 2021, 40, 443-456.	0.8	40
1539	Evaluating the Efficacy of Therapies in Patients With Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2021, 72, 1093-1100.	2.9	5
1540	Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study. <i>Leukemia</i> , 2021, 35, 1121-1133.	3.3	61

#	ARTICLE	IF	CITATIONS
1541	Efficacy of favipiravir for an end stage renal disease patient on maintenance hemodialysis infected with novel coronavirus disease 2019. <i>CEN Case Reports</i> , 2021, 10, 126-131.	0.5	22
1542	Chemosensory Dysfunction in COVID-19: Prevalences, Recovery Rates, and Clinical Associations on a Large Brazilian Sample. <i>Otolaryngology - Head and Neck Surgery</i> , 2021, 164, 512-518.	1.1	59
1543	SARS-CoV-2 infection in people living with HIV : a systematic review. <i>Reviews in Medical Virology</i> , 2021, 31, 1-12.	3.9	64
1544	Impact of COVID-19 Pandemic on Health-Related Quality of Life in Uro-oncologic Patients: What Should We Wait For?. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e63-e68.	0.9	28
1545	Beyond dexamethasone, emerging immunothrombotic therapies for COVID-19. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 845-857.	1.1	6
1546	Therapeutics for COVID-19: from computation to practices"where we are, where we are heading to. <i>Molecular Diversity</i> , 2021, 25, 625-659.	2.1	53
1547	Comment on: Favipiravir, an antiviral for COVID-19?. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 279-280.	1.3	2
1548	Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis. <i>BMJ Supportive and Palliative Care</i> , 2021, 11, 45-52.	0.8	36
1549	Double-blind, Randomized, Placebo-controlled Trial With N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by Coronavirus Disease 2019 (COVID-19). <i>Clinical Infectious Diseases</i> , 2021, 72, e736-e741.	2.9	70
1550	Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: A preliminary report. <i>Journal of Medical Virology</i> , 2021, 93, 1678-1686.	2.5	37
1551	Pregnancy and COVID-19: pharmacologic considerations. <i>Ultrasound in Obstetrics and Gynecology</i> , 2021, 57, 195-203.	0.9	57
1552	Multisystem inflammatory syndrome associated with COVID-19 from the pediatric emergency physician's point of view. <i>Jornal De Pediatria</i> , 2021, 97, 140-159.	0.9	38
1553	Molecular dynamics simulation of docking structures of SARS-CoV-2 main protease and HIV protease inhibitors. <i>Journal of Molecular Structure</i> , 2021, 1225, 129143.	1.8	30
1554	Cardiovascular Pathophysiology, Epidemiology, and Treatment Considerations of Coronavirus Disease 2019 (COVID-19): A Review. <i>CJC Open</i> , 2021, 3, 28-40.	0.7	7
1555	Single-cell transcriptomic atlas of primate cardiopulmonary aging. <i>Cell Research</i> , 2021, 31, 415-432.	5.7	88
1556	The effect of antivirals on COVID-19: a systematic review. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 473-486.	2.0	10
1557	Drugs, host proteins and viral proteins: how their promiscuities shape antiviral design. <i>Biological Reviews</i> , 2021, 96, 205-222.	4.7	7
1558	Impact of COVID-19 on the Cardiovascular System: A Review of Available Reports. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 411-425.	1.3	48

#	ARTICLE	IF	CITATIONS
1559	The Longitudinal Immune Response to Coronavirus Disease 2019: Chasing the Cytokine Storm. <i>Arthritis and Rheumatology</i> , 2021, 73, 23-35.	2.9	47
1560	Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with Cardioactive Medications. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 427-440.	1.3	18
1561	Multicenter Interim Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 34-48.	0.6	85
1562	SARS-CoV-2: Mechanism of infection and emerging technologies for future prospects. <i>Reviews in Medical Virology</i> , 2021, 31, e2168.	3.9	28
1563	Antibody Responses and Clinical Outcomes in Adults Hospitalized With Severe Coronavirus Disease 2019 (COVID-19): A Post hoc Analysis of LOTUS China Trial. <i>Clinical Infectious Diseases</i> , 2021, 72, e545-e551.	2.9	34
1564	Potential small-molecule drugs as available weapons to fight novel coronavirus (<sc>2019-nCoV</sc>): A review. <i>Cell Biochemistry and Function</i> , 2021, 39, 4-9.	1.4	8
1565	Management of SARS-CoV-2 pneumonia. <i>Journal of Medical Virology</i> , 2021, 93, 1276-1287.	2.5	22
1566	A novel approach to managing COVID-19 patients; results of lopinavir plus doxycycline cohort. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 407-411.	1.3	8
1567	Coronavirus Disease-2019 Treatment Strategies Targeting Interleukin-6 Signaling and Herbal Medicine. <i>OMICS A Journal of Integrative Biology</i> , 2021, 25, 13-22.	1.0	16
1568	COVID-19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays. <i>Medicinal Research Reviews</i> , 2021, 41, 5-28.	5.0	72
1569	Lines of Treatment of COVID-19 Infection. , 2021, , 91-144.		1
1570	Immune response and possible therapeutics in COVID-19. <i>RSC Advances</i> , 2021, 11, 960-977.	1.7	7
1571	COVID-19 FAQs in paediatric and congenital cardiology: AEPC position paper. <i>Cardiology in the Young</i> , 2021, 31, 344-351.	0.4	7
1572	ACE2 Can Act as the Secondary Receptor in the FcγR-Dependent ADE of SARS-CoV-2. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1574	Exploration of FDA-approved drug interactions with SARS-CoV2 main protease using structure-based virtual screening and MM-GBSA binding free energy methods. <i>AIP Conference Proceedings</i> , 2021, , .	0.3	1
1575	Diagnosis and treatment of 471 patients with 2019 novel coronavirus disease (COVID-19). <i>Annals of Translational Medicine</i> , 2021, 9, 163-163.	0.7	0
1576	DETAILED VIEW ON REPURPOSED DRUGS, TRACKING OF VACCINES, AND BRIEF VIEW ON PROPHYLACTIC NANOMEDICINES AS AN ALTERNATIVE APPROACH AND PATIENT CARE FOR COVID-19. <i>International Journal of Applied Pharmaceutics</i> , 0, , 19-26.	0.3	2
1577	COVID-19: What Should the General Practitioner Know?. <i>Clinical Interventions in Aging</i> , 2021, Volume 16, 43-56.	1.3	7

#	ARTICLE	IF	CITATIONS
1578	The Current Understanding and Potential Therapeutic Options to Combat COVID-19. SSRN Electronic Journal, 0, , .	0.4	0
1579	COVID-19 Treatment: Drug Safety Prior to Conception and During Pregnancy and Breastfeeding. Geburtshilfe Und Frauenheilkunde, 2021, 81, 46-60.	0.8	7
1580	Overview of an Emerging Coronavirus Infection, COVID-19: Current Status of Vaccine Development and Therapeutics. Pharmacology & Pharmacy, 2021, 12, 25-41.	0.2	0
1581	Arrhythmias in the Age of Coronavirus Disease 2019. Journal of Innovations in Cardiac Rhythm Management, 2021, 12, 4345-4348.	0.2	0
1583	A Narration: 20th v/s 21st Century: Pandemic v/s Another Pandemic: Virus v/s Another Virus (Spanish) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.1	0
1584	Characteristics of Tâ€œcell responses in COVIDâ€™19 patients with prolonged SARSâ€™CoVâ€™2 positivity â€œ a cohort study. Clinical and Translational Immunology, 2021, 10, e1259.	1.7	17
1585	The soluble catalytic ectodomain of ACE2 a biomarker of cardiac remodelling: new insights for heart failure and COVID19. Heart Failure Reviews, 2021, 26, 961-971.	1.7	10
1586	Is liver involvement overestimated in COVID-19 patients? A meta-analysis. International Journal of Medical Sciences, 2021, 18, 1285-1296.	1.1	11
1587	New Insights Into Drug Repurposing for COVID-19 Using Deep Learning. IEEE Transactions on Neural Networks and Learning Systems, 2021, 32, 4770-4780.	7.2	10
1588	Causal Therapy of COVID-19: Critical Review and Prospects. Obshchaya Reanimatologiya, 2021, 16, 65-90.	0.2	8
1589	The Use of <i>In Silico</i> Tools for the Toxicity Prediction of Potential Inhibitors of SARS-CoV-2. ATLA Alternatives To Laboratory Animals, 2021, 49, 22-32.	0.7	9
1590	Could repurposing existing vaccines and antibiotics help to control the COVID-19 pandemic?. , 2021, , 245-255.		0
1591	Pathogenic Human Coronaviruses. , 2021, , .		5
1592	Respiratory Tract Infections: Viruses. , 2021, , .		0
1593	Utility of early warning scores to predict mortality in COVID-19 patients: A retrospective observational study. International Journal of Critical Illness and Injury Science, 2021, 11, 161.	0.2	9
1594	Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents. Communications Biology, 2021, 4, 93.	2.0	158
1595	Review of pharmacologic and immunologic agents in the management of COVID-19. Biosafety and Health, 2021, 3, 148-155.	1.2	7
1596	Drug Discovery by Drug Repurposing: Combating COVID-19 in the 21st Century. Mini-Reviews in Medicinal Chemistry, 2021, 21, 3-9.	1.1	6

#	ARTICLE	IF	CITATIONS
1597	Cardiovascular disease in patients with COVID-19: evidence from cardiovascular pathology to treatment. <i>Acta Biochimica Et Biophysica Sinica</i> , 2021, 53, 273-282.	0.9	30
1598	Old Drugs for New Purpose—Fast Pace Therapeutic Identification for SARS-CoV-2 Infections by Pharmacophore Guided Drug Repositioning Approach. <i>Bulletin of the Korean Chemical Society</i> , 2021, 42, 212-226.	1.0	10
1599	Pharmacists' Role and Pharmaceutical Care During the COVID-19 Pandemic. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1318, 605-622.	0.8	7
1600	Inflammatory pathways and potential therapies for COVID-19: A mini review. <i>European Journal of Inflammation</i> , 2021, 19, 205873922110029.	0.2	6
1601	COVID-19: Recent Developments in Therapeutic Approaches. , 2021, , 249-274.		4
1602	Therapeutic options for COVID-19: a quick review. <i>Journal of Chemotherapy</i> , 2021, 33, 67-84.	0.7	10
1603	A literature review of consent declines and consent withdrawals in randomized controlled trials conducted during the COVID-19 pandemic. <i>Journal of Postgraduate Medicine</i> , 2021, 67, 134-138.	0.2	1
1604	Influence of patient characteristics and immunosuppressant management on mortality in kidney transplant recipients hospitalized with coronavirus disease 2019 (COVID-19). <i>Clinical Transplantation</i> , 2021, 35, e14221.	0.8	21
1605	Chinese Medicine in Fighting against Covid-19: Role and Inspiration. <i>Chinese Journal of Integrative Medicine</i> , 2021, 27, 3-6.	0.7	16
1606	Risk factors for illness severity in patients with COVID-19 pneumonia: a prospective cohort study. <i>International Journal of Medical Sciences</i> , 2021, 18, 921-928.	1.1	8
1607	Identification of multipotent drugs for COVID-19 therapeutics with the evaluation of their SARS-CoV2 inhibitory activity. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 1998-2017.	1.9	39
1608	Post-transplant patients with COVID-19 associated acute respiratory distress syndrome, a role for Tocilizumab: A case series. <i>Respiratory Medicine Case Reports</i> , 2021, 32, 101319.	0.2	2
1609	Ontological modeling and analysis of experimentally or clinically verified drugs against coronavirus infection. <i>Scientific Data</i> , 2021, 8, 16.	2.4	14
1610	Necessary problems in re-emergence of COVID-19. <i>World Journal of Clinical Cases</i> , 2021, 9, 1-7.	0.3	3
1611	Transcriptome profiling of different types of human respiratory tract cells infected by SARS-CoV-2 highlight an unique role for inflammatory and interferon response. <i>International Journal of Transgender Health</i> , 2021, 14, 110-119.	1.1	1
1612	Knowledge-based Modeling of SARS-CoV-2 Proteins and Predicting its Potential Drugs. <i>Seibutsu Butsuri</i> , 2021, 61, 102-106.	0.0	0
1613	Therapeutic and Diagnostic Approaches for SARS-CoV-2. <i>Voice of the Publisher</i> , 2021, 07, 63-79.	0.0	1
1614	COVID-19: can we treat the mother without harming her baby?. <i>Journal of Developmental Origins of Health and Disease</i> , 2021, , 1-11.	0.7	4

#	ARTICLE	IF	CITATIONS
1616	Application of machine learning for the diagnosis of COVID-19. , 2021, , 175-194.		21
1617	Corticosteroid treatment has no effect on hospital mortality in COVID-19 patients. Scientific Reports, 2021, 11, 1015.	1.6	20
1619	An overview of the use of biomaterials, nanotechnology, and stem cells for detection and treatment of COVID-19: towards a framework to address future global pandemics. Emergent Materials, 2021, 4, 19-34.	3.2	21
1620	A review on Coronavirus Disease and potentially active drugs targeting Coronavirus. Biomedical and Biotechnology Research Journal, 2021, 5, 110.	0.3	4
1621	Predictors of Coronavirus Disease 2019 Severity: A Retrospective Study of 64 Cases. Japanese Journal of Infectious Diseases, 2021, 74, 54-60.	0.5	21
1622	Nanotechnology Enabled Solutions to Combat Covid-19: Prevention, Treatment, and Diagnosis. Current Pharmaceutical Biotechnology, 2022, 23, 98-111.	0.9	2
1623	COVID-19 Pandemisinde Kullanılan İlaçlar, Etki Mekanizmaları ve Etkililikleri. Osmangazi Journal of Medicine, 0, 00, .	0.1	2
1624	Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial. Trials, 2021, 22, 71.	0.7	24
1625	Characteristics and outcomes of patients with COVID-19 admitted to hospital and intensive care in the first phase of the pandemic in Canada: a national cohort study. CMAJ Open, 2021, 9, E181-E188.	1.1	49
1626	Computational molecular docking and virtual screening revealed promising SARS-CoV-2 drugs. Precision Clinical Medicine, 2021, 4, 1-16.	1.3	66
1627	Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 147-153.	2.5	29
1628	Review on COVID-19 Etiopathogenesis, Clinical Presentation and Treatment Available with Emphasis on ACE2. Indian Journal of Clinical Biochemistry, 2021, 36, 3-22.	0.9	8
1629	The role of chemical biology in the fight against SARS-CoV-2. Biochemical Journal, 2021, 478, 157-177.	1.7	2
1631	A Recent Achievement in the Discovery and Development of Vaccines and Therapeutic Agents in the Race for COVID-19 Protection and Treatment. Journal of Evidence-based Integrative Medicine, 2021, 26, 2515690X2110037.	1.4	2
1632	Missing clinical trial data: the evidence gap in primary data for potential COVID-19 drugs. Trials, 2021, 22, 59.	0.7	21
1634	COVID-19 Outbreak in Italy: Report on the First 124 Consecutive Patients Treated at Home. Tohoku Journal of Experimental Medicine, 2021, 255, 61-69.	0.5	6
1635	Clinical Characteristics and Prognosis of COPD Patients Hospitalized with SARS-CoV-2. International Journal of COPD, 2020, Volume 15, 3433-3445.	0.9	42
1636	Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19. JAMA - Journal of the American Medical Association, 2021, 325, 254.	3.8	299

#	ARTICLE	IF	CITATIONS
1637	Cancer patients with COVID-19: a retrospective study of 51 patients in the district of Piacenza, Northern Italy. <i>Future Science OA</i> , 2021, 7, FSO645.	0.9	19
1638	COVID-19: treatments and the potential for cardiotoxicity. <i>British Journal of Cardiology</i> , 2021, , .	0.7	3
1639	A Borderless Solution Is Needed for A Borderless Complexity, Like COVID-19, the Universal Invader. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1318, 891-910.	0.8	0
1640	Ongoing Clinical Trials and the Potential Therapeutics for COVID-19 Treatment. , 2021, , 27-89.		0
1641	protocol for a living systematic review. <i>BMJ Open</i> , 2021, 11, e042008.	0.8	5
1642	Transmission, diagnosis, and treatment of coronavirus disease 2020: a review. <i>Journal of Biochemical and Clinical Genetics</i> , 0, , 381-386.	0.1	0
1643	Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies. <i>Frontiers in Physiology</i> , 2021, 12, 593223.	1.3	113
1644	A Narrative Review of Pharmacologic Treatments for <scp>COVID</scp>â€19: Safety Considerations and Ototoxicity. <i>Laryngoscope</i> , 2021, 131, 1626-1632.	1.1	20
1645	Phenolics from the heartwood of <i>Tecoma mollis</i> as potential inhibitors of COVID-19 virus main protease and spike proteins: An In silico study. <i>Pharmacognosy Magazine</i> , 2021, 17, 278.	0.3	3
1646	Safety of pharmacological options for the management of COVID-19 in pregnant women: An Indian perspective. <i>International Journal of Risk and Safety in Medicine</i> , 2021, 32, 3-17.	0.3	4
1647	Why proper understanding of confidence intervals and statistical significance is important. <i>Medical Journal of Australia</i> , 2021, 214, 116.	0.8	10
1648	The protease inhibitor lopinavir, boosted with ritonavir, as treatment for COVID-19: a rapid review. <i>Antiviral Therapy</i> , 2021, 25, 365-376.	0.6	5
1649	â€Update vision on COVID-19: Structure, immune pathogenesis, treatment and safety assessmentâ€. <i>Sensors International</i> , 2021, 2, 100073.	4.9	23
1650	Clinical effectiveness of drugs in hospitalized patients with COVID-19: a systematic review and meta-analysis. <i>Therapeutic Advances in Respiratory Disease</i> , 2021, 15, 175346662110072.	1.0	12
1651	Clinical and Virologic Effectiveness of Remdesivir Treatment for Severe Coronavirus Disease 2019 (COVID-19) in Korea: a Nationwide Multicenter Retrospective Cohort Study. <i>Journal of Korean Medical Science</i> , 2021, 36, e83.	1.1	24
1652	Lessons from the COVID-19 pandemic for advancing computational drug repurposing strategies. <i>Nature Computational Science</i> , 2021, 1, 33-41.	3.8	88
1653	Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study. <i>Emerging Microbes and Infections</i> , 2021, 10, 664-676.	3.0	69
1654	Paucity and Disparity of Publicly Available Sex-Disaggregated Data for the COVID-19 Epidemic Hamper Evidence-Based Decision-Making. <i>Archives of Sexual Behavior</i> , 2021, 50, 407-426.	1.2	15

#	ARTICLE	IF	CITATIONS
1655	Myocarditis and Pericarditis. , 2021, , .		1
1656	Pharmacistsâ€™ role in infectious pandemics: illustration with COVID-19. , 2021, , 849-876.		3
1657	The Main Protease of SARS COV-2 and Its Specific Inhibitors. , 2021, , 121-147.		2
1658	MASPs at the crossroad between the complement and the coagulation cascades - the case for COVID-19. Genetics and Molecular Biology, 2021, 44, e20200199.	0.6	17
1659	Exploring the effect of ritonavir and TMC-310911 on SARS-CoV-2 and SARS-CoV main proteases: potential from a molecular perspective. Future Science OA, 2021, 7, FSO640.	0.9	3
1660	COVID-19: A Single-Center ICU Experience of the First Wave in the Philippines. Critical Care Research and Practice, 2021, 2021, 1-12.	0.4	1
1661	Severe Acute Respiratory Syndrome Coronavirus-2-Associated Acute Kidney Injury: A Narrative Review Focused Upon Pathophysiology. Critical Care Medicine, 2021, 49, e533-e540.	0.4	4
1662	Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	136
1664	Specific epitopes form extensive hydrogen-bonding networks to ensure efficient antibody binding of SARS-CoV-2: Implications for advanced antibody design. Computational and Structural Biotechnology Journal, 2021, 19, 1661-1671.	1.9	7
1665	Effective virus-neutralizing activities in antisera from the first wave of severe COVID-19 survivors. JCI Insight, 2021, 6, .	2.3	10
1666	Acute respiratory distress syndrome in COVID-19: experience with cytokine inhibitors. Italian Journal of Emergency Medicine, 2020, 9, .	0.0	0
1667	CORTICOSTEROIDS AND SECONDARY INFECTIONS: AN INSIGHT INTO CORONAVIRUS DISEASE-2019. Asian Journal of Pharmaceutical and Clinical Research, 0, , 36-47.	0.3	0
1668	Novel severe acute respiratory syndrome corona virus. A review of current status and strategies in India. International Journal of Clinical Biochemistry and Research, 2021, 7, 416-425.	0.0	0
1670	SARS-CoV-2 viral load: Implication in COVID-19 pathogenesis, clinical presentation, diagnosis, treatment, prognosis and infectivity. Journal of Medical Evidence, 2021, .	0.2	0
1671	An overview of SARS-COV-2 related hepatic injury. Hepatology Forum, 2021, , .	0.3	3
1672	Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants. Emerging Microbes and Infections, 2021, 10, 1227-1240.	3.0	17
1673	ACE2 Can Act as the Secondary Receptor in the FcÎ³R-Dependent ADE of SARS-CoV-2. SSRN Electronic Journal, 0, , .	0.4	0
1674	Molecular mechanisms and pharmacological interventions in the replication cycle of human coronaviruses. Genetics and Molecular Biology, 2021, 44, e20200212.	0.6	11

#	ARTICLE	IF	CITATIONS
1675	Similarities and differences between HIV and SARS-CoV-2. <i>International Journal of Medical Sciences</i> , 2021, 18, 846-851.	1.1	34
1676	Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab. <i>Journal of Translational Autoimmunity</i> , 2021, 4, 100083.	2.0	38
1678	A prospective, observational study to evaluate adverse drug reactions in patients with COVID-19 treated with remdesivir or hydroxychloroquine: a preliminary report. <i>European Journal of Hospital Pharmacy</i> , 2021, 28, 248-253.	0.5	13
1679	Effect of a genetically engineered interferon-alpha versus traditional interferon-alpha in the treatment of moderate-to-severe COVID-19: a randomised clinical trial. <i>Annals of Medicine</i> , 2021, 53, 391-401.	1.5	28
1680	Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19: A Review. <i>Clinics</i> , 2021, 76, e2342.	0.6	8
1681	COVID-19 pathogenesis, prognostic factors, and treatment strategy: Urgent recommendations. <i>Journal of Medical Virology</i> , 2021, 93, 2694-2704.	2.5	27
1682	HIV-1 Infection Does Not Change Disease Course or Inflammatory Pattern of SARS-CoV-2-Infected Patients Presenting at a Large Urban Medical Center in New York City. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab029.	0.4	15
1683	Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence. <i>Infection</i> , 2021, 49, 401-410.	2.3	66
1684	Corona Viruses: A Review on SARS, MERS and COVID-19. <i>Microbiology Insights</i> , 2021, 14, 117863612110024.	0.9	41
1685	Antivirals that target the host IMP21-virus interface. <i>Biochemical Society Transactions</i> , 2021, 49, 281-295.	1.6	25
1686	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up. <i>European Heart Journal</i> , 2022, 43, 1059-1103.	1.0	111
1687	Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. <i>AAPS Journal</i> , 2021, 23, 14.	2.2	291
1688	Introduction on Coronavirus Disease (COVID-19) Pandemic: The Global Challenge. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1318, 1-22.	0.8	11
1689	Therapeutic Development in COVID-19. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1318, 435-448.	0.8	2
1690	A Global Review on Short Peptides: Frontiers and Perspectives. <i>Molecules</i> , 2021, 26, 430.	1.7	190
1691	Immune dysregulation and system pathology in COVID-19. <i>Virulence</i> , 2021, 12, 918-936.	1.8	74
1692	Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial. <i>Respiration</i> , 2021, 100, 116-126.	1.2	99
1693	The Adrenal Cortex, an Underestimated Site of SARS-CoV-2 Infection. <i>Frontiers in Endocrinology</i> , 2020, 11, 593179.	1.5	69

#	ARTICLE	IF	CITATIONS
1694	Traditional Chinese Medicine and Western Medicine Share Similar Philosophical Approaches to Fight COVID-19. , 2021, 12, 1162.		13
1695	The role of physical activities for patients infected with SARS-CoV-2 after convalescence period. , 2021, , 135-147.		1
1696	Stay (GI) Healthy: COVID-19 and Gastrointestinal Manifestations. Techniques and Innovations in Gastrointestinal Endoscopy, 2021, 23, 179-189.	0.4	17
1697	A review on the advancements in the development of vaccines to combat coronavirus disease 2019. Clinical and Experimental Vaccine Research, 2021, 10, 6.	1.1	45
1698	Probiotics use is associated with improved clinical outcomes among hospitalized patients with COVID-19. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110356.	1.4	30
1699	Prevalence and Clinical Significance of Persistent Viral Shedding in Hospitalized Adult Patients with SARS-CoV-2 Infection: A Prospective Observational Study. Infectious Diseases and Therapy, 2021, 10, 387-398.	1.8	11
1700	COVID-19 in Qatar: Ways forward in public health and treatment. Qatar Medical Journal, 2021, 2020, 38.	0.2	2
1703	Therapeutic Strategies in the Management of COVID-19. Frontiers in Molecular Biosciences, 2020, 7, 636738.	1.6	10
1704	Coronavirus disease 2019 management. Current Opinion in Pulmonary Medicine, 2021, 27, 169-175.	1.2	3
1705	Plasma Concentrations and Safety of Lopinavir/Ritonavir in COVID-19 Patients. Therapeutic Drug Monitoring, 2021, 43, 131-135.	1.0	8
1706	Targeting allosteric pockets of SARS-CoV-2 main protease M ^{pro} . Journal of Biomolecular Structure and Dynamics, 2022, 40, 6603-6618.	2.0	11
1707	COVID-19 and Its Implications for Thrombosis and Anticoagulation. Seminars in Respiratory and Critical Care Medicine, 2021, 42, 316-326.	0.8	16
1708	Atteintes pulmonaires liées à la COVID-19. La Presse Médicale Formation, 2021, 2, 14-24.	0.1	1
1709	A Comparative Analysis of SARS-CoV-2 Antivirals Characterizes 3CL ^{pro} Inhibitor PF-00835231 as a Potential New Treatment for COVID-19. Journal of Virology, 2021, 95, .	1.5	94
1710	Four Cases of Coronavirus Disease 2019 Transferred from a Cruise Ship. Internal Medicine, 2021, 60, 479-485.	0.3	0
1711	Modalities and Mechanisms of Treatment for Coronavirus Disease 2019. Frontiers in Pharmacology, 2020, 11, 583914.	1.6	8
1712	COVID-19 and Dentistry in 72 Questions: An Overview of the Literature. Journal of Clinical Medicine, 2021, 10, 779.	1.0	21
1713	Expert Opinions on the Most Promising Treatments and Vaccine Candidates for COVID-19: Global Cross-sectional Survey of Virus Researchers in the Early Months of the Pandemic. JMIR Public Health and Surveillance, 2021, 7, e22483.	1.2	2

#	ARTICLE	IF	CITATIONS
1714	Safety and Outcomes Associated with the Pharmacological Inhibition of the Kininâ€“Kallikrein System in Severe COVID-19. <i>Viruses</i> , 2021, 13, 309.	1.5	35
1715	SARS-CoV-2 infection in children. <i>Turkish Archives of Pediatrics</i> , 2021, 55, 95-102.	0.5	22
1716	Host Diversity and Potential Transmission Pathways of SARS-CoV-2 at the Human-Animal Interface. <i>Pathogens</i> , 2021, 10, 180.	1.2	33
1717	Severe COVID-19 pneumonia in Piacenza, Italy â€” A cohort study of the first pandemic wave. <i>Journal of Infection and Public Health</i> , 2021, 14, 263-270.	1.9	8
1719	Antiviral and immunomodulatory activity of curcumin: A case for prophylactic therapy for COVID-19. <i>Heliyon</i> , 2021, 7, e06350.	1.4	86
1720	T-Helper Cell Subset Response Is a Determining Factor in COVID-19 Progression. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 624483.	1.8	110
1721	De novo design and bioactivity prediction of SARS-CoV-2 main protease inhibitors using recurrent neural network-based transfer learning. <i>BMC Chemistry</i> , 2021, 15, 8.	1.6	49
1722	Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities. <i>Pharmaceutics</i> , 2021, 13, 302.	2.0	24
1723	Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. <i>New England Journal of Medicine</i> , 2021, 384, 610-618.	13.9	748
1724	Intensive care management of patients with COVID-19: a practical approach. <i>Annals of Intensive Care</i> , 2021, 11, 36.	2.2	73
1725	COVID-19 Cardiac Complication- Myocarditis. <i>The Open Covid Journal</i> , 2021, 1, 1-5.	0.4	0
1726	The Use of Antiviral Agents against SARS-CoV-2: Ineffective or Time and Age Dependent Result? A Retrospective, Observational Study among COVID-19 Older Adults. <i>Journal of Clinical Medicine</i> , 2021, 10, 686.	1.0	2
1728	Effectiveness of Antiviral and Immunomodulatory Agents in the Treatment of COVID-19: A Systematic Review. <i>Current Respiratory Medicine Reviews</i> , 2021, 16, 165-183.	0.1	0
1729	COVID-19: unanswered questions and work for a better knowledge. <i>Minerva Medica</i> , 2021, 112, 111-113.	0.3	4
1730	Yindan Jiedu Granules, a Traditional Chinese Medicinal Formulation, as a Potential Treatment for Coronavirus Disease 2019. <i>Frontiers in Pharmacology</i> , 2020, 11, 634266.	1.6	8
1731	Multicenter point prevalence evaluation of the utilization and safety of drug therapies for COVID-19 at the onset of the pandemic timeline in the United States. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 568-577.	0.5	4
1732	An Updated Systematic Review and Network Meta-Analysis of 25 Randomized Trials Assessing the Efficacy and Safety of Treatments in Covid-19 Disease. <i>Journal of Public Health Research</i> , 2021, 10, jphr.2021.1945.	0.5	5
1733	The COVID-19 Treatment Landscape: A South African Perspective on a Race Against Time. <i>Frontiers in Medicine</i> , 2021, 8, 604087.	1.2	1

#	ARTICLE	IF	CITATIONS
1734	Factors Influencing Participation in COVID-19 Clinical Trials: A Multi-National Study. <i>Frontiers in Medicine</i> , 2021, 8, 608959.	1.2	14
1735	Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. <i>The Cochrane Library</i> , 2021, 2021, CD013587.	1.5	134
1736	COVID-19 in patients living with human immunodeficiency virus (HIV) infection: Challenges and way-forward. <i>Drug Discoveries and Therapeutics</i> , 2021, 15, 42-43.	0.6	7
1737	Clinical Characteristics and Remedy Profiles of Patients with COVID-19: A Retrospective Cohort Study. <i>Homeopathy</i> , 2021, 110, 086-093.	0.5	29
1738	COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics—a review. <i>Archives of Microbiology</i> , 2021, 203, 2043-2057.	1.0	9
1739	Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH). <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1127-1141.	0.9	9
1740	Statistical Opportunities to Accelerate Development for COVID-19 Therapeutics. <i>Statistics in Biopharmaceutical Research</i> , 0, , 1-17.	0.6	5
1741	The use of aromatic plants and their therapeutic potential as antiviral agents: A hope for finding anti-COVID 19 essential oils. <i>Journal of Essential Oil Research</i> , 2021, 33, 105-113.	1.3	10
1742	Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prospects. <i>Frontiers in Immunology</i> , 2020, 11, 616595.	2.2	20
1743	Consultation psychiatry in COVID-19 patients: Lopinavir/ritonavir interactions with main psychiatric drugs. <i>Psychiatry and Clinical Neurosciences</i> , 2021, 75, 145-146.	1.0	3
1744	Targeting Host Cell Proteases to Prevent SARS-CoV-2 Invasion. <i>Current Drug Targets</i> , 2021, 22, 192-201.	1.0	29
1745	Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19. <i>Molecular Diversity</i> , 2021, 25, 1905-1927.	2.1	29
1746	Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2—azithromycin trial. <i>Trials</i> , 2021, 22, 126.	0.7	10
1747	Effectiveness of early therapeutic intervention in phases one and two after COVID-19 infection: systematic review. <i>Revista Da Associação Médica Brasileira</i> , 2021, 67, 302-312.	0.3	1
1748	Neurological Consequences of SARS-CoV-2 Infection and Concurrence of Treatment-Induced Neuropsychiatric Adverse Events in COVID-19 Patients: Navigating the Uncharted. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 627723.	1.6	37
1749	A molecular modelling approach for identifying antiviral selenium-containing heterocyclic compounds that inhibit the main protease of SARS-CoV-2: an <i>in silico</i> investigation. <i>Briefings in Bioinformatics</i> , 2021, 22, 1476-1498.	3.2	58
1750	Predicting Potential SARS-COV-2 Drugs—In Depth Drug Database Screening Using Deep Neural Network Framework SSnet, Classical Virtual Screening and Docking. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1573.	1.8	27
1751	EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 698-706.	0.5	37

#	ARTICLE	IF	CITATIONS
1752	Bepridil is potent against SARS-CoV-2 in vitro. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	80
1753	Antithrombotic and Anti-Inflammatory Effects of Fondaparinux and Enoxaparin in Hospitalized COVID-19 Patients: The FONDENOXAVID Study. Journal of Blood Medicine, 2021, Volume 12, 69-75.	0.7	16
1754	SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19. PLoS Computational Biology, 2021, 17, e1008686.	1.5	72
1756	COVID-19 vaccine hesitancy and attitudes in Qatar: A national cross-sectional survey of a migrant-majority population. Influenza and Other Respiratory Viruses, 2021, 15, 361-370.	1.5	119
1757	Reply to "Novoferon, treatment in COVID-19 patients". International Journal of Infectious Diseases, 2021, 103, 336-337.	1.5	1
1758	Aggregation hot spots in the SARS-CoV-2 proteome may constitute potential therapeutic targets for the suppression of the viral replication and multiplication. Journal of Proteins and Proteomics, 2021, 12, 1-13.	1.0	4
1759	Point-of-care ultrasonography for risk stratification of non-critical COVID-19 patients on admission (POCUSCO): a study protocol of an international study. BMJ Open, 2021, 11, e041118.	0.8	5
1760	Distance learning during the COVID-19 pandemic: School closure in Indonesia. International Journal of Mathematical Education in Science and Technology, 2022, 53, 1934-1954.	0.8	51
1761	A matched cohort study of convalescent plasma therapy for COVID-19. Journal of Clinical Apheresis, 2021, 36, 523-532.	0.7	14
1762	Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro. Viruses, 2021, 13, 354.	1.5	113
1763	Both Chloroquine and Lopinavir/Ritonavir Are Ineffective for COVID-19 Treatment and Combined Worsen the Pathology: A Single-Center Experience with Severely Ill Patients. BioMed Research International, 2021, 2021, 1-12.	0.9	5
1764	Validation of the STANDARD Q COVID-19 antigen test in Vojvodina, Serbia. PLoS ONE, 2021, 16, e0247606.	1.1	51
1765	Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening. Combinatorial Chemistry and High Throughput Screening, 2021, 24, 441-454.	0.6	39
1766	Diabetes is most important cause for mortality in COVID-19 hospitalized patients: Systematic review and meta-analysis. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 275-296.	2.6	152
1767	Nucleoside Analogs and Nucleoside Precursors as Drugs in the Fight against SARS-CoV-2 and Other Coronaviruses. Molecules, 2021, 26, 986.	1.7	60
1768	Adjunctive Nutraceutical Therapies for COVID-19. International Journal of Molecular Sciences, 2021, 22, 1963.	1.8	33
1769	Clinical and Laboratory Profile of Hospitalized Symptomatic COVID-19 Patients: Case Series Study From the First COVID-19 Center in the UAE. Frontiers in Cellular and Infection Microbiology, 2021, 11, 632965.	1.8	20
1770	Balancing clinical evidence in the context of a pandemic. Nature Biotechnology, 2021, 39, 270-274.	9.4	6

#	ARTICLE	IF	CITATIONS
1771	Management of COVID-19 in cancer patients receiving cardiotoxic anti-cancer therapy. Future recommendations for cardio-oncology. <i>Oncology Reviews</i> , 2021, 15, 510.	0.8	2
1772	A Scoping Insight on Potential Prophylactics, Vaccines and Therapeutic Weaponry for the Ongoing Novel Coronavirus (COVID-19) Pandemic- A Comprehensive Review. <i>Frontiers in Pharmacology</i> , 2020, 11, 590154.	1.6	8
1773	Potential immunomodulatory effects of vitamin D in the prevention of severe coronavirus disease 2019: An ally for Latin America (Review). <i>International Journal of Molecular Medicine</i> , 2021, 47, .	1.8	21
1774	A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Moderate COVID-19 Infections. <i>Biochemistry Research International</i> , 2021, 2021, 1-12.	1.5	11
1775	Drug Repurposing and Polypharmacology to Fight SARS-CoV-2 Through Inhibition of the Main Protease. <i>Frontiers in Pharmacology</i> , 2021, 12, 636989.	1.6	28
1776	The Surviving Sepsis Campaign: Research Priorities for Coronavirus Disease 2019 in Critical Illness. <i>Critical Care Medicine</i> , 2021, 49, 598-622.	0.4	49
1777	Role of the SphKα1/PAK1 pathway in invasion of the nervous system by SARS-CoV-2 infection. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2021, 48, 637-650.	0.9	10
1778	Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2785-2793.	2.9	92
1779	The relationship between positivity for COVID-19 RT-PCR and symptoms, clinical findings, and mortality in Turkey. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 245-250.	1.5	9
1780	Viral load and contact heterogeneity predict SARS-CoV-2 transmission and super-spreading events. <i>ELife</i> , 2021, 10, .	2.8	142
1781	SARS-CoV-2: An Update on Genomics, Risk Assessment, Potential Therapeutics and Vaccine Development. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 1626.	1.2	17
1782	Clinical features and prognostic factors of critically ill patients with COVID-19 in Daegu, South Korea. <i>Medicine (United States)</i> , 2021, 100, e24437.	0.4	7
1783	Alterations in Phenotypes and Responses of T Cells Within 6 Months of Recovery from COVID-19: A Cohort Study. <i>Virologica Sinica</i> , 2021, 36, 859-868.	1.2	13
1784	A recent update on the clinical trials and effectiveness of drugs used in COVID-19, MERS and SARS Coronaviruses.. <i>Anti-Infective Agents</i> , 2021, 19, .	0.1	0
1785	Repurposing drugs and identification of inhibitors of integral proteins (spike protein and main) Tj ETQqO 0 0 rgBT /Qverlock 10 Tf 50 182	2.0	22
1786	A Journey From SARS-CoV-2 to COVID-19 and Beyond: A Comprehensive Insight of Epidemiology, Diagnosis, Pathogenesis, and Overview of the Progress into Its Therapeutic Management. <i>Frontiers in Pharmacology</i> , 2021, 12, 576448.	1.6	11
1787	In silico prediction of SARS-CoV-2 main protease and polymerase inhibitors: 3D-Pharmacophore modelling. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 6569-6586.	2.0	5
1788	Symptom Profiles and Progression in Hospitalized and Nonhospitalized Patients with Coronavirus Disease, Colorado, USA, 2020. <i>Emerging Infectious Diseases</i> , 2021, 27, 385-395.	2.0	32

#	ARTICLE	IF	CITATIONS
1789	Epigenetic Landscapes of Single-Cell Chromatin Accessibility and Transcriptomic Immune Profiles of T Cells in COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 625881.	2.2	30
1790	The COVID-19 immune landscape is dynamically and reversibly correlated with disease severity. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	32
1791	Nonspecific Binding Considerations in the Rational Design and Development of Small Molecule COVID-19 Therapeutics. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 294-296.	2.3	4
1792	Potential Effects of COVID-19 on Cytochrome P450-Mediated Drug Metabolism and Disposition in Infected Patients. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021, 46, 185-203.	0.6	41
1793	Identification of candidate repurposable drugs to combat COVID-19 using a signature-based approach. <i>Scientific Reports</i> , 2021, 11, 4495.	1.6	22
1794	Efficacy and tolerability of bevacizumab in patients with severe Covid-19. <i>Nature Communications</i> , 2021, 12, 814.	5.8	101
1795	Clinical outcomes of different therapeutic options for COVID-19 in two Chinese case cohorts: A propensity-score analysis. <i>EClinicalMedicine</i> , 2021, 32, 100743.	3.2	24
1796	Promising phytochemicals of traditional Indian herbal steam inhalation therapy to combat COVID-19 – An in silico study. <i>Food and Chemical Toxicology</i> , 2021, 148, 111966.	1.8	44
1797	Targeting SARS-CoV-2 viral proteases as a therapeutic strategy to treat COVID-19. <i>Journal of Medical Virology</i> , 2021, 93, 2722-2734.	2.5	41
1798	Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19). <i>Current Pharmaceutical Design</i> , 2021, 27, 115-126.	0.9	13
1799	The clinical characteristics and treatment approaches of COVID-19: a concise review. <i>Pharmaceutical Sciences</i> , 2021, , .	0.1	0
1800	COVID-19 Pandemic: Advances in Diagnosis, Treatment, Organoid Applications and Impacts on Cancer Patient Management. <i>Frontiers in Medicine</i> , 2021, 8, 606755.	1.2	4
1801	An Integrative <i>in silico</i> Drug Repurposing Approach for Identification of Potential Inhibitors of SARS-CoV-2 Main Protease. <i>Molecular Informatics</i> , 2021, 40, e2000187.	1.4	7
1802	Discovering treatment effectiveness via median treatment effects – Applications to COVID-19 clinical trials. <i>Health Economics (United Kingdom)</i> , 2021, 30, 1050-1069.	0.8	0
1803	Efficacy and Effect of Inhaled Adenosine Treatment in Hospitalized COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 613070.	2.2	22
1804	Modeling of SARS-CoV-2 Treatment Effects for Informed Drug Repurposing. <i>Frontiers in Pharmacology</i> , 2021, 12, 625678.	1.6	11
1806	Routes to cubic ice through heterogeneous nucleation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	15
1807	The Situation of Small Molecules Targeting Key Proteins in combatting SARS-CoV-2: Synthesis, Metabolic Pathway, Mechanism of Action, and Potential Therapeutic Applications. <i>Mini-Reviews in Medicinal Chemistry</i> , 2022, 22, 273-311.	1.1	3

#	ARTICLE	IF	CITATIONS
1808	In-silico network-based analysis of drugs used against COVID-19: Human well-being study. Saudi Journal of Biological Sciences, 2021, 28, 2029-2039.	1.8	2
1809	Development and Characterization of Inhaled Ethanol as a Novel Pharmacological Strategy Currently Evaluated in a Phase II Clinical Trial for Early-Stage SARS-CoV-2 Infection. Pharmaceutics, 2021, 13, 342.	2.0	8
1810	The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2. European Journal of Medicinal Chemistry, 2021, 213, 113157.	2.6	35
1811	Could Targeting HMGB1 be Useful for the Clinical Management of COVID-19 Infection?. Combinatorial Chemistry and High Throughput Screening, 2021, 24, 587-590.	0.6	3
1813	Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19. European Journal of Clinical Pharmacology, 2021, 77, 1297-1307.	0.8	4
1814	Investigation of the disease process and drug combinations in patients with suspected/confirmed COVID-19 using favipiravir. International Journal of Clinical Practice, 2021, 75, e14167.	0.8	3
1815	Evaluation of the Current Therapeutic Approaches for COVID-19: A Systematic Review and a Meta-analysis. Frontiers in Pharmacology, 2021, 12, 607408.	1.6	15
1816	Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19. International Journal of Infectious Diseases, 2021, 104, 441-451.	1.5	14
1817	Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review. Journal of Clinical Pharmacology, 2021, 61, 429-460.	1.0	22
1818	State-of-the-Art of Nanodiagnostics and Nanotherapeutics against SARS-CoV-2. ACS Applied Materials & Interfaces, 2021, 13, 14816-14843.	4.0	27
1819	A novel cell culture system modeling the SARS-CoV-2 life cycle. PLoS Pathogens, 2021, 17, e1009439.	2.1	102
1820	ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida. PLoS ONE, 2021, 16, e0249038.	1.1	97
1821	The Good Treatment, the Bad Virus, and the Ugly Inflammation: Pathophysiology of Kidney Involvement During COVID-19. Frontiers in Physiology, 2021, 12, 613019.	1.3	12
1822	Repurposing functional inhibitors of acid sphingomyelinase (fiasmas): an opportunity against SARS-CoV-2 infection?. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 1213-1219.	0.7	16
1823	Safety and effectiveness concerns of lopinavir/ritonavir in COVID-19 affected patients: a retrospective series. Clinical Toxicology, 2021, 59, 644-647.	0.8	7
1824	Casual Sex among Men Who Have Sex with Men (MSM) during the Period of Sheltering in Place to Prevent the Spread of COVID-19. International Journal of Environmental Research and Public Health, 2021, 18, 3266.	1.2	36
1825	Higher vs lower doses of dexamethasone in patients with COVID-19 and severe hypoxia (COVID STEROID) Tj ETQg0,0 0 rgBT /Overlock	0.7	21
1826	COVID-19 second wave mortality in Europe and the United States. Chaos, 2021, 31, 031105.	1.0	80

#	ARTICLE	IF	CITATIONS
1827	A review of potential suggested drugs for coronavirus disease (COVID-19) treatment. <i>European Journal of Pharmacology</i> , 2021, 895, 173890.	1.7	86
1828	Why do we lack a specific magic anti-COVID-19 drug? Analyses and solutions. <i>Drug Discovery Today</i> , 2021, 26, 631-636.	3.2	7
1829	Impact of Cardiovascular Diseases on COVID-19: A Systematic Review. <i>Medical Science Monitor</i> , 2021, 27, e930032.	0.5	4
1830	Discovery of potential inhibitors of the receptor-binding domain (RBD) of pandemic disease-causing SARS-CoV-2 Spike Glycoprotein from <i>Triphala</i> through molecular docking. <i>Current Chinese Chemistry</i> , 2021, 01, .	0.3	16
1831	Predictive factors of six-week mortality in critically ill patients with SARS-CoV-2: A multicenter prospective study. <i>Medicina Intensiva</i> , 2022, 46, 179-191.	0.4	17
1833	Broad phenotypic alterations and potential dysfunction of lymphocytes in individuals clinically recovered from COVID-19. <i>Journal of Molecular Cell Biology</i> , 2021, 13, 197-209.	1.5	17
1834	Therapeutic Potential of EGCG, a Green Tea Polyphenol, for Treatment of Coronavirus Diseases. <i>Life</i> , 2021, 11, 197.	1.1	25
1835	COVID-19 and cardiovascular complications: an update from the underlying mechanism to consequences and possible clinical intervention. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1083-1092.	2.0	13
1836	Individuals'™ conceptions of COVID-19 pandemic through metaphor analysis. <i>Current Psychology</i> , 2022, 41, 449-458.	1.7	18
1837	Effect of COVID-19 medications on corrected QT interval and induction of torsade de pointes: Results of a multicenter national survey. <i>International Journal of Clinical Practice</i> , 2021, 75, e14182.	0.8	20
1838	Effect of immunosuppression maintenance in solid organ transplant recipients with COVID-19: Systematic review and meta-analysis. <i>Transplant Infectious Disease</i> , 2021, 23, e13595.	0.7	16
1839	A computational drug repurposing approach in identifying the cephalosporin antibiotic and anti-hepatitis C drug derivatives for COVID-19 treatment. <i>Computers in Biology and Medicine</i> , 2021, 130, 104186.	3.9	26
1840	Easing COVID-19 lockdown measures while protecting the older restricts the deaths to the level of the full lockdown. <i>Scientific Reports</i> , 2021, 11, 5839.	1.6	14
1841	Combination therapy of IFN β 21 with lopinavir-ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients. <i>International Immunopharmacology</i> , 2021, 92, 107329.	1.7	15
1842	Nano-therapeutic strategies to target coronavirus. <i>View</i> , 2021, 2, 20200155.	2.7	11
1843	COVID-19 with spontaneous pneumothorax, pneumomediastinum, and subcutaneous emphysema in the intensive care unit: Two case reports. <i>Journal of Infection and Public Health</i> , 2021, 14, 290-292.	1.9	9
1844	Statistical consideration when adding new arms to ongoing clinical trials: the potentials and the caveats. <i>Trials</i> , 2021, 22, 203.	0.7	15
1845	Discrete Time Multistate Model With Regime Switching for Modeling COVID-19 Disease Progression and Clinical Outcomes. <i>Statistics in Biopharmaceutical Research</i> , 2022, 14, 52-66.	0.6	5

#	ARTICLE	IF	CITATIONS
1846	Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019. <i>Korean Journal of Internal Medicine</i> , 2021, 36, S253-S263.	0.7	31
1847	Mushroom-derived bioactive compounds potentially serve as the inhibitors of SARS-CoV-2 main protease: An in silico approach. <i>Journal of Traditional and Complementary Medicine</i> , 2021, 11, 158-172.	1.5	59
1848	COVID-19 and liver disease: mechanistic and clinical perspectives. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 348-364.	8.2	272
1850	Effectiveness and quality analysis of methods in studies for the treatment of COVID-19. <i>Research on Biomedical Engineering</i> , 0, , 1.	1.5	0
1851	SARS-CoV-2 and Human Immunodeficiency Virus: Pathogen Pincer Attack. <i>HIV/AIDS - Research and Palliative Care</i> , 2021, Volume 13, 361-375.	0.4	5
1852	Cellular Therapy as Promising Choice of Treatment for COVID-19. , 0, , .		0
1854	Clinical Effect of Traditional Chinese Medicine Shenhuang Granule in Critically Ill Patients with COVID-19: A Single-Centered, Retrospective, Observational Study. <i>Journal of Microbiology and Biotechnology</i> , 2021, 31, 380-386.	0.9	14
1855	Management of liver disease patients in different clinical situations during COVID-19 pandemic. <i>Egyptian Liver Journal</i> , 2021, 11, 21.	0.3	5
1856	Regulation of the expression of proinflammatory cytokines induced by SARS-CoV-2. <i>World Journal of Clinical Cases</i> , 2021, 9, 1513-1523.	0.3	3
1857	Genomic Variation and Treatment Strategies of COVID-19: A Descriptive Review. <i>The Open Covid Journal</i> , 2021, 1, 6-19.	0.4	0
1858	A Review of the Progress of COVID-19 Vaccine Development. <i>Duzce Universitesi Tip Fakültesi Dergisi</i> , 2021, 23, 1-23.	0.3	7
1859	Trends in Prescribing of Antibiotics and Drugs Investigated for Coronavirus Disease 2019 (COVID-19) Treatment in US Nursing Home Residents During the COVID-19 Pandemic. <i>Clinical Infectious Diseases</i> , 2022, 74, 74-82.	2.9	19
1860	Current evidence for COVID-19 therapies: a systematic literature review. <i>European Respiratory Review</i> , 2021, 30, 200384.	3.0	37
1861	Risk factors for mortality in COVID-19 patients in a community teaching hospital. <i>Journal of Medical Virology</i> , 2021, 93, 3184-3193.	2.5	13
1862	Real-life use of remdesivir in hospitalized patients with COVID-19. <i>Revista Espanola De Quimioterapia</i> , 2021, 34, 136-140.	0.5	20
1863	Characteristics and outcomes of patients with COVID-19 in Hainan, South China. <i>Medicine (United TJ ETQq1 1 0.784314 rgBT /Overl</i>	0.4	2
1865	A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2. <i>PLoS Biology</i> , 2021, 19, e3001128.	2.6	99
1866	Emerging Therapeutic Approaches to Combat COVID-19: Present Status and Future Perspectives. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 604447.	1.6	28

#	ARTICLE	IF	CITATIONS
1867	The right immune-modulation at the right time: thymosin $\hat{1}\pm 1$ for prevention of severe COVID-19 in cancer patients. <i>Future Oncology</i> , 2021, 17, 1097-1104.	1.1	9
1868	Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study. <i>International Journal of Infectious Diseases</i> , 2021, 104, 433-440.	1.5	47
1869	Reduced mortality in COVID-19 patients treated with colchicine: Results from a retrospective, observational study. <i>PLoS ONE</i> , 2021, 16, e0248276.	1.1	29
1870	The study of antiviral drugs targeting SARS-CoV-2 nucleocapsid and spike proteins through large-scale compound repurposing. <i>Heliyon</i> , 2021, 7, e06387.	1.4	25
1871	Abnormal Liver Function Test in Patients Infected with Coronavirus (SARS-CoV-2): A Retrospective Single-Center Study from Spain. <i>Journal of Clinical Medicine</i> , 2021, 10, 1039.	1.0	10
1872	A systematic review of clinical and laboratory parameters associated with increased severity among COVID-19 patients. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021, 15, 535-541.	1.8	21
1873	Revisiting Pleiotropic Effects of Type I Interferons: Rationale for Its Prophylactic and Therapeutic Use Against SARS-CoV-2. <i>Frontiers in Immunology</i> , 2021, 12, 655528.	2.2	19
1874	COVID-19: Potential Repurposing Drugs. <i>Infectious Disorders - Drug Targets</i> , 2021, 21, .	0.4	4
1875	Clinical characteristics of older patients with COVID-19: a systematic review of case reports. <i>Dementia E Neuropsychologia</i> , 2021, 15, 1-15.	0.3	9
1876	Deficiencies in Planning Interventional Trial Registration of COVID-19 in China. <i>Frontiers in Medicine</i> , 2021, 8, 618185.	1.2	0
1877	Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH). <i>Medicina Intensiva (English Edition)</i> , 2021, 45, 104-121.	0.1	11
1878	BCG Vaccine-Induced Trained Immunity and COVID-19: Protective or Bystander?. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 1169-1184.	1.1	11
1879	An Overview of Current Knowledge of Deadly CoVs and Their Interface with Innate Immunity. <i>Viruses</i> , 2021, 13, 560.	1.5	15
1880	Management and Perspective of Coronavirus Disease 2019 (COVID-19), Pregnancy, and Hypercoagulability. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 1081-1084.	0.3	4
1881	The in-vitro effect of famotidine on SARS-CoV-2 proteases and virus replication. <i>Scientific Reports</i> , 2021, 11, 5433.	1.6	22
1882	Wuhan to World: The COVID-19 Pandemic. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 596201.	1.8	115
1883	Impact of montelukast as add on treatment to the novel coronavirus pneumonia (COVID-19): protocol for an investigator-initiated open labeled randomized controlled pragmatic trial. <i>Porto Biomedical Journal</i> , 2021, 6, e134.	0.4	2
1884	QT prolongation associated with hydroxychloroquine and protease inhibitors in COVID-19. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 800-806.	0.7	3

#	ARTICLE	IF	CITATIONS
1885	A review of novel coronavirus disease (COVID-19): based on genomic structure, phylogeny, current shreds of evidence, candidate vaccines, and drug repurposing. 3 Biotech, 2021, 11, 198.	1.1	15
1886	Inhibition of Human Coronaviruses by Antimalarial Peroxides. ACS Infectious Diseases, 2021, 7, 1985-1995.	1.8	19
1887	Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). PLoS ONE, 2021, 16, e0248132.	1.1	41
1888	COVID-19 after kidney transplantation: Early outcomes and renal function following antiviral treatment. International Journal of Infectious Diseases, 2021, 104, 426-432.	1.5	23
1889	Diabetes mellitus in combination with COVID-19: modern views on therapy. Reproductive Endocrinology, 2021, , 8-20.	0.0	0
1891	Potential Anti-Coronavirus Agents and the Pharmacologic Mechanisms. Drug Design, Development and Therapy, 2021, Volume 15, 1213-1223.	2.0	5
1892	The management of surgical patients in the emergency setting during COVID-19 pandemic: the WSES position paper. World Journal of Emergency Surgery, 2021, 16, 14.	2.1	42
1893	A systematic review of the role of hypovitaminosis D in coronavirus disease-19 (COVID-19) infection and mortality: Is there a role of recommending high dose vitamin D supplementation?. Human Nutrition and Metabolism, 2021, 23, 200120.	0.8	0
1895	COVID-19 in Children: Respiratory Involvement and Some Differences With the Adults. Frontiers in Pediatrics, 2021, 9, 622240.	0.9	15
1896	Baseline use of hydroxychloroquine or immunosuppressive drugs and the risk of coronavirus disease 2019. Korean Journal of Internal Medicine, 2022, 37, 673-680.	0.7	2
1897	1,2,3,4,6-Pentagalloyl Glucose, a RBD-ACE2 Binding Inhibitor to Prevent SARS-CoV-2 Infection. Frontiers in Pharmacology, 2021, 12, 634176.	1.6	28
1898	Intravenous immunoglobulins: A therapeutic alternative to consider in kidney transplant patients with COVID-19. Nefrologia, 2021, 41, 220-222.	0.2	4
1899	<i>De novo</i> design of new chemical entities for SARS-CoV-2 using artificial intelligence. Future Medicinal Chemistry, 2021, 13, 575-585.	1.1	66
1900	Systems and Clinical Pharmacology of COVID-19 Therapeutic Candidates: A Clinical and Translational Medicine Perspective. Journal of Pharmaceutical Sciences, 2021, 110, 1002-1017.	1.6	14
1901	Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment. Frontiers in Immunology, 2021, 12, 635371.	2.2	46
1902	The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue. Scientific Reports, 2021, 11, 5890.	1.6	98
1903	Drug Re-purposing Approach and Potential Therapeutic Strategies to Treat COVID-19. Mini-Reviews in Medicinal Chemistry, 2021, 21, 704-723.	1.1	7
1904	COVID-19 vaccines: The status and perspectives in delivery points of view. Advanced Drug Delivery Reviews, 2021, 170, 1-25.	6.6	262

#	ARTICLE	IF	CITATIONS
1905	COVID-19 and the small intestine. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 343-347.	0.2	4
1906	SAveRUNNER: an R-based tool for drug repurposing. <i>BMC Bioinformatics</i> , 2021, 22, 150.	1.2	42
1907	Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 275-284.	5.2	198
1908	Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. <i>European Respiratory Journal</i> , 2021, 57, 2100048.	3.1	152
1909	Risk management strategies and therapeutic modalities to tackle COVID-19/SARS-CoV-2. <i>Journal of Infection and Public Health</i> , 2021, 14, 331-346.	1.9	12
1910	A Review on Repurposed Drugs and Vaccine Trials for Combating SARS CoV-2. <i>Current Drug Research Reviews</i> , 2021, 13, 203-221.	0.7	2
1911	Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial. <i>Trials</i> , 2021, 22, 224.	0.7	8
1912	Experimental therapies under investigation for COVID-19. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2021, 11, 187-193.	0.4	3
1913	The Trilogy of SARS-CoV-2 in Pediatrics (Part 1): Acute COVID-19 in Special Populations. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2021, 26, 220-239.	0.3	6
1914	Primera y segunda oleada de enfermedad por coronavirus-19: un estudio comparativo en pacientes hospitalizados en una UCI de un hospital universitario de tercer nivel. <i>Medicina Intensiva</i> , 2021, .	0.4	4
1915	Nowcasting epidemics of novel pathogens: lessons from COVID-19. <i>Nature Medicine</i> , 2021, 27, 388-395.	15.2	32
1916	The characteristics of HIV-positive patients with mild/asymptomatic and moderate/severe course of COVID-19 disease—A report from Central and Eastern Europe. <i>International Journal of Infectious Diseases</i> , 2021, 104, 293-296.	1.5	14
1917	Recent Advances in the Discovery of Potent Proteases Inhibitors Targeting the SARS Coronaviruses. <i>Current Topics in Medicinal Chemistry</i> , 2021, 21, 307-328.	1.0	4
1918	Clinical Features and Prognostic Factors of 245 Portuguese Patients Hospitalized With COVID-19. <i>Cureus</i> , 2021, 13, e13687.	0.2	1
1919	Renal Involvement in COVID-19: A Review of the Literature. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 895-903.	1.1	21
1920	Neglecting Plasma Protein Binding in COVID-19 Patients Leads to a Wrong Interpretation of Lopinavir Overexposure. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1030-1033.	2.3	9
1921	COVID-19: Antiviral agents and enzyme inhibitors/receptor blockers in development. <i>Experimental Biology and Medicine</i> , 2021, 246, 1533-1540.	1.1	2
1922	Epidemiology and outcomes of COVID-19 in HIV-infected individuals: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2021, 11, 6283.	1.6	189

#	ARTICLE	IF	CITATIONS
1923	Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: The TACROVID trial protocol. <i>Contemporary Clinical Trials Communications</i> , 2021, 21, 100716.	0.5	17
1924	Human coronaviruses and therapeutic drug discovery. <i>Infectious Diseases of Poverty</i> , 2021, 10, 28.	1.5	12
1925	TREATMENT MODALITIES OF THE COVID-19 PANDEMIC THROUGH REPURPOSED DRUGS AND STATUS OF VACCINES. <i>International Journal of Applied Pharmaceutics</i> , 0, , 48-58.	0.3	4
1926	Precision therapeutic targets for COVID-19. <i>Virology Journal</i> , 2021, 18, 66.	1.4	40
1927	Cyclodextrins in Antiviral Therapeutics and Vaccines. <i>Pharmaceutics</i> , 2021, 13, 409.	2.0	24
1928	Early postmortem mapping of SARS-CoV-2 RNA in patients with COVID-19 and the correlation with tissue damage. <i>ELife</i> , 2021, 10, .	2.8	87
1929	Minimizing the impact of the triple burden of COVID-19, tuberculosis and HIV on health services in sub-Saharan Africa. <i>International Journal of Infectious Diseases</i> , 2021, 113, S16-S21.	1.5	37
1930	Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT). <i>Clinical Microbiology and Infection</i> , 2021, 27, 389-395.	2.8	37
1931	Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 7367-7380.	2.0	13
1933	Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease. <i>Frontiers in Chemistry</i> , 2021, 9, 622898.	1.8	213
1934	An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?. <i>Frontiers in Pharmacology</i> , 2021, 12, 632677.	1.6	65
1935	Race and ethnicity, gender, and age on perceived threats and fear of COVID-19: Evidence from two national data sources. <i>SSM - Population Health</i> , 2021, 13, 100717.	1.3	120
1936	Bridging Learning in Medicine and Citizenship During the COVID-19 Pandemic: A Telehealth-Based Case Study. <i>JMIR Public Health and Surveillance</i> , 2021, 7, e24795.	1.2	11
1937	COVID-19 epidemic in a Respiratory Diseases Unit: predictor ranking and mining. <i>Journal of Thoracic Disease</i> , 2021, 13, 2569-2574.	0.6	1
1938	Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies. <i>CNS Drugs</i> , 2021, 35, 345-384.	2.7	8
1939	COVID-19 Treatment Guidelines: Do They Really Reflect Best Medical Practices to Manage the Pandemic?. <i>Infectious Disease Reports</i> , 2021, 13, 259-284.	1.5	27
1940	Is COVID-19-induced liver injury different from other RNA viruses? World Journal of Meta-analysis, 2021, 9, 108-127.	0.1	0
1941	Old drug, new Trick? The rationale for the treatment of COVID-19 with activated protein C. <i>Medical Hypotheses</i> , 2021, 149, 110537.	0.8	5

#	ARTICLE	IF	CITATIONS
1942	Clinical features and outcomes of critically ill patients with coronavirus disease 2019 (COVID-19): A multicenter cohort study. <i>International Journal of Infectious Diseases</i> , 2021, 105, 180-187.	1.5	40
1943	The therapeutic effect and safety of the drugs for COVID-19. <i>Medicine (United States)</i> , 2021, 100, e25532.	0.4	3
1944	Combination Drug Therapy in COVID-19: Are We Using Sound Science in the Management of These Patients?. <i>International Journal of Infection</i> , 2021, 8, .	0.4	0
1945	Perspectives on Drug Repurposing. <i>Current Medicinal Chemistry</i> , 2021, 28, 2085-2099.	1.2	22
1947	Regional Survey in Lombardy, Northern Italy, on Vascular Surgery Intervention Outcomes During The COVID-19 Pandemic. <i>European Journal of Vascular and Endovascular Surgery</i> , 2021, 61, 688-697.	0.8	15
1948	Inflammation, immunity and potential target therapy of SARS-COV-2: A total scale analysis review. <i>Food and Chemical Toxicology</i> , 2021, 150, 112087.	1.8	17
1949	Coronavirus Disease 2019 and Gastrointestinal Involvement: A Systematic Review. <i>Medicinus</i> , 2021, 8, 62.	0.2	0
1950	Covid 19: Risk faktörleri, Tedavide Kullanılan İlaçlar ve İlaçların Oranları. <i>Van Sağlık Bilimleri Dergisi</i> , 0, , 98-105.	0.6	0
1951	New challenges to fighting COVID-19: Virus variants, potential vaccines, and development of antivirals. <i>BioScience Trends</i> , 2021, 15, 126-128.	1.1	32
1952	Ten things you need to know about intensive care unit management of mechanically ventilated patients with COVID-19. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1293-1302.	1.0	12
1953	TLR4 as a therapeutic target for respiratory and neurological complications of SARS-CoV-2. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 491-508.	1.5	36
1954	Convalescent plasma treatment is associated with lower mortality and better outcomes in high-risk COVID-19 patients â€” propensity-score matched case-control study. <i>International Journal of Infectious Diseases</i> , 2021, 105, 209-215.	1.5	29
1955	Autoimmune Diseases and COVID-19 as Risk Factors for Poor Outcomes: Data on 13,940 Hospitalized Patients from the Spanish Nationwide SEMI-COVID-19 Registry. <i>Journal of Clinical Medicine</i> , 2021, 10, 1844.	1.0	12
1956	Current and New Drugs for COVID-19 Treatment and Its Effects on the Liver. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	6
1957	Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment. <i>IScience</i> , 2021, 24, 102367.	1.9	126
1958	Predictive association of ABCB1 C3435T genetic polymorphism with the efficacy or safety of lopinavir and ritonavir in COVID-19 patients. <i>Pharmacogenomics</i> , 2021, 22, 375-381.	0.6	5
1959	Coronavirus-related Disease Pandemic: A Review on Machine Learning Approaches and Treatment Trials on Diagnosed Population for Future Clinical Decision Support. <i>Current Medical Imaging</i> , 2022, 18, 104-112.	0.4	8
1960	Multiscale statistical physics of the pan-viral interactome unravels the systemic nature of SARS-CoV-2 infections. <i>Communications Physics</i> , 2021, 4, .	2.0	16

#	ARTICLE	IF	CITATIONS
1961	COVID-19 vaccine research focusses on safety, efficacy, immunoinformatics, and vaccine production and delivery: a bibliometric analysis based on VOSviewer. <i>BioScience Trends</i> , 2021, 15, 64-73.	1.1	43
1962	SARS-CoV-2-Seronegative Subjects Target CTL Epitopes in the SARS-CoV-2 Nucleoprotein Cross-Reactive to Common Cold Coronaviruses. <i>Frontiers in Immunology</i> , 2021, 12, 627568.	2.2	18
1963	<scp>QTc</scp> prolongation in <scp>COVID</scp>-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 694-706.	0.9	30
1964	Epidemiological and clinical characteristics of 65 hospitalized patients with COVID-19 in Liaoning, China. <i>World Journal of Clinical Cases</i> , 2021, 9, 2205-2217.	0.3	3
1965	Inactivating SARS-CoV-2 by electrochemical oxidation. <i>Science Bulletin</i> , 2021, 66, 720-726.	4.3	18
1966	Nanocarrier vaccines for SARS-CoV-2. <i>Advanced Drug Delivery Reviews</i> , 2021, 171, 215-239.	6.6	66
1967	Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study. <i>International Journal of Infectious Diseases</i> , 2021, 105, 319-325.	1.5	10
1968	Compassionate Use of Remdesivir in Children With Severe COVID-19. <i>Pediatrics</i> , 2021, 147, .	1.0	81
1969	Current updates on adaptive immune response by B cell and T cell stimulation and therapeutic strategies for novel coronavirus disease 2019 (COVID-19) treatment. <i>Heliyon</i> , 2021, 7, e06894.	1.4	4
1970	Present and future treatment strategies for coronavirus disease 2019. <i>Future Journal of Pharmaceutical Sciences</i> , 2021, 7, 84.	1.1	12
1971	SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study. <i>European Journal of Pharmacology</i> , 2021, 896, 173922.	1.7	29
1972	Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab. <i>Scientific Reports</i> , 2021, 11, 8816.	1.6	21
1973	Pharmacological Modulators of Autophagy as a Potential Strategy for the Treatment of COVID-19. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4067.	1.8	27
1974	Neutralizing Antibody Therapeutics for COVID-19. <i>Viruses</i> , 2021, 13, 628.	1.5	99
1975	Etanercept Ameliorates Cardiac Fibrosis in Rats with Diet-Induced Obesity. <i>Pharmaceuticals</i> , 2021, 14, 320.	1.7	5
1977	Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. <i>Aging</i> , 2021, 13, 10833-10852.	1.4	16
1978	Coronavirus disease in children: A multicentre study from the Kingdom of Saudi Arabia. <i>Journal of Infection and Public Health</i> , 2021, 14, 543-549.	1.9	20
1979	Clinical features in coronavirus disease 2019 (COVID-19) patients with early clearance and prolonged shedding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA. <i>Annals of Translational Medicine</i> , 2021, 9, 665-665.	0.7	16

#	ARTICLE	IF	CITATIONS
1980	Therapeutic Agents for COVID-19: an Overview. <i>Current Drug Therapy</i> , 2021, 16, 22-44.	0.2	1
1981	In-silico analysis of the inhibition of the SARS-CoV-2 main protease by some active compounds from selected African plants. <i>Journal of Taibah University Medical Sciences</i> , 2021, 16, 162-176.	0.5	28
1982	The proportion and effect of corticosteroid therapy in patients with COVID-19 infection: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2021, 16, e0249481.	1.1	35
1984	Spectrum and Clinical Characteristics of Symptomatic and Asymptomatic Coronavirus Disease 2019 (COVID-19) With and Without Pneumonia. <i>Frontiers in Medicine</i> , 2021, 8, 645651.	1.2	29
1985	Inositol and vitamin D may naturally protect human reproduction and women undergoing assisted reproduction from Covid-19 risk. <i>Journal of Reproductive Immunology</i> , 2021, 144, 103271.	0.8	15
1986	Darunavir/Cobicistat Is Associated with Negative Outcomes in HIV-Negative Patients with Severe COVID-19 Pneumonia. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 283-291.	0.5	4
1987	Simeprevir Potently Suppresses SARS-CoV-2 Replication and Synergizes with Remdesivir. <i>ACS Central Science</i> , 2021, 7, 792-802.	5.3	59
1988	COVID-19 and ARDS: Update on Preventive and Therapeutic Venues. <i>Current Molecular Medicine</i> , 2022, 22, 312-324.	0.6	5
1989	Dodging COVID-19 infection: low expression and localization of ACE2 and TMPRSS2 in multiple donor-derived lines of human umbilical cord-derived mesenchymal stem cells. <i>Journal of Translational Medicine</i> , 2021, 19, 149.	1.8	14
1990	Guidelines for clinical management of SARS-CoV-2 infection. <i>Gaceta Medica De Mexico</i> , 2021, 156, 576-583.	0.5	1
1991	No Efficacy of the Combination of Lopinavir/Ritonavir Plus Hydroxychloroquine Versus Standard of Care in Patients Hospitalized With COVID-19: A Non-Randomized Comparison. <i>Frontiers in Pharmacology</i> , 2021, 12, 621676.	1.6	6
1993	Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 49, 102754.	0.9	12
1994	Discovery of Small Anti-ACE2 Peptides to Inhibit SARS-CoV-2 Infectivity. <i>Advanced Therapeutics</i> , 2021, 4, 2100087.	1.6	16
1995	Publications and retracted articles of COVID-19 pharmacotherapy-related research: A systematic review. <i>Science Progress</i> , 2021, 104, 003685042110169.	1.0	15
1996	Two Key Takeaways From a Year of Pandemic Research. <i>Critical Care Medicine</i> , 2021, Publish Ahead of Print, 1223-1226.	0.4	1
1997	A Perspective on COVID-19 Management. <i>Journal of Clinical Medicine</i> , 2021, 10, 1586.	1.0	8
1998	Facing coronavirus disease 2019: What do we know so far? (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 21, 658.	0.8	6
1999	Na ⁺ /K ⁺ -ATPase as a Target of Cardiac Glycosides for the Treatment of SARS-CoV-2 Infection. <i>Frontiers in Pharmacology</i> , 2021, 12, 624704.	1.6	17

#	ARTICLE	IF	CITATIONS
2000	Covid-19: UK launches antivirals taskforce to deliver home treatments by autumn. <i>BMJ, The</i> , 2021, 373, n1077.	3.0	10
2001	Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial. <i>EBioMedicine</i> , 2021, 66, 103288.	2.7	21
2002	An evaluation of the mental health impact of SARS-CoV-2 on patients, general public and healthcare professionals: A systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2021, 34, 100806.	3.2	82
2003	Quinine Inhibits Infection of Human Cell Lines with SARS-CoV-2. <i>Viruses</i> , 2021, 13, 647.	1.5	41
2004	In-hospital outcomes of COVID-19 ST-elevation myocardial infarction patients. <i>EuroIntervention</i> , 2021, 16, 1426-1433.	1.4	61
2005	Para-infectious anti-GD2/GD3 IgM myelitis during the Covid-19 pandemic: Case report and literature review. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 49, 102783.	0.9	15
2006	Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2021, 27, 520-531.	2.8	512
2007	Drug Repurposing Approach, Potential Drugs, and Novel Drug Targets for COVID-19 Treatment. <i>Journal of Environmental and Public Health</i> , 2021, 2021, 1-11.	0.4	24
2008	Effects of Shuanghuanglian oral liquids on patients with COVID-19: a randomized, open-label, parallel-controlled, multicenter clinical trial. <i>Frontiers of Medicine</i> , 2021, 15, 704-717.	1.5	33
2009	Ethical dimensions in randomized trials and off-label use of investigational drugs for COVID-19 treatment. <i>Clinical Ethics</i> , 2022, 17, 95-104.	0.5	1
2010	A review on the clinical trials of repurposing therapeutic drugs, mechanisms and preventive measures against SARS-CoV-2. <i>Drug Metabolism and Personalized Therapy</i> , 2021, .	0.3	0
2011	Molecular Dynamic Simulation Search for Possible Amphiphilic Drug Discovery for Covid-19. <i>Molecules</i> , 2021, 26, 2214.	1.7	0
2012	Homology Modeling of Coronavirus Structural Proteins and Molecular Docking of Potential Drug Candidates for the Treatment of COVID-19. <i>Coronaviruses</i> , 2021, 2, 241-250.	0.2	1
2013	Structure-based assortment of herbal analogues against spike protein to restrict COVID-19 entry through hACE2 receptor: An in-silico approach. <i>Acta Biologica Szegediensis</i> , 2021, 64, 159-171.	0.7	5
2014	Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico. <i>International Journal of Infectious Diseases</i> , 2021, 105, 598-605.	1.5	27
2015	Current COVID-19 treatments: Rapid review of the literature. <i>Journal of Global Health</i> , 2021, 11, 10003.	1.2	26
2016	Risk Factors of Viral RNAemia and Its Association With Clinical Prognosis Among Patients With Severe COVID-19. <i>Chest</i> , 2021, 159, 1382-1386.	0.4	12
2017	A hybrid data envelopment analysis-artificial neural network prediction model for COVID-19 severity in transplant recipients. <i>Artificial Intelligence Review</i> , 2021, 54, 4653-4684.	9.7	9

#	ARTICLE	IF	CITATIONS
2018	CRISPR/Cas System: A Potential Technology for the Prevention and Control of COVID-19 and Emerging Infectious Diseases. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 639108.	1.8	13
2019	A COVID-19 Drug Repurposing Strategy through Quantitative Homological Similarities Using a Topological Data Analysis-Based Framework. <i>Pharmaceutics</i> , 2021, 13, 488.	2.0	13
2020	SARS-CoV-2 Mpro: A Potential Target for Peptidomimetics and Small-Molecule Inhibitors. <i>Biomolecules</i> , 2021, 11, 607.	1.8	97
2021	The time to offer treatments for COVID-19. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 505-518.	1.9	20
2022	Clinical characteristics and outcome of influenza virus infection among adults hospitalized with severe COVID-19: a retrospective cohort study from Wuhan, China. <i>BMC Infectious Diseases</i> , 2021, 21, 341.	1.3	6
2023	Are overweight and obesity risk factors for invasive mechanical ventilation in severe coronavirus disease 2019 pneumonia?. <i>Archives of Endocrinology and Metabolism</i> , 2021, 65, 462-467.	0.3	4
2024	COVID-19: Challenges, Preventive Measures and Remediation. <i>Oriental Journal of Chemistry</i> , 2021, 37, 285-294.	0.1	0
2025	Development and validation of a simple-to-use nomogram to predict the deterioration and survival of patients with COVID-19. <i>BMC Infectious Diseases</i> , 2021, 21, 356.	1.3	7
2027	Research on repurposed antivirals currently available in Colombia as treatment alternatives for COVID-19. <i>Ingenieria Y Competitividad</i> , 2020, 23, e10290.	0.1	0
2028	The Progress and Challenges of Convalescent Plasma Therapy for Coronavirus Disease 2019. <i>Infectious Diseases & Immunity</i> , 2021, 1, 52-58.	0.2	0
2029	COVID19â€™un Ã¼ocuk YoÃ¼n BakÃ±mnda Ã°zlemi. SÃ¼leyman Demirel Ãœniversitesi TÃ±p FakÃ¼ltesi Dergisi, 0,0.	0,0	0
2030	Genetically Engineered Live-Attenuated Middle East Respiratory Syndrome Coronavirus Viruses Confer Full Protection against Lethal Infection. <i>MBio</i> , 2021, 12, .	1.8	13
2031	Discovery of potent Covidâ€™19 main protease inhibitors using integrated drugâ€™repurposing strategy. <i>Biotechnology and Applied Biochemistry</i> , 2021, 68, 712-725.	1.4	3
2032	COVID-19: An Insight on the Third Respiratory Global Emergency of the Century. <i>Coronaviruses</i> , 2021, 2, 339-345.	0.2	1
2033	Natural Products, a Potential Therapeutic Modality in Management and Treatment of nCoV-19 Infection: Preclinical and Clinical Based Evidence. <i>Current Pharmaceutical Design</i> , 2021, 27, 1153-1169.	0.9	5
2034	COVID-19 infection and rheumatoid arthritis: mutual outburst cytokines and remedies. <i>Current Medical Research and Opinion</i> , 2021, 37, 929-938.	0.9	9
2035	Repeated Pulses of Methyl-Prednisolone in Adults Hospitalized With COVID-19 Pneumonia and Acute Respiratory Distress Syndrome: A Preliminary Beforeâ€™After Study (CortiCOVID Study). <i>Open Respiratory Archives</i> , 2021, 3, 100086.	0.0	3
2036	COVID-19 Impacts, Diagnosis and Possible Therapeutic Techniques: A Comprehensive Review. <i>Current Pharmaceutical Design</i> , 2021, 27, 1170-1184.	0.9	13

#	ARTICLE	IF	CITATIONS
2037	Bronchoalveolar lavage-detected SARS-CoV-2 infection in presence of serial negative nasopharyngeal swabs: a case report. <i>Annals of Translational Medicine</i> , 2021, 9, 583-583.	0.7	7
2038	Epigallocatechin-3-gallate, an active ingredient of Traditional Chinese Medicines, inhibits the 3CLpro activity of SARS-CoV-2. <i>International Journal of Biological Macromolecules</i> , 2021, 176, 1-12.	3.6	77
2039	Evolving changes in mortality of 13,301 critically ill adult patients with COVID-19 over 8 months. <i>Intensive Care Medicine</i> , 2021, 47, 538-548.	3.9	72
2040	Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial. <i>Scientific Reports</i> , 2021, 11, 8059.	1.6	99
2041	Efficiency of antiviral treatment in COVID-19. <i>Experimental and Therapeutic Medicine</i> , 2021, 21, 648.	0.8	19
2042	Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1426.	3.8	284
2043	Drugs intervention study in COVID-19 management. <i>Drug Metabolism and Personalized Therapy</i> , 2021, .	0.3	7
2044	Ongoing COVID-19 Pandemic: A Concise but Updated Comprehensive Review. <i>Current Microbiology</i> , 2021, 78, 1718-1729.	1.0	11
2045	Race and ethnicity do not impact eligibility for remdesivir: A single-center experience. <i>PLoS ONE</i> , 2021, 16, e0250735.	1.1	3
2046	Coronavirus Disease 2019: An Overview of the Complications and Management. , 0, , 1-28.		1
2047	Clinical course and outcome of patients with COVID-19 in Mumbai City: an observational study. <i>BMJ Open</i> , 2021, 11, e042943.	0.8	19
2048	The Anti-Viral and Anti-Inflammatory Properties of Edible Bird's Nest in Influenza and Coronavirus Infections: From Pre-Clinical to Potential Clinical Application. <i>Frontiers in Pharmacology</i> , 2021, 12, 633292.	1.6	10
2049	COVID-19-Associated Pneumonia: Radiobiological Insights. <i>Frontiers in Pharmacology</i> , 2021, 12, 640040.	1.6	4
2050	Virtual screening of quinoline derived library for SARS-COV-2 targeting viral entry and replication. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 8464-8493.	2.0	4
2051	Liver injury, SARS-CoV-2 infection and COVID-19: What physicians should really know?. <i>GastroHep</i> , 2021, 3, 121-130.	0.3	11
2052	Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab278.	0.4	31
2053	In silico studies on stilbenolignan analogues as SARS-CoV-2 Mpro inhibitors. <i>Chemical Physics Letters</i> , 2021, 771, 138563.	1.2	18
2054	Rational design of potent anti-COVID-19 main protease drugs: An extensive multi-spectrum in silico approach. <i>Journal of Molecular Liquids</i> , 2021, 330, 115636.	2.3	10

#	ARTICLE	IF	CITATIONS
2055	Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2021, 24, 716-728.	0.6	39
2056	Cardiovascular Impacts on COVID-19 Infected Patients. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 670659.	1.1	8
2057	An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN- β -1a and hydroxychloroquine in hospitalized patients with COVID-19. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1826-1837.	2.8	77
2058	Improvement of Oral Bioavailability of Pyrazolo-Pyridone Inhibitors of the Interaction of DCN1/2 and UBE2M. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 5850-5862.	2.9	8
2059	COVID-19 in Kidney Transplant Patients From a Large UK Transplant Center: Exploring Risk Factors for Disease Severity. <i>Transplantation Proceedings</i> , 2021, 53, 1160-1168.	0.3	9
2060	Therapeutic approaches for SARS-CoV-2 infection. <i>Methods</i> , 2021, 195, 29-43.	1.9	14
2061	COVID-19: breaking down a global health crisis. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2021, 20, 35.	1.7	175
2062	Repurposed drug against COVID-19: nanomedicine as an approach for finding new hope in old medicines. <i>Nano Express</i> , 2021, 2, 022007.	1.2	6
2063	STATE-OF-THE-ART NANOTECHNOLOGY BASED DRUG DELIVERY STRATEGIES TO COMBAT COVID-19. <i>International Journal of Applied Pharmaceutics</i> , 0, , 18-29.	0.3	2
2064	Exploring protein hotspots by optimized fragment pharmacophores. <i>Nature Communications</i> , 2021, 12, 3201.	5.8	28
2065	A Mini Review: Origin, Treatments, Preventions, Real Facts and Viability of the Recent Pandemic of Novel Coronavirus-2019. <i>Coronaviruses</i> , 2021, 2, .	0.2	0
2066	Risk factors associated with the need for oxygen therapy in patients with COVID-19. <i>Medicine (United Tj ETQq1 1 0.784314rgBT /Over</i>	0.4	5
2067	Latest updates on SARS-CoV-2 genomic characterization, drug, and vaccine development; a comprehensive bioinformatics review. <i>Microbial Pathogenesis</i> , 2021, 154, 104809.	1.3	4
2068	Thromboembolic Complications of SARS-CoV-2 and Metabolic Derangements: Suggestions from Clinical Practice Evidence to Causative Agents. <i>Metabolites</i> , 2021, 11, 341.	1.3	10
2069	Strategy, Progress, and Challenges of Drug Repurposing for Efficient Antiviral Discovery. <i>Frontiers in Pharmacology</i> , 2021, 12, 660710.	1.6	15
2070	Covid-19: predictive mathematical formulae for the number of deaths during lockdown and possible scenarios for the post-lockdown period. <i>Proceedings of the Royal Society A: Mathematical, Physical and Engineering Sciences</i> , 2021, 477, 20200745.	1.0	7
2071	The Perfect Storm: A Rheumatologist's Point of View on COVID-19 Infection. <i>Current Rheumatology Reviews</i> , 2021, 17, 141-152.	0.4	3
2072	COVID-19 and syndemic challenges in â€ˆBattling the Big Threeâ€™: HIV, TB and malaria. <i>International Journal of Infectious Diseases</i> , 2021, 106, 29-32.	1.5	19

#	ARTICLE	IF	CITATIONS
2073	Phenotyping coronavirus disease 2019 during a global health pandemic: Lessons learned from the characterization of an early cohort. <i>Journal of Biomedical Informatics</i> , 2021, 117, 103777.	2.5	11
2074	Measuring the QT interval on the go. <i>Cardiology Journal</i> , 2021, 28, 358-359.	0.5	0
2075	Will Healthcare Workers Accept a COVID-19 Vaccine When It Becomes Available? A Cross-Sectional Study in China. <i>Frontiers in Public Health</i> , 2021, 9, 664905.	1.3	33
2076	The Course of COVID-19 in Four Patients with HIV During the Pandemic. <i>Current HIV Research</i> , 2021, 19, 286-291.	0.2	3
2077	Therapeutic strategies to fight COVID-19: Which is the <i>status artis</i> ?. <i>British Journal of Pharmacology</i> , 2022, 179, 2128-2148.	2.7	33
2078	COVID-19 is not "just another flu": a real-life comparison of severe COVID-19 and influenza in hospitalized patients in Vienna, Austria. <i>Infection</i> , 2021, 49, 907-916.	2.3	7
2079	Targeting Multiple Signal Transduction Pathways of SARS-CoV-2: Approaches to COVID-19 Therapeutic Candidates. <i>Molecules</i> , 2021, 26, 2917.	1.7	13
2080	How COVID-19 has fundamentally changed clinical research in global health. <i>The Lancet Global Health</i> , 2021, 9, e711-e720.	2.9	122
2081	Adapting for the COVID-19 pandemic in Ecuador, a characterization of hospital strategies and patients. <i>PLoS ONE</i> , 2021, 16, e0251295.	1.1	4
2082	Practice of adjunctive treatments in critically ill COVID-19 patients: rational for the multicenter observational PRoAcT-COVID study in The Netherlands. <i>Annals of Translational Medicine</i> , 2021, 9, 813-813.	0.7	6
2083	Repurposed Antiviral Drugs for the Treatment of COVID-19: Syntheses, Mechanism of Infection and Clinical Trials. <i>Mini-Reviews in Medicinal Chemistry</i> , 2021, 21, 1123-1143.	1.1	8
2084	Favipiravir use in children with COVID-19 and acute kidney injury: is it safe?. <i>Pediatric Nephrology</i> , 2021, 36, 3771-3776.	0.9	12
2085	Neurological manifestations in COVID-19: an overview. <i>Minerva Respiratory Medicine</i> , 2021, 60, .	0.1	4
2086	Antiviral treatment selection for SARS-CoV-2 pneumonia. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 985-992.	1.0	4
2087	A comprehensive review of imaging findings in COVID-19 - status in early 2021. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2500-2524.	3.3	31
2088	Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients. <i>BMC Infectious Diseases</i> , 2021, 21, 411.	1.3	71
2089	Existing Drugs Considered as Promising in COVID-19 Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5434.	1.8	24
2090	COVID-19 and HIV infection co-pandemics and their impact: a review of the literature. <i>AIDS Research and Therapy</i> , 2021, 18, 28.	0.7	59

#	ARTICLE	IF	CITATIONS
2091	New Approaches and Repurposed Antiviral Drugs for the Treatment of the SARS-CoV-2 Infection. <i>Pharmaceuticals</i> , 2021, 14, 503.	1.7	6
2092	Viral Proteases as Targets for Coronavirus Disease 2019 Drug Development. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 378, 166-172.	1.3	19
2093	An update review of emerging small-molecule therapeutic options for COVID-19. <i>Biomedicine and Pharmacotherapy</i> , 2021, 137, 111313.	2.5	52
2094	Identification of potential inhibitors of SARS-CoV-2 S protein-ACE2 interaction by in silico drug repurposing. <i>F1000Research</i> , 2021, 10, 358.	0.8	1
2095	Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection. <i>Pharmaceuticals</i> , 2021, 14, 454.	1.7	34
2096	Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. <i>Scientific Reports</i> , 2021, 11, 9927.	1.6	87
2097	Discovery of Cyclic Peptide Ligands to the SARS-CoV-2 Spike Protein Using mRNA Display. <i>ACS Central Science</i> , 2021, 7, 1001-1008.	5.3	47
2098	Drug Repurposing for the Treatment of COVID-19: A Knowledge Graph Approach. <i>Advanced Therapeutics</i> , 2021, 4, 2100055.	1.6	12
2099	Brief review on repurposed drugs and vaccines for possible treatment of COVID-19. <i>European Journal of Pharmacology</i> , 2021, 898, 173977.	1.7	29
2100	Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.. <i>EClinicalMedicine</i> , 2021, 35, 100849.	3.2	146
2101	Essentials in the Treatment of COVID-19. <i>Anti-Infective Agents</i> , 2021, 19, .	0.1	0
2102	Analysis on the risk of respiratory virus transmission by air conditioning system operation based on experimental evidence. <i>Environmental Science and Pollution Research</i> , 2021, 28, 56376-56391.	2.7	3
2103	Pharmacotherapy for COVID-19: A Ray of Hope. , 0, , .		0
2104	The Chronicle of COVID-19 and Possible Strategies to Curb the Pandemic. <i>Current Medicinal Chemistry</i> , 2021, 28, 2852-2886.	1.2	20
2105	The 15-Months Clinical Experience of SARS-CoV-2: A Literature Review of Therapies and Adjuvants. <i>Antioxidants</i> , 2021, 10, 881.	2.2	20
2106	Emergent Drug and Nutrition Interactions in COVID-19: A Comprehensive Narrative Review. <i>Nutrients</i> , 2021, 13, 1550.	1.7	26
2107	Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 601-621.	1.3	144
2108	Current Strategies of Antiviral Drug Discovery for COVID-19. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 671263.	1.6	75

#	ARTICLE	IF	CITATIONS
2109	Effective drugs used to combat SARS-CoV-2 infection and the current status of vaccines. <i>Biomedicine and Pharmacotherapy</i> , 2021, 137, 111330.	2.5	33
2110	COVID-19 fatality rates in hospitalized patients: systematic review and meta-analysis. <i>Annals of Epidemiology</i> , 2021, 57, 14-21.	0.9	107
2111	In silico identification and validation of triarylchromones as potential inhibitor against main protease of severe acute respiratory syndrome coronavirus 2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, , 1-16.	2.0	2
2112	Evidence and the Main Adverse Effects Regarding Drug Therapies in the War Against COVID-19. <i>Current Medicinal Chemistry</i> , 2021, 28, 3147-3157.	1.2	0
2113	Current Paradigms in COVID-19 Research: Proposed Treatment Strategies, Recent Trends and Future Directions. <i>Current Medicinal Chemistry</i> , 2021, 28, 3173-3192.	1.2	5
2114	Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients. <i>PLoS ONE</i> , 2021, 16, e0249760.	1.1	9
2115	Interferon- α 2b aerosol inhalation is associated with improved clinical outcomes in patients with coronavirus disease-2019. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4737-4746.	1.1	13
2116	Mechanism involved in the pathogenesis and immune response against SARS-CoV-2 infection. <i>VirusDisease</i> , 2021, 32, 211-219.	1.0	6
2117	Smartwatch Electrocardiogram and Artificial Intelligence for Assessing Cardiac-Rhythm Safety of Drug Therapy in the COVID-19 Pandemic. The QT-logs study. <i>International Journal of Cardiology</i> , 2021, 331, 333-339.	0.8	29
2118	Antibiotics in treatment of COVID-19 complications: a review of frequency, indications, and efficacy. <i>Journal of Infection and Public Health</i> , 2021, 14, 570-576.	1.9	111
2119	Statistical Decision Properties of Imprecise Trials Assessing Coronavirus Disease 2019 (COVID-19) Drugs. <i>Value in Health</i> , 2021, 24, 641-647.	0.1	7
2120	SARS CoV-2 (COVID-19) Current Pharmacotherapy for Mother and Infant. <i>Neonatal Network: NN</i> , 2021, 40, 175-182.	0.1	0
2121	COVID-19 and Diabetes Mellitus: A Complex Interplay. <i>Journal of Pure and Applied Microbiology</i> , 2021, 15, 512-523.	0.3	1
2122	Response of the Authors. <i>Annals of Noninvasive Electrocardiology</i> , 2021, 26, e12852.	0.5	1
2123	HIV and COVID-19 pandemic collision: turning challenges into opportunity. <i>Future Virology</i> , 2021, 16, 311-313.	0.9	2
2124	Therapeutic Agents Against COVID-19 with Clinical Evidence. <i>Current Pharmaceutical Design</i> , 2021, 27, 1608-1617.	0.9	4
2125	Brief review of the mRNA vaccines COVID-19. <i>Inflammopharmacology</i> , 2021, 29, 645-649.	1.9	42
2126	Intravenous immunoglobulin-based adjuvant therapy for severe COVID-19: a single-center retrospective cohort study. <i>Virology Journal</i> , 2021, 18, 101.	1.4	11

#	ARTICLE	IF	CITATIONS
2127	Management of COVID-19: current status and future prospects. <i>Microbes and Infection</i> , 2021, 23, 104832.	1.0	18
2128	SARS-CoV-2: From the pathogenesis to potential anti-viral treatments. <i>Biomedicine and Pharmacotherapy</i> , 2021, 137, 111352.	2.5	23
2129	Molecular Docking and Dynamics Simulation Study of HyrtiosÂerectus Isolated Scalarane Sesterterpenes as Potential SARS-CoV-2 Dual Target Inhibitors. <i>Biology</i> , 2021, 10, 389.	1.3	34
2130	In silico Exploration of Interactions Between Potential COVID-19 Antiviral Treatments and the Pore of the hERG Potassium Channelâ€”A Drug Antitarget. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 645172.	1.1	4
2131	Kawasaki like illness due to COVID-19: a review of the literature. <i>Journal of Infection in Developing Countries</i> , 2021, 15, 630-638.	0.5	9
2132	The Rise and Fall of Chloroquine/Hydroxychloroquine as Compassionate Therapy of COVID-19. <i>Frontiers in Pharmacology</i> , 2021, 12, 584940.	1.6	28
2133	Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2. <i>Medicine (United States)</i> , 2021, 100, e25923.	0.4	3
2134	Convalescent plasma therapy and mortality in COVID-19 patients admitted to the ICU: a prospective observational study. <i>Annals of Intensive Care</i> , 2021, 11, 73.	2.2	9
2135	Transmission risk of viruses in large mucosal droplets on the surface of objects: A time-based analysis. <i>Infectious Diseases Now</i> , 2021, 51, 219-227.	0.7	9
2137	Could Histamine H1 Receptor Antagonists Be Used for Treating COVID-19?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5672.	1.8	16
2138	Evaluation of the role and usefulness of clinical pharmacists at the Fangcang Hospital during COVIDâ€”19 outbreak. <i>International Journal of Clinical Practice</i> , 2021, 75, e14271.	0.8	9
2139	Lopinavir/Ritonavir: A Review of Analytical Methodologies for the Drug Substances, Pharmaceutical Formulations and Biological Matrices. <i>Critical Reviews in Analytical Chemistry</i> , 2021, , 1-17.	1.8	3
2140	Efficacy and safety of Xiyanping injection in the treatment of <sc>COVID</sc>â€”19: A multicenter, prospective, openâ€”label and randomized controlled trial. <i>Phytotherapy Research</i> , 2021, 35, 4401-4410.	2.8	74
2141	Structure, Transmission, Diagnostic Symptoms, Host and Entry Mechanism of COVID-19: A Review. <i>Coronaviruses</i> , 2021, 2, .	0.2	1
2142	Synthesis and Cytotoxic Activity of Novel Indole Derivatives and Their in silico Screening on Spike Glycoprotein of SARS-CoV-2. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 637989.	1.6	5
2143	Tocilizumab in the treatment of coronavirus disease 2019 pneumonia: real-world data from a case series. <i>Future Virology</i> , 2021, 16, 321-329.	0.9	2
2144	Benefits of treatment with favipiravir in hospitalized patients for COVID-19: a retrospective observational caseâ€”control study. <i>Virology Journal</i> , 2021, 18, 102.	1.4	7
2145	Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review. <i>Reviews on Recent Clinical Trials</i> , 2021, 16, 138-145.	0.4	18

#	ARTICLE	IF	CITATIONS
2146	Clinical Management of COVID-19: A Review of Pharmacological Treatment Options. <i>Pharmaceuticals</i> , 2021, 14, 520.	1.7	24
2147	Pharmacophore Modelling-Based Drug Repurposing Approaches for SARS-CoV-2 Therapeutics. <i>Frontiers in Chemistry</i> , 2021, 9, 636362.	1.8	22
2148	A potential solution to avoid overdose of mixed drugs in the event of Covid-19: Nanomedicine at the heart of the Covid-19 pandemic. <i>Journal of Molecular Graphics and Modelling</i> , 2021, 104, 107834.	1.3	6
2149	Screening of FDA-approved compound library identifies potential small-molecule inhibitors of SARS-CoV-2 non-structural proteins NSP1, NSP4, NSP6 and NSP13: molecular modeling and molecular dynamics studies. <i>Journal of Proteins and Proteomics</i> , 2021, 12, 161-175.	1.0	14
2150	COVID-19 pneumonia in Galicia (Spain): Impact of prognostic factors and therapies on mortality and need for mechanical ventilation. <i>PLoS ONE</i> , 2021, 16, e0253465.	1.1	1
2151	Effectiveness of interventions as part of the One Health approach to control coronavirus disease 2019 and stratified case features in Anhui Province, China: A real-world population-based cohort study. <i>One Health</i> , 2021, 12, 100224.	1.5	10
2152	Antiviral Activity of Metabolites from Peruvian Plants against SARS-CoV-2: An In Silico Approach. <i>Molecules</i> , 2021, 26, 3882.	1.7	23
2153	Direct derivation of human alveolospheres for SARS-CoV-2 infection modeling and drug screening. <i>Cell Reports</i> , 2021, 35, 109218.	2.9	38
2154	COVID-19 and the liver – Lessons learned. <i>Liver International</i> , 2021, 41, 1-8.	1.9	22
2156	Gastrointestinal manifestations of human immunodeficiency virus and coronavirus disease 2019: Understanding the intersecting regions between the two epidemics. <i>Arab Journal of Gastroenterology</i> , 2021, 22, 75-87.	0.4	2
2157	Efficacy of Brazilian green propolis (EPP-AF [®]) as an adjunct treatment for hospitalized COVID-19 patients: A randomized, controlled clinical trial. <i>Biomedicine and Pharmacotherapy</i> , 2021, 138, 111526.	2.5	77
2158	Clinical Management of COVID-19 Patients – An Update. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 4-10.	2.5	33
2159	Macrophage biomimetic nanocarriers for anti-inflammation and targeted antiviral treatment in COVID-19. <i>Journal of Nanobiotechnology</i> , 2021, 19, 173.	4.2	45
2160	Antimicrobial Use in COVID-19 Patients in the First Phase of the SARS-CoV-2 Pandemic: A Scoping Review. <i>Antibiotics</i> , 2021, 10, 745.	1.5	39
2161	A Repurposed Drug Screen Identifies Compounds That Inhibit the Binding of the COVID-19 Spike Protein to ACE2. <i>Frontiers in Pharmacology</i> , 2021, 12, 685308.	1.6	12
2162	COVID-19 and Indirect Liver Injury: A Narrative Synthesis of the Evidence. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	12
2163	Synthesis of hydroxy benzoin/benzil analogs and investigation of their antioxidant, antimicrobial, enzyme inhibition, and cytotoxic activities. <i>Turkish Journal of Chemistry</i> , 2021, 45, 788-804.	0.5	3
2164	Potential Drugs for the Treatment of COVID-19: Synthesis, Brief History and Application. <i>Current Drug Research Reviews</i> , 2021, 13, 184-202.	0.7	3

#	ARTICLE	IF	CITATIONS
2165	The role of 5-lipoxygenase in the pathophysiology of COVID-19 and its therapeutic implications. <i>Inflammation Research</i> , 2021, 70, 877-889.	1.6	12
2166	Guiding axes for drug safety management of pharmacovigilance centres during the COVID-19 era. <i>International Journal of Clinical Pharmacy</i> , 2021, 43, 1133-1138.	1.0	2
2167	A Minireview of the Promising Drugs and Vaccines in Pipeline for the Treatment of COVID-19 and Current Update on Clinical Trials. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 637378.	1.6	13
2168	HIV and COVID-19: Lessons From HIV and STI Harm Reduction Strategies. <i>Current HIV/AIDS Reports</i> , 2021, 18, 261-270.	1.1	5
2169	SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise. <i>Microorganisms</i> , 2021, 9, 1389.	1.6	4
2170	A Multidisciplinary Approach to Coronavirus Disease (COVID-19). <i>Molecules</i> , 2021, 26, 3526.	1.7	14
2171	Associated risk factors with disease severity and antiviral drug therapy in patients with COVID-19. <i>BMC Infectious Diseases</i> , 2021, 21, 549.	1.3	10
2172	Bibliometric Analysis of Pfizer-BioNTech (BNT162B2): A COVID-19 Vaccine. <i>Journal of Pure and Applied Microbiology</i> , 2021, 15, 1211-1229.	0.3	1
2173	Genetic Structure, Transmission, Clinical Characteristics, Diagnosis, Treatment and Prevention of Coronavirus Disease 2019 (COVID-19): A Review. <i>Iraqi Journal of Pharmaceutical Sciences</i> , 2021, 30, 56-65.	0.1	4
2174	Assessing efficacy of antiviral therapy for COVID-19 patients: A case study on remdesivir with bayesian synthesis design and multistate analysis. <i>Journal of the Formosan Medical Association</i> , 2021, 120, S77-S85.	0.8	5
2176	Drug-drug Interactions between COVID-19 Treatments and Antidepressants, Mood Stabilizers/Anticonvulsants, and Benzodiazepines: Integrated Evidence from 3 Databases. <i>Pharmacopsychiatry</i> , 2022, 55, 40-47.	1.7	11
2177	Introspecting Scope of Ultra-Diluted Homeopathic Preparations in Human SARS-CoV-2 Infection: A Perspective Review. <i>Homopathic Links</i> , 2021, 34, 112-118.	0.1	0
2178	A transferable deep learning approach to fast screen potential antiviral drugs against SARS-CoV-2. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	29
2179	Strategies to Improve Antimicrobial Utilization with a Special Focus on Developing Countries. <i>Life</i> , 2021, 11, 528.	1.1	95
2180	Role of Chest CT in COVID-19. <i>Journal of Clinical Imaging Science</i> , 2021, 11, 30.	0.4	7
2181	Thymosin Alpha-1 Has no Beneficial Effect on Restoring CD4+ and CD8+ T Lymphocyte Counts in COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 568789.	2.2	9
2182	The significance of bioengineered nanoplatfoms against SARS-CoV-2: From detection to genome editing. <i>Life Sciences</i> , 2021, 274, 119289.	2.0	9
2183	Temporal evolution, most influential studies and sleeping beauties of the coronavirus literature. <i>Scientometrics</i> , 2021, 126, 7005-7050.	1.6	12

#	ARTICLE	IF	CITATIONS
2184	Successful Treatment of a Critically Ill COVID-19 Patient Using Continuous Renal Replacement Therapy With Enhanced Cytokine Removal and Tocilizumab: A Case Report. <i>Frontiers in Medicine</i> , 2021, 8, 649583.	1.2	5
2186	Antimicrobial resistance and COVID-19 syndemic: Impact on public health. <i>Drug Discoveries and Therapeutics</i> , 2021, 15, 124-129.	0.6	3
2187	Drug targets, mechanisms of drug action, and therapeutics against SARS-CoV-2. <i>Chemical Physics Impact</i> , 2021, 2, 100011.	1.7	18
2188	The Effect of COVID-19 on NF- κ B and Neurological Manifestations of Disease. <i>Molecular Neurobiology</i> , 2021, 58, 4178-4187.	1.9	31
2189	Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study. <i>Frontiers in Medicine</i> , 2021, 8, 639970.	1.2	20
2190	Is the Endothelium the Missing Link in the Pathophysiology and Treatment of COVID-19 Complications?. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 547-560.	1.3	37
2191	The Impetus of COVID -19 in Multiple Organ Affliction Apart from Respiratory Infection: Pathogenesis, Diagnostic Measures and Current Treatment Strategy. <i>Infectious Disorders - Drug Targets</i> , 2021, 21, 514-526.	0.4	14
2192	Medication Use Among Patients With COVID-19 in a Large, National Dataset: Cerner Real-World Data. <i>Clinical Therapeutics</i> , 2021, 43, e173-e196.	1.1	3
2193	Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021. <i>Frontiers in Pharmacology</i> , 2021, 12, 659577.	1.6	31
2194	COVID-19 Multi-Targeted Drug Repurposing Using Few-Shot Learning. <i>Frontiers in Bioinformatics</i> , 2021, 1, .	1.0	19
2195	Clinical Course and Risk Factors for In-Hospital Mortality of 205 Patients with SARS-CoV-2 Pneumonia in Como, Lombardy Region, Italy. <i>Vaccines</i> , 2021, 9, 640.	2.1	4
2196	Coronavirus Disease 2019 (COVID-19): Current Situation and Therapeutic Options. <i>Coronaviruses</i> , 2021, 2, 481-491.	0.2	17
2197	Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the Ege University cohort, Turkey. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 912-920.	0.4	15
2198	Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-blind, Randomized, Controlled Clinical Trial. <i>Clinical Therapeutics</i> , 2021, 43, 1007-1019.	1.1	52
2199	A Hepatitis B Virus-Derived Peptide Can Inhibit Infection of Human Lung Cells with SARS-CoV-2 in a Type-1 Interferon-Dependent Manner. <i>Viruses</i> , 2021, 13, 1227.	1.5	3
2200	Coronavirus disease and the cardiovascular system: a narrative review of the mechanisms of injury and management implications. <i>Cardiovascular Diagnosis and Therapy</i> , 2021, 11, 939-953.	0.7	0
2201	Caracterizaço Demogrfica, Curso Clnico e Fatores de Risco para Mortalidade em Doentes Hospitalizados com COVID-19: Experincia de um Hospital Tercirio Portugus na Primeira Vaga da Pandemia. <i>Revista De Medicina Intern, Neurologie, Psihiatrie, Neurochirurgie, Dermato-venerologie Medicina Intern</i> , 2021, 28, 145-154.	0.0	1
2202	O uso de Lopinavir e Ritonavir como alternativa teraputica para a COVID-19. <i>Research, Society and Development</i> , 2021, 10, e43410716505.	0.0	1

#	ARTICLE	IF	CITATIONS
2203	Early outcomes in adults hospitalized with severe SARS-CoV-2 infection receiving tocilizumab. <i>Medicina Clínica</i> , 2022, 158, 509-518.	0.3	4
2204	Antiviral activity of oleandrin and a defined extract of <i>Nerium oleander</i> against SARS-CoV-2. <i>Biomedicine and Pharmacotherapy</i> , 2021, 138, 111457.	2.5	23
2205	Review of epidemic, containment strategies, clinical management, and economic evaluation of COVID-19 pandemic. <i>Journal of the Formosan Medical Association</i> , 2021, 120, S6-S18.	0.8	16
2206	Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials. <i>Journal of Infection and Public Health</i> , 2021, 14, 740-748.	1.9	47
2207	COVID-19 rhapsody: Rage towards advanced diagnostics and therapeutic strategy. <i>Journal of Pharmaceutical Analysis</i> , 2021, 11, 529-540.	2.4	5
2208	Exact sequential test for clinical trials and post-market drug and vaccine safety surveillance with Poisson and binary data. <i>Statistics in Medicine</i> , 2021, 40, 4890-4913.	0.8	5
2209	Combination of (interferon beta-1b, lopinavir/ritonavir and ribavirin) versus favipiravir in hospitalized patients with non-critical COVID-19: A cohort study. <i>PLoS ONE</i> , 2021, 16, e0252984.	1.1	14
2210	Viral Respiratory Pathogens and Lung Injury. <i>Clinical Microbiology Reviews</i> , 2021, 34, .	5.7	76
2211	Neurological Effects of SARS-CoV-2 and Neurotoxicity of Antiviral Drugs Against COVID-19. <i>Mini-Reviews in Medicinal Chemistry</i> , 2022, 22, 213-231.	1.1	2
2212	Correlation between measles immunization coverage and overall morbidity and mortality for COVID-19: an epidemiological study. <i>Environmental Science and Pollution Research</i> , 2021, 28, 62266-62273.	2.7	1
2213	Tailoring management and immunosuppression regimen in kidney transplant recipients with COVID-19 infection – lessons from Singapore. <i>Singapore Medical Journal</i> , 2021, , .	0.3	0
2214	Knowledge and Determinants of Behavioral Responses to the Pandemic of COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 673187.	1.2	7
2216	Emergence of a New Zoonotic COVID-19 that Creates a Pandemic: Update on Current Pharmacotherapeutics and Future Prospective of Plasma Therapy. <i>Coronaviruses</i> , 2021, 2, 422-430.	0.2	0
2217	A prospective study on COVID-19 convalescent plasma donor (CCP) recruitment strategies in a resource constrained blood centre. <i>ISBT Science Series</i> , 2021, , .	1.1	3
2218	Identification and evaluation of the inhibitory effect of <i>Prunella vulgaris</i> extract on SARS-coronavirus 2 virus entry. <i>PLoS ONE</i> , 2021, 16, e0251649.	1.1	23
2219	Flavonoids as Promising Antiviral Agents against SARS-CoV-2 Infection: A Mechanistic Review. <i>Molecules</i> , 2021, 26, 3900.	1.7	43
2220	Potential value of circulating endothelial cells for the diagnosis and treatment of COVID-19. <i>International Journal of Infectious Diseases</i> , 2021, 107, 232-233.	1.5	4
2221	Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia. <i>International Immunopharmacology</i> , 2021, 95, 107522.	1.7	49

#	ARTICLE	IF	CITATIONS
2222	A review on role of nitrous oxide nanoparticles, potential vaccine targets, drug, health care and artificial intelligence to combat COVID-19. <i>Applied Nanoscience (Switzerland)</i> , 2023, 13, 111-118.	1.6	6
2223	Dissecting the novel mechanism of reduning injection in treating Coronavirus Disease 2019 (COVID-19) based on network pharmacology and experimental verification. <i>Journal of Ethnopharmacology</i> , 2021, 273, 113871.	2.0	23
2224	An update on emerging therapeutics to combat COVID-19. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021, 129, 104-129.	1.2	9
2225	The role of probiotics in coronavirus disease-19 infection in Wuhan: A retrospective study of 311 severe patients. <i>International Immunopharmacology</i> , 2021, 95, 107531.	1.7	37
2226	Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 767-775.	1.5	32
2227	COVID-19 Summary Guidelines. <i>Sushruta Journal of Health Policy & Opinions</i> , 2021, 14, 1-5.	0.1	0
2228	Clinical Features and Outcomes of Coronavirus Disease 2019 Among People With Human Immunodeficiency Virus in the United States: A Multicenter Study From a Large Global Health Research Network (TriNetX). <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab272.	0.4	27
2229	Current Trends and Future Approaches in Small-Molecule Therapeutics for COVID-19. <i>Current Medicinal Chemistry</i> , 2021, 28, 3803-3824.	1.2	8
2230	A retrospective analysis of clinical efficacy of ribavirin in adults hospitalized with severe COVID-19. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 876-881.	0.8	17
2231	Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: Results of a large multicenter study. <i>Journal of Infection</i> , 2021, 82, 276-316.	1.7	7
2232	The scientific community in COVID-19 global pandemic: A systematic update on recent progress and challenges. <i>European Journal of Chemistry</i> , 2021, 12, 222-234.	0.3	0
2233	What we have learned from COVID-19 pandemic?. <i>Journal of the Formosan Medical Association</i> , 2021, 120, S1-S5.	0.8	1
2234	Drug-drug interactions between treatment specific pharmacotherapy and concomitant medication in patients with COVID-19 in the first wave in Spain. <i>Scientific Reports</i> , 2021, 11, 12414.	1.6	14
2235	Application of intravenous immunoglobulin (IVIG) to modulate inflammation in critical COVID-19 - A theoretical perspective. <i>Medical Hypotheses</i> , 2021, 151, 110592.	0.8	8
2236	The use of remdesivir for the management of patients with moderate-to-severe COVID-19: a systematic review. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 211-229.	2.0	10
2237	SARS-CoV-2 Antiviral Therapy. <i>Clinical Microbiology Reviews</i> , 2021, 34, e0010921.	5.7	64
2238	Current Treatments and Therapeutic Options for COVID-19 Patients: A Systematic Review. <i>Infectious Disorders - Drug Targets</i> , 2022, 22, .	0.4	27
2239	Comparative effectiveness and safety of 32 pharmacological interventions recommended by guidelines for coronavirus disease 2019: a systematic review and network meta-analysis combining 66 trials. <i>Chinese Medical Journal</i> , 2021, 134, 1920-1929.	0.9	6

#	ARTICLE	IF	CITATIONS
2240	Immunomodulation as a Potent COVID-19 Pharmacotherapy: Past, Present and Future. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 3419-3428.	1.6	25
2241	Ebsulfur and Ebselen as highly potent scaffolds for the development of potential SARS-CoV-2 antivirals. <i>Bioorganic Chemistry</i> , 2021, 112, 104889.	2.0	46
2242	In silico investigation of potential small molecule inhibitors of the SARS-CoV-2 nsp10-nsp16 methyltransferase complex. <i>Chemical Physics Letters</i> , 2021, 774, 138618.	1.2	9
2243	Clinical factors associated with composition of lung microbiota and important taxa predicting clinical prognosis in patients with severe community-acquired pneumonia. <i>Frontiers of Medicine</i> , 2022, 16, 389-402.	1.5	5
2244	Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients. <i>Journal of Medical Virology</i> , 2021, 93, 6557-6565.	2.5	10
2245	Nanotechnology-based Approaches and Investigational Therapeutics against COVID-19. <i>Current Pharmaceutical Design</i> , 2022, 28, 948-968.	0.9	10
2246	Drug-induced liver injury associated with lopinavir-ritonavir in patients with COVID-19: a disproportionality analysis of U.S. food and drug administration adverse event reporting system (FAERS) data. <i>International Journal of Clinical Pharmacy</i> , 2021, 43, 1116-1122.	1.0	10
2247	Promising anti-SARS-CoV-2 drugs by effective dual targeting against the viral and host proteases. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 43, 128099.	1.0	21
2249	Computational Chemistry to Repurposing Drugs for the Control of COVID-19. <i>Biologics</i> , 2021, 1, 111-128.	2.3	8
2250	Clinical course and serial chest ultra-low-dose CT findings in a patient with COVID-19 treated with remdesivir. <i>Minerva Medica</i> , 2021, 112, 516-518.	0.3	2
2251	Anti-COVID-19 Sulfonamides: A DFT, docking and ADMET study. <i>Coronaviruses</i> , 2021, 02, .	0.2	1
2252	Candesartan as a tentative treatment for COVID-19: A prospective non-randomized open-label study. <i>International Journal of Infectious Diseases</i> , 2021, 108, 159-166.	1.5	4
2253	Evaluation of infection risk for SARS-CoV-2 transmission on university campuses. <i>Science and Technology for the Built Environment</i> , 2021, 27, 1165-1180.	0.8	10
2254	Disease-drug and drug-drug interaction in COVID-19: Risk and assessment. <i>Biomedicine and Pharmacotherapy</i> , 2021, 139, 111642.	2.5	50
2255	Macrolactin A as a Novel Inhibitory Agent for SARS-CoV-2 Mpro: Bioinformatics Approach. <i>Applied Biochemistry and Biotechnology</i> , 2021, 193, 3371-3394.	1.4	25
2256	Activation of p21 limits acute lung injury and induces early senescence after acid aspiration and mechanical ventilation. <i>Translational Research</i> , 2021, 233, 104-116.	2.2	14
2257	A tale of two diseases: Sarcoidosis, COVID-19 and new therapeutic options with dual RAS inhibition and tetanus-diphtheria vaccine. <i>Medical Hypotheses</i> , 2021, 152, 110619.	0.8	1
2258	Safety profile of treatments administered in COVID 19 infection in pregnant women. <i>Clinica E Investigacion En Ginecologia Y Obstetricia</i> , 2021, 48, 100663.	0.1	4

#	ARTICLE	IF	CITATIONS
2259	Use of traditional Chinese medicine as an adjunctive treatment for COVID-19. <i>Medicine (United States)</i> , 2021, 100, e26641.	0.4	8
2261	Advances in the computational landscape for repurposed drugs against COVID-19. <i>Drug Discovery Today</i> , 2021, 26, 2800-2815.	3.2	19
2262	Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: A modeling study. <i>PLoS Medicine</i> , 2021, 18, e1003660.	3.9	32
2263	Influencia del tratamiento con estatinas en una cohorte de pacientes ingresados por COVID-19. <i>Medicina Clínica</i> , 2022, 158, 586-595.	0.3	5
2264	COVID-19 Severity: Lung-Heart Interplay. <i>Current Cardiology Reviews</i> , 2021, 17, e230421189016.	0.6	11
2265	<scp>COVID</scp>â€19 convalescent plasma cohort study: Evaluation of the association between both donor and recipient neutralizing antibody titers and patient outcomes. <i>Transfusion</i> , 2021, 61, 2295-2306.	0.8	8
2266	Small Molecules of Natural Origin as Potential Anti-HIV Agents: A Computational Approach. <i>Life</i> , 2021, 11, 722.	1.1	9
2267	Impact of the COVID-19 pandemic on HIV care in Guatemala. <i>International Journal of Infectious Diseases</i> , 2021, 108, 422-427.	1.5	16
2268	One Year of the COVIDâ€19 Pandemic. What Do We Know and What Is Yet to Come? â€” The Summarising Review. <i>International Journal of Public Health</i> , 2021, 66, 1603975.	1.0	3
2269	Antiviral Activity of Influenza A Virus Defective Interfering Particles against SARS-CoV-2 Replication In Vitro through Stimulation of Innate Immunity. <i>Cells</i> , 2021, 10, 1756.	1.8	19
2270	High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19. <i>Frontiers in Pharmacology</i> , 2021, 12, 704767.	1.6	8
2271	Novel corona virus (COVID-19); Global efforts and effective investigational medicines: A review. <i>Journal of Infection and Public Health</i> , 2021, 14, 910-921.	1.9	14
2272	Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	121
2273	Recent advances in developing small-molecule inhibitors against SARS-CoV-2. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 1591-1623.	5.7	57
2274	New perspective towards therapeutic regimen against SARS-CoV-2 infection. <i>Journal of Infection and Public Health</i> , 2021, 14, 852-862.	1.9	3
2275	Synthetic Attempts Towards Eminent Anti-viral Candidates of SARS-CoV. <i>Mini-Reviews in Medicinal Chemistry</i> , 2022, 22, 232-247.	1.1	1
2276	Marine sulfated polysaccharides as potential antiviral drug candidates to treat Corona Virus disease (COVID-19). <i>Carbohydrate Research</i> , 2021, 505, 108326.	1.1	48
2277	SARS-CoV-2: Origin, Pathogenesis and Therapeutic Interventions. <i>Coronaviruses</i> , 2021, 2, .	0.2	2

#	ARTICLE	IF	CITATIONS
2278	Targeting SARS-CoV-2 nonstructural protein nsp15 endoribonuclease: an <i>in silico</i> perspective. <i>Future Virology</i> , 2021, 16, 467-474.	0.9	8
2280	Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy. <i>Cell Reports</i> , 2021, 36, 109432.	2.9	24
2281	Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1219-1244.	2.0	6
2282	Clinimetrics: Core Outcome Set for trials with Coronavirus disease 2019 (COVID-19-COS). <i>Journal of Physiotherapy</i> , 2022, 68, 74.	0.7	0
2283	Use of placebo in clinical trials in COVID-19 pandemic times: considerations on pros, cons, challenges and limitations. <i>Minerva Medica</i> , 2021, , .	0.3	3
2285	Current Perspectives in the Discovery of Newer Medications Against the Outbreak of COVID-19. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 648232.	1.6	1
2286	Efficacy of Different Types of Therapy for COVID-19: A Comprehensive Review. <i>Life</i> , 2021, 11, 753.	1.1	14
2288	Efficacy and Safety of Leflunomide for Refractory COVID-19: A Pilot Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 581833.	1.6	5
2289	Informing selection of drugs for COVID-19 treatment through adverse events analysis. <i>Scientific Reports</i> , 2021, 11, 14022.	1.6	5
2290	Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis. <i>Diseases (Basel, Switzerland)</i> , 2021, 9, 50.	1.0	22
2291	Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group. <i>Leukemia and Lymphoma</i> , 2021, 62, 2928-2938.	0.6	21
2293	Efficacy and safety of remdesivir in hospitalised COVID-19 patients: a systematic review and meta-analysis. <i>Infection</i> , 2022, 50, 27-41.	2.3	46
2294	Why proper understanding of confidence intervals and statistical significance is important. <i>Medical Journal of Australia</i> , 2021, 215, 191.	0.8	0
2295	Antiviral Therapeutic Approaches for SARS-CoV-2 Infection: A Systematic Review. <i>Pharmaceuticals</i> , 2021, 14, 736.	1.7	15
2296	Antiviral drugs arbidol and interferon alpha-1b contribute to reducing the severity of COVID-19 patients: a retrospective cohort study. <i>Virology Journal</i> , 2021, 18, 142.	1.4	9
2297	Effects of Photobiomodulation Therapy Combined with Static Magnetic Field in Severe COVID-19 Patients Requiring Intubation: A Pragmatic Randomized Placebo-Controlled Trial. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 3569-3585.	1.6	16
2298	Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). <i>Infectious Diseases and Therapy</i> , 2021, 10, 1837-1885.	1.8	28
2299	Evaluation of Ivermectin as a Potential Treatment for Mild to Moderate COVID-19: A Double-Blind Randomized Placebo Controlled Trial in Eastern India. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2021, 24, 343-350.	0.9	54

#	ARTICLE	IF	CITATIONS
2300	Pharmacokinetic interactions between the potential COVID-19 treatment drugs lopinavir/ritonavir and arbidol in rats. <i>Journal of Zhejiang University: Science B</i> , 2021, 22, 599-602.	1.3	1
2301	Analysis of COVID-19 Guideline Quality and Change of Recommendations: A Systematic Review. <i>Health Data Science</i> , 2021, 2021, .	1.1	9
2302	Assessment of COVID-19 treatment advised in different ethnic populations. <i>Current Drug Safety</i> , 2021, 16, .	0.3	1
2303	Biochemical features and mutations of key proteins in SARS-CoV-2 and their impacts on RNA therapeutics. <i>Biochemical Pharmacology</i> , 2021, 189, 114424.	2.0	27
2304	Diabetes Mellitus during the Pandemic Covid-19: Prevalence, Pathophysiology, Mechanism, and Management: An updated overview. <i>Current Diabetes Reviews</i> , 2021, 17, .	0.6	2
2305	Clinical and epidemiological profile of Indian COVID-19 patients from Jaipur: a descriptive study. <i>Monaldi Archives for Chest Disease</i> , 2021, 91, .	0.3	2
2306	Drugs that Might Be Possibly Used for Treatment of COVID-19 Patients. <i>Russian Journal of Bioorganic Chemistry</i> , 2021, 47, 789-804.	0.3	1
2307	A dossier on COVID-19 chronicle. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2022, 33, 45-54.	0.7	3
2308	Potential Prophylactic Treatments for COVID-19. <i>Viruses</i> , 2021, 13, 1292.	1.5	13
2309	SARS-CoV-2 (COVID-19), viral load and clinical outcomes; lessons learned one year into the pandemic: A systematic review. <i>World Journal of Critical Care Medicine</i> , 2021, 10, 132-150.	0.8	50
2310	Kidney involvement in COVID-19 and potential treatment opportunities. <i>Journal of Preventive Medicine and Holistic Health</i> , 2021, 7, 12-18.	0.2	0
2311	Utilization of drugs with reports on potential efficacy or harm on COVID-19 before, during, and after the first pandemic wave. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1493-1503.	0.9	17
2312	Inflammatory effect on the gastrointestinal system associated with COVID-19. <i>World Journal of Gastroenterology</i> , 2021, 27, 4160-4171.	1.4	11
2313	Drug Policies Skyline during COVID-19 Pandemic. <i>Journal of Clinical Medicine</i> , 2021, 10, 3117.	1.0	1
2314	COVID-19: Failure of the DisCoVeRy Clinical Trial, and Now "New Hopes?". <i>Pharmaceuticals</i> , 2021, 14, 664.	1.7	3
2315	Validation of a Prospective Urinalysis-Based Prediction Model for ICU Resources and Outcome of COVID-19 Disease: A Multicenter Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 3049.	1.0	12
2316	Comprehensive Consensus Analysis of SARS-CoV-2 Drug Repurposing Campaigns. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 3771-3788.	2.5	17
2317	Determination of Ligand Binding Modes in Hydrated Viral Ion Channels to Foster Drug Design and Repositioning. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 4011-4022.	2.5	10

#	ARTICLE	IF	CITATIONS
2318	Quantitative Insight into Immunopathology of SARS-CoV-2 Infection. <i>Journal of Interferon and Cytokine Research</i> , 2021, 41, 244-257.	0.5	0
2320	Current status of traditional Chinese medicine for the treatment of COVID-19 in China. <i>Chinese Medicine</i> , 2021, 16, 63.	1.6	24
2322	Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0035021.	1.4	18
2323	Incidence, risk factors and outcome of acute kidney injury (AKI) in patients with COVID-19. <i>Clinical and Experimental Nephrology</i> , 2021, 25, 1203-1214.	0.7	27
2324	An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages. <i>International Immunopharmacology</i> , 2021, 96, 107763.	1.7	35
2325	An outline of SARS-CoV-2 pathogenesis and the complement cascade of immune system. <i>Bulletin of the National Research Centre</i> , 2021, 45, 123.	0.7	5
2327	Impact of Tocilizumab on Clinical Outcomes in COVID-19-Associated Cytokine Release Syndrome: A Single-Center Experience. <i>Journal of Pharmacy Practice</i> , 2021, , 089719002110282.	0.5	1
2328	Network-Based Analysis of Fatal Comorbidities of COVID-19 and Potential Therapeutics. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2021, 18, 1271-1280.	1.9	23
2329	Overview of COVID-19 Pandemic: Transmission, Epidemiology and Diagnosis. <i>Journal of Pharmaceutical Research International</i> , 0, , 174-181.	1.0	1
2330	Expression of SARS-CoV-2-related receptors in cells of the neurovascular unit: implications for HIV-1 infection. <i>Journal of Neuroinflammation</i> , 2021, 18, 167.	3.1	44
2331	Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 787-793.	1.5	31
2332	Risk factors for mortality of adult patients with COVID-19 hospitalised in an emerging country: a cohort study. <i>BMJ Open</i> , 2021, 11, e050321.	0.8	17
2333	Multicenter Analysis of Clinical Features and Prognosis of COVID-19 Patients with Hepatic Impairment. <i>Gut and Liver</i> , 2021, 15, 606-615.	1.4	4
2334	SARS-CoV-2 infection during pregnancy and pregnancy-related conditions: Concerns, challenges, management and mitigation strategies—a narrative review. <i>Journal of Infection and Public Health</i> , 2021, 14, 863-875.	1.9	43
2335	Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti-SARS-CoV-2 Antibodies. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	36
2336	Combination therapy of Tocilizumab and steroid for management of COVID-19 associated cytokine release syndrome. <i>Medicine (United States)</i> , 2021, 100, e26705.	0.4	9
2337	Effectiveness of favipiravir in COVID-19: a live systematic review. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 2575-2583.	1.3	43
2338	Optimal strategies for COVID-19 prevention from global evidence achieved through social distancing, stay at home, travel restriction and lockdown: a systematic review. <i>Archives of Public Health</i> , 2021, 79, 150.	1.0	47

#	ARTICLE	IF	CITATIONS
2339	Adverse Cardiovascular Effects of Anti-COVID-19 Drugs. <i>Frontiers in Pharmacology</i> , 2021, 12, 699949.	1.6	15
2340	Saving critically ill COVID-19 patients with mechanical circulatory support. <i>Annals of Translational Medicine</i> , 2021, 9, 1221-1221.	0.7	3
2341	Comparison of outcomes in HIV-positive and HIV-negative patients with COVID-19. <i>Journal of Infection</i> , 2021, 83, 217-227.	1.7	29
2342	Targeting Some Enzymes with Repurposing Approved Pharmaceutical Drugs for Expeditious Antiviral Approaches Against Newer Strains of COVID-19. <i>AAPS PharmSciTech</i> , 2021, 22, 214.	1.5	5
2343	Predicted antiviral drugs Darunavir, Amprenavir, Rimantadine and Saquinavir can potentially bind to neutralize SARS-CoV-2 conserved proteins. <i>Journal of Biological Research</i> , 2021, 28, 18.	2.2	9
2344	Comprehensive Analysis of SARS-COV-2 Drug Targets and Pharmacological Aspects in Treating the COVID-19. <i>Current Molecular Pharmacology</i> , 2022, 15, 393-417.	0.7	6
2345	Management of COVID-19 in patients with seizures: Mechanisms of action of potential COVID-19 drug treatments and consideration for potential drug-drug interactions with anti-seizure medications. <i>Epilepsy Research</i> , 2021, 174, 106675.	0.8	18
2346	Drug-Induced Liver Disturbance During the Treatment of COVID-19. <i>Frontiers in Pharmacology</i> , 2021, 12, 719308.	1.6	15
2347	Antiviral drugs for coronavirus disease 2019 (COVID-19): a systematic review with network meta-analysis. <i>Expert Review of Anti-Infective Therapy</i> , 2021, , 1-12.	2.0	9
2348	Role of Anti-Viral Drugs in Combating SARS-CoV-2. , 0, , .		0
2349	Hospital-Level Variation in Death for Critically Ill Patients with COVID-19. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 403-411.	2.5	39
2350	Current evidence for the risk of PR prolongation, QRS widening, QT prolongation, from lopinavir, ritonavir, atazanavir, and saquinavir. <i>Medicine (United States)</i> , 2021, 100, e26787.	0.4	2
2351	The impact of tocilizumab on respiratory support states transition and clinical outcomes in COVID-19 patients. A Markov model multi-state study. <i>PLoS ONE</i> , 2021, 16, e0251378.	1.1	3
2352	Theory and reality of antivirals against SARS-CoV-2. <i>World Journal of Clinical Cases</i> , 2021, 9, 6663-6673.	0.3	1
2356	Role of Potential COVID-19 Immune System Associated Genes and the Potential Pathways Linkage with Type-2 Diabetes. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2022, 25, 2452-2462.	0.6	11
2357	Ciclesonide Inhaler Treatment for Mild-to-Moderate COVID-19: A Randomized, Open-Label, Phase 2 Trial. <i>Journal of Clinical Medicine</i> , 2021, 10, 3545.	1.0	28
2358	Hydroxychloroquine/chloroquine in patients with COVID-19 in Wuhan, China: a retrospective cohort study. <i>BMC Infectious Diseases</i> , 2021, 21, 805.	1.3	4
2359	COVID-19 pandemic is not the time of trial and error. <i>American Journal of Emergency Medicine</i> , 2021, 46, 774-775.	0.7	11

#	ARTICLE	IF	CITATIONS
2360	Cyclodextrins in the antiviral therapy. <i>Journal of Drug Delivery Science and Technology</i> , 2021, 64, 102589.	1.4	26
2361	Main protease inhibitors and drug surface hotspots for the treatment of COVID-19: A drug repurposing and molecular docking approach. <i>Biomedicine and Pharmacotherapy</i> , 2021, 140, 111742.	2.5	15
2362	Abbreviated Profile of Drugs (APOD): modeling drug safety profiles to prioritize investigational COVID-19 treatments. <i>Heliyon</i> , 2021, 7, e07666.	1.4	3
2363	Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 24-31.	0.9	57
2364	Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 490.	3.8	85
2365	What convalescent plasma in treating severe acute respiratory infections of viral aetiology can hint for COVID-19? Evidence from a meta-analysis. <i>Transfusion Clinique Et Biologique</i> , 2021, 28, 321-329.	0.2	1
2366	Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 infection. <i>Cell Death and Differentiation</i> , 2022, 29, 156-166.	5.0	38
2367	Pressing Questions and Challenges in the HIV-1 and SARS-CoV-2 Syndemic. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 589-600.	0.5	5
2368	Antirheumatic drugs and COVID-19: frustrations and hopes. <i>Meditinskiy Sovet</i> , 2021, , 134-139.	0.1	0
2369	Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial. <i>International Immunopharmacology</i> , 2021, 97, 107702.	1.7	29
2370	The Challenges and Successes of Dealing with the COVID-19 Pandemic in India. <i>Research and Reports in Tropical Medicine</i> , 2021, Volume 12, 205-218.	2.8	3
2371	Identification of known drugs as potential SARS-CoV-2 Mpro inhibitors using ligand- and structure-based virtual screening. <i>Future Medicinal Chemistry</i> , 2021, 13, 1353-1366.	1.1	8
2372	AHR signaling is induced by infection with coronaviruses. <i>Nature Communications</i> , 2021, 12, 5148.	5.8	38
2373	Heterocyclic compounds as antiviral drugs: Synthesis, structure-activity relationship and traditional applications. <i>Journal of Heterocyclic Chemistry</i> , 2021, 58, 2226-2260.	1.4	15
2374	Weighted Gene Co-Expression Network Analysis Combined with Machine Learning Validation to Identify Key Modules and Hub Genes Associated with SARS-CoV-2 Infection. <i>Journal of Clinical Medicine</i> , 2021, 10, 3567.	1.0	30
2376	Immunological map in COVID-19. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 547-556.	1.5	9
2377	Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement. <i>Journal of Neuroimmunology</i> , 2021, 357, 577627.	1.1	33
2378	Molecular mechanism of anti-SARS-CoV2 activity of Ashwagandha-derived withanolides. <i>International Journal of Biological Macromolecules</i> , 2021, 184, 297-312.	3.6	30

#	ARTICLE	IF	CITATIONS
2379	Opportunities and challenges to the use of neutralizing monoclonal antibody therapies for COVID-19. <i>BioScience Trends</i> , 2021, 15, 205-210.	1.1	8
2380	Covid-19 pandemic: Perspectives on management. <i>Journal of Reproductive Immunology</i> , 2021, 146, 103344.	0.8	4
2381	COVID-19: potential therapeutics for pediatric patients. <i>Pharmacological Reports</i> , 2021, 73, 1520-1538.	1.5	12
2382	Montelukast and Coronavirus Disease 2019: A Scoping Review. <i>Iranian Journal of Allergy, Asthma and Immunology</i> , 0, , .	0.3	0
2383	Severe Acute Respiratory Syndrome Coronavirus Associated Myocarditis. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2021, 9, 299-304.	0.1	0
2384	Combating the progression of novel coronavirus SARS-CoV-2 infectious Disease: Current state and future prospects in molecular diagnostic and drug discovery. <i>Current Molecular Medicine</i> , 2021, 21, .	0.6	6
2385	COVID-19 Tanımlı Testleri, Tedavisindeki Aşamalar ve Akut Durum. <i>Uludağ Üniversitesi Tıp Fakültesi Dergisi</i> , 2021, 47, 295-308.	0.2	1
2386	Auricular Neuromodulation for Mass Vagus Nerve Stimulation: Insights From SOS COVID-19 a Multicentric, Randomized, Controlled, Double-Blind French Pilot Study. <i>Frontiers in Physiology</i> , 2021, 12, 704599.	1.3	8
2387	The rapid adaptation of SARS-CoV-2 rise of the variants: transmission and resistance. <i>Journal of Microbiology</i> , 2021, 59, 807-818.	1.3	18
2388	Drug repurposing for COVID-19 using computational screening: Is Fostamatinib/R406 a potential candidate?. <i>Methods</i> , 2022, 203, 564-574.	1.9	18
2389	Sustained expression of inflammatory monocytes and activated T cells in COVID-19 patients and recovered convalescent plasma donors. <i>Immunity, Inflammation and Disease</i> , 2021, 9, 1279-1290.	1.3	14
2391	Identification of Natural Inhibitors Against SARS-CoV-2 Drugable Targets Using Molecular Docking, Molecular Dynamics Simulation, and MM-PBSA Approach. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 730288.	1.8	46
2392	COVID-19 and the Liver: Lessons Learnt from the EAST and the WEST, A Year Later. <i>Journal of Viral Hepatitis</i> , 2022, 29, 4-20.	1.0	36
2393	An observational cohort study to assess N-acetylglucosamine for COVID-19 treatment in the inpatient setting. <i>Annals of Medicine and Surgery</i> , 2021, 68, 102574.	0.5	7
2394	Coronavirus disease 2019-associated pulmonary fibrosis: clinical findings, pathogenesis, and potential treatment. <i>Chinese Medical Journal</i> , 2021, 134, 1792-1794.	0.9	3
2395	An Overview of the Pathogenesis, Transmission, Diagnosis, and Management of Endemic Human Coronaviruses: A Reflection on the Past and Present Episodes and Possible Future Outbreaks. <i>Pathogens</i> , 2021, 10, 1108.	1.2	14
2396	Endomembrane targeting of human OAS1 p46 augments antiviral activity. <i>ELife</i> , 2021, 10, .	2.8	41
2397	Recent SARS-CoV-2 Outlook and Implications in a COVID-19 Vaccination Era. <i>Infectious Microbes & Diseases</i> , 2021, 3, 125-133.	0.5	0

#	ARTICLE	IF	CITATIONS
2398	A review on the COVID-19: Facts and current situation. <i>NeuroPharmac Journal</i> , 0, , 180-191.	0.1	3
2399	Discovery of Novel Small-Molecule Inhibitors of SARS-CoV-2 Main Protease as Potential Leads for COVID-19 Treatment. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 4745-4757.	2.5	12
2400	1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. <i>Lancet, The</i> , 2021, 398, 747-758.	6.3	691
2401	Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection. <i>Current Opinion in Virology</i> , 2021, 49, 36-40.	2.6	100
2402	Clinical Research. <i>Critical Care Medicine</i> , 2021, Publish Ahead of Print, 1866-1882.	0.4	5
2403	COVID-19 infection and liver injury: Clinical features, biomarkers, potential mechanisms, treatment, and management challenges. <i>World Journal of Clinical Cases</i> , 2021, 9, 6178-6200.	0.3	24
2404	SARS-CoV-2 Treatment: Current Therapeutic Options and the Pursuit of Tailored Therapy. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 7457.	1.3	11
2406	Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9124.	1.8	76
2407	Progress and pitfalls of a year of drug repurposing screens against COVID-19. <i>Current Opinion in Virology</i> , 2021, 49, 183-193.	2.6	25
2408	Mesenchymal stem cell transfusion: Possible beneficial effects in COVID-19 patients. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103237.	0.5	1
2409	Detecting Novel Ototoxins and Potentiation of Ototoxicity by Disease Settings. <i>Frontiers in Neurology</i> , 2021, 12, 725566.	1.1	14
2410	Comparative therapeutic efficacy of interferon alfa-2b and combination lopinavir/ritonavir plus interferon alfa-2b against SARS-CoV-2. <i>BMC Infectious Diseases</i> , 2021, 21, 885.	1.3	3
2411	Reversal of SARS-CoV2-Induced Hypoxia by Nebulized Sodium Ibuprofenate in a Compassionate Use Program. <i>Infectious Diseases and Therapy</i> , 2021, 10, 2511-2524.	1.8	5
2412	Medicinal chemistry strategies towards the development of effective SARS-CoV-2 inhibitors. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 581-599.	5.7	33
2413	Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1124-1130.	2.8	34
2414	Epicardial fat inflammation response to COVID-19 therapies. <i>Obesity</i> , 2021, 29, 1427-1433.	1.5	13
2415	A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance. <i>ELife</i> , 2021, 10, .	2.8	23
2416	Repurposable drugs for SARS-CoV-2 and influenza sepsis with scRNA-seq data targeting post-transcription modifications. <i>Precision Clinical Medicine</i> , 2021, 4, 215-230.	1.3	3

#	ARTICLE	IF	CITATIONS
2417	SARS-CoV-2 Infection in the Immunodeficient Host: Necessary and Dispensable Immune Pathways. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3237-3248.	2.0	4
2418	Favipiravir versus standard of care in patients with severe COVID-19 infections: A retrospective comparative study. <i>Journal of Infection and Public Health</i> , 2021, 14, 1247-1253.	1.9	10
2419	Dynamics of the Upper Respiratory Tract Microbiota and Its Association with Mortality in COVID-19. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 1379-1390.	2.5	46
2420	In silico identification of SARS-CoV-2 cell entry inhibitors from selected natural antivirals. <i>Journal of Molecular Graphics and Modelling</i> , 2021, 109, 108038.	1.3	9
2422	Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19. <i>Kidney International Reports</i> , 2021, 6, 2305-2315.	0.4	26
2423	Potential drug development and therapeutic approaches for clinical intervention in COVID-19. <i>Bioorganic Chemistry</i> , 2021, 114, 105016.	2.0	11
2424	Treatment Options for COVID-19-Related Guillain-Barré Syndrome. <i>Neurologist</i> , 2021, 26, 196-224.	0.4	7
2425	Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE). <i>EClinicalMedicine</i> , 2021, 39, 101086.	3.2	27
2426	The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. <i>Inflammation Research</i> , 2021, 70, 1233-1246.	1.6	35
2427	Potenciales efectos pro-arrátmicos de la farmacoterapia contra SARS-CoV-2. <i>Archivos De Cardiologia De Mexico</i> , 2021, 90, 36-40.	0.1	1
2428	Drug-Induced Liver Injury: Highlights and Controversies in the Recent Literature. <i>Drug Safety</i> , 2021, 44, 1125-1149.	1.4	35
2429	Antiviral treatment could not provide clinical benefit in management of mild COVID-19: A Retrospective Experience from Field hospital. <i>Journal of Infection and Public Health</i> , 2021, 14, 1206-1211.	1.9	7
2430	Variation in COVID-19 disease severity at hospital admission over time and across hospitals. <i>Medicine (United States)</i> , 2021, 100, e27265.	0.4	3
2431	Current status of therapeutic alternatives for COVID-19: A narrative review. <i>Infezioni in Medicina</i> , 2021, 29, 312-327.	0.7	8
2432	In Silico Prediction of Novel Inhibitors of SARS-CoV-2 Main Protease through Structure-Based Virtual Screening and Molecular Dynamic Simulation. <i>Pharmaceuticals</i> , 2021, 14, 896.	1.7	21
2433	In Silico Evaluation of Iranian Medicinal Plant Phytoconstituents as Inhibitors against Main Protease and the Receptor-Binding Domain of SARS-CoV-2. <i>Molecules</i> , 2021, 26, 5724.	1.7	39
2434	Clinical outcomes of patients with and without HIV hospitalized with COVID-19 in England during the early stages of the pandemic: a matched retrospective multi-centre analysis (RECEDE-19 study). <i>HIV Medicine</i> , 2022, 23, 121-133.	1.0	14
2435	Interferon \hat{I}^2 , an enhancer of the innate immune response against SARS-CoV-2 infection. <i>Microbial Pathogenesis</i> , 2021, 158, 105105.	1.3	6

#	ARTICLE	IF	CITATIONS
2436	Update on liver disease management during the pandemic of coronavirus disease 2019 (COVID-19): 2021 KASL guideline. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 515-523.	4.5	6
2437	Interactions of anti-COVID-19 drug candidates with hepatic transporters may cause liver toxicity and affect pharmacokinetics. <i>Scientific Reports</i> , 2021, 11, 17810.	1.6	28
2438	Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study. <i>PLoS ONE</i> , 2021, 16, e0257376.	1.1	6
2439	Chemotherapy vs. Immunotherapy in combating nCOVID19: An update. <i>Human Immunology</i> , 2021, 82, 649-658.	1.2	19
2440	Potential Effects of Coronaviruses on the Liver: An Update. <i>Frontiers in Medicine</i> , 2021, 8, 651658.	1.2	38
2441	Clinical trials with antiviral drugs against COVID-19: some progress and many shattered hopes. <i>Environmental Microbiology</i> , 2021, 23, 6364-6376.	1.8	12
2442	COVID-19 Therapeutics for Low- and Middle-Income Countries: A Review of Candidate Agents with Potential for Near-Term Use and Impact. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 105, 584-595.	0.6	10
2443	Combination therapies for COVID-19: An overview of the clinical trials landscape. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1590-1597.	1.1	18
2444	Pneumonia-targeted lopinavir/ritonavir-based treatment for patients with COVID-19: an early-period retrospective single center observational study. <i>BMC Infectious Diseases</i> , 2021, 21, 952.	1.3	1
2445	Timing of ARDS Resolution (TARU): A Pragmatic Clinical Assessment of ARDS Resolution in the ICU. <i>Lung</i> , 2021, 199, 439-445.	1.4	2
2446	Coronavirus disease 2019 in solid organ transplant recipients in the setting of proactive screening and contact tracing of Qatar. <i>Qatar Medical Journal</i> , 2021, 2021, 23.	0.2	2
2447	HLA-B*15 predicts survival in Egyptian patients with COVID-19. <i>Human Immunology</i> , 2022, 83, 10-16.	1.2	10
2448	Comparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of COVID-19 with mild-to-moderate severity: A retrospective observational study. <i>Antiviral Therapy</i> , 2021, 26, 135965352110393.	0.6	3
2449	Melatonin effects on sleep quality and outcomes of COVID-19 patients: An open-label, randomized, controlled trial. <i>Journal of Medical Virology</i> , 2022, 94, 263-271.	2.5	45
2450	Veterinary Experiences can Inform One Health Strategies for Animal Coronaviruses. <i>EcoHealth</i> , 2021, 18, 301-314.	0.9	1
2451	Is glucose-6-phosphatase dehydrogenase deficiency associated with severe outcomes in hospitalized COVID-19 patients?. <i>Scientific Reports</i> , 2021, 11, 19213.	1.6	5
2452	MAITRISE DE LA PREPARATION HOSPITALIERE POUR REpondre A UN CONTEXTE DE PENURIE : EXEMPLE DU DEVELOPPEMENT D'UNE SUSPENSION ORALE DE LOPINAVIR-RITONAVIR LORS DE LA PREMIERE VAGUE DE SARS-COV-2 EN FRANCE. <i>Annales Pharmaceutiques Francaises</i> , 2021, , .	0.4	0
2453	Effectiveness and safety of ivermectin in the treatment of COVID-19: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2021, 11, e050532.	0.8	4

#	ARTICLE	IF	CITATIONS
2454	Impact of COVID-19 on liver. World Journal of Clinical Cases, 2021, 9, 7998-8007.	0.3	13
2455	Chinese Medicine Formula Huashibaidu Granule Early Treatment for Mild COVID-19 Patients: An Unblinded, Cluster-Randomized Clinical Trial. Frontiers in Medicine, 2021, 8, 696976.	1.2	16
2456	Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. Frontiers in Public Health, 2021, 9, 729559.	1.3	27
2457	Determinants of SARS-CoV-2 entry and replication in airway mucosal tissue and susceptibility in smokers. Cell Reports Medicine, 2021, 2, 100421.	3.3	11
2458	Repurposing pharmaceutical excipients as an antiviral agent against SARS-CoV-2. Journal of Biomaterials Science, Polymer Edition, 2022, 33, 110-136.	1.9	4
2459	La pandemia de Coronavirus SARS-CoV-2 (COVID-19): Situación actual e implicaciones para México. Archivos De Cardiología De Mexico, 2021, 90, 7-14.	0.1	15
2461	Repurposing an Antiviral Drug against SARS-CoV-2 Main Protease. Angewandte Chemie - International Edition, 2021, 60, 23492-23494.	7.2	17
2462	Repurposing an Antiviral Drug against SARS-CoV-2 Main Protease. Angewandte Chemie, 2021, 133, 23684-23686.	1.6	0
2463	Liver Injury in COVID-19: A Direct Hit or Collateral Damage?. Infectious Disorders - Drug Targets, 2022, 22, .	0.4	2
2464	Possibility of new shielding device for upper gastrointestinal endoscopy. Endoscopy International Open, 2021, 09, E1536-E1541.	0.9	7
2465	Repurposed drugs for COVID-19: threshold and proof requirements for trials. Clinical Microbiology and Infection, 2021, 27, 1716-1717.	2.8	3
2466	Therapeutic and Protective Potential of Mesenchymal Stem Cells, Pharmaceutical Agents and Current Vaccines Against COVID-19. Current Stem Cell Research and Therapy, 2022, 17, 166-185.	0.6	5
2467	Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients - a hypothetical study. BMC Health Services Research, 2021, 21, 986.	0.9	13
2468	Candidate antiviral drugs for COVID-19 and their environmental implications: a comprehensive analysis. Environmental Science and Pollution Research, 2021, 28, 59570-59593.	2.7	39
2469	Pharmacology and Adverse Events of Emergency-Use Authorized Medication in Moderate to Severe COVID-19. Pharmaceuticals, 2021, 14, 955.	1.7	12
2470	Characterisation of Drug-Induced Liver Injury in Patients with COVID-19 Detected by a Proactive Pharmacovigilance Program from Laboratory Signals. Journal of Clinical Medicine, 2021, 10, 4432.	1.0	20
2472	Antiviral Combination Clinically Better Than Standard Therapy in Severe but Not in Non-Severe COVID-19. Clinical Pharmacology: Advances and Applications, 2021, Volume 13, 185-195.	0.8	3
2473	The Cardiac Effects of COVID-19: Review of articles. Current Problems in Cardiology, 2022, 47, 100981.	1.1	3

#	ARTICLE	IF	CITATIONS
2474	Consensus statement and recommendations on the treatment of COVID-19: 2021 update. Journal of the Chinese Medical Association, 2022, 85, 5-17.	0.6	6
2475	Childhood Bacille Calmette-Guerin Vaccination and Its Association With Less Severe COVID-19 Pneumonia. American Journal of Preventive Medicine, 2021, 61, e119-e126.	1.6	3
2476	Coinfections with Other Respiratory Pathogens among Patients with COVID-19. Microbiology Spectrum, 2021, 9, e0016321.	1.2	79
2477	Clinical Efficacy and Safety of Antiviral Drugs in the Extended Use against COVID-19: What We Know So Far. Biologics, 2021, 1, 252-284.	2.3	11
2478	Repurpose but also (nano)-reformulate! The potential role of nanomedicine in the battle against SARS-CoV2. Journal of Controlled Release, 2021, 337, 258-284.	4.8	12
2479	Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Respiratory Medicine, the, 2021, 9, 957-968.	5.2	83
2480	Cinobufacini Improves the Respiratory Function of Severe COVID-19 Patients. Pharmacological Research Modern Chinese Medicine, 2021, 1, 100007.	0.5	3
2481	Structure-based virtual screening suggests inhibitors of 3-Chymotrypsin-Like Protease of SARS-CoV-2 from Vernonia amygdalina and Occinum gratissimum. Computers in Biology and Medicine, 2021, 136, 104671.	3.9	22
2482	Potential of application of the RNA interference phenomenon in the treatment of new coronavirus infection COVID-19. Voprosy Virusologii, 2021, 66, 241-251.	0.1	4
2483	2019 novel Coronavirus: current knowledge, cardiovascular implications and management. Minerva Cardiology and Angiology, 2021, 69, 377-388.	0.4	1
2484	Factors predicting readmission in patients with COVID-19. BMC Research Notes, 2021, 14, 374.	0.6	15
2485	Determination of camostat and its metabolites in human plasma " Preservation of samples and quantification by a validated UHPLC-MS/MS method. Clinical Biochemistry, 2021, 96, 56-62.	0.8	2
2486	Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial. Lancet Respiratory Medicine, the, 2021, 9, 1130-1140.	5.2	65
2487	How Can We Treat the Virus and Prevent Infections?. , 2021, , 100-113.		0
2488	Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics. Frontiers in Immunology, 2021, 12, 752227.	2.2	25
2489	Delayed Kinetics of IgG, but Not IgA, Antispike Antibodies in Transplant Recipients following SARS-CoV-2 Infection. Journal of the American Society of Nephrology: JASN, 2021, 32, 3221-3230.	3.0	14
2490	An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a in severe COVID-19: The COVIFERON II randomized controlled trial. International Immunopharmacology, 2021, 99, 107916.	1.7	12
2493	What Is a Coronavirus?. , 2021, , 22-33.		0

#	ARTICLE	IF	CITATIONS
2496	Discovery and evolution of 12N-substituted aloperine derivatives as anti-SARS-CoV-2 agents through targeting late entry stage. <i>Bioorganic Chemistry</i> , 2021, 115, 105196.	2.0	5
2499	Understanding the immunological aspects of SARS-CoV-2 causing COVID-19 pandemic: A therapeutic approach. <i>Clinical Immunology</i> , 2021, 231, 108804.	1.4	5
2500	How Is the Coronavirus Spreading?. , 2021, , 7-21.		0
2501	Repurposing methylene blue in the management of COVID-19: Mechanistic aspects and clinical investigations. <i>Biomedicine and Pharmacotherapy</i> , 2021, 142, 112023.	2.5	21
2505	COVID-19 and adult-onset Still's disease as part of hyperferritinemic syndromes. <i>Modern Rheumatology Case Reports</i> , 2022, 6, 101-105.	0.3	5
2506	Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial. <i>International Immunopharmacology</i> , 2021, 99, 107969.	1.7	23
2507	How Did the COVID-19 Outbreak Start and Evolve?. , 2021, , 45-77.		0
2508	How Is the Coronavirus Changing?. , 2021, , 34-44.		0
2509	How Does the COVID-19 Outbreak Compare to Seasonal and Pandemic Influenza?. , 2021, , 88-99.		0
2510	How Does the COVID-19 Outbreak Compare to the SARS Outbreak in 2003?. , 2021, , 78-87.		0
2511	Atorvastatin therapy in COVID-19 adult inpatients: A double-blind, randomized controlled trial. <i>IJC Heart and Vasculature</i> , 2021, 36, 100875.	0.6	15
2513	Clinical trials in COVID-19 management & prevention: A meta-epidemiological study examining methodological quality. <i>Journal of Clinical Epidemiology</i> , 2021, 139, 68-79.	2.4	11
2514	Trends in COVID-19 prevalence and mortality: A year in review. <i>Physica D: Nonlinear Phenomena</i> , 2021, 425, 132968.	1.3	25
2515	Quality of life among Bangladeshi Youth during the early stage of the COVID-19 pandemic: A single-site survey. <i>Public Health in Practice</i> , 2021, 2, 100157.	0.7	2
2516	Mesenchymal stem cells in SARS-CoV-2 infection: A hype or hope. <i>Life Sciences</i> , 2021, 284, 119901.	2.0	3
2517	Neural connectome prospectively encodes the risk of post-traumatic stress disorder (PTSD) symptom during the COVID-19 pandemic. <i>Neurobiology of Stress</i> , 2021, 15, 100378.	1.9	8
2518	Docking of disordered independent molecules of novel crystal structure of		

#	ARTICLE	IF	CITATIONS
2520	Liver Injury in COVID-19 Patients. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2022, , 141-158.	0.1	0
2521	Management of Coronavirus Disease 2019 (COVID-19) Pneumonia. , 2022, , 342-349.		4
2522	The Study of Traditional Medicine for the Treatment of COVID-19. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2022, , 221-241.	0.1	3
2523	Therapeutic Management of COVID-19 Patients. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2022, , 210-220.	0.1	2
2524	Is the efficacy of remdesivir so different from that of lopinavir-ritonavir in severe COVID-19? The answer by real time-PCR: a narrative review. <i>Anaesthesiology Intensive Therapy</i> , 2021, 53, 363-365.	0.4	0
2525	COVID-19 Infection in the Human Reproductive Tract of Men and Nonpregnant Women. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, , .	0.6	14
2526	Efficacy of the current investigational drugs for the treatment of COVID-19: a scoping review. <i>Annals of Medicine</i> , 2021, 53, 318-334.	1.5	27
2527	COVID-19: should we consider it as a septic shock? (The treatment of COVID-19 patients in the ICU). <i>Current Opinion in Anaesthesiology</i> , 2021, 34, 119-124.	0.9	5
2528	Utilisation, Availability and Price Changes of Medicines and Protection Equipment for COVID-19 Among Selected Regions in India: Findings and Implications. <i>Frontiers in Pharmacology</i> , 2020, 11, 582154.	1.6	23
2529	Comparisons of the immunological landscape between COVID-19, influenza, and respiratory syncytial virus patients by clustering analysis. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 2347-2355.	1.9	1
2530	What the HIV Pandemic Experience Can Teach the United States About the COVID-19 Response. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 1-10.	0.9	10
2531	A review on clinical, pathological characteristics and drug designing for COVID-19. <i>Arab Journal of Basic and Applied Sciences</i> , 2021, 28, 172-186.	1.0	1
2532	Experimental Pharmacotherapy for COVID-19: The Latest Advances. <i>Journal of Experimental Pharmacology</i> , 2021, Volume 13, 1-13.	1.5	22
2533	Clinical Profile and Outcomes of Confirmed COVID 19 at Manila Doctors Hospital. <i>Asian Journal of Epidemiology</i> , 2021, 14, 1-10.	0.5	0
2534	Antiviral treatment in COVID-19: which is the most promising? a narrative review. <i>Annals of Palliative Medicine</i> , 2021, 10, 707-720.	0.5	4
2535	Hydroxychloroquine can potentially interfere with immune function in COVID-19 patients: Mechanisms and insights. <i>Redox Biology</i> , 2021, 38, 101810.	3.9	13
2536	COVID-19 pandemic and the answer of science: a year in review. <i>Anais Da Academia Brasileira De Ciencias</i> , 2021, 93, e20210543.	0.3	4
2537	Novel coronavirus disease (COVID-19) pandemic: A recent mini review. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 612-623.	1.9	35

#	ARTICLE	IF	CITATIONS
2538	Cheminformatics-Based Identification of Potential Novel Anti-SARS-CoV-2 Natural Compounds of African Origin. <i>Molecules</i> , 2021, 26, 406.	1.7	35
2539	Maternal endothelial dysfunction in HIV-associated preeclampsia comorbid with COVID-19: a review. <i>Hypertension Research</i> , 2021, 44, 386-398.	1.5	14
2540	A Comprehensive Summary of the Knowledge on COVID-19 Treatment. , 2021, 12, 155.		25
2541	COVID-19: Before the Fall, An Evidence-Based Narrative Review of Treatment Options. <i>Infectious Diseases and Therapy</i> , 2021, 10, 93-113.	1.8	13
2542	Bidirectional contact tracing could dramatically improve COVID-19 control. <i>Nature Communications</i> , 2021, 12, 232.	5.8	100
2543	COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs. <i>Internal and Emergency Medicine</i> , 2021, 16, 281-308.	1.0	46
2544	Clinical Characteristics and Risk Factors of Liver Dysfunction in COVID-19 Patients. <i>Journal of Translational Critical Care Medicine</i> , 2021, 3, 7.	0.0	0
2545	More skilled clinical management of COVID-19 patients modified mortality in an intermediate respiratory intensive care unit in Italy. <i>Respiratory Research</i> , 2021, 22, 16.	1.4	11
2546	Perspectives for antivirals to limit SARS-CoV-2 infection (COVID-19). <i>Microbiology Australia</i> , 2021, 42, 47.	0.1	2
2547	Pregnancy and COVID-19: prevention, vaccination, therapy, and beyond. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 3312-3326.	0.4	21
2548	An update of anti-viral treatment of COVID-19. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 3372-3390.	0.4	55
2549	COVID-19 Transmission, Current Treatment, and Future Therapeutic Strategies. <i>Molecular Pharmaceutics</i> , 2021, 18, 754-771.	2.3	193
2550	Pharmacotherapeutics of SARS-CoV-2 Infections. <i>Journal of NeuroImmune Pharmacology</i> , 2021, 16, 12-37.	2.1	4
2551	Persistent vomiting as a manifestation of coronavirus disease-2019. <i>Nigerian Journal of Medicine: Journal of the National Association of Resident Doctors of Nigeria</i> , 2021, 30, 218.	0.0	0
2553	Wir können über uns nachdenken " der Computer nicht. , 2021, , 215-229.		0
2554	Impact of repurposed drugs on the symptomatic COVID-19 patients. <i>Journal of Infection and Public Health</i> , 2021, 14, 24-38.	1.9	8
2555	Case Management of COVID-19 (Secondary Version). <i>JMA Journal</i> , 2021, 4, 191-197.	0.6	18
2556	Host Defence RNases as Antiviral Agents against Enveloped Single Stranded RNA Viruses. <i>Virulence</i> , 2021, 12, 444-469.	1.8	26

#	ARTICLE	IF	CITATIONS
2557	Severe COVID-19: A distinct entity. <i>Journal of Family Medicine and Primary Care</i> , 2021, 10, 84.	0.3	5
2558	Penanganan Pasien Covid-19 Pada Rumah Sakit di Indonesia. <i>Jurnal Kesehatan</i> , 2020, 8, 162-170.	0.0	1
2559	A Bioelectromagnetic Proposal Approaching the Complex Challenges of COVID-19. <i>Open Journal of Biophysics</i> , 2021, 11, 1-67.	0.7	1
2560	Clinical features and potential mechanism of coronavirus disease 2019-associated liver injury. <i>World Journal of Clinical Cases</i> , 2021, 9, 528-539.	0.3	11
2561	Are Patients with Asthma and Chronic Obstructive Pulmonary Disease Preferred Targets of COVID-19?. <i>Tuberculosis and Respiratory Diseases</i> , 2021, 84, 22-34.	0.7	14
2562	SARS-CoV-2 therapeutics: how far do we stand from a remedy?. <i>Pharmacological Reports</i> , 2021, 73, 750-768.	1.5	17
2563	Recent advances made in the synthesis of small drug molecules for clinical applications: An insight. <i>Current Research in Green and Sustainable Chemistry</i> , 2021, 4, 100097.	2.9	14
2564	Clinical characteristics of COVID-19 in a tertiary health facility in northeast Nigeria. <i>Nigerian Journal of Medicine: Journal of the National Association of Resident Doctors of Nigeria</i> , 2021, 30, 334.	0.0	0
2565	Hospital Preparedness for COVID-19: The Known and The Known Unknown. <i>Keio Journal of Medicine</i> , 2021, 70, 25-34.	0.5	10
2566	Genetic Aspects and Immune Responses in Covid-19: Important Organ Involvement. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1327, 3-22.	0.8	5
2567	An update of coronavirus disease 2019 (COVID-19): an essential brief. <i>Modern Medical Laboratory Journal</i> , 2021, 4, 19-38.	0.2	0
2568	Revised Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency Guidelines on the Treatment of Patients with COVID-19. <i>Infection and Chemotherapy</i> , 2021, 53, 166.	1.0	21
2569	Review of investigational drugs for coronavirus disease 2019. <i>Journal of Education and Health Promotion</i> , 2021, 10, 31.	0.3	6
2570	Prescription, over-the-counter (OTC), herbal, and other treatments and preventive uses for COVID-19. , 2021, , 379-416.		16
2571	Remdesivir: A Closer Look at Its Effect in COVID-19 Pandemic. <i>Pharmacology</i> , 2021, 106, 462-468.	0.9	16
2572	Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CLpro Inhibitors. <i>Viruses</i> , 2021, 13, 173.	1.5	37
2573	Natural products as environmentally safe and green approach to combat Covid-19. <i>Current Research in Green and Sustainable Chemistry</i> , 2021, 4, 100114.	2.9	6
2574	In silico analysis of <i>Phyllanthus amarus</i> phytochemicals as potent drugs against SARS-CoV-2 main protease. <i>Current Research in Green and Sustainable Chemistry</i> , 2021, 4, 100159.	2.9	11

#	ARTICLE	IF	CITATIONS
2575	Why does the spread of COVID-19 vary greatly in different countries? Revealing the efficacy of face masks in epidemic prevention. <i>Epidemiology and Infection</i> , 2021, 149, e24.	1.0	18
2576	Current state of vaccine development and targeted therapies for COVID-19: impact of basic science discoveries. <i>Cardiovascular Pathology</i> , 2021, 50, 107278.	0.7	55
2578	Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review. <i>Psychopharmacology</i> , 2021, 238, 329-340.	1.5	42
2579	Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00705.	1.1	30
2580	Benefits of early aggressive immunomodulatory therapy (tocilizumab and methylprednisolone) in COVID-19: Single center cohort study of 685 patients. <i>Journal of Translational Autoimmunity</i> , 2021, 4, 100086.	2.0	12
2581	Management of Coronavirus Disease 2019 (COVID-19) Pandemic: From Diagnosis to Treatment Strategies. <i>Advanced Therapeutics</i> , 2021, 4, 2000173.	1.6	3
2582	Severe Acute Lung Injury Related to COVID-19 Infection: A Review and the Possible Role for Escin. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 815-825.	1.0	81
2583	A preliminary evaluation on the efficacy of ozone therapy in the treatment of COVID-19. <i>Journal of Medical Virology</i> , 2020, 92, 2348-2350.	2.5	36
2584	Progresses in clinical studies on antiviral therapies for COVID-19: Experience and lessons in design of clinical trials. <i>Pediatric Investigation</i> , 2020, 4, 263-274.	0.6	7
2585	Therapeutic approaches against coronaviruses acute respiratory syndrome. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00691.	1.1	7
2586	Targeting host cell proteases as a potential treatment strategy to limit the spread of SARS-CoV-2 in the respiratory tract. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00698.	1.1	14
2587	Therapeutic Development and Drugs for the Treatment of COVID-19. <i>Medical Virology</i> , 2020, , 109-126.	2.1	21
2590	Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients. , 2020, 41, 2353.		1
2591	Perspective on the Role of Antibodies and Potential Therapeutic Drugs to Combat COVID-19. <i>Protein Journal</i> , 2020, 39, 631-643.	0.7	3
2592	Toward understanding the 2019 Coronavirus and its impact on the heart. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 33-42.	1.0	23
2593	Does this patient have COVID-19? A practical guide for the internist. <i>Internal and Emergency Medicine</i> , 2020, 15, 791-800.	1.0	15
2594	Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations. <i>Hepatology International</i> , 2020, 14, 415-428.	1.9	65
2595	Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment. <i>Drugs in R and D</i> , 2021, 21, 9-27.	1.1	31

#	ARTICLE	IF	CITATIONS
2596	An overview of current COVID-19 clinical trials and ethical considerations editorial. <i>Annals of Medicine and Surgery</i> , 2020, 58, 84-86.	0.5	2
2597	Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19. <i>Bioorganic Chemistry</i> , 2020, 104, 104269.	2.0	74
2598	COVID-19 therapy: What weapons do we bring into battle?. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115757.	1.4	22
2599	Chemistry and Biology of SARS-CoV-2. <i>CheM</i> , 2020, 6, 1283-1295.	5.8	98
2600	Coronavirus and other airborne agents with pandemic potential. <i>Current Opinion in Environmental Science and Health</i> , 2020, 17, 41-48.	2.1	9
2601	Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. <i>Drug Resistance Updates</i> , 2020, 53, 100721.	6.5	80
2602	Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 641-648.	1.8	142
2603	Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy. <i>European Journal of Internal Medicine</i> , 2020, 76, 36-42.	1.0	158
2604	Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. <i>European Journal of Internal Medicine</i> , 2020, 76, 43-49.	1.0	349
2605	QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review. <i>Heart Rhythm</i> , 2020, 17, 1472-1479.	0.3	143
2606	Nanotheranostics against COVID-19: From multivalent to immune-targeted materials. <i>Journal of Controlled Release</i> , 2020, 328, 112-126.	4.8	35
2607	Comparison of short-term mortality between mechanically ventilated patients with COVID-19 and influenza in a setting of sustainable healthcare system. <i>Journal of Infection</i> , 2020, 81, e76-e78.	1.7	7
2608	Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial. <i>Med</i> , 2020, 1, 105-113.e4.	2.2	256
2609	COVID-19 in clinical practice: A narrative synthesis. <i>MÃ©decine Et Maladies Infectieuses</i> , 2020, 50, 639-647.	5.1	2
2610	A new pharmacological approach based on remdesivir aerosolized administration on SARS-CoV-2 pulmonary inflammation: A possible and rational therapeutic application. <i>Medical Hypotheses</i> , 2020, 144, 109876.	0.8	15
2611	Diagnostic approaches and potential therapeutic options for coronavirus disease 2019. <i>New Microbes and New Infections</i> , 2020, 38, 100770.	0.8	12
2612	Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study. <i>ReumatologÃ¡a ClÃ¡nica</i> , 2022, 18, 150-156.	0.2	44
2613	Monitoring Proteolytic Activity in Real Time: A New World of Opportunities for Biosensors. <i>Trends in Biochemical Sciences</i> , 2020, 45, 604-618.	3.7	13

#	ARTICLE	IF	CITATIONS
2615	How Is the Coronavirus Spreading?. , 2020, , 7-20.		2
2616	How Does the COVID-19 Outbreak Compare to Seasonal and Pandemic Influenza?. , 2020, , 73-84.		1
2617	Hopes rise for coronavirus drug remdesivir. Nature, 2020, , .	13.7	41
2618	Dynamic data-driven meta-analysis for prioritisation of host genes implicated in COVID-19. Scientific Reports, 2020, 10, 22303.	1.6	31
2619	A pocket guide on how to structure SARS-CoV-2 drugs and therapies. Biochemical Society Transactions, 2020, 48, 2625-2641.	1.6	10
2620	Suppressed anti-inflammatory heat shock response in high-risk COVID-19 patients: lessons from basic research (inclusive bats), light on conceivable therapies. Clinical Science, 2020, 134, 1991-2017.	1.8	25
2621	SARS-CoV-2/COVID-19: Evidence-Based Recommendations on Diagnosis and Therapy. Geburtshilfe Und Frauenheilkunde, 2020, 80, 491-498.	0.8	13
2622	Remdesivir for the Treatment of Covid-19 – Final Report. New England Journal of Medicine, 2020, 383, 1813-1826.	13.9	5,834
2623	Therapeutics for COVID-19: established and in development. Microbiology Australia, 2020, 41, 217.	0.1	2
2624	Association of ACEI/ARB, inflammatory cytokines, and antiviral drugs with liver dysfunction in patients with hypertension and COVID-19. Clinical and Experimental Hypertension, 2021, 43, 305-310.	0.5	6
2625	Treatments in the COVID-19 pandemic: an update on clinical trials. Expert Opinion on Emerging Drugs, 2020, 25, 81-88.	1.0	11
2626	Repurposing therapeutic agents against SARS-CoV-2 infection: most promising and neoteric progress. Expert Review of Anti-Infective Therapy, 2021, 19, 1009-1027.	2.0	23
2627	Natural history of COVID-19 and therapeutic options. Expert Review of Clinical Immunology, 2020, 16, 1159-1184.	1.3	101
2628	Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells. Clinical Infectious Diseases, 2020, 71, 2150-2157.	2.9	117
2629	Coronavirus disease 2019 in chronic kidney disease. CKJ: Clinical Kidney Journal, 2020, 13, 297-306.	1.4	59
2630	Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection. Journal of Antimicrobial Chemotherapy, 2021, 76, 482-486.	1.3	9
2631	Acute Respiratory Distress Syndrome. Anesthesiology, 2021, 134, 270-282.	1.3	44
2632	Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). Critical Care Medicine, 2020, 48, e440-e469.	0.4	816

#	ARTICLE	IF	CITATIONS
2633	Harmonizing Heterogeneous Endpoints in Coronavirus Disease 2019 Trials Without Loss of Information. <i>Critical Care Medicine</i> , 2021, 49, e11-e19.	0.4	18
2634	The interplay between HIV and COVID-19: summary of the data and responses to date. <i>Current Opinion in HIV and AIDS</i> , 2021, 16, 63-73.	1.5	131
2635	Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 360-368.	1.0	48
2636	The Race for a COVID-19 Vaccine: Current Trials, Novel Technologies, and Future Directions. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2020, 8, e3206.	0.3	9
2637	Clinical manifestation and disease progression in COVID-19 infection. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 3-8.	0.6	115
2638	COVID-19 in Chronic Liver Disease and Liver Transplantation. <i>Journal of Clinical Gastroenterology</i> , 2021, 55, 187-194.	1.1	39
2639	Internal treatment in traditional Chinese medicine for patients with COVID-19. <i>Medicine (United States)</i> , 2021, 100, e23068.	0.4	8
2640	Current drugs with potential for coronavirus disease 2019 therapy: a literature review. <i>Reviews in Medical Microbiology</i> , 2022, 33, e148-e160.	0.4	3
2641	Caring for Critically Ill Children With Suspected or Proven Coronavirus Disease 2019 Infection: Recommendations by the Scientific Sections of the European Society of Pediatric and Neonatal Intensive Care*. <i>Pediatric Critical Care Medicine</i> , 2021, 22, 56-67.	0.2	34
2642	COVID-19 in Solid Organ Transplantation: A Matched Retrospective Cohort Study and Evaluation of Immunosuppression Management. <i>Transplantation</i> , 2021, 105, 138-150.	0.5	50
2643	COVID-19 Therapeutics for Solid Organ Transplant Recipients; 6 Months Into the Pandemic: Where Are We Now?. <i>Transplantation</i> , 2021, 105, 56-60.	0.5	24
2644	Incidence and Outcomes of COVID-19 in Kidney and Liver Transplant Recipients With HIV: Report From the National HOPE in Action Consortium. <i>Transplantation</i> , 2021, 105, 216-224.	0.5	18
2645	Organ Donation and Transplantation During the COVID-19 Pandemic: A Summary of the Spanish Experience. <i>Transplantation</i> , 2021, 105, 29-36.	0.5	49
2646	Solid Organ Transplantation in the Era of COVID-19: Lessons from France. <i>Transplantation</i> , 2021, 105, 61-66.	0.5	26
2647	COVID-19 in Kidney Transplantation: Epidemiology, Management Considerations, and the Impact on Kidney Transplant Practice. <i>Transplantation Direct</i> , 2020, 6, e582.	0.8	21
2648	Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients. <i>Journal of Medical Microbiology</i> , 2020, 69, 1228-1234.	0.7	115
2767	Coronavirus disease (COVID-19): An updated review based on current knowledge and existing literature for dermatologists. <i>Dermatologic Therapy</i> , 2020, 33, e13677.	0.8	18
2768	A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2. <i>FEBS Journal</i> , 2020, 287, 3633-3650.	2.2	192

#	ARTICLE	IF	CITATIONS
2769	<scp>COVID-19 SAFER</scp>: Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 1636-1646.	1.3	29
2770	Successful recovery from severe COVID-19 pneumonia after kidney transplantation: The interplay between immunosuppression and novel therapy including tocilizumab. <i>Transplant Infectious Disease</i> , 2020, 22, e13334.	0.7	28
2771	A Case of COVID-19 Pneumonia in an 83-year-old Woman Living with a Suspected SARS-CoV-2 Carrier, Who Repeatedly Tested Negative by the PCR Test. <i>Journal of the Japanese Association for Infectious Diseases</i> , 2020, 94, 542-544.	0.0	1
2772	Lopinavir/ritonavir, a new galenic oral formulation from commercial solid form, fine-tuned by nuclear magnetic resonance spectroscopy. <i>European Journal of Hospital Pharmacy</i> , 2022, 29, 259-263.	0.5	2
2773	COVID-19 and lung cancer: risks, mechanisms and treatment interactions. , 2020, 8, e000892.		43
2774	Use of specific antimicrobials for COVID-19: should we prescribe them now or wait for more evidence?. <i>Postgraduate Medical Journal</i> , 2020, 96, 377-378.	0.9	3
2775	COVID-19 and the heart: what we have learnt so far. <i>Postgraduate Medical Journal</i> , 2021, 97, 655-666.	0.9	10
2776	Clinical presentation, case management and outcomes for the first 32 COVID-19 patients in Nigeria. <i>Pan African Medical Journal</i> , 2020, 35, 24.	0.3	46
2778	HIV Protease Inhibitor Ritonavir Impairs Endothelial Function Via Reduction in Adipose Mass and Endothelial Leptin Receptor-Dependent Increases in NADPH Oxidase 1 (Nox1), CCR5 Chemokine Receptor Type 5 (CCR5), and Inflammation. <i>Journal of the American Heart Association</i> , 2020, 9, e018074.	1.6	19
2779	An elderly couple with COVID-19 pneumonia treated in Singapore: contrasting clinical course and management. <i>Singapore Medical Journal</i> , 2020, 61, 392-394.	0.3	5
2780	Clinical and pathological investigation of patients with severe COVID-19. <i>JCI Insight</i> , 2020, 5, .	2.3	232
2781	Clinical trials for COVID-19 should include sex as a variable. <i>Journal of Clinical Investigation</i> , 2020, 130, 3350-3352.	3.9	81
2782	Prioritizing clinical research studies during the COVID-19 pandemic: lessons from New York City. <i>Journal of Clinical Investigation</i> , 2020, 130, 4522-4524.	3.9	10
2783	Safety of Psychotropic Medications in People With COVID-19: Evidence Review and Practical Recommendations. <i>Focus (American Psychiatric Publishing)</i> , 2020, 18, 466-481.	0.4	6
2784	Critical Care Surge During the COVID-19 Pandemic: Implementation and Feedback From Frontline Providers. <i>Journal of Intensive Care Medicine</i> , 2021, 36, 233-240.	1.3	30
2785	Effectiveness of Convalescent Plasma Therapy for COVID-19 Patients in Hunan, China. <i>Dose-Response</i> , 2020, 18, 155932582097992.	0.7	11
2786	Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial. <i>European Respiratory Journal</i> , 2021, 58, 2003725.	3.1	117
2787	Therapeutic strategies for critically ill patients with COVID-19. <i>Annals of Intensive Care</i> , 2020, 10, 45.	2.2	100

#	ARTICLE	IF	CITATIONS
2788	Lack of viral clearance by the combination of hydroxychloroquine and azithromycin or lopinavir and ritonavir in SARS-CoV-2-related acute respiratory distress syndrome. <i>Annals of Intensive Care</i> , 2020, 10, 63.	2.2	23
2789	Management of critically ill patients with COVID-19 in ICU: statement from front-line intensive care experts in Wuhan, China. <i>Annals of Intensive Care</i> , 2020, 10, 73.	2.2	151
2790	Characteristics and outcomes of acute respiratory distress syndrome related to COVID-19 in Belgian and French intensive care units according to antiviral strategies: the COVADIS multicentre observational study. <i>Annals of Intensive Care</i> , 2020, 10, 131.	2.2	39
2791	Battling COVID-19: using old weapons for a new enemy. <i>Tropical Diseases, Travel Medicine and Vaccines</i> , 2020, 6, 6.	0.9	20
2792	Pearls & Oysters: Facial nerve palsy in COVID-19 infection. <i>Neurology</i> , 2020, 95, 364-367.	1.5	83
2793	Clinical Characteristics and Risk Factors of Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients in Beijing, China: A Retrospective Study. <i>Medical Science Monitor</i> , 2020, 26, e925974.	0.5	13
2794	Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. <i>F1000Research</i> , 2020, 9, 129.	0.8	242
2795	Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. <i>F1000Research</i> , 2020, 9, 129.	0.8	368
2796	Word embedding mining for SARS-CoV-2 and COVID-19 drug repurposing. <i>F1000Research</i> , 0, 9, 585.	0.8	4
2797	The COVID-19 pandemic: catching up with the cataclysm. <i>F1000Research</i> , 2020, 9, 638.	0.8	8
2798	Novel respiratory infectious diseases in Korea. <i>Yeungnam University Journal of Medicine</i> , 2020, 37, 286-295.	0.7	4
2799	Abdominal Pain: A Real Challenge in Novel COVID-19 Infection. <i>European Journal of Case Reports in Internal Medicine</i> , 2019, 7, 001632.	0.2	30
2800	Understanding the immunopathogenesis of COVID-19: Its implication for therapeutic strategy. <i>World Journal of Clinical Cases</i> , 2020, 8, 5835-5843.	0.3	11
2801	Symptomatic and optimal supportive care of critical COVID-19: A case report and literature review. <i>World Journal of Clinical Cases</i> , 2020, 8, 6181-6189.	0.3	2
2803	Antiviral treatment of COVID-19: a clinical pharmacology narrative review. <i>Medical Journal of Indonesia</i> , 2020, 29, 332-45.	0.2	8
2804	A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19. <i>PLoS Biology</i> , 2020, 18, e3000970.	2.6	139
2805	Clinical course and potential predictive factors for pneumonia of adult patients with Coronavirus Disease 2019 (COVID-19): A retrospective observational analysis of 193 confirmed cases in Thailand. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008806.	1.3	36
2806	Machine learning in predicting respiratory failure in patients with COVID-19 pneumonia—Challenges, strengths, and opportunities in a global health emergency. <i>PLoS ONE</i> , 2020, 15, e0239172.	1.1	43

#	ARTICLE	IF	CITATIONS
2807	Scientific quality of COVID-19 and SARS CoV-2 publications in the highest impact medical journals during the early phase of the pandemic: A case control study. PLoS ONE, 2020, 15, e0241826.	1.1	59
2808	Clinical characteristics of 199 discharged patients with COVID-19 in Fujian Province: A multicenter retrospective study between January 22nd and February 27th, 2020. PLoS ONE, 2020, 15, e0242307.	1.1	8
2809	A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19). PLoS ONE, 2020, 15, e0242763.	1.1	65
2810	Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis. PLoS ONE, 2020, 15, e0243705.	1.1	62
2811	Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study. PLoS ONE, 2020, 15, e0243961.	1.1	15
2812	The hallmarks of COVID-19 disease. PLoS Pathogens, 2020, 16, e1008536.	2.1	342
2813	Caution With the Use of Lopinavir/Ritonavir in Severely Ill Patients for the Treatment of SARS-CoV-2: A Report of Severe Jaundice. American Journal of Gastroenterology, 2020, 115, 1716-1718.	0.2	7
2814	COVID-19 Pandemic Causing Acute Kidney Injury and Impact on Patients With Chronic Kidney Disease and Renal Transplantation. Journal of Clinical Medicine Research, 2020, 12, 352-361.	0.6	86
2815	Medical Management of COVID-19: Evidence and Experience. Journal of Clinical Medicine Research, 2020, 12, 329-343.	0.6	35
2816	Exploring Repurposing Potential of Existing Drugs in the Management of COVID-19 Epidemic: A Critical Review. Journal of Clinical Medicine Research, 2020, 12, 463-471.	0.6	5
2817	COVID-19 and Possible Pharmacological Preventive Options. Journal of Clinical Medicine Research, 2020, 12, 758-772.	0.6	3
2818	Genome Organization of Covid-19 and Emerging Severe Acute Respiratory Syndrome Covid-19 Outbreak: A Pandemic. Eurasian Journal of Medicine and Oncology, 0, , .	1.0	9
2819	What hepatologists need to know about COVID-19?. Hepatology Forum, 2020, , .	0.3	3
2820	An evidence-based systematic review on emerging therapeutic and preventive strategies to treat novel coronavirus (SARS-CoV-2) during an outbreak scenario. Journal of Basic and Clinical Physiology and Pharmacology, 2020, 31, .	0.7	12
2821	Drug Repurposing for Prevention and Treatment of COVID-19: A Clinical Landscape. Discoveries, 2020, 8, e121.	1.5	15
2822	Structures of the <scp>SARS</scp> nucleocapsid and their perspectives for drug design. EMBO Journal, 2020, 39, e105938.	3.5	198
2823	A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2. EMBO Molecular Medicine, 2021, 13, e13105.	3.3	62
2824	Emerging Treatment Options of Regenerative Medicine in Severe Corona Virus/COVID 19 Infections. International Journal of Stem Cells, 2020, 13, 305-311.	0.8	4

#	ARTICLE	IF	CITATIONS
2826	The Novel Coronavirus 2019 Epidemic and the Kidneys. <i>Journal of Renal and Hepatic Disorders</i> , 2020, 4, 11-20.	0.1	1
2827	Coronaviral Infection (COVID-19) in Children (Situation on April 2020). <i>PediatriĀeskaĀĀ FarmakologiĀĀĀ</i> , 2020, 17, 85-94.	0.1	14
2828	Management of Children with Disease Caused by New Coronaviral Infection (SARS-CoV-2). <i>PediatriĀeskaĀĀ FarmakologiĀĀĀ</i> , 2020, 17, 103-118.	0.1	10
2829	Clinical Features and Management of the Disease Caused by New Coronaviral Infection (COVID-19) in Children. Version 2. <i>PediatriĀeskaĀĀ FarmakologiĀĀĀ</i> , 2020, 17, 187-212.	0.1	12
2830	New Coronaviral Infection: Features of Clinical Course, Capabilities of Diagnostics, Treatment and Prevention in Adults and Children. <i>Voprosy Sovremennoi Pediatrii - Current Pediatrics</i> , 2020, 19, 123-131.	0.1	30
2831	COVID-19: etiology, clinical picture, treatment. <i>Russian Journal of Infection and Immunity</i> , 2020, 10, 421-445.	0.2	36
2832	Management of patients with comorbidity during novel coronavirus (COVID-19) pandemic. National Consensus Statement 2020. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2020, 19, 2630.	0.4	60
2833	COVID-19: therapeutic approaches description and discussion. <i>Anais Da Academia Brasileira De Ciencias</i> , 2020, 92, e20200466.	0.3	9
2834	COVID-19: molecular targets, drug repurposing and new avenues for drug discovery. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2020, 115, e200254.	0.8	26
2835	Terapia medicamentosa para infecĀĀes por coronavĀrus em humanos: revisĀo sistemĀtica rĀjida. <i>Ciencia E Saude Coletiva</i> , 2020, 25, 3517-3554.	0.1	2
2836	Evaluation of knowledge and attitudes among intensive care physicians during the COVID-19 pandemic: a cross-sectional survey. <i>Sao Paulo Medical Journal</i> , 2020, 138, 317-321.	0.4	8
2837	Fighting COVID-19. <i>Brazilian Journal of Biology</i> , 2020, 80, 698-701.	0.4	11
2838	Comment on "The importance of physical exercise during the coronavirus (COVID-19) pandemic". <i>Revista Da AssociaĀo MĀdica Brasileira</i> , 2020, 66, 1311-1313.	0.3	5
2839	SCIENTIFIC PRODUCTION IN ONLINE JOURNALS ABOUT THE NEW CORONAVIRUS (COVID-19): BIBLIOMETRIC RESEARCH. <i>Texto E Contexto Enfermagem</i> , 0, 29, .	0.4	12
2840	Medicamentos e tratamentos para a Covid-19. <i>Estudos Avancados</i> , 2020, 34, 7-27.	0.2	15
2841	Early experience with COVID-19 in kidney transplantation recipients: update and review. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2020, 46, 145-155.	0.7	12
2842	Treatment and research lines for the patient with COVID-19. What do we have and where are we going?. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2020, 46, 125-132.	0.7	5
2844	New coronavirus infection COVID-19. <i>Molekuliarnaia Genetika, Mikrobiologiia I Virusologiia</i> , 2020, 38, 51.	0.1	7

#	ARTICLE	IF	CITATIONS
2845	The importance of zinc in maintaining the activity of antiviral innate immunity proteins: analysis of publications on COVID-19. <i>Profilakticheskaya Meditsina</i> , 2020, 23, 131.	0.2	18
2846	Current coronavirus (SARS-CoV-2) epidemiological, diagnostic and therapeutic approaches: An updated review until June 2020. <i>EXCLI Journal</i> , 2020, 19, 992-1016.	0.5	25
2849	COVID-19 and children. <i>Pulmonologiya</i> , 2020, 30, 609-628.	0.2	15
2850	ERLKG: Entity Representation Learning and Knowledge Graph based association analysis of COVID-19 through mining of unstructured biomedical corpora. , 2020, , .		7
2851	Prospects for a COVID-19 treatment: review. <i>Translational Medicine</i> , 2020, 7, 30-37.	0.1	7
2852	COVID-19 and the Rationale for Pharmacotherapy: A South African Perspective. <i>Wits Journal of Clinical Medicine</i> , 2020, 2, 11.	0.0	8
2853	Potential Impact of SARS-CoV-2 Infection in HIV-positive Patients in South Africa. <i>Wits Journal of Clinical Medicine</i> , 2020, 2, 19.	0.0	5
2854	Editorial: Immunosuppression for COVID-19: repurposing medicines in a pandemic. <i>Australian Prescriber</i> , 2020, 43, 106-107.	0.5	5
2855	EFFICACY AND SAFETY OF SOME ETIOTROPIC THERAPEUTIC SCHEMES FOR TREATING PATIENTS WITH NOVEL CORONAVIRUS INFECTION (COVID-19). <i>Farmatsiya I Farmakologiya</i> , 2020, 8, 150-159.	0.2	6
2856	New Coronavirus Infection (Covid-19): Clinical and Epidemiological Aspects. <i>Russian Archives of Internal Medicine</i> , 2020, 10, 87-93.	0.0	6
2857	New Coronavirus Infection (Covid-19): Clinical and Epidemiological Aspects. <i>Russian Archives of Internal Medicine</i> , 2020, 10, 87-93.	0.0	50
2859	Global Ranking of COVID-19-Related Mortality by Country using a Novel Pandemic Efficiency Index (PEI). <i>International Journal of MCH and AIDS</i> , 2020, 9, 182-185.	0.3	8
2863	A Critical Appraisal of COVID-19 in Malaysia and Beyond. <i>The Malaysian Journal of Medical Sciences</i> , 2020, 27, 1-9.	0.3	40
2864	Ivermectin: Potential Role as Repurposed Drug for COVID-19. <i>The Malaysian Journal of Medical Sciences</i> , 2020, 27, 154-158.	0.3	11
2866	<p>Repurposing Disulfiram as an Anti-Obesity Drug: Treating and Preventing Obesity in High-Fat-Fed Rats<p>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 1473-1480.	1.1	13
2867	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 4673-4695.	1.1	43
2868	COVID-19: Virology, Pathogenesis and Potential Therapeutics. <i>Afro-Egyptian Journal of Infectious and Endemic Diseases</i> , 2020, 10, 93-99.	0.1	6
2869	A Favipiravir-induced Fever in a Patient with COVID-19. <i>Internal Medicine</i> , 2020, 59, 2951-2953.	0.3	7

#	ARTICLE	IF	CITATIONS
2870	Targeting COVID-19 in Parkinson's Patients: Drugs Repurposed. <i>Current Medicinal Chemistry</i> , 2021, 28, 2392-2408.	1.2	13
2871	Current Scenario and Future Prospect in the Management of COVID-19. <i>Current Medicinal Chemistry</i> , 2020, 28, 284-307.	1.2	23
2872	Prevalence of COVID-19-like Symptoms among People Living with HIV, and Using Antiretroviral Therapy for Prevention and Treatment. <i>Current HIV Research</i> , 2020, 18, 373-380.	0.2	19
2873	COVID-19: A Therapeutic Approach Based on Pathophysiological Staging. <i>Open Respiratory Medicine Journal</i> , 2020, 14, 32-37.	1.3	1
2874	Potential Drug Options for Treatment of COVID-19: A Review. <i>Coronaviruses</i> , 2020, 1, 42-48.	0.2	7
2875	COVID-19 Mobile Positioning Data Contact Tracing and Patient Privacy Regulations: Exploratory Search of Global Response Strategies and the Use of Digital Tools in Nigeria. <i>JMIR MHealth and UHealth</i> , 2020, 8, e19139.	1.8	94
2876	Global Infectious Disease Surveillance and Case Tracking System for COVID-19: Development Study. <i>JMIR Medical Informatics</i> , 2020, 8, e20567.	1.3	22
2877	The P Value Line Dance: When Does the Music Stop?. <i>Journal of Medical Internet Research</i> , 2020, 22, e21345.	2.1	16
2880	Existing antiviral options against SARS-CoV-2 replication in COVID-19 patients. <i>Future Microbiology</i> , 2020, 15, 1747-1758.	1.0	31
2881	Virtual screening of immunomodulatory medicinal compounds as promising anti-SARS-CoV-2 inhibitors. <i>Future Virology</i> , 2020, 15, 267-275.	0.9	32
2882	Current Clinical Trials and Vaccine Development Strategies for Corona Virus Disease (COVID-19). <i>Journal of Pure and Applied Microbiology</i> , 2020, 14, 979-988.	0.3	1
2883	Pandemia de COVID-19 y enfermedad renal ¿quién sabemos actualmente?. <i>Revista Colombiana De Nefrología</i> , 2020, 7, 23-24.	0.1	4
2884	Repurposing of drugs for COVID-19: a systematic review and meta-analysis. <i>Panminerva Medica</i> , 2022, 64, .	0.2	8
2885	Management of critically ill patients with COVID-19: suggestions and instructions from the coordination of intensive care units of Lombardy. <i>Minerva Anestesiologica</i> , 2020, 86, 1234-1245.	0.6	31
2886	Assessment and treatment of older individuals with COVID 19 multi-system disease: Clinical and ethical implications. <i>Acta Biomedica</i> , 2020, 91, 150-168.	0.2	18
2887	Proximal femur fractures in COVID-19 emergency: the experience of two Orthopedics and Traumatology Departments in the first eight weeks of the Italian epidemic. <i>Acta Biomedica</i> , 2020, 91, 89-96.	0.2	80
2888	Identification of potential COVID-19 main protease inhibitors using structure-based pharmacophore approach, molecular docking and repurposing studies. <i>Acta Pharmaceutica</i> , 2021, 71, 163-174.	0.9	26
2889	Severe bradyarrhythmia requiring temporary pacemaker in a COVID-19 patient receiving lopinavir/ritonavir treatment: a case report. <i>Heart Vessels and Transplantation</i> , 0, 4, 79.	0.0	4

#	ARTICLE	IF	CITATIONS
2890	COVID-19: A 2020 update. Indian Journal of Medical Sciences, 0, 72, 88-94.	0.1	8
2891	Making sense of the infodemic – A bibliometric analysis of publications on COVID-19 in trauma and orthopedics. Indian Journal of Medical Sciences, 0, 72, 155-166.	0.1	2
2892	The effect of COVID-19 on global population and its fatality rate: Retrospective study by online database. Indian Journal of Medical Sciences, 0, 72, 13-16.	0.1	4
2900	Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28 February 2020. Eurosurveillance, 2020, 25, .	3.9	119
2901	Pathogenesis, Diagnosis and Possible Therapeutic Options for COVID-19. Journal of Clinical and Experimental Investigations, 2020, 11, em00755.	0.1	6
2902	Pharmacological treatment of COVID-19: an update. Journal of Global Health Reports, 0, , .	1.0	2
2903	Relationship between COVID-19 and liver diseases: the role of hepatologists in clinical practice. Acta Hepatologica Japonica, 2020, 61, 496-503.	0.0	2
2904	Pride and Prejudice during the COVID-19 Pandemic: The Misfortune of Inappropriate Clinical Trial Design. Journal of Epidemiology and Global Health, 2021, 11, 15.	1.1	4
2905	Koronavirüs Hastalığı (COVID-19) Tedavisinde Kullanılan İlaçlar. Kocaeli Üniversitesi Sağlık Bilimleri Dergisi, 2020, 6, 167-173.	0.3	6
2906	Donación de Órganos y trasplante en la era COVID-19: ¿Realmente se deben parar los programas?. Revista Colombiana De Cirugía, 2020, 35, 227-234.	0.2	3
2907	COVID-19, Australia: Epidemiology Report 16: Reporting week ending 23:59 AEST 17 May 2020. Communicable Diseases Intelligence (2018), 2020, 44, .	0.3	14
2908	COVID-19, Australia: Epidemiology Report 17: Fortnightly reporting period ending 24 May 2020. Communicable Diseases Intelligence (2018), 2020, 44, .	0.3	6
2909	COVID-19, Australia: Epidemiology Report 19 (Fortnightly reporting period ending 21 June 2020). Communicable Diseases Intelligence (2018), 2020, 44, .	0.3	10
2910	COVID-19, Australia: Epidemiology Report 20. Fortnightly reporting period ending 5 July 2020. Communicable Diseases Intelligence (2018), 2020, 44, .	0.3	10
2911	COVID-19 Australia: Epidemiology Report 24. Fortnightly reporting period ending 30 August 2020. Communicable Diseases Intelligence (2018), 2020, 44, .	0.3	7
2912	Convalescent Plasma Therapy in Coronavirus Disease 2019: a Case Report and Suggestions to Overcome Obstacles. Journal of Korean Medical Science, 2020, 35, e239.	1.1	24
2913	Clinical Course and Outcomes of 3,060 Patients with Coronavirus Disease 2019 in Korea, January–May 2020. Journal of Korean Medical Science, 2020, 35, e280.	1.1	62
2914	The First Case of an HIV Patient Diagnosed with COVID-19 in Korea. Journal of Korean Medical Science, 2020, 35, e358.	1.1	3

#	ARTICLE	IF	CITATIONS
2915	Use of Darunavir-Cobicistat as a Treatment Option for Critically Ill Patients with SARS-CoV-2 Infection. <i>Yonsei Medical Journal</i> , 2020, 61, 826.	0.9	12
2916	Management of liver diseases during the pandemic of coronavirus disease-19. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 243-250.	4.5	8
2918	Anti-SARS-CoV Natural Products With the Potential to Inhibit SARS-CoV-2 (COVID-19). <i>Frontiers in Pharmacology</i> , 2020, 11, 561334.	1.6	113
2919	Severe Acute Respiratory Syndrome Coronavirus-2 Induces Cytokine Storm and Inflammation During Coronavirus Disease 19: Perspectives and Possible Therapeutic Approaches. <i>Frontiers in Pharmacology</i> , 2020, 11, 592169.	1.6	9
2920	COVID-19-Associated Hyper-Fibrinolysis: Mechanism and Implementations. <i>Frontiers in Physiology</i> , 2020, 11, 596057.	1.3	15
2921	The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9775.	1.8	40
2922	Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review. <i>Viruses</i> , 2020, 12, 1092.	1.5	34
2923	Plant-Based Drugs and Vaccines for COVID-19. <i>Vaccines</i> , 2021, 9, 15.	2.1	34
2924	Combating the Coronavirus Pandemic: Early Detection, Medical Treatment, and a Concerted Effort by the Global Community. <i>Research</i> , 2020, 2020, 6925296.	2.8	26
2928	Coronavirus disease 2019 (COVID-19): research progress and clinical practice. <i>Global Health & Medicine</i> , 2020, 2, 78-88.	0.6	16
2929	Consensus Statement for Pharmacological Management of Coronavirus Disease 2019 (COVID-19): A Pragmatic Approach. , 2020, 3, 241-256.		5
2930	Functional studies of the coronavirus nonstructural proteins. <i>STEMedicine</i> , 2020, 1, e39.	0.5	27
2931	The first 100 cases of COVID-19 in a Hospital in Madrid with a 2-month follow-up. <i>Revista Espanola De Quimioterapia</i> , 2020, 33, 369-378.	0.5	17
2932	SARS-COV-2 infection (coronavirus disease 2019) for the gastrointestinal consultant. <i>World Journal of Gastroenterology</i> , 2020, 26, 1546-1553.	1.4	46
2933	COVID-19 pandemic: Its impact on liver disease and liver transplantation. <i>World Journal of Gastroenterology</i> , 2020, 26, 2987-2999.	1.4	54
2934	Etiology and management of liver injury in patients with COVID-19. <i>World Journal of Gastroenterology</i> , 2020, 26, 4753-4762.	1.4	56
2935	Challenges in COVID-19 drug treatment in patients with advanced liver diseases: A hepatology perspective. <i>World Journal of Gastroenterology</i> , 2020, 26, 7272-7286.	1.4	12
2936	PHARMACOTHERAPY of COVID-19. <i>Veteriner Farmakoloji Ve Toksikoloji Derneği Bülteni</i> , 2020, 11, 80-114.	0.1	4

#	ARTICLE	IF	CITATIONS
2937	COVID-19: What We Know So Far. <i>International Journal of Clinical Research</i> , 2020, 1, 73-108.	0.1	1
2938	SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection. <i>Antiviral Therapy</i> , 2020, 25, 345-347.	0.6	9
2939	[Comment] Treatment strategies to fight the new coronavirus SARS-CoV-2: A challenge for a Rubik's Cube solver. <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 147-150.	0.8	4
2940	Repurposing current therapeutic regimens against SARS-CoV-2 (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 1845-1855.	0.8	8
2941	COVID-19 in China: From epidemiology to treatment (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 1-1.	0.8	4
2942	Towards a more effective strategy for COVID-19 prevention (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 21, 1-1.	0.8	4
2943	Comprehensive analysis of drugs to treat SARS-CoV-2 infection: Mechanistic insights into current COVID-19 therapies (Review). <i>International Journal of Molecular Medicine</i> , 2020, 46, 467-488.	1.8	116
2944	An integrative look at SARS-CoV-2 (Review). <i>International Journal of Molecular Medicine</i> , 2020, 47, 415-434.	1.8	17
2945	In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 782-787.	0.7	52
2946	Clinical and Epidemiological Characteristics of Coronavirus Disease 2019 in the Early Stage of Outbreak. <i>Korean Journal of Medicine</i> , 2020, 95, 67-73.	0.1	24
2947	Empirical Treatment and Prevention of COVID-19. <i>Infection and Chemotherapy</i> , 2020, 52, 142.	1.0	18
2948	Interim Guidelines on Antiviral Therapy for COVID-19. <i>Infection and Chemotherapy</i> , 2020, 52, 281.	1.0	29
2949	Treatment Options for Severe Acute Respiratory Syndrome, Middle East Respiratory Syndrome, and Coronavirus Disease 2019: a Review of Clinical Evidence. <i>Infection and Chemotherapy</i> , 2020, 52, 317.	1.0	7
2950	Clinical Experience with Use of Remdesivir in the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2: a Case Series. <i>Infection and Chemotherapy</i> , 2020, 52, 369.	1.0	12
2951	Severe Thrombocytopenia in a Patient with COVID-19. <i>Infection and Chemotherapy</i> , 2020, 52, 410.	1.0	12
2952	COVID-19 and the kidney. <i>Cleveland Clinic Journal of Medicine</i> , 2020, 87, 619-631.	0.6	52
2953	Antivirals for COVID-19. <i>Cleveland Clinic Journal of Medicine</i> , 2020, , .	0.6	26
2954	COVID-19 treatment: Combining anti-inflammatory and antiviral therapeutics using a network-based approach. <i>Cleveland Clinic Journal of Medicine</i> , 2020, , .	0.6	21

#	ARTICLE	IF	CITATIONS
2955	COVID-19 pneumonia in a patient with adult T-cell leukemia-lymphoma. Journal of Clinical and Experimental Hematopathology: JCEH, 2020, 60, 174-178.	0.3	11
2956	Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2. Journal of Microbiology and Biotechnology, 2020, 30, 1843-1853.	0.9	17
2957	COVID-19: general overview, pharmacological options and ventilatory support strategies. Multidisciplinary Respiratory Medicine, 2020, 15, 708.	0.6	2
2958	Seroprevalence of anti SARS-CoV2 antibodies in Umbrian persons living with HIV. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020080.	0.5	9
2959	Palestinian strategies, guidelines, and challenges in the treatment and management of coronavirus disease-2019 (COVID-19). Avicenna Journal of Medicine, 2020, 10, 135.	0.3	8
2960	Clinical management of COVID-19. Indian Journal of Medical Research, 2020, 151, 401.	0.4	68
2961	COVID 19 and acute kidney injury. Indian Journal of Nephrology, 2020, 30, 161.	0.2	14
2962	Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future. Indian Journal of Ophthalmology, 2020, 68, 693.	0.5	78
2963	COVID-19 pandemic: A review based on current evidence. Indian Journal of Pharmacology, 2020, 52, 117.	0.4	44
2964	Safety and efficacy of lopinavir/ritonavir combination in COVID-19: A systematic review, meta-analysis, and meta-regression analysis. Indian Journal of Pharmacology, 2020, 52, 313-323.	0.4	18
2965	Coronavirus and Its effect on the respiratory system: Is there any association between pneumonia and immune cells. Journal of Family Medicine and Primary Care, 2020, 9, 4729.	0.3	13
2966	The 2019â€“2020 novel coronavirus (severe acute respiratory syndrome coronavirus 2) pandemic: A joint american college of academic international medicine-world academic council of emergency medicine multidisciplinary COVID-19 working group consensus paper. Journal of Global Infectious Diseases, 2020, 12, 47.	0.2	270
2967	Systemic manifestations of COVID-19. Journal of Anaesthesiology Clinical Pharmacology, 2020, 36, 435.	0.2	13
2968	Guide on diabetes and COVID-19 for healthcare professionals in Bangladesh. Journal of Diabetology, 2020, 11, 137.	0.1	4
2969	The saudi critical care society clinical practice guidelines on the management of COVID-19 patients in the intensive care unit. Saudi Critical Care Journal, 2020, 4, 27.	0.4	18
2970	COVID-19: What we all intensivists should know. Saudi Critical Care Journal, 2020, 4, 45.	0.4	1
2971	Gastrointestinal and liver manifestations of COVID-19. Saudi Journal of Gastroenterology, 2020, 26, 226.	0.5	23
2972	Abnormal liver-related biomarkers in COVID-19 patients and the role of prealbumin. Saudi Journal of Gastroenterology, 2020, 26, 272.	0.5	9

#	ARTICLE	IF	CITATIONS
2973	Important Management Considerations In Patients With Pituitary Disorders During The Time Of The Covid-19 Pandemic. <i>Endocrine Practice</i> , 2020, 26, 915-922.	1.1	8
2974	Immediate and long-term impact of the COVID-19 pandemic on cardiovascular clinical trials: considerations for study conduct and endpoint determination. <i>EuroIntervention</i> , 2020, 16, 787-793.	1.4	5
2975	Stem cell therapy for COVID-19 and other respiratory diseases: Global trends of clinical trials. <i>World Journal of Stem Cells</i> , 2020, 12, 471-480.	1.3	15
2976	Severe COVID-19 after liver transplantation, surviving the pitfalls of learning on-the-go: Three case reports. <i>World Journal of Hepatology</i> , 2020, 12, 870-879.	0.8	6
2977	COVID-19 and Fake News in the Dominican Republic. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 102, 1172-1174.	0.6	38
2978	Rigorous Randomized Controlled Trial Implementation in the Era of COVID-19. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 102, 1154-1155.	0.6	8
2979	Case Report: Right Bundle Branch Block and QTc Prolongation in a Patient with COVID-19 Treated with Hydroxychloroquine. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 79-82.	0.6	10
2980	Review of Burden, Clinical Definitions, and Management of COVID-19 Cases. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 625-638.	0.6	47
2981	Case Report: COVID-19 Associated Renal Infarction and Ascending Aortic Thrombosis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 1989-1992.	0.6	25
2982	Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 1635-1639.	0.6	113
2983	Pragmatic Recommendations for Therapeutics of Hospitalized COVID-19 Patients in Low- and Middle-Income Countries. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, , .	0.6	3
2984	Childhood Rheumatic Diseases and COVID-19 Pandemic: An Intriguing Linkage and a New Horizon. <i>Balkan Medical Journal</i> , 2020, 37, 184-188.	0.3	24
2985	Characteristics and Management of Children With COVID-19 in Turkey. <i>Balkan Medical Journal</i> , 2020, 37, 341-347.	0.3	52
2986	Current Approaches to COVID-19: Therapy and Prevention. <i>Indian Journal of Critical Care Medicine</i> , 2020, 24, 838-846.	0.3	19
2987	Evaluating the Efficacy and Safety of the Existing Repurposed Pharmacological Agents for Treating COVID-19: A Meta-analysis and Systematic Review of Clinical Trials. <i>Indian Journal of Critical Care Medicine</i> , 2020, 24, 1106-1113.	0.3	1
2988	Tratamento precoce para COVID-19 baseado em evidência científica. <i>Revista Brasileira Em Promoção Da Saúde</i> , 0, 33, 1-11.	0.1	2
2989	Principles of Care for Patients with Liver Disease During the Coronavirus Disease 2019 (COVID-19) Pandemic: Position Statement of the Saudi Association for the Study of Liver Disease and Transplantation. <i>Annals of Saudi Medicine</i> , 2020, 40, 273-280.	0.5	10
2990	The COVID-19 pandemic: Clinical practice advice for gastroenterologists, hepatologists, and liver transplant specialists. <i>Turkish Journal of Gastroenterology</i> , 2020, 31, 348-355.	0.4	6

#	ARTICLE	IF	CITATIONS
2991	Critically ill patients with COVID-19 in Hong Kong: a multicentre retrospective observational cohort study. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2020, 22, 119-125.	0.0	41
2992	Post-transplant immunosuppression and COVID-19: From a double whammy to a mixed blessing. <i>World Journal of Transplantation</i> , 2020, 10, 267-276.	0.6	6
2993	Current status of COVID-19 treatment: An opinion review. <i>World Journal of Virology</i> , 2020, 9, 27-37.	1.3	12
2994	COVID-19 and acute kidney injury. <i>Tuberkuloz Ve Toraks</i> , 2020, 68, 407-418.	0.2	30
2995	Efficacy of early hydroxychloroquine treatment in preventing COVID-19 pneumonia aggravation, the experience from Shanghai, China. <i>BioScience Trends</i> , 2020, 14, 408-414.	1.1	4
2996	An overview of potential therapeutic agents to treat COVID-19. <i>BioScience Trends</i> , 2020, 14, 318-327.	1.1	5
2997	COVID-19 – Toward a comprehensive understanding of the disease. <i>Cardiology Journal</i> , 2020, 27, 99-114.	0.5	47
2998	Cardiovascular disease during the COVID-19 pandemic: Think ahead, protect hearts, reduce mortality. <i>Cardiology Journal</i> , 2020, 27, 616-624.	0.5	18
2999	COVID-19 Pandemic and Children: A Review. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2020, 25, 574-585.	0.3	25
3000	Guidelines for the pharmacological treatment of COVID-19. The task force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology. <i>Revista Brasileira De Terapia Intensiva</i> , 2020, 32, 166-196.	0.1	38
3001	Pharmacogenomics landscape of COVID-19 therapy response in Serbian population and comparison with worldwide populations. <i>Journal of Medical Biochemistry</i> , 2020, 39, 488-499.	0.7	6
3002	COVID-19 Diagnostic and Management Protocol for Pediatric Patients. <i>Clinics</i> , 2020, 75, e1894.	0.6	64
3003	Update on the diagnosis and management of COVID-19 in pediatric patients. <i>Clinics</i> , 2020, 75, e2353.	0.6	11
3004	Medical management of COVID-19 clinic. <i>Journal of Biomedical Research</i> , 2020, 34, 416.	0.7	6
3005	Coronavirus disease 2019 (COVID-19): latest developments in potential treatments. <i>Drugs in Context</i> , 2020, 9, 1-14.	1.0	14
3006	Pharmacological treatment of COVID-19: lights and shadows. <i>Drugs in Context</i> , 2020, 9, 1-11.	1.0	13
3007	Genomic diversity and evolution, diagnosis, prevention, and therapeutics of the pandemic COVID-19 disease. <i>PeerJ</i> , 2020, 8, e9689.	0.9	34
3008	Therapeutic Options for COVID-19: A Review. <i>Cureus</i> , 2020, 12, e10480.	0.2	23

#	ARTICLE	IF	CITATIONS
3009	Brief Review on COVID-19: The 2020 Pandemic Caused by SARS-CoV-2. <i>Cureus</i> , 2020, 12, e7386.	0.2	117
3010	A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19). <i>Cureus</i> , 2020, 12, e7560.	0.2	358
3011	A Comprehensive Review of Severe Acute Respiratory Syndrome Coronavirus 2. <i>Cureus</i> , 2020, 12, e7943.	0.2	12
3012	Gastrointestinal Manifestations in COVID-19 Infection and Its Practical Applications. <i>Cureus</i> , 2020, 12, e8750.	0.2	13
3013	Potential Treatment Options for COVID-19: A Comprehensive Review of Global Pharmacological Development Efforts. <i>Cureus</i> , 2020, 12, e8845.	0.2	15
3014	Spontaneous Pneumomediastinum Associated With SARS-CoV-2: Infrequent Complication of the Novel Disease. <i>Cureus</i> , 2020, 12, e9189.	0.2	9
3015	Effectiveness of early treatment of lopinavir-ritonavir in patients with severe COVID-19: a case series. <i>Clinical Medicine</i> , 2021, 21, e80-e83.	0.8	1
3016	Inhaled and systemic heparin as a repurposed direct antiviral drug for prevention and treatment of COVID-19. <i>Clinical Medicine</i> , 2020, 20, e218-e221.	0.8	39
3017	An updated review on potential therapeutic drug candidates, vaccines and an insight on patents filed for COVID-19. <i>Current Research in Pharmacology and Drug Discovery</i> , 2021, 2, 100063.	1.7	7
3018	Various Combinations of Favipiravir, Lopinavir-Ritonavir, Darunavir-Ritonavir, High-Dose Oseltamivir, and Hydroxychloroquine for the Treatment of COVID-19: A Randomized Controlled Trial (FIGHT-COVID-19 Study). <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
3019	SARS-CoV-2: Pathogenic Mechanisms and Host Immune Response. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1313, 99-134.	0.8	6
3021	A review of COVID-19: Treatment strategies and CRISPR/Cas9 gene editing technology approaches to the coronavirus disease. <i>Saudi Journal of Biological Sciences</i> , 2021, 29, 860-860.	1.8	5
3022	Development of a Novel Pharmacophore Model Guided by the Ensemble of Waters and Small Molecule Fragments Bound to SARS-CoV-2 Main Protease. <i>Molecular Informatics</i> , 2022, 41, e2100178.	1.4	3
3023	Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166294.	1.8	28
3024	Coronavirus infection recovery in 101-years-old female patient. <i>Russian Journal of Geriatric Medicine</i> , 2021, , 365-367.	0.3	0
3025	Haste makes waste: A critical review of docking-based virtual screening in drug repurposing for SARS-CoV-2 main protease (M ^{pro}) inhibition. <i>Medicinal Research Reviews</i> , 2022, 42, 744-769.	5.0	46
3026	Impact of SARS-CoV-2 on pregnancy outcomes (Review). <i>Medicine International</i> , 2021, 1, .	0.2	0
3027	COVID-19 in Children. <i>Infektoloski Glasnik</i> , 2021, 41, 15-21.	0.2	2

#	ARTICLE	IF	CITATIONS
3028	Terapias medicamentosas empregadas no tratamento da Covid-19 no Brasil: revisão bibliográfica narrativa. <i>Research, Society and Development</i> , 2021, 10, e213101321068.	0.0	0
3029	Date of introduction and epidemiologic patterns of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Mogadishu, Somalia: estimates from transmission modelling of satellite-based excess mortality data in 2020. <i>Wellcome Open Research</i> , 2021, 6, 255.	0.9	0
3030	Structure-guided antibody cocktail for prevention and treatment of COVID-19. <i>PLoS Pathogens</i> , 2021, 17, e1009704.	2.1	12
3031	Exploring Health Impact and Safety Measures against Transmission of COVID-19 Pandemic in Saudi Arabia. <i>Journal of Public Health Research</i> , 2022, 11, jphr.2021.2440.	0.5	0
3032	Statin Use and COVID-19 Infectivity and Severity in South Korea: Two Population-Based Nationwide Cohort Studies. <i>JMIR Public Health and Surveillance</i> , 2021, 7, e29379.	1.2	8
3033	Efficacy of Persian medicine herbal formulations (capsules and decoction) compared to standard care in patients with COVID-19, a multicenter open-label, randomized, controlled clinical trial. <i>Phytotherapy Research</i> , 2021, 35, 6295-6309.	2.8	29
3034	Drug repositioning by merging active subnetworks validated in cancer and COVID-19. <i>Scientific Reports</i> , 2021, 11, 19839.	1.6	6
3035	Assessing unproven interventions in the COVID-19 pandemic: discussion on the ethics of "compassionate therapies" in times of catastrophic pandemics. <i>Journal of Medical Ethics</i> , 2022, 48, 1000-1005.	1.0	6
3037	Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments. <i>Current Molecular Medicine</i> , 2022, 22, 621-639.	0.6	2
3038	COVID-19 in children: an approach for multisystem inflammatory syndrome. <i>The Gazette of the Egyptian Paediatric Association</i> , 2021, 69, .	0.1	1
3039	Liver and COVID-19: From care of patients with liver diseases to liver injury. <i>World Journal of Hepatology</i> , 2021, 13, 1367-1377.	0.8	10
3040	Triple jeopardy in ageing: COVID-19, co-morbidities and inflamm-ageing. <i>Ageing Research Reviews</i> , 2022, 73, 101494.	5.0	11
3042	Cutaneous Virus Infections. , 2022, , 37-76.		2
3043	Novel coronavirus pathogen in humans and animals: an overview on its social impact, economic impact, and potential treatments. <i>Environmental Science and Pollution Research</i> , 2021, 28, 68071-68089.	2.7	15
3044	Physicochemical Characteristics and In Vitro Toxicity/Anti-SARS-CoV-2 Activity of Favipiravir Solid Lipid Nanoparticles (SLNs). <i>Pharmaceuticals</i> , 2021, 14, 1059.	1.7	18
3045	Drug Repurposing to Identify Nilotinib as a Potential SARS-CoV-2 Main Protease Inhibitor: Insights from a Computational and In Vitro Study. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 5469-5483.	2.5	26
3046	Personalized therapy: can it tame the COVID-19 monster?. <i>Personalized Medicine</i> , 2021, 18, 583-593.	0.8	4
3047	Caracterización clínica y perspectivas de tratamiento de la COVID-19. <i>Revista Científica UPAP</i> , 2021, 1, 83-93.	0.0	0

#	ARTICLE	IF	CITATIONS
3048	Coronavirus disease 2019 in kidney transplant recipients: a systematic review and meta-analysis. Singapore Medical Journal, 2023, 64, 593-602.	0.3	8
3049	Secondary Metabolites in Functionalized Titanium Dioxide (TiO ₂) Nanoparticles: A Novel and Safe Virucide against SARS-CoV-2. Journal of Nano Research, 0, 70, 137-145.	0.8	3
3050	Comparative effectiveness of pharmacological interventions on mortality and the average length of hospital stay of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. Expert Review of Anti-Infective Therapy, 2022, 20, 585-609.	2.0	5
3051	De novo design of novel protease inhibitor candidates in the treatment of SARS-CoV-2 using deep learning, docking, and molecular dynamic simulations. Computers in Biology and Medicine, 2021, 139, 104967.	3.9	55
3052	COVID-19 Advanced Care. Journal of Personalized Medicine, 2021, 11, 1082.	1.1	1
3053	The Omic Insights on Unfolding Saga of COVID-19. Frontiers in Immunology, 2021, 12, 724914.	2.2	3
3054	COVID-19: A review of newly formed viral clades, pathophysiology, therapeutic strategies and current vaccination tasks. International Journal of Biological Macromolecules, 2021, , .	3.6	14
3055	Clostridioides difficile and Vancomycin-Resistant Enterococci in COVID-19 Patients with Severe Pneumonia. Life, 2021, 11, 1127.	1.1	8
3056	Coronavirus disease 2019 in liver transplant patients: Clinical and therapeutic aspects. World Journal of Hepatology, 2021, 13, 1299-1315.	0.8	1
3057	Impact of COVID-19 pandemic on liver, liver diseases, and liver transplantation programs in intensive care units. World Journal of Hepatology, 2021, 13, 1215-1233.	0.8	3
3058	Vitamins, supplements and COVID-19: a review of currently available evidence. Drugs in Context, 2021, 10, 1-15.	1.0	24
3059	Drugs and liver injury: a not to be overlooked binomial in COVID-19. Journal of Chemotherapy, 2022, 34, 207-220.	0.7	3
3060	Combating Oxidative Stress and Inflammation in COVID-19 by Molecular Hydrogen Therapy: Mechanisms and Perspectives. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-17.	1.9	63
3061	Suggestion of active 3-chymotrypsin like protease (3CL ^{Pro}) inhibitors as potential anti-SARS-CoV-2 agents using predictive QSAR model based on the combination of ALASSO with an ANN model. SAR and QSAR in Environmental Research, 2021, 32, 863-888.	1.0	2
3062	Elevated Humoral Immune Response to SARS-CoV-2 at High Altitudes Revealed by an Anti-RBD <i>In-House</i> ELISA. Frontiers in Medicine, 2021, 8, 720988.	1.2	5
3063	Follow-Up Study of the Cardiopulmonary and Psychological Outcomes of COVID-19 Survivors Six Months After Discharge in Sichuan, China. International Journal of General Medicine, 2021, Volume 14, 7207-7217.	0.8	11
3064	Early administration of remdesivir to COVID-19 patients associates with higher recovery rate and lower need for ICU admission: A retrospective cohort study. PLoS ONE, 2021, 16, e0258643.	1.1	28
3065	Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: a randomised Phase II clinical trial. EClinicalMedicine, 2021, 41, 101169.	3.2	52

#	ARTICLE	IF	CITATIONS
3066	Efficacy of naproxen in the management of patients hospitalized with COVID-19 infection: A randomized, double-blind, placebo-controlled, clinical trial. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021, 15, 102319.	1.8	12
3067	Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment. <i>European Journal of Medicinal Chemistry Reports</i> , 2021, 3, 100013.	0.6	25
3068	Repurposing old molecules for new indications: Defining pillars of success from lessons in the past. <i>European Journal of Pharmacology</i> , 2021, 912, 174569.	1.7	9
3069	SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies. <i>International Immunopharmacology</i> , 2021, 101, 108232.	1.7	14
3070	Normalization of SARS-CoV-2 viral load via RT-qPCR provides higher-resolution data for comparison across time and between patients. <i>Virus Research</i> , 2021, 306, 198604.	1.1	7
3071	COVID-19: Older drugs for a novel disease—Chloroquine, hydroxychloroquine, and possible Pentoxifylline—set to start the second innings?. <i>Journal of Family Medicine and Primary Care</i> , 2020, 9, 2172.	0.3	2
3072	Anti-corona Drugs: Current scenario. <i>Indian Journal of Nephrology</i> , 2020, 30, 179.	0.2	0
3073	Geriatric Patients and COVID-19. , 2020, , 209-224.		0
3074	Induced Pluripotent Stem Cell Derived Human Lung Organoids to Map and Treat the SARS-CoV2 Infections In Vitro. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1312, 1-17.	0.8	2
3075	Impact of COVID-19 infections on hemodialysis patients in the province of Blida, Algeria. <i>Pan African Medical Journal</i> , 2020, 37, 51.	0.3	3
3076	Therapeutic Approach to Coronavirus Disease. , 2020, , 67-97.		1
3077	Hepatocellular carcinoma care during The Coronavirus disease (COVID-19) era. <i>Sohag Medical Journal (SMJ)</i> , 2020, 24, 76-81.	0.1	0
3079	Infección por SARS-CoV2 en pacientes con trasplante de Órgano sólido: Cinco preguntas importantes.. <i>Revista Colombiana De Cirugía</i> , 2020, 35, 216-226.	0.2	1
3080	Availability of drugs for severe COVID-19 in sub-Saharan Africa. <i>Pan African Medical Journal</i> , 2020, 35, 48.	0.3	3
3081	A literature review of drugs for the treatment of COVID-19. <i>Caribbean Medical Journal</i> , 0, , .	0.1	0
3089	Tratamiento De COVID-19. Mitos Y Realidades Bajo La Perspectiva De La Investigación Clínica [Treatment Of COVID-19. Myths And Realities Under The Perspective Of Clinical Research]. <i>Revista Centroamericana De Obstetricia Y Ginecología</i> , 2020, 24, .	0.0	0
3090	Pharmacy and Therapeutics Committee Preparedness Plan for COVID-19. <i>Global Journal on Quality and Safety in Healthcare</i> , 2020, 3, 55-64.	0.1	3
3091	COVID-19 — A new viral infection: pathogenesis, diagnostics, treatment. <i>Tuberculosis Lung Diseases HIV Infection</i> , 2020, .	0.3	2

#	ARTICLE	IF	CITATIONS
3093	A Silent Attacker SARS-CoV-2 - A Review. European Journal of Medical and Health Sciences, 2020, 2, .	0.1	0
3097	An early assessment of the efficacy of medicines in the treatment of patients with COVID-19. Russian Journal of Infection and Immunity, 2020, 10, 277-286.	0.2	2
3098	Current Status of Treatment Options, Clinical Trials, and Vaccine Development for SARS-CoV-2 Infection. Journal of Pure and Applied Microbiology, 2020, 14, 733-740.	0.3	2
3101	Humidifier Use and Prone Positioning in a Patient with Severe COVID-19 Pneumonia and Endotracheal Tube Impaction Due to Highly Viscous Sputum. Cureus, 2020, 12, e8626.	0.2	9
3102	First COVID-19 sub-intensive respiratory unit in Europe: the Italian experience. Multidisciplinary Respiratory Medicine, 2020, 15, 682.	0.6	2
3105	(Facts and thoughts on COVID-19 pandemic). Cor Et Vasa, 2020, 62, 11-14.	0.1	1
3107	Global Pandemic Conditions and List of Possible Medications and Vaccines for the Treatment of COVID-19: A Review. Borneo Journal of Pharmacy, 2020, 3, 90-102.	0.1	1
3109	Lessons Learned from SARS-CoV and MERS-CoV: Preparation for SARS-CoV-2 induced COVID-19. Journal of Bacteriology and Virology, 2020, 50, 76-96.	0.0	1
3110	Re-tasking the use of pre-existing medications and potential therapeutic options for coronavirus disease (COVID-19): systematic review of clinical studies. Drug Discoveries and Therapeutics, 2020, 14, 109-116.	0.6	4
3111	COVID-19, Australia: Epidemiology Report 18: Fortnightly reporting period ending 7 June 2020. Communicable Diseases Intelligence (2018), 2020, 44, .	0.3	6
3112	Clinical Management and Nursing of COVID-19. GÃ¼mÃ¼rtÃ¼n Ãœniversitesi SaÄŸlÃ¼k Bilimleri Dergisi, 2020, 9, 222-231.	0.1	7
3114	As Drugs Assemble to Treat SARS-COV-2, Which Drug will Prove Efficacious : A Search for Suitable Drug or Vaccine to Manage COVID-19 Pandemic. Western Journal of Medical and Biomedical Sciences, 2020, 1, 1-18.	0.2	0
3116	SARS-CoV-2 and its dynamic impact on emergency department preparedness and management. Journal of Emergency Practice and Trauma, 2020, 6, 102-108.	0.3	0
3117	Az Ã©j tÃ©pusÃ© koronavÃ©rus okozta megbetegedÃ©s (COVID-19): Ã©sszefoglalÃ© hematolÃ³gusoknak II. â€œ a diagnosztika, terÃ©pia Ã©s prevenciÃ³ lehetÃ©sÃ©gei. Transfusio, 2020, 53, 81-95.	0.0	0
3118	A new model for clinical trials to address the COVID-19 emergency. Breathe, 2020, 16, 200220.	0.6	0
3124	Predictors of Severe COVID-19 Pneumonia. Journal of the Japanese Association for Infectious Diseases, 2020, 94, 483-489.	0.0	5
3128	The Effects of COVID-19 from Fertilization until Birth: A Literature Review. Preventive Care in Nursing and Midwifery Journal, 2020, 10, 22-33.	0.1	0
3129	COVID-19 Australia: Epidemiology Report 22: Fortnightly reporting period ending 2 August 2020. Communicable Diseases Intelligence (2018), 2020, 44, .	0.3	2

#	ARTICLE	IF	CITATIONS
3130	Coronaviral Infection (COVID-19) in Children (Situation on June 2020). <i>Pediatric Farmakologi</i> , 2020, 17, 162-178.	0.1	6
3132	Coronavirus Disease 2019 in Neonates – What Is Known and What Needs to Be Known. <i>Cureus</i> , 2020, 12, e10171.	0.2	5
3133	COVID-19, Australia: Epidemiology Report 21: Fortnightly reporting period ending 19 July 2020. <i>Communicable Diseases Intelligence</i> (2018), 2020, 44, .	0.3	4
3134	Features of the course and approaches to the treatment of coronavirus infection COVID- 19 patients with cardiovascular diseases. <i>Kardiologicheskii Vestnik</i> , 2020, , 64-71.	0.1	0
3135	COVID-19: update in innovazione, ricerca e sviluppo. <i>Giornale Di Clinica Nefrologica E Dialisi</i> , 2020, 32, 111-123.	0.0	0
3136	Tratamiento farmacológico para COVID-19 en protocolos latinoamericanos: Una revisión narrativa de la eficacia y seguridad. , 2020, 8, 150-160.		4
3137	A pragmatic approach and treatment of coronavirus disease 2019 (COVID-19) in intensive care unit. <i>Revista Da Associação Médica Brasileira</i> , 2020, 66, 1157-1163.	0.3	2
3139	Arrhythmias in COVID-19: clinical significance and management. <i>Heart Vessels and Transplantation</i> , 0, 4, .	0.0	1
3142	Review of current clinical management guidelines for COVID-19 with special reference to India. <i>Drug Discoveries and Therapeutics</i> , 2020, 14, 171-176.	0.6	4
3143	Comparison of the Clinical Course of COVID-19 Pneumonia and Acute Respiratory Distress Syndrome in 2 Passengers from the Cruise Ship Diamond Princess in February 2020. <i>American Journal of Case Reports</i> , 2020, 21, e926835.	0.3	3
3145	COVID-19 Australia: Epidemiology Report 23. Fortnightly reporting period ending 16 August 2020. <i>Communicable Diseases Intelligence</i> (2018), 2020, 44, .	0.3	4
3146	Diagnóstico da COVID-19: importância dos testes laboratoriais e dos exames de imagem. <i>Research, Society and Development</i> , 2020, 9, e259997162.	0.0	4
3148	Treatment changes of coronavirus infection disease (SARS-COV-2). What general practitioner should know? Part 1. <i>Russian Family Doctor</i> , 2020, 24, 31-38.	0.1	0
3149	Rational pharmacological approach to clinical studies for the treatment of SARS-COV-2 infection. <i>Enfermagem Brasil</i> , 2020, 19, 42.	0.0	0
3150	Revealing Potential Binding Affinity of FDA Approved Therapeutics Targeting Main Protease (3CLpro) in Impairing Novel Coronavirus (SARSCoV- 2) Replication that Causes COVID-19. <i>Coronaviruses</i> , 2020, 1, 98-107.	0.2	4
3151	Epidemiological Predictive Modeling of COVID-19 Infection: Development, Testing, and Implementation on the Population of the Benelux Union. <i>Frontiers in Public Health</i> , 2021, 9, 727274.	1.3	11
3152	SARS-COV-2, infection, transmission, transcription, translation, proteins, and treatment: A review. <i>International Journal of Biological Macromolecules</i> , 2021, 193, 1249-1273.	3.6	19
3153	Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database. <i>Clinical and Translational Science</i> , 2022, 15, 501-513.	1.5	21

#	ARTICLE	IF	CITATIONS
3154	Occurrence, Fate, Effects, and Risks of Dexamethasone: Ecological Implications Post-COVID-19. International Journal of Environmental Research and Public Health, 2021, 18, 11291.	1.2	18
3155	Untapping host-targeting cross-protective efficacy of anticoagulants against SARS-CoV-2. , 2022, 233, 108027.		2
3156	Arrhythmogenic Risk and Mechanisms of QT-Prolonging Drugs to Treat COVID-19. Cardiac Electrophysiology Clinics, 2022, 14, 95-104.	0.7	5
3157	The impact of the hypoxia-induced VEGF-induced vascular permeability on COVID-19-infected patients. Exploration, 2021, 1, 20210051.	5.4	20
3158	Telehealth and Pharmacological Strategies of COVID-19 Prevention: Current and Future Developments. Studies in Systems, Decision and Control, 2022, , 897-927.	0.8	0
3159	Drug-Repositioning Approaches Based on Medical and Life Science Databases. Frontiers in Pharmacology, 2021, 12, 752174.	1.6	8
3160	COVID-19 Drug Repositioning: Present Status and Prospects. Studies in Systems, Decision and Control, 2022, , 645-671.	0.8	1
3161	Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays. Acta Pharmaceutica Sinica B, 2022, 12, 1636-1651.	5.7	55
3162	Immunosuppression for liver transplant recipients during the COVID-19 pandemic. Annals of Liver Transplantation, 2021, , .	0.4	0
3163	Potential inhibitors and plant based technology: An alternative approach to treat corona virus. Bioorganic Chemistry, 2021, 117, 105460.	2.0	2
3164	Robust Statistical Modeling of COVID-19 Prevalence in African Epicentres™. Studies in Systems, Decision and Control, 2022, , 315-358.	0.8	1
3165	Guidelines on the treatment with integrated traditional Chinese medicine and western medicine for severe coronavirus disease 2019. Pharmacological Research, 2021, 174, 105955.	3.1	15
3166	Anesthetic Consideration for Patients with Corona Virus Disease. , 2020, , 99-112.		0
3167	COVID-19 THERAPY: WHAT HAVE WE LEARNED IN 8 MONTHS?. Postepy Mikrobiologii, 2020, 59, 207-225.	0.1	2
3168	COVID-19 in Pregnancy: A Clinical Review. SBV Journal of Basic Clinical and Applied Health Science, 2020, 3, 47-52.	0.2	0
3169	Basic Critical Care for Management of COVID-19 Patients: Position Paper of the Indian Society of Critical Care Medicine, Part II. Indian Journal of Critical Care Medicine, 2020, 24, S254-S262.	0.3	3
3170	Potenciales efectos proarrítmicos de la farmacoterapia contra SARS-CoV-2. , 2020, 31, 199-204.		0
3171	COVID-19 therapy: from myths to reality and hopes. Medical Immunology (Russia), 2020, 22, 827-836.	0.1	0

#	ARTICLE	IF	CITATIONS
3172	COVID-19 in Geriatric Age Group - A Review. <i>Journal of Communicable Diseases</i> , 2020, 52, 81-87.	0.0	0
3174	Available Antiretrovirals in the Treatment and Pre-Exposure Prophylaxis of SARS-CoV-2: Quo Vadis?. <i>Intervirology</i> , 2021, 64, 52-54.	1.2	0
3175	The effects of exercise therapy on the prognosis of patients with COVID-19. <i>Medicine (United States)</i> , 2020, 99, e23762.	0.4	1
3176	CLINICAL FEATURES, DIAGNOSIS AND TREATMENT OF COVID-19. <i>Biological & Clinical Sciences Research Journal</i> , 2020, 2020, .	0.4	7
3177	Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines. <i>Molecular Biomedicine</i> , 2020, 1, 16.	1.7	4
3178	COVID-19 Treatment at a Glance. <i>Turkish Thoracic Journal</i> , 2020, 21, 438-445.	0.2	2
3180	Antiviral Treatment for COVID-19: A Systematic Review. <i>Journal of Pharmaceutical Research International</i> , 0, , 39-51.	1.0	0
3181	COVID-19 Hastalarında Lopinavir/Ritonavir ve Favipravir Deneyimi. <i>Journal of Contemporary Medicine</i> , 2020, 10, 642-646.	0.1	0
3182	COVID-19: A Critical Review on Viral Biochemistry, Environmental Transmission, Therapeutics and Safety Measures. <i>European Journal of Biology and Biotechnology</i> , 2020, 1, .	0.2	0
3183	Potential Antiviral Drug Intervention for Treatment of COVID-19: A Minireview. <i>Avicenna Journal of Pharmaceutical Research</i> , 2020, 1, 87-90.	0.2	1
3184	Predicting severe or critical symptoms in hospitalized patients with COVID-19 from Yichang, China. <i>Aging</i> , 2021, 13, 1608-1619.	1.4	3
3186	A Review on Drug Repurposing: A Strategy to Treat Human Coronavirus Disease (COVID-19). <i>International Journal of Tropical Disease & Health</i> , 0, , 42-54.	0.1	0
3187	RE: "EARLY OUTPATIENT TREATMENT OF SYMPTOMATIC, HIGH-RISK COVID-19 PATIENTS THAT SHOULD BE RAMPED UP IMMEDIATELY AS KEY TO THE PANDEMIC CRISIS". <i>American Journal of Epidemiology</i> , 2021, 190, 1434-1435.	1.6	1
3189	Covid-19: The Biggest Threat of the 21st Century: In Respectful Memory of the Warriors All Over the World. <i>Turkish Thoracic Journal</i> , 2020, 21, 409-418.	0.2	10
3190	Pharmacodynamics of Remdesivir: How to Improve for COVID-19 Treatment. <i>Journal of Biomedical Research & Environmental Sciences</i> , 2020, 1, 431-438.	0.1	2
3191	Role of Kaletra (combination of lopinavir and ritonavir) in the treatment of COVID-19 virus infection; an issue related to kidney transplant patients " A review study on current knowledge. <i>Journal of Preventive Epidemiology</i> , 2020, 5, e28-e28.	0.1	0
3192	COVID-19 and Acute Respiratory Distress Syndrome. Impact of corticosteroid treatment and predictors of poor outcome. <i>Revista Espanola De Quimioterapia</i> , 2021, 34, 33-43.	0.5	8
3193	Vaccines and Treatment of Coronavirus Disease 2019. <i>Korean Journal of Medicine</i> , 2020, 95, 364-369.	0.1	1

#	ARTICLE	IF	CITATIONS
3194	The Novel Coronavirus (nCoV) – A Worldwide Threat. Journal of Infectious Diseases & Case Reports, 0, 1-4.	0.0	0
3195	Study protocol for a multicentre, prospective cohort study of the association of angiotensin II type 1 receptor blockers on outcomes of coronavirus infection. BMJ Open, 2020, 10, e040768.	0.8	7
3197	Strategies for search of pharmacological drugs against SARS-CoV-2 on the base of studying the structural-genetic features of coronaviruses SARS-CoV, MERS-CoV and SARS-CoV-2. Reviews on Clinical Pharmacology and Drug Therapy, 2020, 18, 269-296.	0.2	2
3198	Retrospective analysis of severe COVID-19 pneumonia patients treated with lopinavir/ritonavir: A comparison with survivor and non-survivor patients. Southern African Journal of Infectious Diseases, 2020, 35, 233.	0.3	2
3199	Clinical efficacy of low-dose emetine for patients with COVID-19: a real-world study. Journal of Bio-X Research, 2021, 4, 53-59.	0.3	11
3200	Investigating Side Effects of Existing Drugs Used in Covid-19 Treatment. , 2020, , .		0
3201	Evolution Toward Severe Covid-19 From Biological Monitoring to Therapeutic Considerations. Frontiers in Immunology, 2020, 11, 562038.	2.2	0
3202	Symptomatic and optimal supportive care of critical COVID-19: A case report and literature review. World Journal of Clinical Cases, 2020, 8, 6173-6181.	0.3	1
3203	Major drugs used in COVID-19 treatment: molecular mechanisms, validation and current progress in trials. Coronaviruses, 2020, 01, .	0.2	1
3204	What is in the Myopathy Literature?. Journal of Clinical Neuromuscular Disease, 2020, 22, 77-83.	0.3	2
3205	Clinical Features and Treatment of Coronavirus Disease-19 (Severe Acute Respiratory Syndrome) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 3	0.1	1
3206	Emergency Medicine in the Time of COVID. The University of Louisville Journal of Respiratory Infections, 2020, 4, .	0.2	1
3207	Inflammation and thrombosis in patients with COVID-19: a prothrombotic and inflammatory disease caused by SARS Coronavirus-2. Anatolian Journal of Cardiology, 2020, 24, 224-234.	0.5	22
3208	Coronavirus Could Be a –Chimera–™ of Two Different Viruses. , 2020, 01, .		0
3209	Clinical trials during the COVID-19 pandemic: Challenges of putting scientific and ethical principles into practice. Perspectives in Clinical Research, 2020, 11, 59.	0.5	14
3210	A systematic review of contemporary evidence on SARS-CoV-2 and HIV coinfection: What does it look like up to date?. Avicenna Journal of Medicine, 2020, 10, 189.	0.3	4
3212	Real-world outcomes in thoracic cancer patients with severe Acute respiratory syndrome Coronavirus 2 (COVID-19): Single UK institution experience. Cancer Treatment and Research Communications, 2020, 25, 100261.	0.7	3
3213	Familiar fixes for a modern malady: a discussion on the possible cures of COVID-19. AIMS Molecular Science, 2020, 7, 269-280.	0.3	2

#	ARTICLE	IF	CITATIONS
3214	La pandemia de coronavirus SARS-CoV-2 (COVID-19): situación actual e implicaciones para México. , 2020, 31, 170-177.		7
3215	COVID-19 pandemic: Case studies and perspectives. Side Effects of Drugs Annual, 2020, 42, 291-297.	0.6	2
3216	Rational Drug Usage Suggestion for COVID-19 Patients at Prime Stage. Pharmacy Information, 2020, 09, 181-185.	0.1	0
3220	One product, many patents: Imperfect intellectual property rights in the pharmaceutical industry. SSRN Electronic Journal, 0, , .	0.4	3
3222	Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single Agent. Pharmacology & Pharmacy, 2020, 11, 85-104.	0.2	0
3223	Survival Time, Mortality Rate, and Predicted Deaths for COVID-19 In-Patients in the United Kingdom. SSRN Electronic Journal, 0, , .	0.4	0
3224	Management of COVID-19: A brief overview of the various treatment strategies. Cancer Research Statistics and Treatment, 2020, 3, 233.	0.1	4
3225	Cutaneous Virus Infections. , 2020, , 1-40.		0
3226	Coronavirus disease 2019 (COVID-19)-induced pneumonia in an elderly hemodialysis patient with diabetes. Nihon Toseki Igakkai Zasshi, 2020, 53, 567-572.	0.2	0
3227	Transcriptomic Signatures and Immunomodulatory Treatments for COVID-19 Patients. SSRN Electronic Journal, 0, , .	0.4	0
3228	Pharmacological approaches to the treatment of COVID-19 patients. Journal of Translational Science, 2020, 6, .	0.2	0
3229	Factors Associated with the Duration of Viral Shedding and the Role of Lopinavir/Ritonavir in Patients with COVID-19. Annals of Clinical and Medical Case Reports, 2020, 04, .	0.0	0
3231	Basic Critical Care for Management of COVID-19 Patients: Position Paper of Indian Society of Critical Care Medicine, Part-I. Indian Journal of Critical Care Medicine, 2020, 24, S244-S253.	0.3	5
3232	Impaired T Cell Functions Along with Elevated Activated Tregs at the Early Stage of Asymptomatic SARS-CoV-2 Infection. SSRN Electronic Journal, 0, , .	0.4	3
3233	A Multicenter Questionnaire-Based Study to Know the Awareness and Medical Treatment Plan of Physicians Involved in the Management of COVID-19 Patients. Indian Journal of Critical Care Medicine, 2020, 24, 919-925.	0.3	2
3234	Medikamente gegen COVID-19 (Stand Ende März 2020). Pharma-Kritik (discontinued), 2020, 41, .	0.0	0
3235	Searching an Effective Therapy for the Coronavirus Pandemic: Do We See Light at the End of the Tunnel?. Cureus, 2020, 12, e7415.	0.2	2
3236	Understanding the Mosaic of COVID-19: A Review of the Ongoing Crisis. Cureus, 2020, 12, e7366.	0.2	3

#	ARTICLE	IF	CITATIONS
3237	Current Treatment Options Available for COVID-19 : A Review. Asian Journal of Pharmaceutical Research and Health Care, 2020, 12, 141-147.	0.0	0
3238	Fast reshaping of intensive care unit facilities in a large metropolitan hospital in Milan, Italy: facing the COVID-19 pandemic emergency. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2020, 22, 91-94.	0.0	82
3240	Evidence Based Treatment of SARS-CoV2: A Narrative Review. Turkish Thoracic Journal, 2020, 21, 221-222.	0.2	2
3243	COVID-19 (An International Trauma): A Brief Analysis on Research Trends, Impacts and Solutions. International Journal for Research in Applied Sciences and Biotechnology, 2020, 07, 1-8.	0.2	3
3244	THERAPEUTIC MANAGEMENT OF PATIENTS INFECTED WITH SARS-CoV-2 VIRUS - A REVIEW. Proceedings of CBU in Medicine and Pharmacy, 0, 2, 9-16.	0.0	0
3245	Efficacy and Safety of Sarilumab in COVID-19: A Systematic Review. Interdisciplinary Perspectives on Infectious Diseases, 2021, 2021, 1-8.	0.6	13
3246	Complex Pathophysiological Mechanisms and the Propose of the Three-Dimensional Schedule For Future COVID-19 Treatment. Frontiers in Immunology, 2021, 12, 716940.	2.2	1
3247	Design aspects of COVID-19 treatment trials: Improving probability and time of favorable events. Biometrical Journal, 2021, , .	0.6	6
3248	Association of HIV infection with outcomes among adults hospitalized with COVID-19. Aids, 2022, 36, 391-398.	1.0	21
3249	Emerging importance of nanotechnology-based approaches to control the COVID-19 pandemic; focus on nanomedicine iterance in diagnosis and treatment of COVID-19 patients. Journal of Drug Delivery Science and Technology, 2022, 67, 102967.	1.4	19
3250	Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications. International Journal of Molecular Sciences, 2021, 22, 12081.	1.8	21
3251	Nanotechnology Applications of Flavonoids for Viral Diseases. Pharmaceutics, 2021, 13, 1895.	2.0	24
3252	Drug Interactions for Patients with Respiratory Diseases Receiving COVID-19 Emerged Treatments. International Journal of Environmental Research and Public Health, 2021, 18, 11711.	1.2	10
3253	Potent Anti-SARS-CoV-2 Activity by the Natural Product Gallinamide A and Analogues via Inhibition of Cathepsin L. Journal of Medicinal Chemistry, 2022, 65, 2956-2970.	2.9	46
3255	Phototherapy and optical waveguides for the treatment of infection. Advanced Drug Delivery Reviews, 2021, 179, 114036.	6.6	26
3256	Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial. EClinicalMedicine, 2021, 42, 101188.	3.2	5
3257	COVID-19'İN DA SÄ°TOKÄ°N SALINIM SENDROMU VE TEDAVÄ° YAKLAŞIMLARI. Turkish Journal of Pediatric Disease, 0, , 55-59.	0.0	0
3259	How Did the COVID-19 Outbreak Start and Evolve?. , 2020, , 45-62.		1

#	ARTICLE	IF	CITATIONS
3260	What Is a Coronavirus?. , 2020, , 21-32.		1
3264	Çocuklarda COVID-19 Tedavisi. Turkish Journal of Pediatric Disease, 0, , 9-14.	0.0	0
3265	How Is the Coronavirus Changing?. , 2020, , 33-44.		0
3268	Overview of COVID 19 in Children with the Current Situation in Saudi Arabia. The Egyptian Journal of Hospital Medicine, 2020, 80, 704-714.	0.0	0
3270	Two Cases of COVID-19 Pneumoniai¼šOne Case from the Cruise ship, <i>Diamond Princess</i>, and the Other, A Case of Community Transmission. Journal of the Japanese Association for Infectious Diseases, 2020, 94, 528-534.	0.0	0
3271	COVID-19 Management: What We Need to Know?. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 441-445.	0.1	0
3272	Potential target plants as anti- sars-cov-2 (Coronavirus): Expectations and challenges. Indian Journal of Pharmacy and Pharmacology, 2020, 7, 57-65.	0.1	1
3274	Statistical Issues and Lessons Learned From COVID-19 Clinical Trials With Lopinavir-Ritonavir and Remdesivir. JMIR Public Health and Surveillance, 2020, 6, e19538.	1.2	3
3275	COVID-19: An Update Regarding the Quest for Finding an Effective Cure. Cureus, 2020, 12, e9010.	0.2	0
3276	COVID-19: challenges and opportunities. Clinical and Experimental Emergency Medicine, 2020, 7, 141-143.	0.5	0
3277	El riÃ±n en cuidado intensivo durante la pandemia por SARS-COV-2. Revista Colombiana De NefrologÃa, 2020, 7, 37-38.	0.1	0
3279	Are There Therapeutic Options?. , 2020, , 85-90.		0
3280	How Does the COVID-19 Outbreak Compare to the SARS Outbreak in 2003?. , 2020, , 63-72.		1
3281	COVID-19 Management in India: Medical Aspects, Current Concepts, and Evolving Directions. Annals of the National Academy of Medical Sciences (India), 2020, 56, 197-207.	0.2	0
3283	Caring for patients in a new pandemic: the necessity and challenges of observational research. Journal of Clinical Investigation, 2020, 130, 6225-6227.	3.9	5
3284	Drugs of unproven benefit for COVID-19: a pharma perspective on ethical allocation of available therapies. Journal of Clinical Investigation, 2020, 130, 5622-5623.	3.9	1
3285	An Unexpected Diagnosis of COVID-19 in a Trauma Patient. Phoenix Medical Journal, 0, , .	0.2	0
3286	Implications of COVID-19 for inflammatory bowel disease: Opportunities and challenges amidst the pandemic. World Journal of Meta-analysis, 2020, 8, 383-399.	0.1	0

#	ARTICLE	IF	CITATIONS
3287	COVID-19 Therapeutics: Making Sense of It All. AACN Advanced Critical Care, 2020, 31, 239-249.	0.6	0
3288	What is Efficacy of Chloroquine/Hydroxychloroquine in Clinical Cure of SARS-CoV 2?; Evidence From an Iranian Population. International Journal of Health and Life Sciences, 2020, 7, .	0.5	0
3289	Potential Drugs for Treating COVID-19 Infection. International Journal of Infection, 2020, 7, .	0.4	0
3291	Coronavirus and Homo Sapiens. Journal of Cardiac Critical Care TSS, 0, , .	0.0	0
3294	What are the indications for combined use of hydroxychloroquine and lopinavir/ritonavir, and how should treatment safety monitoring be performed?. Kachestvennaya Klinicheskaya Praktika, 2020, , 47-49.	0.2	1
3302	Comparative effectiveness and safety of antiviral agents for patients with COVID-19: Protocol for a systematic review and individual-patient data network meta-analysis. PLoS ONE, 2020, 15, e0241947.	1.1	6
3303	Diabetes mellitus and COVID-19: current issues of pathogenesis, clinic and therapy. Literature review. Reproductive Endocrinology, 2020, .	0.0	1
3304	Estudios â€œSolidaridadâ€ a la medida de LatinoamÃ©rica. Revista Bionatura, 2020, 5, 1293-1294.	0.1	0
3305	Development of research on COVID-19 by the World Scientific Community in the first half of 2020. Revista Bionatura, 2020, 5, 1410-1417.	0.1	1
3306	Comparison of non-severe COVID-19 pneumonia patients treated with lopinavir/ritonavir and favipiravir. Journal of Surgery and Medicine, 2020, 4, 970-973.	0.0	1
3307	In Silico Drug Repurposing of Penicillins to Target Main Protease M^{pro} of SARS-CoV-2. Pharmaceutical Sciences, 2020, 26, S52-S62.	0.1	3
3308	Investigational Drugs for the COVID 19 Pandemic â€œ A Concise Review. Pharmaceutical Sciences, 2020, 26, S36-S48.	0.1	0
3309	Analysis of Structure, Mechanism of Action and Efficacy of Potential and Ideal COVID-19 Treatments. , 2020, 1, 197-208.		0
3310	In Silico Study of Pacific oyster Antiviral Polypeptides as Potential Inhibitory Compounds for SARS-CoV-2 Main Protease. Jentashapir Journal of Cellular and Molecular Biology, 2020, 11, .	0.1	3
3311	Therapeutic options in the treatment of severe acute respiratory syndrome coronavirus 2 in pregnant patient. American Journal of Obstetrics & Gynecology MFM, 2020, 2, 100224.	1.3	1
3312	The COVID-19 war and the battles of rheumatologists. Beyond Rheumatology, 2020, 2, 41-42.	0.3	0
3313	JAK out of the Box; The Rationale behind Janus Kinase Inhibitors in the COVID-19 setting, and their potential in obese and diabetic populations. Cardiovascular Endocrinology and Metabolism, 2021, 10, 80-88.	0.5	4
3319	Treatments for COVID-19: emerging drugs against the coronavirus. Acta Biomedica, 2020, 91, 118-136.	0.2	18

#	ARTICLE	IF	CITATIONS
3320	Current therapeutic options for coronavirus disease 2019 (COVID-19)â€”lessons learned from severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) therapy: a systematic review protocol. <i>Annals of Translational Medicine</i> , 2020, 8, 1527-1527.	0.7	4
3321	Antiviral therapy in management of COVID-19: a systematic review on current evidence. <i>Archives of Academic Emergency Medicine</i> , 2020, 8, e45.	0.2	33
3322	COVID-19 and Cancer Patients. , 2020, 3, 40-48.		9
3323	Clinical interventions for severe and critical COVID-19: what are the options. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 2110-2117.	0.0	2
3324	What We Learned about COVID-19 So Far? Notes from Underground. <i>Turkish Thoracic Journal</i> , 2020, 21, 185-192.	0.2	2
3325	Towards COVID-19 Prophylaxis: An AIDS Preclinical Research Perspective. <i>Biological and Applied Environmental Research: an Open Access Peer Reviewed Journal</i> , 2020, 5, .	0.1	0
3326	Pharmacological approaches to the treatment of COVID-19 patients. <i>Journal of Translational Science</i> , 2020, 6, .	0.2	0
3327	Retrospective analysis of the effect of current clinical medications and clinicopathological factors on viral shedding in COVID-19 patients. <i>Biomedical Reports</i> , 2020, 13, 68.	0.9	0
3328	Real Clinical Practice and Therapeutic Management Following COVID-19 Crisis in two Hospitals in Iran: A Statistical and Conceptual View. <i>Tanaffos</i> , 2020, 19, 112-121.	0.5	0
3329	NRITLD Protocol for the Management of Patients with COVID-19 Admitted to Hospitals. <i>Tanaffos</i> , 2020, 19, 91-99.	0.5	10
3330	Could dantrolene be explored as a repurposed drug to treat COVID-19 patients by restoring intracellular calcium homeostasis?. <i>European Review for Medical and Pharmacological Sciences</i> , 2020, 24, 10228-10238.	0.5	6
3331	How to overcome cardiovascular challenges in COVID-19 patients: a guide for common practice. <i>Acta Biomedica</i> , 2020, 91, e2020021.	0.2	0
3332	Therapeutic strategies against COVID-19. <i>Acta Biomedica</i> , 2020, 91, e2020038.	0.2	3
3333	Approaches for the Treatment of SARS-CoV-2 Infection: A Pharmacologic View and Literature Review. <i>Iranian Journal of Pharmaceutical Research</i> , 2020, 19, 258-281.	0.3	1
3334	Cardiovascular Complications of COVID-19 and Associated Concerns: A Review. <i>Acta Cardiologica Sinica</i> , 2021, 37, 9-17.	0.1	5
3335	The Pathogenesis and Treatment of COVID-19: A System Review. <i>Biomedical and Environmental Sciences</i> , 2021, 34, 50-60.	0.2	4
3336	Efficacy and safety of sofosbuvir/ ledipasvir in treatment of patients with COVID-19; A randomized clinical trial. <i>Acta Biomedica</i> , 2020, 91, e2020102.	0.2	11
3337	Considerations When Managing Heart Failure during the COVID-19 Pandemic-Consensus from the Taiwan Society of Cardiology. <i>Acta Cardiologica Sinica</i> , 2021, 37, 125-129.	0.1	1

#	ARTICLE	IF	CITATIONS
3338	Medication use during COVID-19: Review of recent evidence. Canadian Family Physician, 2021, 67, 171-179.	0.1	1
3340	The COVID-19 pandemic and the potential treatment of the novel coronavirus SARS-CoV-2. American Journal of Translational Research (discontinued), 2021, 13, 871-881.	0.0	1
3341	Innovative diagnostic approach and investigation trends in COVID19-A systematic review. Journal of Oral and Maxillofacial Pathology, 2020, 24, 421-436.	0.3	1
3342	Coronavirus Disease and Cardiovascular Disease: A Literature Review. Journal of Clinical and Translational Research, 2021, 7, 156-162.	0.3	3
3343	Addressing the global surge of COVID-19 cases: Insights from diagnostics, improved treatment strategies, vaccine development and application. Journal of Clinical and Translational Research, 2021, 7, 127-139.	0.3	1
3344	A Narrative Review of Antiviral Drugs Used for COVID-19 Pharmacotherapy. Journal of Pharmacy and Bioallied Sciences, 2021, 13, 163-171.	0.2	1
3345	identification of natural products from as severe acute respiratory syndromecoronavirus 2 main protease inhibitor. Journal of Advanced Pharmaceutical Technology and Research, 2021, 12, 261-266.	0.4	1
3346	Clinical Evidences and Pathophysiology of Cardiac Arrhythmia in the Era of Coronavirus Disease-2019. Heart Views, 2021, 22, 121-126.	0.1	0
3347	Case fatality rate of COVID-19: a systematic review and meta-analysis. Journal of Preventive Medicine and Hygiene, 2021, 62, E311-E320.	0.9	6
3348	Methodological Development of a Multi-Readout Assay for the Assessment of Antiviral Drugs against SARS-CoV-2. Pathogens, 2021, 10, .	1.2	3
3349	Duration of Supplemental Oxygen Requirement and Predictors in Severe COVID-19 Patients in Ethiopia: A Survival Analysis. Ethiopian Journal of Health Sciences, 2021, 31, 699-708.	0.2	5
3350	Role of environmental factors in transmission of COVID-19. , 2022, , 35-72.		0
3351	Treatment and therapeutic agents. , 2022, , 121-176.		0
3352	CCR5 antagonist treatment inhibits vascular injury by regulating NADPH oxidase 1. Biochemical Pharmacology, 2022, 195, 114859.	2.0	8
3353	The potential of drug delivery nanosystems to treat COVID-19. , 2022, , 307-337.		0
3354	Molecular docking and dynamics studies on propolis sulabiroid-A as a potential inhibitor of SARS-CoV-2. Journal of King Saud University - Science, 2022, 34, 101707.	1.6	28
3355	Socio-economic impact of COVID-19. , 2022, , 153-190.		18
3356	Current Updates on Covid-19 Vaccine Research and an Overview of Therapeutic Drug Research. Biosciences, Biotechnology Research Asia, 2021, 18, 439-457.	0.2	0

#	ARTICLE	IF	CITATIONS
3357	Time-Dependent COVID-19 Mortality in Patients With Cancer. <i>JAMA Oncology</i> , 2022, 8, 114.	3.4	50
3358	The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies. <i>Frontiers in Pharmacology</i> , 2021, 12, 704205.	1.6	89
3359	IgG seroprevalence of COVID-19 among people living with HIV or at high risk of HIV in south-west Germany: A seroprevalence study. <i>HIV Medicine</i> , 2021, , .	1.0	3
3360	Herb-Drug Interaction Between Xiyanning Injection and Lopinavir/Ritonavir, Two Agents Used in COVID-19 Pharmacotherapy. <i>Frontiers in Pharmacology</i> , 2021, 12, 773126.	1.6	7
3361	Learning in times of stress: Lessons from COVID-19 that will last throughout this century. <i>European Journal of Internal Medicine</i> , 2021, , .	1.0	1
3362	SARS-CoV-2: Overview and Its Impact on Oral Health. <i>Biomedicines</i> , 2021, 9, 1690.	1.4	7
3363	Both Baicalein and Gallic acid Effectively Inhibit SARS-CoV-2 Replication by Targeting Mpro and Sepsis in Mice. <i>Inflammation</i> , 2022, 45, 1076-1088.	1.7	23
3364	Acute Respiratory Distress Syndrome: Focus on Viral Origin and Role of Pulmonary Lymphatics. <i>Biomedicines</i> , 2021, 9, 1732.	1.4	1
3365	Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review. <i>International Journal of General Medicine</i> , 2021, Volume 14, 8557-8571.	0.8	33
3366	Roles of host mitochondria in the development of COVID-19 pathology: Could mitochondria be a potential therapeutic target?. <i>Molecular Biomedicine</i> , 2021, 2, 38.	1.7	19
3367	In Silico Evaluation of Different Flavonoids from Medicinal Plants for Their Potency against SARS-CoV-2. <i>Biologics</i> , 2021, 1, 416-434.	2.3	17
3368	Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review. <i>Respiratory Research</i> , 2021, 22, 304.	1.4	7
3369	Pharmacological Treatment Options for Coronavirus Disease-19 in Renal Patients. <i>International Journal of Nephrology</i> , 2021, 2021, 1-9.	0.7	8
3370	Nanovesicles derived from bispecific CAR-T cells targeting the spike protein of SARS-CoV-2 for treating COVID-19. <i>Journal of Nanobiotechnology</i> , 2021, 19, 391.	4.2	17
3371	Clinical and virological impact of single and dual infections with influenza A (H1N1) and SARS-CoV-2 in adult inpatients. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009997.	1.3	24
3372	Impact of Chronic HIV Infection on SARS-CoV-2 Infection, COVID-19 Disease and Vaccines. <i>Current HIV/AIDS Reports</i> , 2022, 19, 5-16.	1.1	9
3373	Unraveling the Molecular Mechanism of Recognition of Human Interferon-Stimulated Gene Product 15 by Coronavirus Papain-Like Proteases: A Multiscale Simulation Study. <i>Journal of Chemical Information and Modeling</i> , 2021, , .	2.5	12
3374	Treatment of SARS-CoV-2 (COVID-19): A safety perspective. <i>World Journal of Pharmacology</i> , 2021, 10, 1-32.	1.3	1

#	ARTICLE	IF	CITATIONS
3375	Harnessing CRISPR-Cas to Combat COVID-19: From Diagnostics to Therapeutics. <i>Life</i> , 2021, 11, 1210.	1.1	10
3376	Mechanisms of COVID-19-induced kidney injury and current pharmacotherapies. <i>Inflammation Research</i> , 2022, 71, 39-56.	1.6	23
3377	Prognostic factors and combined use of tocilizumab and corticosteroids in a Spanish cohort of elderly COVID-19 patients. <i>Journal of Medical Virology</i> , 2022, 94, 1540-1549.	2.5	13
3378	Drug repurposing for COVID-19 using graph neural network and harmonizing multiple evidence. <i>Scientific Reports</i> , 2021, 11, 23179.	1.6	28
3379	Identification of potential inhibitors of SARS-CoV-2 S protein-ACE2 interaction by in silico drug repurposing. <i>F1000Research</i> , 0, 10, 358.	0.8	1
3380	A possible potential COVID-19 drug candidate: Diethyl 2-(2-(2-(3-methyl-2-oxoquinoxalin-1(2H)-yl)acetyl)hydrazono)malonate: Docking of disordered independent molecules of a novel crystal structure, HSA/DFT/XRD and cytotoxicity. <i>Arabian Journal of Chemistry</i> , 2022, 15, 103595.	2.3	17
3381	Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review. <i>Drug Development Research</i> , 2022, 83, 16-54.	1.4	13
3382	Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview. <i>Vaccines</i> , 2021, 9, 1317.	2.1	35
3383	Treatment effect of nafamostat mesylate in patients with COVID-19 pneumonia: study protocol for a randomized controlled trial. <i>Trials</i> , 2021, 22, 832.	0.7	8
3384	Recent Updates in Experimental Research and Clinical Evaluation on Drugs for COVID-19 Treatment. <i>Frontiers in Pharmacology</i> , 2021, 12, 732403.	1.6	13
3385	Coronavirus Disease 2019: Clinics, Treatment, and Prevention. <i>Frontiers in Microbiology</i> , 2021, 12, 761887.	1.5	21
3386	Pregnancy as a Risk Factor of Severe COVID-19. <i>Journal of Clinical Medicine</i> , 2021, 10, 5458.	1.0	28
3387	COVID-19 Pandemic Between Severity Facts and Prophylaxis. <i>Natural Product Communications</i> , 2021, 16, 1934578X2110412.	0.2	1
3388	A Narrative Review of Existing Options for COVID-19-Specific Treatments. <i>Advances in Virology</i> , 2021, 2021, 1-13.	0.5	0
3389	Multimodal Identification by Transcriptomics and Multiscale Bioassays of Active Components in Xuanfeibaidu Formula to Suppress Macrophage-Mediated Immune Response. <i>Engineering</i> , 2023, 20, 63-76.	3.2	10
3390	Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV. <i>Future Microbiology</i> , 2021, 16, 1341-1370.	1.0	25
3391	Role of Flavonoids against COVID-19. <i>The Open Biology Journal</i> , 2021, 9, 47-55.	0.5	0
3392	Identifying SARS-CoV-2 memory NK cells from COVID-19 convalescent donors for adoptive cell therapy. <i>Immunology</i> , 2022, 165, 234-249.	2.0	18

#	ARTICLE	IF	CITATIONS
3393	A multi-centre, randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of chloroquine phosphate, hydroxychloroquine sulphate and lopinavir/ritonavir for the treatment of COVID-19 in Lagos State: study protocol for a randomized controlled trial. <i>Trials</i> , 2021, 22, 869.	0.7	3
3394	Drug-based therapeutic strategies for COVID-19-infected patients and their challenges. <i>Future Microbiology</i> , 2021, 16, 1415-1451.	1.0	12
3395	A Clinical Update on Employing Tocilizumab to Fight COVID-19. , 0, , .		0
3396	Learning for the next pandemic: the Wuhan experience of managing critically ill people. <i>BMJ</i> , The, 2021, 375, e066090.	3.0	4
3397	History of COVID-19 Symptoms and Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Northern France after the First Wave of the Pandemic. <i>Microorganisms</i> , 2021, 9, 2491.	1.6	0
3398	SARS-CoV-2 at the human-animal interface: A review. <i>Heliyon</i> , 2021, 7, e08496.	1.4	9
3399	HIV Diagnosis and the Clinical Course of COVID-19 Among Patients Seeking Care Within the New York City Public Hospital System During the Initial Pandemic Peak. <i>AIDS Patient Care and STDs</i> , 2021, 35, 457-466.	1.1	7
3400	Respiratory Tract Infections: Viruses. , 2021, , .		0
3401	A comparison between virus- versus patients-centred therapeutic attempts to reduce COVID-19 mortality. <i>Emerging Microbes and Infections</i> , 2021, 10, 2256-2263.	3.0	6
3402	Recent Advances on Drugs and Vaccines for COVID-19. <i>Inquiry (United States)</i> , 2021, 58, 004695802110556.	0.5	3
3405	Arrhythmias in COVID-19. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 17, 73-82.	0.5	7
3406	QTc prolongation in patients with COVID-19: a retrospective chart review. <i>Translational and Clinical Pharmacology</i> , 2021, 29, 197.	0.3	2
3407	COVID-19, An early investigation from exposure to treatment outcomes in Tehran, Iran. <i>Journal of Research in Medical Sciences</i> , 2021, 26, 114.	0.4	3
3408	Study of epidemiological, clinical and evolutionary characteristics of a population of patients hospitalized for COVID-19 in Morocco. <i>E3S Web of Conferences</i> , 2021, 319, 01035.	0.2	1
3409	Assessment of novel technologies in healthcare - off-label use of drugs and the ethics of implementation and distribution of COVID-19 vaccines. <i>Einstein (Sao Paulo, Brazil)</i> , 2021, 19, eED6840.	0.3	0
3411	Potential Influence of Parasitic Interactions on COVID-19 Pathology and Epidemiology. , 2021, , 381-399.		0
3412	Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications. <i>Phytomedicine</i> , 2022, 98, 153930.	2.3	25
3413	Post-traumatic Stress Disorder Symptoms and Quality of Life of COVID-19 Survivors at 6-Month Follow-Up: A Cross-Sectional Observational Study. <i>Frontiers in Psychiatry</i> , 2021, 12, 782478.	1.3	11

#	ARTICLE	IF	CITATIONS
3414	Household transmission of SARS-CoV-2 infection in the Paris/Ile-de-France area. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2022, 41, 445-454.	1.3	5
3415	Lead optimization, pharmacophore development and scaffold design of protein kinase CK2 inhibitors as potential COVID-19 therapeutics. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 1811-1827.	2.0	5
3416	Acriflavine, a clinically approved drug, inhibits SARS-CoV-2 and other betacoronaviruses. <i>Cell Chemical Biology</i> , 2022, 29, 774-784.e8.	2.5	34
3417	The Interaction Between Pulmonary Fibrosis and COVID-19 and the Application of Related Anti-Fibrotic Drugs. <i>Frontiers in Pharmacology</i> , 2021, 12, 805535.	1.6	19
3418	Impact of Metabolic Syndrome on Severity of COVID-19 Illness. <i>Metabolic Syndrome and Related Disorders</i> , 2022, 20, 191-198.	0.5	12
3419	Effect of linagliptin plus insulin in comparison to insulin alone on metabolic control and prognosis in hospitalized patients with SARS-CoV-2 infection. <i>Scientific Reports</i> , 2022, 12, 536.	1.6	11
3420	Thermodynamic properties of active pharmaceutical ingredients that are of interest in COVID-19. <i>Chemical Data Collections</i> , 2022, 37, 100820.	1.1	2
3421	COVID-19: Invasion, pathogenesis and possible cure – A review. <i>Journal of Virological Methods</i> , 2022, 300, 114434.	1.0	18
3422	RdRp inhibitors and COVID-19: Is molnupiravir a good option?. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112517.	2.5	49
3423	A critical analysis of SARS-CoV-2 (COVID-19) complexities, emerging variants, and therapeutic interventions and vaccination strategies. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112550.	2.5	26
3424	Pharmaceutical compounds used in the COVID-19 pandemic: A review of their presence in water and treatment techniques for their elimination. <i>Science of the Total Environment</i> , 2022, 814, 152691.	3.9	77
3425	O SARS-CoV-2 e a prãtica odontolãgica. <i>Research, Society and Development</i> , 2020, 9, e751997884.	0.0	0
3426	Preface to the revised and updated edition. , 2020, , vii-ix.		0
3427	Therapeutic Management of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Treatment Algorithm. <i>Journal of Pharmaceutical Research International</i> , 0, , 119-134.	1.0	0
3428	An overview of treatment options for COVID-19. <i>International Journal of Basic and Clinical Pharmacology</i> , 2020, 9, 1770.	0.0	0
3429	Lessons from the COVID-19 Pandemic: Knowledge and Preventive Actions Among a Mexican Population Sample. <i>Archivos De Medicina</i> , 2020, 21, .	0.1	1
3431	Emerging Prophylactic Strategies against COVID-19: A Systematic Literature Review. <i>Pakistan Journal of Surgery and Medicine</i> , 2020, 1, e146.	0.4	0
3433	¿Profilaxis con Cloroquina y/o Hidroxicloroquina para COVID-19?. <i>Investigatio</i> , 2020, 15, 1-10.	0.3	0

#	ARTICLE	IF	CITATIONS
3434	Alvos Moleculares dos Fármacos no Tratamento da COVID-19. Cadernos De Prospecção, 2020, 13, 1251.	0.0	0
3435	Retrospective analysis of the effect of current clinical medications and clinicopathological factors on viral shedding in COVID-19 patients. Biomedical Reports, 2020, 13, 1-1.	0.9	1
3436	Evidencia disponible sobre el abordaje terapéutico de pacientes con COVID-19: una revisión narrativa. Ciencia, Tecnología Y Salud, 2020, 7, 363-380.	0.0	1
3437	Clinical effectiveness and safety of sofosbuvir+velpatasvir as add-on treatment for COVID-19 patients: Study protocol and preliminary data for the randomized controlled trial. Journal of Reports in Pharmaceutical Sciences, 2021, 10, 294.	0.5	0
3438	The effect of temperature on the binding affinity of Remdesivir and RdRp enzyme of SARS-COV-2 virus using steered molecular dynamics simulation. Journal of Control, 2021, 14, 39-47.	0.1	1
3439	Methodological Development of a Multi-Readout Assay for the Assessment of Antiviral Drugs against SARS-CoV-2. Pathogens, 2021, 10, 1076.	1.2	7
3440	SARS-CoV-2: A Professional and social gamechanger - Medical and dental aspects. Brazilian Dental Journal, 2021, 32, 41-54.	0.5	0
3441	Peptide Drug Thymalin Regulates Immune Status in Severe COVID-19 Older Patients. Advances in Gerontology, 2021, 11, 368-376.	0.1	2
3442	Clinical and immunological characteristics of moderate-to-severe forms of COVID-19 at different levels of the tissue damage marker (lactate dehydrogenase). Medical Herald of the South of Russia, 2021, 12, 108-115.	0.2	1
3443	Establishment of a quantitative RT-PCR detection of SARS-CoV-2 virus. European Journal of Medical Research, 2021, 26, 147.	0.9	9
3444	Virtual screening of natural products inspired in-house library to discover potential lead molecules against the SARS-CoV-2 main protease. Journal of Biomolecular Structure and Dynamics, 2023, 41, 2033-2045.	2.0	6
3445	Insights on Epidemiology, Pathogenesis, Diagnosis and Possible Treatment of COVID-19 Infection. Proceedings of the National Academy of Sciences India Section B - Biological Sciences, 2022, , 1-9.	0.4	1
3446	Low Selectivity Indices of Ivermectin and Macrocyclic Lactones on SARS-CoV-2 Replication In Vitro. Covid, 2022, 2, 60-75.	0.7	10
3447	Thiol-based chemical probes exhibit antiviral activity against SARS-CoV-2 via allosteric disulfide disruption in the spike glycoprotein. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	28
3448	Looking at COVID-19 from a Systems Biology Perspective. Biomolecules, 2022, 12, 188.	1.8	1
3449	Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of molnupiravir. Environmental and Molecular Mutagenesis, 2022, 63, 37-63.	0.9	39
3452	COVID-19: Âles thérapeutiques. , 2022, 1, 13-13.		0
3453	Use of glucocorticoids megadoses in SARS-CoV-2 infection in a spanish registry: SEMI-COVID-19. PLoS ONE, 2022, 17, e0261711.	1.1	1

#	ARTICLE	IF	CITATIONS
3454	COVID-19 IN CHILDREN AND ADOLESCENT: CHARACTERISTICS AND SPECIFICITIES IN IMMUNOCOMPETENT AND ONCOHEMATOLOGICAL PATIENTS. Mediterranean Journal of Hematology and Infectious Diseases, 2022, 14, e2022009.	0.5	5
3455	Adverse Effects of COVID-19 Treatments: A Special Focus on Susceptible Populations. Journal of Environmental Pathology, Toxicology and Oncology, 2022, , .	0.6	0
3456	Exposure to valproic acid is associated with less pulmonary infiltrates and improvements in diverse clinical outcomes and laboratory parameters in patients hospitalized with COVID-19. PLoS ONE, 2022, 17, e0262777.	1.1	7
3457	Potential antiviral therapies forÂcoronavirus disease 2019 (COVID-19). , 2022, , 729-748.		0
3458	Practical recommendations for implementing a Bayesian adaptive phase I design during a pandemic. BMC Medical Research Methodology, 2022, 22, 25.	1.4	4
3459	Coronavirus enzyme inhibitors-experimentally proven natural compounds from plants. Journal of Microbiology, 2022, 60, 347-354.	1.3	9
3460	First and second waves among hospitalised patients with COVID-19 with severe pneumonia: a comparison of 28-day mortality over the 1-year pandemic in a tertiary university hospital in Italy. BMJ Open, 2022, 12, e054069.	0.8	13
3461	Characterization of two SARS-CoV-2 subgenomic RNA dynamics in severe COVID-19 patients. Virologica Sinica, 2022, , .	1.2	2
3462	Discovery of compounds inhibiting SARS-COV-2 multi-targets. Journal of Biomolecular Structure and Dynamics, 2023, 41, 2602-2617.	2.0	3
3463	Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality. Clinical Reviews in Allergy and Immunology, 2023, 64, 90-107.	2.9	200
3464	â€“Long Covidâ€™ (post-covid syndrome): Mechanism of occurrence, diagnosis and rehabilitation. Medical Alphabet, 2022, , 20-26.	0.0	2
3465	Toward an optimized strategy of using various airway mucus clearance techniques to treat critically ill COVID-19 patients. Biocell, 2022, 46, 855-871.	0.4	4
3466	Multiple secondary outcome analyses: precise interpretation is important. Trials, 2022, 23, 27.	0.7	13
3467	A new glimpse on the active site of SARS-CoV-2 3CLpro, coupled with drug repurposing study. Molecular Diversity, 2022, 26, 2631-2645.	2.1	3
3468	Kidneys in SARSâ€“CoV â€“2 Era; a challenge of multiple faces. Therapeutic Apheresis and Dialysis, 2022, , .	0.4	2
3469	Analysis of Critical COVID-19 Cases Among Children in Korea. Journal of Korean Medical Science, 2022, 37, e13.	1.1	27
3470	Estimating a continuously varying offset between multivariate time series with application to COVID-19 in the United States. European Physical Journal: Special Topics, 2022, 231, 3419-3426.	1.2	17
3471	A Portrait of SARS-CoV-2 Infection in Patients Undergoing Hematopoietic Cell Transplantation: A Systematic Review of the Literature. Current Oncology, 2022, 29, 337-349.	0.9	15

#	ARTICLE	IF	CITATIONS
3472	Nutraceuticals in HIV and COVID-19-Related Neurological Complications: Opportunity to Use Extracellular Vesicles as Drug Delivery Modality. <i>Biology</i> , 2022, 11, 177.	1.3	5
3473	Less is more in Corona Virus Disease 2019. <i>Journal of Translational Critical Care Medicine</i> , 2022, 4, 3.	0.0	0
3474	Selección de lo mejor del año 2021 en cardiología clínica y COVID-19. REC: <i>CardioClinics</i> , 2022, 57, S17-S22.	0.1	0
3475	Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials. <i>BMC Infectious Diseases</i> , 2022, 22, 107.	1.3	63
3476	COVID-19 Drug Development. <i>Journal of Microbiology and Biotechnology</i> , 2022, 32, 1-5.	0.9	26
3477	A Peek into Pandora's Box: COVID-19 and Neurodegeneration. <i>Brain Sciences</i> , 2022, 12, 190.	1.1	9
3478	Health literacy as a social vaccine in the COVID-19 pandemic. <i>Health Promotion International</i> , 2023, 38, .	0.9	52
3479	Repurposing of <i>Mycobacterium indicus pranii</i> for the severe form of COVID-19 patients in India: A cohort study. <i>Journal of Medical Virology</i> , 2021, . .	2.5	5
3480	In silico Design and Characterization of Multi-epitopes Vaccine for SARS-CoV2 from Its Spike Protein. <i>International Journal of Peptide Research and Therapeutics</i> , 2022, 28, 37.	0.9	2
3481	Elevated D-Dimer levels are strongly associated with High Mortality Rate in COVID-19 patients. An observational Study. <i>Pakistan Biomedical Journal</i> , 2021, 5, .	0.0	0
3482	HIV and COVID-19 in Latin America and the Caribbean. <i>Current HIV/AIDS Reports</i> , 2022, 19, 37-45.	1.1	3
3483	ACE2 can act as the secondary receptor in the FcγR-dependent ADE of SARS-CoV-2 infection. <i>IScience</i> , 2022, 25, 103720.	1.9	21
3484	A case series of myocardial infarction in SARS-CoV-2 infected patients: Same complication, different outcomes. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, e05304.	0.2	2
3485	Identification of potential edible mushroom as SARS-CoV-2 main protease inhibitor using rational drug designing approach. <i>Scientific Reports</i> , 2022, 12, 1503.	1.6	15
3486	Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWN-AZITHRO). <i>ERJ Open Research</i> , 2022, 8, 00610-2021.	1.1	5
3487	A review on covid-19: From molecular variability, drug development to status of vaccine clinical trials. <i>International Journal of Pharma and Bio Sciences</i> , 2022, 12, 55-71.	0.1	0
3488	Efficacy of lopinavir-ritonavir combination therapy for the treatment of hospitalized COVID-19 patients: a meta-analysis. <i>Future Virology</i> , 2022, 17, 169-189.	0.9	13
3489	A Randomized, Single-Blind, Group Sequential, Active-Controlled Study to Evaluate the Clinical Efficacy and Safety of Î±-Lipoic Acid for Critically Ill Patients With Coronavirus Disease 2019 (COVID-19). <i>Frontiers in Medicine</i> , 2021, 8, 566609.	1.2	13

#	ARTICLE	IF	CITATIONS
3490	A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry. <i>Journal of Thoracic Oncology</i> , 2022, 17, 661-674.	0.5	9
3491	HIV and SARS-CoV-2 Co-infection: Epidemiological, Clinical Features, and Future Implications for Clinical Care and Public Health for People Living with HIV (PLWH) and HIV Most-at-Risk Groups. <i>Current HIV/AIDS Reports</i> , 2022, 19, 17-25.	1.1	8
3492	Benefits from Shortening Viral Shedding by Traditional Chinese Medicine Treatment for Moderate COVID-19: An Observational Study. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-10.	0.5	0
3493	The immunomodulatory effects of Qushi Jianpi Hwei Decoction (QJHD) for patients with COVID-19 by metagenomics and transcriptomic sequencing. <i>Pharmacological Research Modern Chinese Medicine</i> , 2022, 2, 100049.	0.5	0
3494	Development of superior antibodies against the S-protein of SARS-Cov-2 using macrocyclic epitopes. <i>Arabian Journal of Chemistry</i> , 2022, 15, 103631.	2.3	1
3495	Bias as a source of inconsistency in ivermectin trials for COVID-19: A systematic review. Ivermectin's suggested benefits are mainly based on potentially biased results. <i>Journal of Clinical Epidemiology</i> , 2022, 144, 43-55.	2.4	19
3496	Comparing the dynamics of COVID-19 infection and mortality in the United States, India, and Brazil. <i>Physica D: Nonlinear Phenomena</i> , 2022, 432, 133158.	1.3	23
3497	Seaweeds as potential source of bioactive compounds with special emphasis on bioprospecting in COVID-19 situation. , 2022, , 455-469.		0
3498	Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. <i>Annals of Medicine</i> , 2022, 54, 524-540.	1.5	225
3499	The "Invisible Enemy" SARS-CoV-2: Viral Spread and Drug Treatment. <i>Medicina (Lithuania)</i> , 2022, 58, 261.	0.8	3
3500	Therapeutics for COVID-19 and post COVID-19 complications: An update. <i>Current Research in Pharmacology and Drug Discovery</i> , 2022, 3, 100086.	1.7	55
3501	Targeting TNF- α for COVID-19: Recent Advanced and Controversies. <i>Frontiers in Public Health</i> , 2022, 10, 833967.	1.3	67
3502	Determinants of persistence of symptoms and impact on physical and mental wellbeing in Long COVID: A prospective cohort study. <i>Journal of Infection</i> , 2022, 84, 566-572.	1.7	49
3503	Add-on inhaled budesonide in the treatment of hospitalised patients with COVID-19: a randomised clinical trial. <i>European Respiratory Journal</i> , 2022, 59, 2103036.	3.1	9
3504	Design of a multi-epitope-based peptide vaccine against the S and N proteins of SARS-COV-2 using immunoinformatics approach. <i>Egyptian Journal of Medical Human Genetics</i> , 2022, 23, .	0.5	9
3505	Attitudes towards influenza, and COVID-19 vaccines during the COVID-19 pandemic among a representative sample of the Jewish Israeli population. <i>PLoS ONE</i> , 2022, 17, e0255495.	1.1	5
3506	HIV and SARS-CoV-2 Co-infection: Epidemiological, Clinical Features, and Future Implications for Clinical Care and Public Health for People Living with HIV (PLWH) and HIV Most-at-Risk Groups. <i>Current HIV/AIDS Reports</i> , 2021, 18, 518-526.	1.1	10
3507	Efficacy and safety of current treatment interventions for patients with severe COVID-19 infection: A network meta-analysis of randomized controlled trials. <i>Journal of Medical Virology</i> , 2022, 94, 1617-1626.	2.5	11

#	ARTICLE	IF	CITATIONS
3508	Therapeutic Options for Coronavirus Disease 2019 (COVID-19): Where Are We Now?. <i>Current Infectious Disease Reports</i> , 2021, 23, 28.	1.3	5
3509	Azvadine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 414.	7.1	91
3510	The impact of therapeutics on mortality in hospitalised patients with COVID-19: systematic review and meta-analyses informing the European Respiratory Society living guideline. <i>European Respiratory Review</i> , 2021, 30, 210171.	3.0	20
3511	Prevalence and predictors of Post-Acute COVID-19 Syndrome (PACS) after hospital discharge: A cohort study with 4 months median follow-up. <i>PLoS ONE</i> , 2021, 16, e0260568.	1.1	52
3515	A Randomized Clinical Trial of Linagliptin vs. Standard of Care in Patients Hospitalized With Diabetes and COVID-19. <i>Frontiers in Endocrinology</i> , 2021, 12, 794382.	1.5	17
3517	An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment. <i>Drug Resistance Updates</i> , 2021, 59, 100794.	6.5	175
3518	Clinical Features, Diagnostic Evaluation, and Management of COVID-19 Patients. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1353, 1-22.	0.8	0
3519	The Molecular Virology of Coronaviruses with Special Reference to SARS-CoV-2. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1352, 15-31.	0.8	3
3520	COVID-19 AND CANCER COMORBIDITY: THERAPEUTIC OPPORTUNITIES AND CHALLENGES (RUSSIAN) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.1	0
3521	Treatment of Myasthenia Gravis Patients with COVID-19: Review of the Literature. <i>Acta Clinica Croatica</i> , 2021, 60, 496-509.	0.1	6
3522	Epidemiology and Etiopathogeny of COVID-19. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1352, 45-71.	0.8	1
3523	Patterns of Otorhinolaryngological Manifestations of Covid-19: A Longitudinal Questionnaire-Based Prospective Study in a Tertiary Hospital in Saudi Arabia. <i>Journal of Primary Care and Community Health</i> , 2022, 13, 215013192210841.	1.0	3
3524	Antiviral cyclic peptides targeting the main protease of SARS-CoV-2. <i>Chemical Science</i> , 2022, 13, 3826-3836.	3.7	29
3525	Educational Impact of #IDJClub, a Twitter-Based Infectious Diseases Journal Club. <i>Clinical Infectious Diseases</i> , 2022, 74, S244-S250.	2.9	7
3526	The Role of Hyaluronic Acid in Tissue Engineering. , 2022, , 1063-1116.		1
3527	Physiologically-based pharmacokinetic modeling of nafamostat to support dose selection for treatment of pediatric patients with COVID-19. <i>Translational and Clinical Pharmacology</i> , 2022, 30, 24.	0.3	3
3528	Current therapeutic choices for coronavirus disease 2019: a state-of-the-art review. , 2022, , 79-93.		0
3529	Drummondin E and Flinderole B are potential inhibitors of RNA-dependent RNA polymerase of SARS-CoV-2: an in silico study. <i>Biotechnologia</i> , 2022, 103, 53-70.	0.3	1

#	ARTICLE	IF	CITATIONS
3531	Dental students and COVID 19: An online multinational survey on perception and knowledge. <i>Annals of African Medicine</i> , 2022, 21, 91.	0.2	1
3532	Inhibition of the main protease of SARS-CoV-2 (Mpro) by repurposing/designing drug-like substances and utilizing nature's toolbox of bioactive compounds. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 1306-1344.	1.9	38
3533	Computer-aided discovery, design, and investigation of COVID-19 therapeutics. <i>Tzu Chi Medical Journal</i> , 2022, .	0.4	3
3534	Clinical features of 162 fatal cases of COVID-19: a multi-center retrospective study. <i>Emergency and Critical Care Medicine</i> , 2022, 2, 109-115.	0.1	1
3535	A comprehensive review of adverse events to drugs used in COVID-19 patients: Recent clinical evidence. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13763.	1.7	5
3536	Appendectomy versus nonoperative management of simple appendicitis: A post hoc analysis of an Eastern Association for the Surgery of Trauma multicenter study using a hierarchical ordinal scale. <i>Journal of Trauma and Acute Care Surgery</i> , 2022, 92, 1031-1038.	1.1	1
3537	Date of introduction and epidemiologic patterns of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Mogadishu, Somalia: estimates from transmission modelling of satellite-based excess mortality data in 2020. <i>Wellcome Open Research</i> , 0, 6, 255.	0.9	0
3538	Targeting the Ubiquitylation and ISGylation Machinery for the Treatment of COVID-19. <i>Biomolecules</i> , 2022, 12, 300.	1.8	11
3539	Guidance for the pharmacological management of COVID-19 in the emergency setting. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 639-642.	0.9	5
3540	A multi-disciplinary rehabilitation approach for people surviving severe COVID-19—a case series and literature review. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 2408-2415.	0.8	4
3541	Osteoarthritis, Corticosteroids and Role of CYP Genes in COVID-19 Patients: A Mini Review. <i>Journal of Pure and Applied Microbiology</i> , 2022, 16, 18-25.	0.3	1
3542	Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies. <i>Frontiers in Pharmacology</i> , 2022, 13, 835136.	1.6	17
3543	SARS-CoV-2: una revisión rápida de algunas de las opciones de tratamiento disponibles.. , 2022, 25, 39-43.		0
3544	The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 57.	7.1	34
3546	Efficacy of repurposed antiviral drugs: Lessons from COVID-19. <i>Drug Discovery Today</i> , 2022, 27, 1954-1960.	3.2	24
3547	Gut bacterial dysbiosis and instability is associated with the onset of complications and mortality in COVID-19. <i>Gut Microbes</i> , 2022, 14, 2031840.	4.3	52
3548	Healthy Immunity on Preventive Medicine for Combating COVID-19. <i>Nutrients</i> , 2022, 14, 1004.	1.7	9
3550	Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture. <i>Communications Biology</i> , 2022, 5, 154.	2.0	40

#	ARTICLE	IF	CITATIONS
3551	Executable network of SARS-CoV-2-host interaction predicts drug combination treatments. <i>Npj Digital Medicine</i> , 2022, 5, 18.	5.7	5
3552	COVID-19 can be called a treatable disease only after we have antivirals. <i>Science Bulletin</i> , 2022, 67, 999-1002.	4.3	5
3553	COVID-19: A systematic review and update on prevention, diagnosis, and treatment. <i>MedComm</i> , 2022, 3, e115.	3.1	30
3555	Mechanism of Action of Small-Molecule Agents in Ongoing Clinical Trials for SARS-CoV-2: A Review. <i>Frontiers in Pharmacology</i> , 2022, 13, 840639.	1.6	17
3556	Molecular Insights of SARS-CoV-2 Antivirals Administration: A Balance between Safety Profiles and Impact on Cardiovascular Phenotypes. <i>Biomedicines</i> , 2022, 10, 437.	1.4	5
3557	Geraniin as a potential inhibitor of SARS-CoV-2 3CL ^{pro} . <i>Natural Product Research</i> , 2022, 36, 6060-6063.	1.0	2
3558	What's new on the management of obstetric patients who tested positive for Covid-19?. <i>Minerva Anestesiologica</i> , 2022, , .	0.6	0
3559	What Should Be Learned From Repurposed Antivirals Against SARS-CoV-2?. <i>Frontiers in Microbiology</i> , 2022, 13, 843587.	1.5	1
3560	Review of Anti-inflammatory and Anti-viral therapeutics for hospitalized patients infected with SARS-CoV-2. <i>Critical Care Clinics</i> , 2022, , .	1.0	3
3561	Nasal Nanovaccines for SARS-CoV-2 to Address COVID-19. <i>Vaccines</i> , 2022, 10, 405.	2.1	14
3562	First and second wave of coronavirus-19 disease: A comparative study in patients hospitalized in an ICU of a third-level university hospital. <i>Medicina Intensiva (English Edition)</i> , 2022, 46, 166-168.	0.1	2
3563	The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors. <i>Frontiers in Public Health</i> , 2022, 10, 816848.	1.3	6
3564	Ribavirin for treating Lassa fever: A systematic review of pre-clinical studies and implications for human dosing. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010289.	1.3	17
3565	Prolonged fecal shedding of SARS-CoV-2 in a young immunocompetent COVID-19 patient: A case report and literature overview. <i>Journal of Medical Virology</i> , 2022, 94, 3133-3137.	2.5	4
3566	Mesenchymal stem/stromal cell therapy for COVID-19 pneumonia: potential mechanisms, current clinical evidence, and future perspectives. <i>Stem Cell Research and Therapy</i> , 2022, 13, 124.	2.4	17
3567	Inhibitory effects of selected isoquinoline alkaloids against main protease (Mpro) of SARS-CoV-2, in silico study. <i>In Silico Pharmacology</i> , 2022, 10, 5.	1.8	8
3568	In silico analysis of SARS-CoV-2 proteins as targets for clinically available drugs. <i>Scientific Reports</i> , 2022, 12, 5320.	1.6	15
3569	A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval. <i>Drug Design, Development and Therapy</i> , 2022, Volume 16, 685-715.	2.0	30

#	ARTICLE	IF	CITATIONS
3570	Impact of Hypogammaglobulinemia on the Course of COVID-19 in a Non-Intensive Care Setting: A Single-Center Retrospective Cohort Study. <i>Frontiers in Immunology</i> , 2022, 13, 842643.	2.2	6
3571	Examining Visfatin As a New Sarcoidosis Biomarker Tanrıverdi et al. Patients with Large-Cell Neuroendocrine Carcinoma Akçakrak et al. Asthma, Preoperative Risk Assessment Erdoğan et al. HIGHLY CITED ARTICLES Chronic Pulmonary Diseases and COVID-19 By: Edis, EC Turkish Thoracic Society Experts Consensus Report: Recommendations for Pulmonary Function Tests During and After COVID-19 Pandemic By: Gemicioglu, B; Borekci, S; Dilektaşlı, AG; et al. <i>Health Hazards and Complications</i> , 2022, 23, 162-172.		2
3572	Functional food: complementary to fight against COVID-19. <i>Beni-Suef University Journal of Basic and Applied Sciences</i> , 2022, 11, 33.	0.8	24
3573	Post-Immune Antibodies in HIV-1 Infection in the Context of Vaccine Development: A Variety of Biological Functions and Catalytic Activities. <i>Vaccines</i> , 2022, 10, 384.	2.1	3
3574	Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study. <i>Reumatologia Clínica (English Edition)</i> , 2022, 18, 150-156.	0.2	12
3575	Clusters of inflammation in COVID-19: descriptive analysis and prognosis on more than 15,000 patients from the Spanish SEMI-COVID-19 Registry. <i>Internal and Emergency Medicine</i> , 2022, 17, 1115-1127.	1.0	4
3576	Clinical profile, risk factors and outcomes of pediatric COVID-19: a retrospective cohort multicentre study in Saudi Arabia. <i>BMJ Open</i> , 2022, 12, e053722.	0.8	6
3577	Beyond $p < .05$: a critical review of new Bayesian proposals for assessing the p -value. <i>Journal of Biopharmaceutical Statistics</i> , 2022, 32, 308-329.	0.4	1
3578	An <i>in silico</i> discovery of potential 3CL protease inhibitors of SARS-CoV-2 based upon inactivation of the cysteine 145-Histidine 41 catalytic dyad. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, , 1-20.	2.0	3
3579	Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19. <i>BMC Infectious Diseases</i> , 2022, 22, 211.	1.3	59
3580	Computed tomography findings and prognosis in older COVID-19 patients. <i>BMC Geriatrics</i> , 2022, 22, 166.	1.1	17
3581	Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody JS016 in Hospitalized Chinese Patients with COVID-19: a Phase 2/3, Multicenter, Randomized, Open-Label, Controlled Trial. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0204521.	1.4	6
3582	Efficacy of early use of remdesivir: a systematic review of subgroup analysis. <i>Revista Espanola De Quimioterapia</i> , 2022, 35, 249-259.	0.5	3
3583	Evaluation of Antibacterial and Antiviral Drug Effectiveness in COVID-19 Therapy: A Data-Driven Retrospective Approach. <i>Pathophysiology</i> , 2022, 29, 92-105.	1.0	1
3584	In Silico Multi-Target Approach Revealed Potential Lead Compounds as Scaffold for the Synthesis of Chemical Analogues Targeting SARS-CoV-2. <i>Biology</i> , 2022, 11, 465.	1.3	2
3585	Computational Repurposing of Drugs and Natural Products Against SARS-CoV-2 Main Protease (Mpro) as Potential COVID-19 Therapies. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 781039.	1.6	7
3586	Impaired Endothelial Function in Convalescent Phase of COVID-19: A 3 Month Follow Up Observational Prospective Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 1774.	1.0	15
3587	Efficacy of pharmacological interventions in COVID-19: A network meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2022, , .	1.1	5

#	ARTICLE	IF	CITATIONS
3588	The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication <i>in Vitro</i> and Decreases Viral Titers and Disease Progression in Syrian Hamsters. <i>MBio</i> , 2022, 13, e0370521.	1.8	22
3589	Pharmacological consideration of COVID-19 infection and vaccines in pregnancy. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 537-542.	0.6	6
3590	Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials. <i>BMJ Open</i> , 2022, 12, e048502.	0.8	28
3591	Therapeutic Strategies for COVID-19 Lung Disease in Children. <i>Frontiers in Pediatrics</i> , 2022, 10, 829521.	0.9	6
3592	On the Test Accuracy and Effective Control of the COVID-19 Pandemic: A Case Study in Singapore. <i>INFORMS Journal on Applied Analytics</i> , 2022, 52, 524-538.	0.7	2
3593	Open-label use of an aliphatic polyamine immunomodulator in patients hospitalized with COVID-19. <i>Drugs in Context</i> , 2022, 11, 1-15.	1.0	0
3594	Current challenges in different approaches to control COVID-19: a comprehensive review. <i>Bulletin of the National Research Centre</i> , 2022, 46, 47.	0.7	4
3595	Potential Resistance of SARS-CoV-2 Main Protease (Mpro) against Protease Inhibitors: Lessons Learned from HIV-1 Protease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3507.	1.8	45
3596	Prognosis and treatment of complications associated with COVID-19: a systematic review and meta-analysis. , 2022, 1, .		7
3597	Care of the Hepatology Patient in the COVID-19 Era. <i>Current Hepatology Reports</i> , 2022, , 1-12.	0.4	2
3598	Rheumatic Symptoms Following Coronavirus Disease 2019 (COVID-19): A Chronic Postâ€“COVID-19 Condition. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	7
3599	High-cited favorable studies for COVID-19 treatments ineffective in large trials. <i>Journal of Clinical Epidemiology</i> , 2022, 148, 1-9.	2.4	4
3600	Overview of clinical outcome and therapeutic effectiveness of Favipiravir in patients with COVID-19 admitted to intensive care unit, Riyadh, Saudi Arabia. <i>Journal of Infection and Public Health</i> , 2022, 15, 389-394.	1.9	6
3601	Convalescent plasma therapy in patients with severe COVID-19, A single-arm, retrospective study. <i>Microbial Pathogenesis</i> , 2022, 165, 105482.	1.3	1
3602	Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 834942.	2.2	10
3603	Bioinformaticians: the hidden heroes of the COVID-19 pandemic. <i>BioTechniques</i> , 2022, 72, 171-174.	0.8	1
3604	Molecular insights to the binding interactions of APNS containing HIV-protease inhibitors against SARS-CoV-2 M ^{pro} : an <i>in silico</i> approach towards drug repurposing. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 3900-3913.	2.0	2
3605	COVID-19 Clinical Presentation Among HIV-Infected Persons in China: A Systematic Review. <i>Current HIV/AIDS Reports</i> , 2022, 19, 167-176.	1.1	5

#	ARTICLE	IF	CITATIONS
3606	PREDICTING MORTALITY OF COVID PATIENTS WITH COMORBIDITIES (Review Article). Ek'sperimentuli Da Klinikuri Medic'ina, 0, , .	0.0	0
3607	Molnupiravir and Its Antiviral Activity Against COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 855496.	2.2	81
3608	Antiviral Used among Non-Severe COVID-19 Cases in Relation to Time till Viral Clearance: A Retrospective Cohort Study. <i>Antibiotics</i> , 2022, 11, 498.	1.5	3
3609	TREATMENT PROFILE AND SURVIVAL ANALYSIS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) COVID-19 PATIENTS. <i>International Journal of Applied Pharmaceutics</i> , 0, , 54-56.	0.3	6
3610	Production of carrier/antioxidant particles by Supercritical Assisted Atomization as an adjuvant treatment of the CoVID-19 pathology. <i>Journal of Supercritical Fluids</i> , 2022, 186, 105604.	1.6	5
3611	Trial of Early Antiviral Therapies during Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19: a summary of the protocol and analysis plan for a decentralized randomized controlled trial. <i>Trials</i> , 2022, 23, 273.	0.7	4
3612	Jumping from Fragment to Drug via Smart Scaffolds. <i>ChemMedChem</i> , 2022, 17, .	1.6	5
3613	A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors. <i>Antiviral Research</i> , 2022, 201, 105272.	1.9	9
3614	COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?. <i>Pharmacological Research</i> , 2022, 179, 106201.	3.1	23
3615	HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect. <i>Antiviral Research</i> , 2022, 202, 105311.	1.9	8
3616	The Role of Molecular Modeling and Bioinformatics in Treating a Pandemic Disease: The Case of COVID-19. <i>The Open Covid Journal</i> , 2021, 1, 216-234.	0.4	1
3617	Interplay of Nutrition and Psychoneuroendocrineimmune Modulation: Relevance for COVID-19 in BRICS Nations. <i>Frontiers in Microbiology</i> , 2021, 12, 769884.	1.5	3
3618	The protective role of vitamin C in the management of COVID-19: A Review. <i>Journal of the Egyptian Public Health Association</i> , The, 2021, 96, 33.	1.0	10
3619	Mortality Predictors in Severe COVID-19 Patients from an East European Tertiary Center: A Never-Ending Challenge for a No Happy Ending Pandemic. <i>Journal of Clinical Medicine</i> , 2022, 11, 58.	1.0	15
3620	Gastrointestinal and hepatic side effects of potential treatment for COVID-19 and vaccination in patients with chronic liver diseases. <i>World Journal of Hepatology</i> , 2021, 13, 1850-1874.	0.8	10
3621	Effect of Chloroquine and Hydroxychloroquine on Cytokine Release Syndrome in Patients with COVID-19. <i>Clinical Medicine and Research</i> , 2021, 19, 179-182.	0.4	1
3622	Pediatrics Infected with COVID-19: A Case Series Study on Pediatrics Hospitalized in a Referral Pediatric Hospital. <i>International Journal of Pediatrics (United Kingdom)</i> , 2021, 2021, 1-8.	0.2	1
3623	Molecular Evolution of Severe Acute Respiratory Syndrome Coronavirus 2: Hazardous and More Hazardous Strains Behind the Coronavirus Disease 2019 Pandemic and Their Targeting by Drugs and Vaccines. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 763687.	1.8	3

#	ARTICLE	IF	CITATIONS
3624	A sequential test to compare the real-time fatality rates of a disease among multiple groups with an application to COVID-19 data. <i>Statistical Methods in Medical Research</i> , 2022, 31, 348-360.	0.7	2
3625	Tratamiento farmacológico en pacientes con COVID-19: una revisión integradora. <i>Sanus</i> , 0, 6, e250.	0.3	1
3626	Drug repurposing and other strategies for rapid coronavirus antiviral development: lessons from the early stage of the COVID-19 pandemic. , 2021, , 39-68.		0
3627	A computational biology approach for the identification of potential SARS-CoV-2 main protease inhibitors from natural essential oil compounds.. <i>F1000Research</i> , 0, 10, 1313.	0.8	1
3628	Clinical trials during the COVID-19 pandemic: research design and lessons. , 2021, , 214-231.		0
3629	Treatment of patients with Covid-19 with a high dose of ulinastatin. <i>Experimental and Therapeutic Medicine</i> , 2021, 23, 121.	0.8	6
3630	Comparison of Clinical Findings in SARS-CoV-2 with Other Respiratory Viruses in Critically Ill Children during the COVID-19 Pandemic. <i>Journal of Tropical Pediatrics</i> , 2021, 67, .	0.7	0
3631	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2 "care pathways, treatment, and follow-up. <i>Cardiovascular Research</i> , 2022, 118, 1618-1666.	1.8	32
3632	COVID-19: management in the ICU. , 2021, , 124-143.		2
3633	Computational modeling of human-nCoV protein-protein interaction network. <i>Methods</i> , 2022, 203, 488-497.	1.9	5
3634	Development of post-COVID-19 cardiovascular events: an analysis of clinical features and risk factors from a single hospital retrospective study. <i>Infezioni in Medicina</i> , 2021, 29, 538-549.	0.7	3
3635	Current strategies in diagnostics and therapeutics against novel coronavirus disease (COVID-19). <i>Acta Pharmaceutica</i> , 2022, 72, 171-197.	0.9	2
3636	Ribavirin Treatment for Critically Ill COVID-19 Patients: An Observational Study. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 5287-5291.	1.1	9
3637	Chitosan Nanoparticles for Antiviral Drug Delivery: A Novel Route for COVID-19 Treatment. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 8141-8158.	3.3	12
3638	Recent Advancements on COVID-19: A Comprehensive Review. <i>International Journal of General Medicine</i> , 2021, Volume 14, 10351-10372.	0.8	7
3639	COVID-19 in renal transplant recipients and general population: a comparative study of clinical, laboratory, and radiological features, severity, and outcome. <i>Virology Journal</i> , 2021, 18, 243.	1.4	10
3640	Drug repurposing strategies and key challenges for COVID-19 management. <i>Journal of Drug Targeting</i> , 2022, 30, 413-429.	2.1	13
3641	Nanoscience versus Viruses: The SARS-CoV-2 Case. <i>Advanced Functional Materials</i> , 2022, 32, 2107826.	7.8	8

#	ARTICLE	IF	CITATIONS
3642	Liaison Psychiatry During the Peak of the Coronavirus Pandemic: A Description of Referrals and Interventions. <i>Frontiers in Psychiatry</i> , 2021, 12, 555080.	1.3	3
3643	Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection. <i>Infection</i> , 2022, 50, 295-308.	2.3	19
3645	Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management. <i>Pneumonia (Nathan Qld)</i> , 2021, 13, 14.	2.5	67
3647	The Novel Coronavirus 2019 Epidemic and the Kidneys. <i>Journal of Renal and Hepatic Disorders</i> , 2020, 4, 11-20.	0.1	0
3648	COVID-19: The question of genetic diversity and therapeutic intervention approaches. <i>Genetics and Molecular Biology</i> , 2021, 44, e20200452.	0.6	1
3649	COVID-19 Treatment Options and Their Mechanism of Action up to Now: An Overview of Clinical Trials. <i>Journal of Advances in Medical and Biomedical Research</i> , 2022, 30, 75-85.	0.1	1
3650	Slower Recovery with Early Lopinavir/Ritonavir use in Pediatric COVID-19 Patients: A Retrospective Observational Study. <i>Paediatric Drugs</i> , 2022, 24, 269.	1.3	3
3651	Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	6
3652	Identification of Compounds With Antiviral Activity Against SARS-CoV-2 in the MMV Pathogen Box Using a Phenotypic High-Throughput Screening Assay. <i>Frontiers in Virology</i> , 2022, 2, .	0.7	6
3653	Development of COVID-19 Health-Risk Assessment and Self-Evaluation (CHaSe): a health screening system for university students and staff during the movement control order (MCO). <i>Network Modeling Analysis in Health Informatics and Bioinformatics</i> , 2022, 11, 21.	1.2	2
3654	Evaluation of the Potential Impact of Medical Ozone Therapy on Covid-19: A Review Study. <i>Ozone: Science and Engineering</i> , 2023, 45, 213-231.	1.4	8
3655	Assessment of Awake Prone Positioning in Hospitalized Adults With COVID-19. <i>JAMA Internal Medicine</i> , 2022, 182, 612.	2.6	47
3656	Global Gene Expression and Docking Profiling of COVID-19 Infection. <i>Frontiers in Genetics</i> , 2022, 13, 870836.	1.1	9
3657	Bedside Peripheral Ultrasound-Guided Vascular Access in 253 Patients Hospitalized With COVID-19 Pneumonia: A Retrospective Italian Study. <i>Cureus</i> , 2022, 14, e24157.	0.2	0
3658	Discriminant models for the prediction of postponed viral shedding time and disease progression in COVID-19. <i>BMC Infectious Diseases</i> , 2022, 22, 366.	1.3	1
3659	Favipiravir in SARS-CoV-2 Infection: Is it Worth it?. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2022, 25, 2413-2428.	0.6	7
3661	Clinical progress of therapeutics and vaccines: Rising hope against COVID-19 treatment. <i>Process Biochemistry</i> , 2022, 118, 154-170.	1.8	4
3662	Unethical studies of ivermectin for covid-19. <i>BMJ, The</i> , 2022, 377, o917.	3.0	9

#	ARTICLE	IF	CITATIONS
3663	Predictive factors of six-week mortality in critically ill patients with SARS-CoV-2: A multicenter prospective study. <i>Medicina Intensiva (English Edition)</i> , 2022, 46, 179-191.	0.1	3
3664	Flavonols and dihydroflavonols inhibit the main protease activity of SARS-CoV-2 and the replication of human coronavirus 229E. <i>Virology</i> , 2022, 571, 21-33.	1.1	24
3700	Clinical management of COVID-19 in hospitals and the community: A snapshot from a medical insurance database in South Africa. <i>International Journal of Infectious Diseases</i> , 2022, 120, 170-173.	1.5	1
3701	Liver, NAFLD and COVID-19. <i>Hormone and Metabolic Research</i> , 2022, 54, 522-531.	0.7	11
3702	Evaluation of phytoconstituents of <i>Tinospora cordifolia</i> against K417N and N501Y mutant spike glycoprotein and main protease of SARS-CoV-2- an in silico study. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 4106-4123.	2.0	1
3703	Nanovectorization of Ivermectin to avoid overdose of drugs. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 4272-4285.	2.0	0
3706	Clinical characteristics of 71 patients with coronavirus disease 2019. <i>Journal of Central South University (Medical Sciences)</i> , 2020, 45, 790-796.	0.1	4
3707	A threefold approach including quantum chemical, molecular docking and molecular dynamic studies to explore the natural compounds from <i>Centaurea jacea</i> as the potential inhibitors for COVID-19. <i>Brazilian Journal of Biology</i> , 2021, 83, e247604.	0.4	3
3709	Anti-inflammatory Effect of Metronidazole in Hospitalized Patients with Pneumonia due to COVID-19.. <i>Iranian Journal of Pharmaceutical Research</i> , 2021, 20, 532-540.	0.3	1
3710	Comparison of the Efficacy and Safety of Atazanavir/Ritonavir Plus Hydroxychloroquine with Lopinavir/Ritonavir Plus Hydroxychloroquine in Patients with Moderate COVID-19, A Randomized, Double-blind Clinical Trial.. <i>Iranian Journal of Pharmaceutical Research</i> , 2021, 20, 278-288.	0.3	1
3713	SARS-COV-2 – the pandemic of the XXI century, clinical manifestations – neurological implications. <i>Journal of Medicine and Life</i> , 2022, 15, 319-327.	0.4	2
3714	Antiviral and anti-inflammatory drugs to combat COVID-19: Effects on cardiac ion channels and risk of ventricular arrhythmias.. <i>BiolImpacts</i> , 2022, 12, 9-20.	0.7	4
3716	The Effectiveness of Antiviral Treatment in Severe COVID-19 Patients in Wuhan, China: A Multicenter Study.. <i>Biomedical and Environmental Sciences</i> , 2022, 35, 58-63.	0.2	0
3717	Clinical evidences and pathophysiology of cardiac arrhythmia in the era of Coronavirus Disease-2019. <i>Heart Views</i> , 2021, 22, 121.	0.1	0
3719	Innovative diagnostic approach and investigation trends in COVID19-A systematic review. <i>Journal of Oral and Maxillofacial Pathology</i> , 2020, 24, 421.	0.3	2
3720	A narrative review of antiviral drugs used for COVID-19 pharmacotherapy. <i>Journal of Pharmacy and Bioallied Sciences</i> , 2021, 13, 163.	0.2	3
3722	Medication use during COVID-19. <i>Canadian Family Physician</i> , 2021, 67, 171-179.	0.1	6
3723	Médicaments utilisés durant la COVID-19. <i>Canadian Family Physician</i> , 2021, 67, e69-e78.	0.1	0

#	ARTICLE	IF	CITATIONS
3724	What We Learned about COVID-19 So Far? Notes from Underground. , 2023, 21, 185-192.		3
3727	Mesenchymal stem cell therapy for COVID-19.. American Journal of Stem Cells, 2021, 10, 79-89.	0.4	0
3728	Activated neutrophils in the initiation and progression of COVID-19: hyperinflammation and immunothrombosis in COVID-19.. American Journal of Translational Research (discontinued), 2022, 14, 1454-1468.	0.0	0
3730	Validation of Machine Learning Models to Predict Adverse Outcomes in Patients with COVID-19: A Prospective Pilot Study. Yonsei Medical Journal, 2022, 63, 422.	0.9	3
3731	Dynamic response landscape of immune cells identified immune dysfunction which predicts disease progression in COVID-19 infected patients. International Journal of Biological Sciences, 2022, 18, 3066-3081.	2.6	1
3732	Epidemiology and Clinical Characteristics of People with Confirmed SARS-CoV-2 Infection during the Early COVID-19 Pandemic in Saudi Arabia. Medicines (Basel, Switzerland), 2022, 9, 32.	0.7	1
3733	Effects of Drugs Formerly Proposed for COVID-19 Treatment on Connexin43 Hemichannels. International Journal of Molecular Sciences, 2022, 23, 5018.	1.8	1
3734	Overview of Drug Therapy of COVID-19 with Safety and the Potential Clinical Benefits. Current Drug Therapy, 2022, 17, .	0.2	0
3735	Finding a chink in the armor: Update, limitations, and challenges toward successful antivirals against flaviviruses. PLoS Neglected Tropical Diseases, 2022, 16, e0010291.	1.3	11
3736	The Cytokine Storm in COVID-19: The Strongest Link to Morbidity and Mortality in the Current Epidemic. Covid, 2022, 2, 540-552.	0.7	12
3737	2020 vision? A retrospective study of time-bound curative claims in British and Irish newspapers. British Journal of General Practice, 2022, 72, 213-214.	0.7	0
3738	Metabolomic Profiling of Plasma Reveals Differential Disease Severity Markers in COVID-19 Patients. Frontiers in Microbiology, 2022, 13, 844283.	1.5	15
3739	Risk of SARS-CoV-2 Infection Among People Living With HIV in Wuhan, China. Frontiers in Public Health, 2022, 10, 833783.	1.3	5
3740	Design, Synthesis and Evaluation of Fused Bicyclo[2.2.2]octene as a Potential Core Scaffold for the Non-Covalent Inhibitors of SARS-CoV-2 3CLpro Main Protease. Pharmaceuticals, 2022, 15, 539.	1.7	6
3741	Efficacy and Safety of Blood Derivative Therapy for Patients with COVID-19: A Systematic Review and Meta-Analysis. Transfusion Medicine and Hemotherapy, 2022, 49, 388-400.	0.7	3
3742	A Phase II Study on the Effect of Taurisolo® Administered via AEROSol in Hospitalized Patients with Mild to Moderate COVID-19 Pneumonia: The TAEROVID-19 Study. Cells, 2022, 11, 1499.	1.8	6
3743	COVID-19 and liver diseases, what we know so far. World Journal of Clinical Cases, 2022, 10, 3969-3980.	0.3	12
3744	Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): A multicenter observational study. PLoS ONE, 2022, 17, e0267884.	1.1	7

#	ARTICLE	IF	CITATIONS
3745	Treatment strategies of Covid-19. A rheumatology perspective.. European Journal of Internal Medicine, 2022, , .	1.0	3
3746	Neuropsychological Measures of Long COVID-19 Fog in Older Subjects. Clinics in Geriatric Medicine, 2022, 38, 593-603.	1.0	7
3747	Repurposing of FDA Approved Drugs Against SARS-CoV-2 Papain-Like Protease: Computational, Biochemical, and in vitro Studies. Frontiers in Microbiology, 2022, 13, .	1.5	7
3748	Phenols in Pharmaceuticals: Analysis of a Recurring Motif. Journal of Medicinal Chemistry, 2022, 65, 7044-7072.	2.9	53
3749	Molecular determinants, clinical manifestations and effects of immunization on cardiovascular health during COVID-19 pandemic era - A review. Current Problems in Cardiology, 2022, , 101250.	1.1	3
3750	Use of combined treatment of 3rd-generation cephalosporin, azithromycin and antiviral agents on moderate SARs-CoV-2 patients in South Korea: A retrospective cohort study. PLoS ONE, 2022, 17, e0267645.	1.1	2
3751	Sofosbuvir/ledipasvir in combination or nitazoxanide alone are safe and efficient treatments for COVID-19 infection: A randomized controlled trial for repurposing antivirals. Arab Journal of Gastroenterology, 2022, 23, 165-171.	0.4	9
3752	The Evolutionary Dance between Innate Host Antiviral Pathways and SARS-CoV-2. Pathogens, 2022, 11, 538.	1.2	4
3753	Diretrizes Brasileiras para o tratamento farmacolÃ³gico de pacientes hospitalizados com COVID-19. Jornal Brasileiro De Medicina De EmergÃªncia, 2022, 2, e22006.	0.0	1
3754	Therapeutic approaches and vaccination in fighting COVID-19 infections: A review. Gene Reports, 2022, 27, 101619.	0.4	3
3755	Artificial intelligence approach toward analysis of COVID-19 developmentâ€™Personalized and epidemiological model. , 2022, , 237-269.		0
3756	Remdesivir plus Dexamethasone in COVID-19: A cohort study of severe patients requiring high flow oxygen therapy or non-invasive ventilation. PLoS ONE, 2022, 17, e0267038.	1.1	4
3757	Effect of Qingfei Paidu decoction combined with Western medicine treatments for COVID-19: A systematic review and meta-analysis. Phytomedicine, 2022, 102, 154166.	2.3	10
3759	Comparison of standard prophylactic, intermediate prophylactic and therapeutic anticoagulation in patients with severe COVID-19: protocol for the ANTICOVID multicentre, parallel-group, open-label, randomised controlled trial. BMJ Open, 2022, 12, e059383.	0.8	3
3760	Risk of mortality in HIV-infected COVID-19 patients: A systematic review and meta-analysis. Journal of Infection and Public Health, 2022, 15, 654-661.	1.9	12
3761	The Effects of the SARS-CoV-2 Virus on the Cardiovascular System and Coagulation State Leading to Cardiovascular Diseases: A Narrative Review. Inquiry (United States), 2022, 59, 004695802210934.	0.5	3
3762	Drugs repurposing for SARS-CoV-2: new insight of COVID-19 druggability. Expert Review of Anti-Infective Therapy, 2022, 20, 1187-1204.	2.0	1
3763	Prospective Medicinal Plants and Their Phytochemicals Shielding Autoimmune and Cancer Patients Against the SARS-CoV-2 Pandemic: A Special Focus on Matcha. Frontiers in Oncology, 2022, 12, .	1.3	5

#	ARTICLE	IF	CITATIONS
3764	Effects of Drugs Formerly Suggested for COVID-19 Repurposing on Pannexin1 Channels. International Journal of Molecular Sciences, 2022, 23, 5664.	1.8	1
3765	Puerarin: A Potential Therapeutic for SARS-CoV-2 and Hantavirus Co-Infection. Frontiers in Immunology, 2022, 13, .	2.2	2
3766	Macroalgae Bioactive Compounds for the Potential Antiviral of SARS-CoV-2: An In Silico Study. Journal of Pure and Applied Microbiology, 2022, 16, 1018-1027.	0.3	11
3767	Nanomedicine to deliver biological macromolecules for treating COVID-19. Vaccine, 2022, 40, 3931-3941.	1.7	9
3768	Reinforcement of the Standard Therapy with Two Infusions of Convalescent Plasma for Patients with COVID-19: A Randomized Clinical Trial. Journal of Clinical Medicine, 2022, 11, 3039.	1.0	4
3769	Cutaneous adverse reactions to the new oral antiviral drugs against SARS-CoV-2. Clinical and Experimental Dermatology, 2022, 47, 1738-1740.	0.6	4
3770	Learning for the next pandemic: when high level evidence is not readily available.... Journal of Thoracic Disease, 2022, 14, 1738-1743.	0.6	0
3771	Influence of statin treatment in a cohort of patients admitted for COVID-19. Medicina Clínica (English) Tj ETQq1 1 0,784314,rgBT /Ove 0.1 2	0.1	2
3772	Repurposing of antiviral drugs for COVID-19 and impact of repurposed drugs on the nervous system. Microbial Pathogenesis, 2022, 168, 105608.	1.3	9
3775	Drug combination therapies for SARS-CoV-2 (COVID-19) treatment. , 2022, , 181-203.		0
3776	Therapeutic options in coronavirus treatment. , 2022, , 101-135.		0
3777	Current therapeutic strategies to combat coronavirus disease 2019. , 2022, , 137-151.		0
3778	Understanding COVID-19 Situation in Nepal and Implications for SARS-CoV-2 Transmission and Management. Environmental Health Insights, 2022, 16, 117863022211043.	0.6	2
3779	FDA Coronavirus Treatment Acceleration Program: approved drugs and those in clinical trials. , 2022, , 249-264.		2
3780	Outcomes of 2111 COVID-19 Hospitalized Patients Treated with Hydroxychloroquine/Azithromycin and Other Regimens in Marseille, France, 2020: A Monocentric Retrospective Analysis. Therapeutics and Clinical Risk Management, 0, Volume 18, 603-617.	0.9	5
3781	High-dose versus standard-dose vitamin D supplementation in older adults with COVID-19 (COVIT-TRIAL): A multicenter, open-label, randomized controlled superiority trial. PLoS Medicine, 2022, 19, e1003999.	3.9	46
3782	Early outcomes in adults hospitalized with severe SARS-CoV-2 infection receiving tocilizumab. Medicina Clínica (English Edition), 2022, 158, 509-518.	0.1	0
3783	Calibration and Validation of a Mechanistic COVID-19 Model for Translational Quantitative Systems Pharmacology - A Proof-of-Concept Model Development for Remdesivir. Clinical Pharmacology and Therapeutics, 2022, 112, 882-891.	2.3	1

#	ARTICLE	IF	CITATIONS
3784	The impact of SARS-CoV-2 treatment on the cardiovascular system: an updated review. <i>Inflammopharmacology</i> , 2022, 30, 1143-1151.	1.9	4
3785	Identifying enhancers of innate immune signaling as broad-spectrum antivirals active against emerging viruses. <i>Cell Chemical Biology</i> , 2022, 29, 1113-1125.e6.	2.5	10
3786	Long-lasting adaptive immune memory specific to SARS-CoV-2 in convalescent coronavirus disease 2019 stable people with HIV. <i>Aids</i> , 2022, 36, 1373-1382.	1.0	6
3787	SARS-CoV-2 and Therapeutic Approaches. <i>The Open Covid Journal</i> , 2022, 2, .	0.4	0
3788	Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment. <i>Journal of Pharmaceutical Sciences</i> , 2022, 111, 2652-2661.	1.6	15
3790	Venetoclax Decreases the Expression of the Spike Protein through Amino Acids Q493 and S494 in SARS-CoV-2. <i>Cells</i> , 2022, 11, 1924.	1.8	2
3791	Infections in lung transplanted patients: A review. <i>Pulmonology</i> , 2022, , .	1.0	6
3792	Coronaviral Infection and Interferon Response: The Virus-Host Arms Race and COVID-19. <i>Viruses</i> , 2022, 14, 1349.	1.5	7
3793	Lessons from SARS-CoV-2 and its variants (Review). <i>Molecular Medicine Reports</i> , 2022, 26, .	1.1	5
3794	Herbal Medicine Intervention for the Treatment of COVID-19: A Living Systematic Review and Cumulative Meta-Analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	8
3795	A computational biology approach for the identification of potential SARS-CoV-2 main protease inhibitors from natural essential oil compounds.. <i>F1000Research</i> , 0, 10, 1313.	0.8	2
3796	The Efficiency of Convalescent Plasma Therapy in the Management of Critically Ill Patients Infected With COVID-19: A Matched Cohort Study. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
3797	Strategies to fight COVID-19: Beyond the difference between SARS-CoV-2 and Influenza virus. <i>International Journal of Sexual and Reproductive Health Care</i> , 2022, 5, 016-029.	0.1	0
3798	Discovery of Triple Inhibitors of Both SARS-CoV-2 Proteases and Human Cathepsin L. <i>Pharmaceuticals</i> , 2022, 15, 744.	1.7	5
3800	Applications of nanoengineered therapeutics and vaccines: special emphasis on COVID-19. , 2022, , 21-63.		0
3801	Bionanomaterials for diagnosis and therapy of SARS-CoV-2. , 2022, , 469-489.		0
3802	Diretrizes Brasileiras para o tratamento farmacológico de pacientes hospitalizados com COVID-19. <i>Revista Brasileira De Terapia Intensiva</i> , 2022, 34, .	0.1	2
3803	Lung-Function Trajectories in COVID-19 Survivors after Discharge: A Two-Year Longitudinal Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
3804	Interaction between Sars-CoV-2 structural proteins and host cellular receptors: From basic mechanisms to clinical perspectives. <i>Advances in Protein Chemistry and Structural Biology</i> , 2022, , 243-277.	1.0	4
3805	COVID-19 Vaccination Outcomes and Antibiotic Crisis and Overuse During the COVID-19 Pandemic in Bosnia and Herzegovina. <i>Materia Socio-medica</i> , 2022, 34, 112.	0.3	0
3806	The Spectrum of Post-COVID Neurological Syndrome: A Prospective Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
3807	Databases, DrugBank, and virtual screening platforms for therapeutic development. , 2022, , 291-334.		0
3808	Clinically available/under trial drugs and vaccines for treatment of SARS-COV-2. , 2022, , 451-488.		0
3809	Inhibitors of Deubiquitinating Enzymes Interfere with the SARS-CoV-2 Papain-like Protease and Block Virus Replication In Vitro. <i>Viruses</i> , 2022, 14, 1404.	1.5	7
3810	Temporal trends in clinical characteristics and in-hospital mortality among patients with COVID-19 in Japan for waves 1, 2, and 3: A retrospective cohort study. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 1393-1401.	0.8	4
3811	Mortality and risk factors for COVID-19 in hemodialysis patients: A systematic review and meta-analysis. <i>Science Progress</i> , 2022, 105, 003685042211108.	1.0	12
3812	Therapeutic Interventions Implemented During the First Year of the COVID-19 Pandemic: A Systematic Review of Evidence. <i>Cyprus Journal of Medical Sciences</i> , 2022, 7, 287-302.	0.0	0
3813	Paxlovid: Mechanism of Action, Synthesis, and In Silico Study. <i>BioMed Research International</i> , 2022, 2022, 1-16.	0.9	56
3814	Bacterial Co-infection and Antimicrobial Use Among Patients with COVID-19 Infection in a Referral Center in the Philippines: A Retrospective Cohort Study. <i>IJID Regions</i> , 2022, , .	0.5	1
3815	Virofree, an Herbal Medicine-Based Formula, Interrupts the Viral Infection of Delta and Omicron Variants of SARS-CoV-2. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	7
3816	A trial of arbidol hydrochloride in adults with COVID-19. <i>Chinese Medical Journal</i> , 2022, 135, 1531-1538.	0.9	5
3817	Cell and Animal Models for SARS-CoV-2 Research. <i>Viruses</i> , 2022, 14, 1507.	1.5	9
3818	Significant perspectives on various viral infections targeted antiviral drugs and vaccines including COVID-19 pandemicity. <i>Molecular Biomedicine</i> , 2022, 3, .	1.7	1
3819	The role of multi-omics in the diagnosis of COVID-19 and the prediction of new therapeutic targets. <i>Virulence</i> , 2022, 13, 1101-1110.	1.8	7
3820	In silico discovery of multi-targeting inhibitors for the COVID-19 treatment by molecular docking, molecular dynamics simulation studies, and ADMET predictions. <i>Structural Chemistry</i> , 2022, 33, 1645-1665.	1.0	19
3821	Does awake prone positioning prevent the use of mechanical respiratory support or death in COVID-19 patients on standard oxygen therapy hospitalised in general wards? A multicentre randomised controlled trial: the PROVID-19 protocol. <i>BMJ Open</i> , 2022, 12, e060320.	0.8	3

#	ARTICLE	IF	CITATIONS
3822	COVID-19: gastrointestinal and hepatobiliary manifestations. <i>Human Pathology</i> , 2023, 132, 39-55.	1.1	8
3823	Chronic Administration of COVID-19 Drugs Fluvoxamine and Lopinavir Shortens Action Potential Duration by Inhibiting the Human Ether-à-à-go-à-go-Related Gene and Cav1.2. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
3824	Safety of Drugs Used during the First Wave of COVID-19: A Hospital-Registry-Based Study. <i>Diagnostics</i> , 2022, 12, 1612.	1.3	3
3825	Synthesis, spectral characterization, crystal structure and computational investigation of 2-formyl-6-methoxy-3-carbethoxy quinoline as potential SARS-CoV inhibitor. <i>Journal of Physics and Chemistry of Solids</i> , 2022, 170, 110886.	1.9	1
3826	Coronaviruses. , 2023, , 277-306.		0
3827	COVIDMED â€œ An early pandemic randomized clinical trial of losartan treatment for hospitalized COVID-19 patients. <i>Contemporary Clinical Trials Communications</i> , 2022, 29, 100968.	0.5	5
3828	Long-term functioning status of COVID-19 survivors: a prospective observational evaluation of a cohort of patients surviving hospitalisation. <i>BMJ Open</i> , 2022, 12, e057246.	0.8	12
3829	Evidence-based medicine has already adapted and is very much alive. <i>BMJ Evidence-Based Medicine</i> , 2022, 27, 261-262.	1.7	3
3830	Gastrointestinal prophylaxis for COVID-19: An illustration of severe bias arising from inappropriate comparators in observational studies. <i>Journal of Clinical Epidemiology</i> , 2022, , .	2.4	0
3831	Proteases of SARS Coronaviruses. , 2022, , .		0
3832	Electrocardiographic changes in pregnant women with COVID-19. <i>Journal of the Practice of Cardiovascular Sciences</i> , 2022, 8, 17.	0.0	1
3833	Targeting the Conserved Sequence of the Substrate for the Proteinase of Severe-Acute-Respiratory-Syndrome-Coronavirus-2 (SARS-CoV-2) Using Nano-Networks: Efficacy, Stability, and No Cytotoxicity. <i>Journal of Biomedical Nanotechnology</i> , 2022, 18, 1158-1163.	0.5	2
3835	Ion channel inhibition with amiodarone or verapamil in symptomatic hospitalized nonintensive-care COVID-19 patients: The ReCOV-ery-SIRIO randomized trial. <i>Cardiology Journal</i> , 2022, 29, 739-750.	0.5	3
3836	Human TMPRSS2 non-catalytic ectodomain and SARS-CoV-2 S2' subunit interaction mediated SARS-CoV-2 endocytosis: a model proposal with virtual screening for potential drug molecules to inhibit this interaction. <i>Journal of Biomolecular Structure and Dynamics</i> , 0, , 1-12.	2.0	0
3837	Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19â€”Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT). <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	7
3838	Efficacy and safety of etiotropic antiviral therapy in COVIDâ€™19 in outpatient patients. <i>Medical Alphabet</i> , 2022, , 23-26.	0.0	2
3839	Antiviral drug treatment for nonsevere COVID-19: a systematic review and network meta-analysis. <i>Cmaj</i> , 2022, 194, E969-E980.	0.9	37
3840	A motley of possible therapies of the COVID-19: reminiscing the origin of the pandemic. <i>Environmental Science and Pollution Research</i> , 2022, 29, 67685-67703.	2.7	8

#	ARTICLE	IF	CITATIONS
3841	Assessment of Tocilizumab (Humanized Monoclonal Antibody) for Therapeutic Efficacy and Clinical Safety in Patients with Coronavirus Disease (COVID-19). <i>Medicina (Lithuania)</i> , 2022, 58, 1076.	0.8	4
3842	Real-World Evidence for COVID-19 Delta Variant's Effects on the Digestive System and Protection of Inactivated Vaccines from a Medical Center in Yangzhou, China: A Retrospective Observational Study. <i>International Journal of Clinical Practice</i> , 2022, 2022, 1-9.	0.8	1
3843	Comparison between the first and second COVID-19 waves in Internal Medicine wards in Milan, Italy: a retrospective observational study. <i>Internal and Emergency Medicine</i> , 2022, 17, 2219-2228.	1.0	7
3844	Managing Rheumatic Diseases in COVID-19. <i>The Journal of Tepecik Education and Research Hospital</i> , 2022, 32, 159-165.	0.2	0
3845	Vascular Implications of COVID-19: Role of Radiological Imaging, Artificial Intelligence, and Tissue Characterization: A Special Report. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 268.	0.8	8
3846	Role of tannic acid against SARS-cov-2 cell entry by targeting the interface region between S-protein-RBD and human ACE2. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
3847	Assessment of drugs administered in the Middle East as part of the COVID-19 management protocols. <i>Inflammopharmacology</i> , 0, , .	1.9	3
3848	Treatments for the Infection by SARS-CoV-2. , 0, , .		0
3850	Safety and Efficacy of Antiviral Drugs for the Treatment of COVID-19: A Systematic Review. <i>Infection and Drug Resistance</i> , 0, Volume 15, 4457-4466.	1.1	10
3851	COVID-19: Pathophysiology, Transmission, and Drug Development for Therapeutic Treatment and Vaccination Strategies. <i>Current Pharmaceutical Design</i> , 2022, 28, 2211-2233.	0.9	1
3852	Public Preferences and Willingness to Pay for a COVID-19 Vaccine in Iran: A Discrete Choice Experiment. <i>PharmacoEconomics - Open</i> , 0, , .	0.9	2
3853	A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease. <i>Neurotoxicity Research</i> , 2022, 40, 1553-1569.	1.3	5
3854	Identifying Drug-Induced Liver Injury Associated With Inflammation-Drug and Drug-Drug Interactions in Pharmacologic Treatments for COVID-19 by Bioinformatics and System Biology Analyses: The Role of Pregnane X Receptor. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
3855	How Can Apartment-Complex Landscaping Space Improve Residents's Psychological Well-Being?: The Case of the Capital Region in South Korea. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 10231.	1.2	3
3856	Scope of repurposed drugs against the potential targets of the latest variants of SARS-CoV-2. <i>Structural Chemistry</i> , 2022, 33, 1585-1608.	1.0	6
3857	Survival, mortality, and related comorbidities among COVID-19 patients in Saudi Arabia. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2022, 43, 915-926.	0.5	2
3858	Nanobionics: From plant empowering to the infectious disease treatment. <i>Journal of Controlled Release</i> , 2022, 349, 890-901.	4.8	3
3859	Consequences of COVID-19 on the cardiovascular and renal systems. <i>Sleep Medicine</i> , 2022, 100, 31-38.	0.8	2

#	ARTICLE	IF	CITATIONS
3860	Epigenetic perspectives of COVID-19: Virus infection to disease progression and therapeutic control. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166527.	1.8	4
3861	Comprehensive Fragment Screening of the SARS-CoV-2 Proteome Explores Novel Chemical Space for Drug Development. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	7.2	7
3862	Identification of Drug Combination Therapies for SARS-CoV-2: A Molecular Dynamics Simulations Approach. <i>Drug Design, Development and Therapy</i> , 0, Volume 16, 2995-3013.	2.0	6
3863	Canakinumab in patients with COVID-19 and type 2 diabetes â€œ A multicentre, randomised, double-blind, placebo-controlled trial. <i>EClinicalMedicine</i> , 2022, 53, 101649.	3.2	7
3864	Nanomedicine approaches to reduce cytokine storms in severe infections. <i>Drug Discovery Today</i> , 2022, 27, 103355.	3.2	1
3865	Antimicrobial peptides: A promising tool to combat multidrug resistance in SARS CoV2 era. <i>Microbiological Research</i> , 2022, 265, 127206.	2.5	5
3866	Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses. <i>Biomedical Engineering Advances</i> , 2022, 4, 100054.	2.2	3
3867	Lung-function trajectories in COVID-19 survivors after discharge: A two-year longitudinal cohort study. <i>EClinicalMedicine</i> , 2022, 54, 101668.	3.2	25
3868	Pre-hospital Management of COVID-19: Looking for a Future Perspective. , 2022, , 395-419.		0
3869	Molecular dynamic simulation with protein and detection of repurposable drugs for COVID-19. , 2022, , 273-297.		0
3870	In silico approaches in drug discovery for SARS-CoV-2. , 2022, , 235-251.		0
3871	Comparison of safety and efficacy of convalescent plasma with fresh frozen plasma in severe covid-19 patients. <i>Anais Da Academia Brasileira De Ciencias</i> , 2022, , .	0.3	6
3872	A systematic review on health scenario after COVID19: Conditions and solutions in ayurvedic perspective. <i>Journal of Ayurveda</i> , 2022, 16, 228.	0.1	0
3873	The Assessment of the Efficacy and Safety of Favipiravir for Patients with SARS-CoV-2 Infection: A Multicenter Non-randomized, Uncontrolled Single-arm Prospective Study. <i>Internal Medicine</i> , 2022, , .	0.3	1
3874	Evaluation of the diagnosis and treatment options for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 4219.	0.3	0
3875	Vitamin D: a potentially important secosteroid for coping with COVID-19. <i>Anais Da Academia Brasileira De Ciencias</i> , 2022, 94, .	0.3	0
3876	Elucidating the pathogenicity, diagnosis, treatment, and prevention of COVID-19: Part I. <i>SRM Journal of Research in Dental Sciences</i> , 2022, 13, 127.	0.1	0
3877	Precision Medicine in Infectious Disease. , 2022, , 221-257.		2

#	ARTICLE	IF	CITATIONS
3878	A Review of Pleiotropic Potential of Erythropoietin as an Adjunctive Therapy for COVID-19. <i>Journal of Clinical and Basic Research</i> , 2022, 6, 11-27.	0.1	0
3879	Efficacy and Safety of Direct Hemoperfusion Using Polymyxin B-Immobilized Polystyrene Column for Patients With COVID-19: Protocol for an Exploratory Study. <i>JMIR Research Protocols</i> , 2022, 11, e37426.	0.5	1
3880	Doxycycline inhibits SARS-CoV-2 replication in vitro. <i>Biomedicine (India)</i> , 2022, 42, 612-615.	0.1	0
3881	Nanomedicine – New Food for an Old Mouth: Novel Approaches for the Treatment of COVID-19. <i>Drug Delivery Letters</i> , 2023, 13, 83-91.	0.2	0
3882	The association of antiviral drugs with COVID-19 morbidity: The retrospective analysis of a nationwide COVID-19 cohort. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
3883	COVID-19 And Chronic Kidney Diseases. , 2022, , 181-229.		0
3884	COVID-19 and Cardiovascular Manifestations. , 2022, , 102-136.		0
3885	Gastrointestinal and Hepatobiliary Manifestations of COVID-19. , 2022, , 71-101.		0
3886	COVID-19 and Pulmonary Diseases. , 2022, , 230-262.		0
3887	Succint review on biological and clinical aspects of Coronavirus disease 2019 (COVID-19). , 2022, 125, 356-365.		0
3888	Neutrophil-Lymphocyte Ratio Predicting Case Severity in SARS-CoV-2 Infection: A Review. <i>Cureus</i> , 2022, , .	0.2	0
3889	Long COVID-19 and the Heart: Is Cardiac Mitochondria the Missing Link?. <i>Antioxidants and Redox Signaling</i> , 0, , .	2.5	6
3890	Comprehensive Fragment Screening of the SARS-CoV-2 Proteome Explores Novel Chemical Space for Drug Development. <i>Angewandte Chemie</i> , 2022, 134, .	1.6	4
3891	Benefits of probiotic use on COVID-19: A systematic review and meta-analysis. <i>Critical Reviews in Food Science and Nutrition</i> , 2024, 64, 2986-2998.	5.4	8
3892	Cardiac Biomarkers and Risk Scores in Relation with History of Atherosclerotic Cardiovascular Disease in Patients Admitted with COVID-19: The Experience of an Eastern European Center. <i>Journal of Clinical Medicine</i> , 2022, 11, 5671.	1.0	1
3893	A computational study of metal-organic frameworks (MOFs) as potential nanostructures to combat SARS-CoV-2. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
3894	High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors. <i>Protein and Cell</i> , 0, , .	4.8	2
3895	Thromboembolic Disease and Cardiac Thrombotic Complication in COVID-19: A Systematic Review. <i>Metabolites</i> , 2022, 12, 889.	1.3	7

#	ARTICLE	IF	CITATIONS
3896	Current status of coronavirus disease 2019 vaccine research based on bibliometric analysis. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	3
3897	A Review on Effectiveness of Plasma Therapy in Severe COVID-19 Patients. Cureus, 2022, , .	0.2	0
3898	Effects of COVID-19 on Arrhythmia. Journal of Cardiovascular Development and Disease, 2022, 9, 292.	0.8	10
3899	A Survey on COVID-19 pandemic in Karnataka State, India. The Open Covid Journal, 2022, 2, .	0.4	0
3900	Failed clinical trials on COVID-19 acute respiratory distress syndrome in hospitalized patients: common oversights and streamlining the development of clinically effective therapeutics. Expert Opinion on Investigational Drugs, 2022, 31, 995-1015.	1.9	4
3901	Ivermectin-Induced Clinical Improvement and Alleviation of Significant Symptoms of COVID-19 Outpatients: A Cross-Sectional Study. Iranian Journal of Science and Technology, Transaction A: Science, 0, , .	0.7	0
3903	Bounded-width confidence interval following optimal sequential analysis of adverse events with binary data. Statistical Methods in Medical Research, 2022, 31, 2323-2337.	0.7	0
3904	Evaluation of the Costs and Outcomes of COVID-19 Therapeutic Regimens in Hospitalized Patients in Shiraz. Iranian Journal of Science and Technology, Transaction A: Science, 0, , .	0.7	0
3905	Recent advances in small-molecular therapeutics for COVID-19. Precision Clinical Medicine, 2022, 5, .	1.3	9
3906	Length of hospital stay and survival of hospitalized COVID-19 patients during the second wave of the pandemic: A single centre retrospective study from Slovenia. Zdravstveno Varstvo, 2022, 61, 201-208.	0.6	1
3907	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With Coronavirus Disease 2019 (COVID-19). Clinical Infectious Diseases, 0, , .	2.9	82
3908	Care for adults with <scp>COVID</scp> â€“19: living guidelines from the National <scp>COVID</scp> â€“19 Clinical Evidence Taskforce. Medical Journal of Australia, 2022, 217, 368-378.	0.8	8
3909	Liver and Biliary Tract Disease in Patients with Coronavirus disease-2019 Infection. Gastroenterology Clinics of North America, 2023, 52, 13-36.	1.0	2
3910	Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CLpro. Antiviral Research, 2022, 207, 105419.	1.9	7
3911	A case report of urticaria as a rare side effect of favipiravir in a patient with COVID-19. Indian Journal of Allergy Asthma and Immunology, 2021, 35, 103.	0.1	0
3912	Candidate Drugs for the Potential Treatment of Coronavirus Diseases. Methods in Pharmacology and Toxicology, 2021, , 85-114.	0.1	0
3913	Misinformation about medication during the COVIDâ€“19 pandemic: A perspective of medical staff. PLoS ONE, 2022, 17, e0276693.	1.1	9
3914	Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics. Molecular Aspects of Medicine, 2023, 91, 101151.	2.7	16

#	ARTICLE	IF	CITATIONS
3915	Critical COVID-19 disease: Clinical course and rehabilitation of neurological deficits. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	3
3916	Comparative efficacy and safety of pharmacological interventions for severe COVID-19 patients: An updated network meta-analysis of 48 randomized controlled trials. <i>Medicine (United States)</i> , 2022, 101, e30998.	0.4	3
3918	COVID-19 Severity and Thrombo-Inflammatory Response Linked to Ethnicity. <i>Biomedicines</i> , 2022, 10, 2549.	1.4	4
3919	COVID-19 and hepatorenal syndrome. <i>World Journal of Gastroenterology</i> , 0, 28, 5666-5678.	1.4	1
3920	A guide to <scp>COVID</scp>â€19 antiviral therapeutics: a summary and perspective of the antiviral weapons against <scp>SARSâ€CoV</scp>â€2 infection. <i>FEBS Journal</i> , 0, , .	2.2	6
3921	Global case fatality rate from COVIDâ€19 has decreased by 96.8% during 2.5 years of the pandemic. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	27
3922	COVID-19-associated Guillain-BarrÃ© syndrome in the early pandemic experience in Lombardia (Italy). <i>Neurological Sciences</i> , 2023, 44, 437-446.	0.9	1
3923	Treatment and case fatality rate of COVID-19 in Africa. <i>Journal of Public Health in Africa</i> , 2022, 13, .	0.2	1
3924	Convalescent Plasma to Treat COVID-19: A Two-Center, Randomized, Double-Blind Clinical Trial. <i>Life</i> , 2022, 12, 1767.	1.1	2
3925	COMPREHENSIVE THERAPEUTIC INTERVENTIONS AGAINST SARS-COV-2: A REVIEW AND PROSPECTIVE. <i>International Journal of Pharmacy and Pharmaceutical Sciences</i> , 0, , 1-12.	0.3	0
3926	A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19. <i>Life</i> , 2022, 12, 1758.	1.1	9
3927	Safety and Efficacy of Interferon Î²-1b in the Treatment of Severe COVID-19 Patients: An Open-Label Randomized Controlled Trial. <i>Archives of Clinical Infectious Diseases</i> , 2022, 17, .	0.1	0
3928	Quinone and SARS-CoV-2. , 2023, , 47-81.		0
3929	Strategies for delivery of antiviral agents. , 2023, , 407-492.		0
3930	V. Current Treatment Approach for COVID-19. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2021, 110, 2374-2382.	0.0	0
3932	Attitudes and beliefs regarding the use of herbs and supplementary medications with COVID-19: A systematic review. <i>Research in Social and Administrative Pharmacy</i> , 2023, 19, 343-355.	1.5	0
3933	Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial. <i>BMJ</i> , The, 0, , e072175.	3.0	16
3934	Virtual screening based on the structure of more than 105 compounds against four key proteins of SARS-CoV-2: MPro, SRBD, RdRp, and PLpro. <i>Informatics in Medicine Unlocked</i> , 2022, 35, 101134.	1.9	3

#	ARTICLE	IF	CITATIONS
3935	A country-based review in COVID-19 related research developments. <i>RAIRO - Operations Research</i> , 0, , .	1.0	0
3936	Efficacy of colchicine in patients with moderate COVID-19: A double-blinded, randomized, placebo-controlled trial. <i>PLoS ONE</i> , 2022, 17, e0277790.	1.1	3
3937	SARS-CoV-2 viral clearance and viral load kinetics in young children (1â€“6 years) compared to adults: Results of a longitudinal study in Germany. <i>Frontiers in Pediatrics</i> , 0, 10, .	0.9	2
3938	Modeling studies on the role of vitamins B1 (thiamin), B3 (nicotinamide), B6 (pyridoxamine), and caffeine as potential leads for the drug design against COVID-19. <i>Journal of Molecular Modeling</i> , 2022, 28, .	0.8	2
3939	The Understanding of the Potential Linkage between COVID-19, Type-2 Diabetes, and Cancer(s) Could Help in Better Drug Targets and Therapeutics. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2022, 25, 2370-2371.	0.6	3
3940	A multi-country study on the impact of sex and age on oral features of COVID-19 infection in adolescents and young adults. <i>BMC Oral Health</i> , 2022, 22, .	0.8	0
3941	The exploration of phytochemicals theoretically combats SARS-CoV-2 pandemic against virus entry, viral replication and immune evasion. <i>Journal of Infection and Public Health</i> , 2023, 16, 42-54.	1.9	4
3942	Potential of Nanotechnology-based Formulations in Combating Pulmonary Infectious Diseases: A Current Scenario. <i>Current Pharmaceutical Design</i> , 2022, 29, .	0.9	0
3943	Does the use of cysteine-rich whey protein supplements (Immunocal®) improve the health well-being of COVID-19 patients? A qualitative study. <i>Electronic Journal of General Medicine</i> , 2023, 20, em433.	0.3	0
3944	Enantioselective inhibition of the SARS-CoV-2 main protease with rhenium(<sc>i</sc>) picolinic acid complexes. <i>Chemical Science</i> , 2023, 14, 711-720.	3.7	9
3945	COVID-19 Outbreak in Daegu City, Korea and Response to COVID-19: How Have We Dealt and What Are the Lessons?. <i>Journal of Korean Medical Science</i> , 2022, 37, .	1.1	6
3946	Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus. , 2022, 10, 251513552211448.	1.4	4
3947	Cardiovascular implications of the COVID-19: Management of complications and drug safety concerns. <i>Journal of Research in Medical Sciences</i> , 2022, 27, 92.	0.4	0
3948	Reduction in the rate of mortality of moderate to severe COVID 19 infected patients with the use of remdesivir - A Tertiary Care Hospital-based retrospective observational study. <i>Anesthesia: Essays and Researches</i> , 2022, 16, 296.	0.2	3
3949	The relationship between oxygen therapy, drug therapy, and COVID-19 mortality. <i>Open Medicine (Poland)</i> , 2022, 17, 1833-1839.	0.6	0
3950	Liver damage in the context of SARS-CoV-2. Covid-19 treatment and its effects on the liver. <i>Journal of Medicine and Life</i> , 2022, 15, 727-734.	0.4	5
3951	SARS-CoV-2: Recent Past and Present: An Unusual Review. , 2022, 2, 1-33.		0
3952	Honey and <sc>i>Nigella sativa</i></sc> against <sc>COVID</sc>â€“19 in Pakistan (<sc>HNSâ€“COVIDâ€“PK</sc>): A multicenter placeboâ€“controlled randomized clinical trial. <i>Phytotherapy Research</i> , 2023, 37, 627-644.	2.8	20

#	ARTICLE	IF	CITATIONS
3953	Exploration of Anti-HIV Phytocompounds against SARS-CoV-2 Main Protease: Structure-Based Screening, Molecular Simulation, ADME Analysis and Conceptual DFT Studies. <i>Molecules</i> , 2022, 27, 8288.	1.7	6
3954	COVID-19-associated liver injury, role of drug therapy and management: a review. <i>Egyptian Liver Journal</i> , 2022, 12, .	0.3	1
3955	Paxlovid accelerates cartilage degeneration and senescence through activating endoplasmic reticulum stress and interfering redox homeostasis. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	5
3956	Antiviral Treatment of COVID-19 Pneumonia. <i>Clinics in Chest Medicine</i> , 2022, , .	0.8	0
3957	Integrative transcriptome analysis of SARS-CoV-2 human-infected cells combined with deep learning algorithms identifies two potential cellular targets for the treatment of coronavirus disease. <i>Brazilian Journal of Microbiology</i> , 0, , .	0.8	1
3958	Drug-induced liver injury in COVID-19 treatment: Incidence, mechanisms and clinical management. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
3959	Homeopathy as an Adjuvant to Standard Care in Moderate and Severe Cases of COVID-19: A Single-Blind, Randomized, Placebo-Controlled Study. <i>Homeopathy</i> , 2023, 112, 184-197.	0.5	5
3960	Selective serotonin reuptake inhibitors: New hope in the fight against COVID-19. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
3961	Label-Free Analysis of Binding and Inhibition of SARS-Cov-19 Spike Proteins to ACE2 Receptor with ACE2-Derived Peptides by Surface Plasmon Resonance. <i>ACS Applied Bio Materials</i> , 2023, 6, 182-190.	2.3	1
3962	On the Role of Geriatric Services in the Diagnosis and Monitoring of Outcomes of Post-Covid Syndrome (Review). <i>Advances in Gerontology</i> , 2022, 12, 357-369.	0.1	0
3963	Efficacy and Safety of Pacritinib vs Placebo for Patients With Severe COVID-19. <i>JAMA Network Open</i> , 2022, 5, e2242918.	2.8	2
3964	Therapeutic Polypeptides and Peptidomimetics: Powerful Tools for COVID-19 Treatment. <i>Clinical Drug Investigation</i> , 2023, 43, 13-22.	1.1	1
3965	Drugs for COVID-19: An Update. <i>Molecules</i> , 2022, 27, 8562.	1.7	18
3966	CURRENT ASPECTS OF ETIOTROPIC COVID-19 THERAPY. <i>Farmatsiya I Farmakologiya</i> , 2022, 10, 432-445.	0.2	2
3967	Therapeutic and diagnostic applications of nanoparticles in the management of COVID-19: a comprehensive overview. <i>Virology Journal</i> , 2022, 19, .	1.4	14
3968	Strategies Tackling Viral Replication and Inflammatory Pathways as Early Pharmacological Treatment for SARS-CoV-2 Infection: Any Potential Role for Ketoprofen Lysine Salt?. <i>Molecules</i> , 2022, 27, 8919.	1.7	2
3969	A Molecular Docking Approach to Evaluate the Pharmacological Properties of 1-(4-amino-1,2,5-oxadiazol-3-yl)-N'-(1-(3-hydroxyphenyl)vinyl)-5-(thiophen-2-yl)1H-1,2,3-triazole-4-carbohydrazide Treatment Candidate for Use against COVID-19. <i>MINAR International Journal of Applied Sciences and Technology</i> , 0, , .	0.0	0
3970	A hypothesis on designing strategy of effective RdRp inhibitors for the treatment of SARS-CoV-2. <i>3 Biotech</i> , 2023, 13, .	1.1	2

#	ARTICLE	IF	CITATIONS
3971	Viral proteases as therapeutic targets. <i>Molecular Aspects of Medicine</i> , 2022, 88, 101159.	2.7	17
3972	HIV and SARS-CoV-2 Co-Infection: From Population Study Evidence to In Vitro Studies. <i>Life</i> , 2022, 12, 2089.	1.1	0
3973	Remdesivir-induced bradycardia in patients hospitalized with SARS-CoV2 infection: a possible vagally-mediated mechanism. <i>Internal and Emergency Medicine</i> , 0, , .	1.0	3
3974	Characteristics of hospitalized patients with COVID-19 during the first to fifth waves of infection: a report from the Japan COVID-19 Task Force. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	20
3975	COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Xenobiotics). <i>Journal of Medical Toxicology</i> , 2023, 19, 26-36.	0.8	5
3976	Lopinavir/ritonavir for treatment of non-hospitalized patients with COVID-19: a randomized clinical trial. <i>International Journal of Infectious Diseases</i> , 2023, 128, 223-229.	1.5	7
3977	Misinterpretation of statistical nonsignificance as a sign of potential bias: Hydroxychloroquine as a case study. <i>Accountability in Research</i> , 0, , 1-20.	1.6	1
3978	Delirium in hospitalized COVID-19 patients: Predictors and implications for patient outcome. <i>PLoS ONE</i> , 2022, 17, e0278214.	1.1	8
3979	Mechanism and potential treatments for gastrointestinal dysfunction in patients with COVID-19. <i>World Journal of Gastroenterology</i> , 0, 28, 6811-6826.	1.4	2
3980	Prevalence of antibiotics prescription amongst patients with and without COVID-19 in low- and middle-income countries: a systematic review and meta-analysis. <i>Pathogens and Global Health</i> , 2023, 117, 437-449.	1.0	3
3981	Identification of Darunavir Derivatives for Inhibition of SARS-CoV-2 3CLpro. <i>International Journal of Molecular Sciences</i> , 2022, 23, 16011.	1.8	2
3982	Pharmacological Effects and Clinical Prospects of Cepharanthine. <i>Molecules</i> , 2022, 27, 8933.	1.7	13
3983	Frailty and hyperactive delirium in hospitalized older patients with COVID-19: an insight from GeroCovid registry. <i>Aging Clinical and Experimental Research</i> , 2023, 35, 433-442.	1.4	3
3984	Smart control of agricultural water wells in western Iran: Application of the Q-methodology. <i>Journal of Soils and Water Conservation</i> , 2023, 78, 58-69.	0.8	0
3985	Use of Antiviral Agents and other Therapies for COVID-19. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 118-129.	0.8	3
3986	HIV and COVID-19 Disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 035-049.	0.8	2
3987	In vitro and in silico evaluation of antiretrovirals against SARS-CoV-2: A drug repurposing approach. <i>AIMS Microbiology</i> , 2023, 9, 20-40.	1.0	2
3988	COVID-19 and hepatic injury: Diversity and risk assessment. <i>World Journal of Gastroenterology</i> , 0, 29, 425-449.	1.4	5

#	ARTICLE	IF	CITATIONS
3989	Baricitinib or imatinib in hospitalized COVID-19 patients: Results from COVINIB, an exploratory randomized clinical trial. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	4
3990	The Outcome of COVID-19 Infection on Kidney Transplantation Recipients in Southern Saudi Arabia: Single-Center Experience. <i>Transplantation Proceedings</i> , 2023, 55, 521-529.	0.3	0
3991	Liver dysfunction-related COVID-19: A narrative review. <i>World Journal of Meta-analysis</i> , 0, 11, 5-17.	0.1	0
3992	Effectiveness of different treatment regimens on patients with COVID-19, hospitalized in Sanandaj hospitals: a retrospective cohort study. <i>Journal of Pharmaceutical Policy and Practice</i> , 2023, 16, .	1.1	1
3993	Liver injury in COVID-19: Clinical features, potential mechanisms, risk factors and clinical treatments. <i>World Journal of Gastroenterology</i> , 0, 29, 241-256.	1.4	8
3994	Utility of chest radiograph severity scoring in emergency department for predicting outcomes in COVID-19: A study of 1275 patients. <i>Clinical Imaging</i> , 2023, 95, 65-70.	0.8	0
3996	The impact of HIV on the risk of COVID-19 death among hospitalized patients. <i>Human Antibodies</i> , 2023, 30, 165-175.	0.6	1
3997	Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial. <i>Nature Cancer</i> , 0, , .	5.7	14
3999	Efficacy of Tocilizumab in Management of COVID-19 Patients Admitted to Intensive Care Units: A Multicenter Retrospective Cohort Study. <i>Medicina (Lithuania)</i> , 2023, 59, 53.	0.8	1
4001	The Role of Hyaluronic Acid in Tissue Engineering. , 2021, , 1-55.		0
4002	2-Deoxy-d-Glucose: A Repurposed Drug for COVID-19 Treatment. , 2023, , 479-500.		0
4003	The Safety and Efficacy of the Protease Inhibitors Lopinavir/Ritonavir as Monotherapy or Combined with Interferon in COVID-19 Patients. <i>Processes</i> , 2023, 11, 398.	1.3	0
4004	Reverse Translational Approach in Repurposing of Drugs for Anticancer Therapy. , 2023, , 299-328.		0
4005	The Potential of Nanobodies for COVID-19 Diagnostics and Therapeutics. <i>Molecular Diagnosis and Therapy</i> , 2023, 27, 193-226.	1.6	6
4006	Longitudinal changes in mental health outcomes after COVID-19 hospitalization: A prospective study. <i>Respiratory Investigation</i> , 2023, 61, 321-331.	0.9	0
4007	An Update of Carbazole Treatment Strategies for COVID-19 Infection. <i>Applied Sciences (Switzerland)</i> , 2023, 13, 1522.	1.3	2
4008	Efficacy and safety of ivermectin in patients with mild and moderate COVID-19: A randomized controlled trial. <i>Asian Pacific Journal of Tropical Medicine</i> , 2023, 16, 3-8.	0.4	0
4009	Remdesivir Influence on SARS-CoV-2 RNA Viral Load Kinetics in Nasopharyngeal Swab Specimens of COVID-19 Hospitalized Patients: A Real-Life Experience. <i>Microorganisms</i> , 2023, 11, 312.	1.6	2

#	ARTICLE	IF	CITATIONS
4010	Repurposing Methylene Blue for the Management of COVID-19: Prospects, Paradox, and Perspective. , 2023, , 501-518.		0
4011	COVID-19 and the liver: Are footprints still there?. World Journal of Gastroenterology, 0, 29, 656-669.	1.4	2
4012	Currently available COVID-19 management options. , 2023, , 111-124.		0
4013	Strict Lockdown versus Flexible Social Distance Strategy for COVID-19 Disease: a Cost-Effectiveness Analysis. Archives of Clinical and Biomedical Research, 2023, 07, .	0.1	0
4014	Antimalarials and macrolides: a review of off-label pharmacotherapies during the first wave of the SARS-CoV-2 pandemic. Brazilian Journal of Pharmaceutical Sciences, 0, 59, .	1.2	0
4015	Miniaturized retractable thin-film sensor for wearable multifunctional respiratory monitoring. Nano Research, 2023, 16, 11846-11854.	5.8	8
4016	The comparison of clinical, laboratory, and radiological findings in immunocompromised and immunocompetent patients with COVID-19: A case-control study. Immunity, Inflammation and Disease, 2023, 11, .	1.3	2
4017	Effect of colchicine and aspirin given together in patients with moderate COVID-19. Contemporary Clinical Trials Communications, 2023, 32, 101070.	0.5	1
4018	Identification of RdRp inhibitors against SARS-CoV-2 through E-pharmacophore-based virtual screening, molecular docking and MD simulations approaches. International Journal of Biological Macromolecules, 2023, 237, 124169.	3.6	10
4019	COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease. Drug Discovery Today, 2023, 28, 103579.	3.2	22
4020	Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?. Biomedicine and Pharmacotherapy, 2023, 162, 114367.	2.5	33
4021	Medicinal Plants used Traditionally in Sudan to Treat Viral Infections Related to the Signs and Symptoms of COVID-19: A Systematic Review. Current Traditional Medicine, 2023, 9, .	0.1	0
4022	The development of COVID-19 treatment. Frontiers in Immunology, 0, 14, .	2.2	59
4023	Adverse Drug Reactions during COVID-19 Treatment: A Comprehensive Analysis Focused on Hospitalized Patients, with the Use of a Survey in Cuba in 2020. Advances in Pharmacological and Pharmaceutical Sciences, 2023, 2023, 1-12.	0.7	0
4024	O que mudou entre os períodos de pico e de platô durante a primeira onda do SARS-CoV-2? Estudo multicêntrico português em unidades de cuidados intensivos. Revista Brasileira De Terapia Intensiva, 2022, 34, .	0.1	0
4025	Are we ready to combat the ecotoxicity of COVID-19 pharmaceuticals? An in silico aquatic risk assessment. Aquatic Toxicology, 2023, 256, 106416.	1.9	3
4026	Impact of COVID-19 on Patients with Decompensated Liver Cirrhosis. Diagnostics, 2023, 13, 600.	1.3	1
4027	An overview on the treatments and prevention against COVID-19. Virology Journal, 2023, 20, .	1.4	19

#	ARTICLE	IF	CITATIONS
4028	COVID-19 Metabolomic-Guided Amino Acid Therapy Protects from Inflammation and Disease Sequelae. <i>Advanced Biology</i> , 2023, 7, .	1.4	2
4029	Harnessing the Power of Venomous Animal-Derived Toxins against COVID-19. <i>Toxins</i> , 2023, 15, 159.	1.5	0
4030	Lung Injury in COVID-19 Has Pulmonary Edema as an Important Component and Treatment with Furosemide and Negative Fluid Balance (NEGBAL) Decreases Mortality. <i>Journal of Clinical Medicine</i> , 2023, 12, 1542.	1.0	1
4031	Circulating Interleukin-8 Dynamics Parallels Disease Course and Is Linked to Clinical Outcomes in Severe COVID-19. <i>Viruses</i> , 2023, 15, 549.	1.5	3
4032	Gastrointestinal and Hepatobiliary Symptoms and Disorders with Long (Chronic) COVID Infection. <i>Gastroenterology Clinics of North America</i> , 2023, 52, 139-156.	1.0	2
4033	Risk of Underlying Diseases and Effectiveness of Drugs on COVID-19 Inpatients Assessed Using Medical Claims in Japan: Retrospective Observational Study. <i>International Journal of General Medicine</i> , 0, Volume 16, 657-672.	0.8	2
4034	Effectiveness of COVID-19 Convalescent Plasma (CCP) During the Pandemic Era: A Literature Review. <i>Journal of Blood Medicine</i> , 0, Volume 14, 159-187.	0.7	2
4035	Identification of a glutamine metabolism reprogramming signature for predicting prognosis, immunotherapy efficacy, and drug candidates in bladder cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	7
4036	Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4401.	1.8	4
4037	Clinical observation of glucocorticoid therapy for critically ill patients with COVID-19 pneumonia. <i>Journal of International Medical Research</i> , 2023, 51, 030006052211492.	0.4	0
4038	Barriers and Facilitators to HIV Treatment Adherence in Indonesia: Perspectives of People Living with HIV and HIV Service Providers. <i>Tropical Medicine and Infectious Disease</i> , 2023, 8, 138.	0.9	5
4039	Evaluation of the Effectiveness of Remdesivir in the Treatment of COVID-19 Outpatients: A retrospective cohort study. <i>Current Drug Therapy</i> , 2023, 18, .	0.2	0
4040	COVID-19 and its long-term impact on the cardiovascular system. <i>Expert Review of Cardiovascular Therapy</i> , 2023, 21, 211-218.	0.6	3
4041	Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery-Genetics Alliance Perspective. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 3664-3702.	2.9	12
4042	We Can Think About Ourselves - The Computer Cannot. , 2023, , 197-211.		0
4043	Promising Repurposed Antiviral Molecules to Combat SARS-CoV-2: A Review. <i>Current Pharmaceutical Biotechnology</i> , 2023, 24, 1727-1739.	0.9	1
4044	The effect of Psidium guajava Leaves™ extract for mild and asymptomatic corona virus Disease-19. <i>Saudi Pharmaceutical Journal</i> , 2023, 31, 592-596.	1.2	0
4045	Urinary L-Type Fatty Acid-Binding Protein Predicts Oxygen Demand of COVID-19 in Initially Mild Cases. , 2023, 5, e0873.		3

#	ARTICLE	IF	CITATIONS
4046	Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study). <i>EClinicalMedicine</i> , 2023, 57, 101895.	3.2	1
4047	Identification of host genomic biomarkers from multiple transcriptomics datasets for diagnosis and therapies of SARS-CoV-2 infections. <i>PLoS ONE</i> , 2023, 18, e0281981.	1.1	1
4048	Effectiveness of Fortified Garlic Extract Oral Capsules as Adjuvant Therapy in Hospitalized Patients with Coronavirus Disease 2019: A Triple-Blind Randomized Controlled Clinical Trial. <i>Current Therapeutic Research</i> , 2023, 98, 100699.	0.5	3
4049	Concerted and multidisciplinary management of COVID-19 drug therapies during the first two epidemic waves in a tertiary hospital in Marseille, France: Results of the PHARMA-COVID study. <i>PLoS ONE</i> , 2023, 18, e0283165.	1.1	0
4050	Modulation of gut microbiota as a potential therapy to manipulate drug-induced hepatic damage in COVID-19 patients. <i>World Journal of Gastroenterology</i> , 0, 29, 1708-1720.	1.4	3
4051	Clinical outcomes of the severe acute respiratory syndrome coronavirus 2 Omicron and Delta variant: systematic review and meta-analysis of 33 studies covering 6144 coronavirus disease 2019 "positive patients. <i>Clinical Microbiology and Infection</i> , 2023, 29, 835-844.	2.8	29
4052	The safety of plasma apheresis from donors recovering from COVID-19 infection in Japan. <i>Transfusion and Apheresis Science</i> , 2023, , 103687.	0.5	0
4053	Effect of SARS-CoV-2 infection on the liver. <i>World Journal of Virology</i> , 0, 12, 109-121.	1.3	1
4054	Effects of Standard-Dose Prophylactic, High-Dose Prophylactic, and Therapeutic Anticoagulation in Patients With Hypoxemic COVID-19 Pneumonia. <i>JAMA Internal Medicine</i> , 2023, 183, 520.	2.6	11
4055	Tocilizumab-coated solid lipid nanoparticles loaded with cannabidiol as a novel drug delivery strategy for treating COVID-19: A review. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
4056	An Oral Galectin Inhibitor in COVID-19 "A Phase II Randomized Controlled Trial. <i>Vaccines</i> , 2023, 11, 731.	2.1	3
4057	Clinical Profile and Risk Factors for Severe COVID-19 in Hospitalized Patients from Rio de Janeiro, Brazil: Comparison between the First and Second Pandemic Waves. <i>Journal of Clinical Medicine</i> , 2023, 12, 2568.	1.0	4
4058	Diagnosis, treatment protocols, and outcomes of liver transplant recipients infected with COVID-19. <i>World Journal of Clinical Cases</i> , 0, 11, 2140-2159.	0.3	1
4059	Virtual and In Vitro Screening of Natural Products Identifies Indole and Benzene Derivatives as Inhibitors of SARS-CoV-2 Main Protease (Mpro). <i>Biology</i> , 2023, 12, 519.	1.3	4
4060	Therapeutic Targets in the Virological Mechanism and in the Hyperinflammatory Response of Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2). <i>Applied Sciences (Switzerland)</i> , 2023, 13, 4471.	1.3	1
4061	Outpatient medications associated with protection from COVID-19 hospitalization. <i>PLoS ONE</i> , 2023, 18, e0282961.	1.1	1
4062	Updated landscape of inhaled medications to combat COVID-19. <i>Therapeutic Delivery</i> , 2023, 14, 5-9.	1.2	0
4063	Features of Liver Injury in COVID-19 Pathophysiological, Biological and Clinical Particularities. <i>Gastroenterology Insights</i> , 2023, 14, 156-169.	0.7	1

#	ARTICLE	IF	CITATIONS
4064	Liver Damage and COVID-19: At Least a "Two-Hit" Story in Systematic Review. <i>Current Issues in Molecular Biology</i> , 2023, 45, 3035-3047.	1.0	3
4065	Therapeutics for COVID-19. , 2024, , 282-307.		0
4066	COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery. <i>Genes and Diseases</i> , 2023, , .	1.5	3
4067	Assessment of the potential value of combining western medicine therapies with traditional chinese medicine in the treatment of COVID-19: Mechanistic perspectives. <i>Technology and Health Care</i> , 2023, , 1-16.	0.5	0
4068	Current Strategies to Combat COVID-19. , 2023, , 361-374.		0
4069	COVID-19: Molecular Pathogenesis and Prospective Therapeutic Interventions. , 2023, , 269-294.		0
4070	Exploring the Link Between Malaria and COVID-19. , 2023, , 311-338.		0
4071	High-Affinity Neutralizing DNA Aptamers against SARS-CoV-2 Spike Protein Variants. <i>Covid</i> , 2023, 3, 520-542.	0.7	2
4072	Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies. <i>Viruses</i> , 2023, 15, 944.	1.5	19
4073	Phytochemicals of <i>Withania somnifera</i> as a Future Promising Drug against SARS-CoV-2: Pharmacological Role, Molecular Mechanism, Molecular Docking Evaluation, and Efficient Delivery. <i>Microorganisms</i> , 2023, 11, 1000.	1.6	2
4074	Trends in management and outcomes of COVID patients admitted to a Swiss tertiary care hospital. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
4075	Acute kidney injury in COVID-19 patients receiving remdesivir: A systematic review and meta-analysis of randomized clinical trials. <i>Clinics</i> , 2023, 78, 100200.	0.6	5
4076	Severe COVID-19: Drugs and Clinical Trials. <i>Journal of Clinical Medicine</i> , 2023, 12, 2893.	1.0	0
4077	Post-Exposure Prophylaxis for COVID-19: A Systematic Review. <i>Infectious Disorders - Drug Targets</i> , 2023, 23, .	0.4	1
4078	Knowledge Mapping of Drug Repositioning's Theme and Development. <i>Drug Design, Development and Therapy</i> , 0, Volume 17, 1157-1174.	2.0	1
4079	Possible nirmatrelvir/ritonavir-induced bradycardia in a patient with asymptomatic COVID-19. <i>SAGE Open Medical Case Reports</i> , 2023, 11, 2050313X2311683.	0.2	1
4080	COVID-19 and immunity. , 2023, , 3-32.		0
4126	Traditional Herbal Medicines: A Prospective Panacea for SARS-CoV-2. , 2023, , 25-52.		0

#	ARTICLE	IF	CITATIONS
4127	Nanotechnological strategies for drug delivery and treatment of COVID-19. , 2023, , 301-333.		0
4155	Iristectorigenin A: Advances on Its Resources, Biological Activities, Molecular Mechanisms of Action, and Future Perspectives. , 2023, , 1-20.		0
4156	In Silico Identification of Potential Antivirals Against SARS-CoV-2 Main Protease and RBD of Spike Protein: A Drug Repurposing Approach. , 2023, , 399-410.		0
4173	Drug Therapies against Acute Respiratory Distress: A Critical Endpoint of COVID-19. , 2023, , 110-149.		0
4192	Therapeutic landscape of SARS-CoV-2. , 2024, , 83-99.		0